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12 Chapter 1
1 1.1 Neurodevelopmental disorders 
Definition
Neurodevelopmental disorders (NDDs) are a group of conditions characterized by 
developmental deficits that produce impairments of personal, social, academic, or 
occupational functioning. These disorders typically become manifest before a child enters 
elementary school (age 6 years).1 Six main subtypes of NDDs can be distinguished (Table 
1.1): 
1. Intellectual disability (ID) or global developmental delay (DD) if age is below 5 years
2. Communication disorder (CD)
3. Autism spectrum disorder (ASD)
4. Attention-deficit hyperactivity disorder (ADHD)
5. Specific learning disorder (SLD)
6. Motor disorder (MD)
Different subtypes of NDDs can be present in a single patient, and the severity of the 
disorders can vary between patients and over time. Subtypes of NDDs have also been 
defined in guidelines published by the World Health Organization (ICD-10, released in 
2016). In general, the section ‘Mental and behavioral disorders’ contains definitions for such 
subtypes, but is not restricted to NDDs, as it also includes other psychiatric diagnosis, such 
as schizophrenia, mood disorders and eating disorders.2
Box 1: DSM and Autism Spectrum Disorders 
The Diagnostic and Statistical Manual of Mental Disorders (DSM) is a handbook used by health care 
professionals as authoritative guide to the diagnosis of mental disorders. Since the introduction in 1952, 
it has been revised six times. The last revision was in 2013, with the publication of the DSM-5 criteria. 
These criteria combined what previously were four separate disorders into one condition:  
DSM-IV        DSM-5
Autistic disorder (autism)
Asperger’s disorder     Autism Spectrum Disorder 
Childhood disintegrative disorder     (ASD) 
Pervasive developmental disorder (PDD-NOS)
In this thesis, the term ‘Autism Spectrum Disorder’ is not always used to describe a psychiatric 
diagnosis for patients. Several patients received their psychiatric diagnosis before the introduction 
of the new DSM criteria in 2013 or in the transition period from DSM-IV to DSM-5. For this reason, 
diagnostic terms such as PDD-NOS and Autism (DSM-IV) are used several times, instead of ‘Autism 
Spectrum Disorders’ (DMS-5). Additionally, the severity scoring of autism spectrum disorders, 
introduced in DSM-5, is often not available.
}
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1Table 1.1 Diagnostic criteria of different subtypes of neurodevelopmental disorders*
Disorder Diagnostic criteria** Diagnostic terms
Intellectual 
disability (ID)
(1) Deficits in intellectual functioning, confirmed by both clinical 
assessment and individualized, standardized intelligence testing. (2) 
Deficits in adaptive functioning that result in failure to meet developmental 
and sociocultural standards for personal independence and social 
responsibility.
Intellectual disability; 
Global developmental 
delay
Communication 
disorder (CD)
(1) Persistent difficulties in the acquisition and use of language across 
modalities due to deficits in comprehension or production. (2) Language 
abilities are substantially and quantifiably below those expected for age, 
resulting in functional limitations. (3) The difficulties are not attributable to 
other disorders.
Language disorder; 
Speech sound disorder; 
Childhood-onset 
fluency disorder; Social 
communication disorder
Autism spectrum 
disorder (ASD)
(1) Persistent deficits in social communication and social interaction 
across multiple contexts. (2) Restricted, repetitive patterns of behavioral 
interest, or activities. (3) Symptoms cause clinically significant impairment 
in social, occupational, or other important areas of current functioning. 
(4) Disturbances are not better explained by ID or global developmental 
delay.
Autism spectrum 
disorder
Attention-deficit 
hyperactivity 
disorder (ADHD)
(1) Persistent pattern of inattention and/or hyperactivity-impulsivity that 
interferes with functioning of development. (2) Several inattentive or 
hyperactive-impulsive symptoms are present in two or more settings. 
(3) There is clear evidence that the symptoms interfere with, or reduce 
the quality of, social, academic, or occupational functioning. (4) The 
symptoms do not occur exclusively during the course of a psychotic 
disorder and are not better explained by another mental disorder.
Attention deficit/
hyperactivity disorder; 
Other specified attention 
deficit/hyperactivity 
disorder
Specific learning 
disorder (SLD)
(1) Difficulties with learning and using academic skills that have persisted 
for at least six months, despite the provision of interventions that target 
the difficulties. (2) The affected academic skills are substantially and 
quantifiably below those expected for the individual. (3) The difficulties are 
not attributable to other disorders.
Specific learning 
disorder; Dyscalculia; 
Dyslexia
Motor disorder 
(MD)
(1) The acquisition and execution of coordinated motor skills is 
substantially below that expected given the individual’s chronological age 
and opportunity for skill learning and use. (2) The deficits significantly and 
persistently interfere with activities of daily living. (3) The difficulties are not 
attributable to other disorders.
Developmental 
coordination disorder; 
Stereotypic movement 
disorder; Tic disorders
* Adapted from Diagnostic and Statistic Manual of Mental Disorders, Fifth edition. 
** All subtypes of NDDs have the diagnostic criterium ‘Onset during the developmental period’ in addition to other criteria.
Severity scoring
For the majority of subtypes of NDDs, severity scores are available in the DSM-5 criteria.1 For 
the subtypes ID and ASD, more extensive severity scoring tables have been developed.1-3 
For these latter disorders, severity scores are based on the level of adaptive functioning of a 
patient (Figure 1.1). The severity of ID is scored on functioning in three different domains: the 
conceptual, social and practical domains, and leads to a classification of ‘Mild’, ‘Moderate’, 
‘Severe’ or ‘Profound’ ID. Severity scoring of ASD is based on the specifiers ‘Social 
communication’ and ‘Restricted, repetitive behaviors’. Scoring on these domains leads to 
three different levels of severity: level 1: ‘Requiring support’, level 2: ‘Requiring substantial 
support’ and level 3: ‘Requiring very substantial support’. Overall, detailed severity scoring 
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1 of NDDs is important to determine the level of support a patient requires. In DSM-5 criteria, 
supported by guidelines of the American Association for Intellectual and Developmental 
Disability, adaptive functioning and not IQ levels of patients are used for severity scoring in 
patients with ID.1; 3 This is in contrast to the ICD-10 guidelines, where IQ scores determine 
the level of severity in a patient with ID. Using this guideline, patients with IQ levels between 
50 and 69 have mild ID (developmental age from 9 to under 12 years), between 35 and 49 
have moderate ID (developmental age from 6 to under 9 years), between 20 and 34 have 
severe ID (developmental age from 3 to under 6 years), and under 20 have profound ID 
(developmental age under 3 years).2
Prevalence 
The overall general population prevalence of different subtypes of NDDs ranges between 
1% (ID; ASD) and 10% (SLD) (Figure 1.2).4-12 For subtypes communication disorders and 
motor disorders, no world-wide prevalence figure has been reported. Prevalence estimates 
of diagnoses within these subtypes are available, such as for language disorders (2.6-6.8%), 
developmental coordination disorders (5.0-5.5%), and tic disorder (0.3-1.0%).13-17 Overall, 
these numbers reflect the high prevalence of NDDs in the population and their large impact 
on health care. 
Figure 1.1: Severity scoring for intellectual disability and autism spectrum disorder based on DMS-5 and ICD-10 
criteria. DSM-5 scoring elements are shown on the left for intellectual disability and right for autism spectrum disorder.
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Figure 1.2: World-wide prevalence of NDD subtypes. ID = intellectual disability; CD = communication disorder;   
ASD = autism spectrum disorder; ADHD = attention-deficit hyperactivity disorder; SLD = specific learning disorder;   
MD = motor disorder
1.2 Establishing a genetic diagnosis in patients with 
neurodevelopmental disorders
Genetic abnormalities contribute substantially to the etiology of NDDs, with or without 
somatic characteristics such as epilepsy, brain abnormalities, congenital malformations 
and syndromic facial appearance.18-21 Therefore, genetic testing is routinely considered 
in the care of patients with NDDs. Establishing a genetic diagnosis is important, because 
identification of the genetic cause of a NDD provides parents with insight in the prognosis 
and disease management for their child. A genetic diagnosis may clarify the recurrence risk 
for parents and other family members, which facilitates decisions on future pregnancies and 
prenatal diagnostic testing.22 The emotional impact of a genetic diagnosis should not be 
underestimated. Parents often searched for a long time in order to find an explanation of the 
NDD in their child, a disorder that has a major impact on quality of life of not only the patient, 
but also parents and family.23-25 A genetic diagnosis allows the parents to name the disorder, 
share emotions and experiences with parents of other patients, become more accepting 
towards the situation, and to cope better with feelings of guilt.26 
For years, genetic testing started with a clinical diagnosis (‘phenotype-first approach’): the 
phenotype of the patient was leading in the decision which tests should be performed. From 
the 1970s, chromosomal karyotyping became a first-tier test in the evaluation of all patients 
with NDDs. For single gene disorders, a clinical diagnosis was followed by a single, targeted 
test, such as testing of the CHD7 gene on Single Nucleotide Variants (SNVs) using Sanger 
sequencing in patients with CHARGE syndrome, or methylation analysis of the FMR1 repeat 
region for males clinically diagnosed with Fragile-X syndrome. With the introduction of the 
chromosomal microarray as diagnostic test, the balance started shifting away from the 
phenotype driven approach, towards a more genotype driven (‘genotype-first’) approach: 
ID ASD ADHD SLD 
1% 2.5 -7% 10%1%
CD MD 
? % ? %
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1 copy number variations (CNVs) such as deletions and duplications, could be found 
genome-wide, and enabled physicians to diagnose patients with a less distinct phenotype 
or suspicion for a specific syndrome. A dramatic increase in diagnostic possibilities was 
brought about with the introduction of Next Generation Sequencing (NGS) technologies, 
mainly Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS). While SNVs 
previously only could be identified by targeted testing of a single gene, NGS enabled the 
analysis of coding regions of all genes (the exome) with a single test. 
In 2010, WES was effectively used in a small cohort of unselected patients with ID.27 In 
the following years, many large-scale WES studies were performed in either research or 
diagnostic settings, and were focused mainly on two subtypes of NDDs: ID and ASD.28-33 
For other subtypes of NDDs, a small number of studies has been published, such as for 
tic disorders (MD), ADHD, and  language disorders (CD),34-38 with relatively small sample 
sizes (range 11-325 patients). For two other disorders, epileptic encephalopathy (EE) and 
schizophrenia, much larger WES studies were performed, that showed a surprisingly large 
overlap of genes involved in EE, schizophrenia and NDDs.39-45 WGS has been reported 
in research settings to be even more powerful than WES for the identification of genetic 
disorders in patients with NDDs.46-48 Diagnostic WGS is not currently available in a diagnostic 
setting with the exception of the United Kingdom where the 100.000 Genomes project is 
championing this approach. 
It can be discussed that for patients with a clear clinical presentation of a disorder with low 
genetic and clinical heterogeneity, such as Fragile X syndrome (FRM1 repeat expansion) or 
Neurofibromatosis (NF1 mutation), a targeted genetic test should precede WES as first-tier 
test.49-52 But for the majority of patients the phenotype is less distinct, and for these, WES is 
likely to be faster and more cost-effective. Indeed, a higher diagnostic yield and lower costs 
than alternative diagnostic routes, including targeted gene tests, metabolic screening and 
brain imaging, have been reported in several studies that used WES.49; 53-57 Currently, early 
use of WES in the diagnostic trajectory of patients with NDDs is an attractive option. 
1.3 Whole Exome Sequencing: a complex diagnostic  
work-flow 
Soon after the publication of the successful results of WES for the identification of disease 
causing variants of patients with unexplained NDDs, this approach was introduced in 
diagnostic settings. The complex diagnostic WES work-flow comprises different steps, 
beginning and ending with the counseling of patients and their parents* (Figure 1.3).
* In this thesis, counseling of ’parents’ refers to parents of patients, but also to caregivers or legal guardians of patient.
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Step 1: Counseling of the patient
Patients with NDDs and their parents are informed about the opportunities, benefits and risks 
of genetic testing. There are usually two options in the WES diagnostic route. The physician 
has the opportunity to order a targeted gene panel analysis, which includes previously 
reported known NDD genes. Depending on the wish of parents and the center where WES is 
performed, analysis of the rest of the exome is offered when targeted gene panel screening 
reveals no diagnosis. For the latter analysis, counseling for the risk of an incidental finding 
is important, referring to a situation where a genetic variant is identified for a condition 
unrelated to the indication for testing but which might have medical value for patient care.58 
These incidental findings are identified in 2% - 4% of the WES analysis, if these variants are 
actively searched for.58-61
Step 2: Collection of patient material
A venous blood sample is taken from patients and their parents. Some patients have clinical 
signs suggesting that the mutation is not present in the germline, but in a specific tissue only. 
Clinical symptoms such as Blaschko lines (see chapter 9) can be indicative for a mosaicism. 
Such somatic mosaicism can be explained by the presence of two or more populations of 
cells with different genotypes.62 Collection of additional tissues, such as skin fibroblasts, 
urine or buccal cells, may provide valuable diagnostic information in such cases.
Step 3: Whole exome sequencing, variant calling and mapping 
The WES analysis, variant calling and mapping, are complex technological processes, that 
can differ between centers, depending on techniques and software used.63-65 Sufficient 
sequencing coverage of the exome and correct mapping to the reference human sequence 
are important aspects to obtain results of good quality.64; 66 To allow better mapping, the 
Figure 1.3: Diagnostic WES work-flow, starting with counseling of patients and parents, followed by collection 
of material of patients and their parents, performance of WES with variant calling and mapping, and data analysis, 
interpretation and classification of variants. The procedure ends where it started: the counseling of patients and their 
parents.
526362-L-bw-Reijnders
Processed on: 20-11-2018 PDF page: 18
18 Chapter 1
1 reference genome is continuously improved by the Genome Reference Consortium. The 
latest version (GRCh37 or Hg38) was released in 2013 (https://www.ncbi.nlm.nih.gov/grc). 
Quality scores can be used to determine if variants identified with WES need to be validated 
by Sanger sequencing. Variants with good quality scores (≥ 500) reliably indicate a true 
variant, for which further confirmation by Sanger sequencing is not needed.67; 68
Step 4: Data analysis, interpretation and classification of results
Computational (in silico) analysis of identified variants occurs in two steps. In the first 
step, both SNVs and CNVs of genes in the NDD gene panel are analyzed. If parents gave 
permission and, preferably, if parental DNA is available, the rest of the exome is analyzed in 
the second step. To detect the relevant disease-causing variants in the patient, variants are 
filtered on different characteristics: mode of inheritance, frequency in the population, protein 
function, variant type, and an overlapping phenotype with other patients who also have been 
detected with a variant in the same gene(s). 
Mode of inheritance
Genetic variation between individuals is common: a typical human genome varies at 4.1 
to 5.0 million positions compared to the human reference genome.69 The average human 
genome only contains between 44 and 82 de novo SNVs: variants that occurred during the 
formation of the gametes which are therefore not present in parental DNA. Only a small part 
of these de novo variants, one to two, affect the coding sequence.70 De novo mutations 
have been shown to represent an important cause of NDDs.28-32 Filtering on these de novo 
mutations, as well as on maternally inherited X-linked variants in males and autosomal 
(bi-allelic) recessive variants, is important in the selection process of potential pathogenic 
variants. 
Frequency in the population
From the millions of genome-wide variants present in every individual, only a small proportion 
are rare in the population (minor allele frequency <0.5%: 40,000-200,000 variants per 
individual).69 Variants that cause severe disorders such as NDDs are unlikely to become 
frequent in the population, given the fact that the reproductive disadvantage, or even 
reproductive lethality, of patients with NDDs will lead to strong negative selection. Inhouse 
databases and online population databases such as GnomAD (including ExAC71), contain 
variants identified in >120,000 exome sequences and >15,000 whole-genome sequences. 
These are helpful in distinguishing between common and rare variants. For interpretation of 
exome data, a minor allele frequency of <1% is often used as the initial cut-off value.72 
Protein function 
For the interpretation of the estimated effect of a variant on cellular and tissue levels, it is 
important to evaluate the function of the protein that could be disturbed by the identified 
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1variant.72; 73 Large studies on expression patterns of proteins provide insight whether a protein 
is involved in important cellular mechanisms in tissues such as the central nervous system, 
a tissue relevant for NDDs.74; 75 Additional information on protein function comes from in vitro 
and in vivo model systems such as the fruitfly, zebrafish, mouse and yeast. If a model system 
with disruption of a homologue gene shows a consistent phenotype with the patient, this 
can provide supporting evidence on the pathogenicity of the variant identified in the patient. 
Absence of a phenotype on disruption in a model system, however, does not exclude the 
gene from consideration in a given patient. Information on animal models can be retrieved 
from the literature, or from specialized databases such as The Mouse Genome Informatics 
database and the SysID database, for mice and Drosophila respectively.76; 77  Finally, variants 
in genes encoding a protein that has been linked to other proteins or protein pathways 
already implicated in NDDs, increase the likelihood that the variant is relevant in the context 
of explaining the patients clinical presentation.78 
Variant type
Different types of variants can be identified. SNVs change a single nucleotide, and are 
further classified by their impact on function as nonsense-, frameshift-, missense, and 
splice-site variants. CNVs are larger structural variations affecting the number of copies of 
a considerable number of base pairs, such as microdeletions or duplications. Nonsense- 
frameshift- and indel variants as well as larger structural deletions generally have a disruptive 
loss-of-function effect. If the loss of function of a single allele suffices to cause a phenotype 
in a patient, this is called haploinsufficiency. Missense variants are often more difficult 
to interpret, as their impact on protein function can be either through a loss-of-function 
(hypomorph), dominant-negative, change-of-function (neomorph) or gain-of-function 
(hypermorph) effect. In general, missense variants that are highly conserved among different 
species are more likely to be pathogenic than those that are not conserved, especially if 
they localize to a protein domain with known function. Further supporting evidence for the 
functional significance of missense variants can be provided by in silico prediction programs 
such as SIFT, Polyphen, MutationTaster and the Combined Annotation-Dependent Depletion 
(CADD) score.79-82 The accuracy of these prediction programs varies between algorithms and 
they are often less informative than direct experimental evidence.73; 83 Variants in the flanking 
regions of the exons are known to have the potential to alter splicing. To predict whether 
these variants indeed lead to disrupted splicing, the Human Splicing Finder tool can be 
used.84  If the gene is expressed in the tissue to be tested, investigation of patient mRNA can 
be valuable to verify pathogenicity of these variants. 
Overlapping phenotype with other patients with (possible) pathogenic variants in the 
same gene  
For interpretation of variants, comparison of clinical features observed in the patient with 
the phenotype associated with the disorder is essential. If the clinical features in the patient 
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1 strongly overlap with those of other patients, the variant is more likely to be pathogenic. 
Conversely, if the phenotype of the patient differs from the clinical spectrum reported in the 
literature, it is less likely that the identified variant is clinically relevant. This criterion is not 
absolute since it is possible that a novel genotype-phenotype correlation is present.
After extensive analysis of WES data, identified variants are classified according to 
appropriate guidelines.85; 86 A diagnostic report with the results and conclusion is written by 
the clinical laboratory specialists and sent to the physician who ordered the test. 
Step 5: Counseling of the patient
Patients and their parents are informed by their physician about the diagnostic findings:
1. A conclusive diagnose is found: a pathogenic (class 5) or likely pathogenic (class 4) variant 
is identified in a gene previously associated with the phenotype of the patient. 
2. A possible diagnosis is reported: a variant of unknown significance (class 3) is present 
in a gene associated with the patient’s phenotype, or a pathogenic variant (class 4 or 
5) is identified in a gene not related to a disorder before. Such variants can be shared 
in matchmaker programs such as Genematcher, Matchmaker exchange (http://www.
matchmakerexchange.org/ ) or PhenomeCentral to find additional patients, and can finally 
lead to the identification of novel NDD genes.87; 88 
3. No diagnosis is identified: no variants that may explain the disorder are observed, or only 
likely benign (class 2) or benign (class 1) variants in known genes are identified. 
Prognostic and therapeutic consequences of the diagnosis should be discussed. This is 
often more difficult for possible diagnoses than for conclusive diagnoses: the novelty of 
the diagnosis is reflected in a lack of knowledge among caregivers. Patients and parents 
experience difficulty in finding information and peer support.26 In addition to the prognostic 
and therapeutic consequences, counseling of the recurrence risk is important. If the variant 
occurred de novo, there is a low recurrence risk for parents to have a second child with the 
same disorder due to germline mosaicism in one of the parents (~0.1-1.3%).89; 90 This risk 
is higher if one of the parents carries the variant in mosaic form90; 91 or for maternal carriers 
of an X-linked variant (50% recurrence risk for male offspring; 50% carrier risk for female 
offspring). Recurrence risk equals the population risk for the estimated 6.5-7.5% of patients 
in whom the mutation occurred post-zygotically.92; 93
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11.4 Diagnostic yield of WES
Studies applying WES to cohorts of patients with NDDs, report an overall diagnostic yield 
of 16%-32% (conclusive diagnosis) and an increase of 4%-24% by adding patients with a 
possible diagnosis.28; 29; 53; 94-100  The diagnostic yield for a conclusive and possible diagnosis 
together ranged between 25% (published in 2013) and 56.6% (published in 2017)53; 96 The 
largest study investigating >4000 individuals with NDDs (2017), reports an estimated 42% 
of patients to carry a pathogenic mutation.33 The increased diagnostic yield over time can 
be explained by improvement in WES techniques and interpretation of variants due to the 
increased use of matchmaker programs and the growing list of genes linked to NDDs.101 In 
addition to SNV analysis, exome-based read-depth CNV screening increases the diagnostic 
yield with ~2%.102 Re-evaluation of WES-data by inspection of recently published literature, 
the use of new bioinformatic pipelines, and critical assessment of the phenotype by a 
medical geneticist, can further increase the diagnostic field of WES further with 4.2% to 
15.4%.103-108 WES is not only effective in children, but also in adults with various forms of 
NDDs: in 27.7% of undiagnosed adults, a diagnosis was found.109 High diagnostic yields are 
also observed in cohorts of abnormal fetuses. Studies report a diagnosis in 24% of deceased 
fetuses and a conclusive or possible diagnosis in 47% of prenatal WES on fetuses with 
developmental anomalies.110-112 Targeted testing using a WES gene panel in probands without 
the availability of DNA from parents (singleton testing) can still be diagnostic although it has a 
lower diagnostic yield (11%).113 
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2.1 The scope of this thesis
With a diagnostic yield up to 50% for patients with unexplained NDDs, WES has proven 
successful as a diagnostic genetic test. It led to the identification of hundreds of novel NDD 
genes, many of which are associated with unique neurodevelopmental syndromes. Still, a 
significant proportion of NDD patients with rare genetic disorders remains undiagnosed. For 
those patients molecularly diagnosed with a NDD that was recently discovered by WES, 
available information on clinical, prognostic and management characteristics is often limited. 
To provide further insight into the genetic, clinical, and biological aspects of NDDs in these 
patients, I aimed in this thesis to (Figure 2.1):  
• Discover rare NDDs by (1) performing WES on large scale, (2) using different approaches 
to interpret WES data, and (3) inclusion of mildly affected patients for WES, a less 
frequently investigated subset of NDD patients.
• Confirm and delineate associated phenotypes of newly identified disorders by (1) using 
matchmaker systems and (inter)national collaborations, and (2) collecting and comparing 
detailed phenotypic data.
• Confirm newly identified disorders and investigate underlying biological mechanisms by 
using functional experiments.
2.2 The outline of this thesis
We established a cohort of 826 patients (56% male; 44% female; median age 8 years 
with interquartile range of 4-16 years) with unexplained ID, defined as the presence of (1) 
deficits in intellectual functioning; (2) deficits in adaptive functioning, and (3) onset during 
developmental period.1 This cohort was composed as a follow-up cohort to previously 
clinically well-defined cohorts (250k SNP array: 1,388 patients19; WES: 10 patients27; WES: 
100 patients28; WGS: 50 patients46). WES was performed in all patients and their parents and 
results were compared with WES results of patients with NDDs who were sequenced in other 
(inter)national centers. For 783 patients (95%) of our cohort, additional detailed clinical data 
were available. 
Cohort (Figure 2.2)
Neurodevelopmental profile
ID was present in all patients and severity varied: 28.0% had mild ID, 20.7% had moderate 
ID, 28.2% had severe ID. For the remaining 23.1%, severity scoring was not performed 
or not possible due to the young age of the patient. In 32.2% of the patients, behavioral 
problems such as NDD subtypes ASD and ADHD were reported. Information on diagnoses of 
the NDD subtypes CM, SLD, or MD was generally not available.
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Figure 2.2: Overview of observed clinical features in the cohort presented in this thesis 
  
Clinical features
The majority of patients (739/783, 94%) had at least one additional feature. The most 
frequent co-morbid features were neurological problems: epilepsy (24.5%), hypotonia 
(20.3%), brain abnormalities (19.8%), spasticity (7.0%), cerebral visual impairment (4.7%) or 
hypertonia (3.2%). Other frequently observed features included gastrointestinal abnormalities 
(23.1%), eye abnormalities (22.3%), skeletal abnormalities (14.7%), urogenital malformations 
(9.9%), cardiac malformations (7.4%), and cleft lip and/or palate (2.1%). Growth was 
abnormal in 38.6% of the patients: 16.9% had abnormal height (13.9% short stature and 
3.0% tall stature), 14.1% had abnormal weight (6.1% low weight and 8.0% obesity), and 
20.7% had aberrant head circumference (6.4% macrocephaly and 14.3% microcephaly). The 
observed frequencies of these features were comparable to previously described cohorts of 
patients with ID or NDDs.18; 19; 28
Results 
Interesting findings of WES in this cohort, combined with results of matchmaking, clinical 
evaluation and functional experiments, are reported in Chapter 3 – 11.
In Chapter 3, we report the identification of candidate ID and NDD genes, by statistical 
meta-analysis of de novo mutations from exome data of patients in our cohort and de 
novo mutations in patients with ID (2,104 patients) or other NDD subtypes (4,102 patients) 
published in the literature. These analyses resulted in the discovery of ten candidate ID genes 
and showed us that there is considerable overlap between patients with ID and patients with 
other subtypes of NDDs. 
In the next three chapters, we further investigated three novel candidate ID and NDD 
genes: SON, TLK2 and RAC1. We compared detailed phenotype data of patients with 
de novo mutations in these genes and performed different types of functional studies to 
investigate underlying disease mechanisms. In Chapter 4, we report that 20 patients with 
de novo mutations in SON, have a severe developmental phenotype and malformations 
of the brain cortex. At a cellular level, we showed that mutations in SON led to disturbed 
splicing of downstream target genes, partly explaining the phenotype observed in the 
patients. In Chapter 5, a large number of individuals (n=40), mostly selected through 
international matchmaking, are reported to have autosomal dominant mutations in TLK2. 
The developmental spectrum of patients with a mutation in this gene is mild and comprises 
a broader NDD spectrum. The large number of patients enabled us to define this clinical 
spectrum in detail. Chapter 6 describes specific de novo missense mutations in the small 
GTPase RAC1 in seven patients. Patients with this novel syndrome show remarkable 
differences in head size. Using mouse fibroblasts and zebrafish as model systems, we 
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provide more insight in the underlying mechanisms of the observed phenotypic differences 
between patients. 
In Chapter 7, de novo mutations in WES data of our patient cohort are analyzed using a 
pathway approach. Genes related to the mTOR pathway were selected and evaluated for 
the presence of de novo mutations. We show that the majority of patients with mutations 
in this pathway have a large head circumference: macrocephaly occurs significantly more 
frequently than in patients without an mTOR-related mutation. In line with this observation, 
we report that the same set of mTOR-related genes significantly contributes to intracranial 
volume in the general population. Finally, we describe three patients with severe ID, epilepsy 
and macrocephaly with mutations in the mTOR activator RHEB, and show in zebrafish and 
mouse models that these clinical features reflect altered mTOR pathway activity. In Chapter 
8, we report two specific missense mutations in the RAB11B small GTPase in five unrelated 
patients and a similar brain phenotype. Functional studies further support the pathogenicity 
of these two recurrent mutations. Chapter 9 describes the discovery of a distinct NDD 
syndrome in females, caused by de novo loss-of-function mutations in the X-linked gene 
USP9X. Females with this syndrome have a variety of congenital malformations and brain 
malformations. We show the recognizability of the syndrome by expanding the initial cohort 
of 13 patients, established by extensive international collaborations, with four patients 
identified through targeted testing. Chapter 10 reports on 10 de novo loss-of-function 
mutations in WAC, collected through searches in matchmaking databases and (inter)national 
collaborations. WAC haploinsuffiency causes a NDD syndrome and partially explains the 
phenotype observed in patients with 10p12p11 microdeletions. We also show that loss-of-
function of WAC in Drosophila leads to learning difficulties, similar to patients. In Chapter 11, 
we delineate the clinical spectrum of the recently discovered PURA syndrome, caused by de 
novo mutations in PURA. In total, we collected clinical data for 32 patients from 24 different 
diagnostic centers in nine different countries. A genotype-phenotype analysis revealed that 
the disease severity is not related to the type and position of the mutation.
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Meta-analysis of 2,104 trios provides 
support for 10 new genes for intellectual 
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Figure 3.1: Genes enriched for LoF and functional DNMs in a cohort of 2,104 ID 
trios from multiple studies. 
The y axis shows the −log10-transformed, corrected P-value of the DNM 
enrichment as listed in Table 1. Corrected P-values based on LoF mutations 
are blue and corrected P-values based on functional mutations are green. Only 
genes with corrected P-values (LoF, functional, or both) less than the significance 
threshold (red dotted line, 0.05) are shown.
Figure 3.2: TLK2 protein (Q86UE8) with DNMs localized to the serine/threonine 
catalytic domain.
Two individuals in the RUMC cohort were found to have a DNM in TLK2; they 
showed overlapping clinical features including facial dysmorphisms (Supplemental 
Note).
Abstract
To identify candidate genes for intellectual disability, we performed a meta-analysis on 2,637 
de novo mutation , id ntified from the exomes of 2,104 patient–parent rios. Statistical 
a alyses identified 10 new candidate ID genes: DLG4, PPM1D, RAC1, SMAD6, SON, SOX5, 
SYNCRIP, TCF20, TLK2 and TRIP12. In a dition, we show tha  these genes ar  intolerant 
to onsynonymous variation and that mutations in these genes are associated with spe ific 
clinical ID ph notypes. 
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Report
Intellectual disability (ID) and other neurodevelopmental disorders are in part due to de novo 
mutations affecting protein-coding genes.31; 40; 46; 114 Large scale exome sequencing studies 
of patient–parent trios have efficiently identified genes enriched for de novo mutations in 
cohorts of individuals with ID compared to controls31 or on the basis of expected gene-
specific mutation rates.32
Here we sequenced the exomes of 820 patients with ID and their parents as part of routine 
genetic testing at the Radboud University Medical Center (RUMC) in the Netherlands. We 
identified 1,083 de novo mutations (DNMs) in the coding and canonical splice site regions 
affecting 915 genes (Supplemental Tables 3.1 and 3.2 and Supplemental Figures 3.1–3.4). In 
our cohort we detected an increased number of loss-of-function (LoF) mutations compared 
to controls (Fisher’s exact test, P = 9.38 × 10−12; Methods) and enrichment for recurrent 
gene mutations (observed versus expected, P < 1 × 10−5; Supplemental Figure 3.5).
Using an established framework of gene specific mutation rates,115 we calculated for each 
gene the probability of identifying the observed number of LoF or functional DNMs in our 
cohort (Methods). To validate this approach we first performed the analysis on the complete 
set of 820 ID patients. After Benjamini–Hochberg correction for multiple testing, 18 well-
known ID-associated genes were significantly enriched for DNMs (Supplemental Tables 3.3 
and 3.4). To optimize our analysis for the identification of new candidate genes in the RUMC 
cohort, we excluded all individuals with mutations in any of the known ID genes (Material 
and methods and Supplemental Figure 3.6). Repeating the analysis for mutation enrichment, 
we identified four genes (DLG4, PPM1D, SOX5 and TCF20) that were not, to our knowledge, 
previously associated with ID and that were significantly enriched for DNMs in our cohort 
(Figure 3.1, Table 3.1 and Supplemental Table 3.5). To achieve the best possible power for 
the identification of candidate ID genes, we next added data from four previously published 
family-based sequencing studies (Supplemental Table 3.1). The combined cohort included 
2,104 patient–parent trios and 2,637 DNMs across 1,990 genes. After again excluding 
individuals with mutations in known ID genes, this cohort consisted of 1,471 individuals with 
1,400 DNMs in 1,235 genes (Material and methods and Supplemental Figure 3.6). Meta-
analysis on this combined cohort identified ten candidate ID genes with more LoF DNMs or 
more functional DNMs than expected a priori. These ten genes included the four candidate 
ID genes previously identified in the RUMC cohort, as well as RAC1, SMAD6, SON, TLK2, 
TRIP12 and SYNCRIP (Figure 3.1, Table 3.1 and Supplemental Table 3.6).
To further evaluate the identification of the ten candidate ID genes, we compared the 
phenotypes of the 18 RUMC individuals with DNMs in these genes. We observed strong 
phenotypic overlap for some of these genes (Figure 3.2, Supplemental Table 3.7 and 
Supplemental Note). Additional genes that were close to statistical significance, such as 
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Table 3.1 Candidate ID genes
Gene RUMC cohort ID cohort Gene description
LoF Functional LoF Functional
DLG4
NM_001365.3
q 1.13E-04 0.086 7.69E-06 8.02E-04 Required for synaptic plasticity 
associated with NMDA receptor 
signaling. Depletion of DLG4 changes the 
ratio of excitatory to inhibitory synapses 
in hippocampal neurons.
p 6.56E-09 7.50E-06 2.24E-10 4.66E-08
c (n=3) (n=3) (n=4) (n=5)
PPM1D
NM_003620.3
q 0.047 0.764 8.22E-04 0.174 Ser/Thr phosphatase which mediates a 
feedback regulation of p38-p53 signaling 
thereby contributing to growth inhibition 
and suppression of stress induced 
apoptosis.
p 5.45E-06 2.56E-04 9.57E-08 3.03E-05
c (n=2) (n=2) (n=3) (n=3)
RAC1
NM_018890.3
q
n.d.
0.217
n.d.
0.020 Plasma membrane-associated small 
GTPase involved in many cellular 
processes. In the synapses, it mediates 
the regulation of F-actin cluster formation 
by SHANK3.
p 3.80E-05 1.75E-06
c (n=2) (n=3)
SMAD6
NM_005585.4
q
n.d. n.d.
0.037 1 Mediates TGF-beta activity and the 
BMP-SMAD1 signaling. Functions as a 
transcriptional co-repressor.
p 8.29E-06 7.50E-04
c (n=2) (n=2)
SON
NM_138927.1
q 1 1 0.003 1 Component of the spliceosome that 
plays pleiotropic roles during mitotic 
progression. Functions in efficient 
cotranscriptional RNA processing.
p 0.086 0.005 4.12E-07 1.67E-03
c (n=1) (n=1) (n=3) (n=3)
SOX5
NM_006940.4
q 0.016 1 0.038 0.216 Member of Transcription factors that 
regulate embryonic development. Plays 
a critical role in neuronal progenitor 
development by regulating the timing of 
differentiation.
p 1.39E-06 3.98E-04 8.79E-06 5.83E-05
c (n=2) (n=2) (n=2) (n=3)
SYNCRIP
NM_006372.4
q 1 1 0.028 1 Heterogeneous nuclear ribonucleoprotein 
(hnRNP) functioning in the CRD-
mediated mRNA stabilization complex 
and the SMN complex, and the apoB 
RNA editing-complex.
p 0.001 0.019 4.94E-06 1.24E-03
c (n=1) (n=1) (n=2) (n=2)
TCF20
NM_005650.1
q 6.22E-06 0.035 1.24E-04 0.174 Transcriptional activator of matrix 
metalloproteinase 3 and (co)activator of 
various other transcriptional activators.
p 1.81E-10 1.00E-06 7.21E-09 3.71E-05
c (n=4) (n=4) (n=4) (n=4)
TLK2
NM_005650.1
q 0.100 1 0.347 5.86E-04 Ser/Thr kinase regulating chromatin 
assembly. Involved in DNA replication, 
transcription, repair and chromosome 
segregation.
p 1.44E-05 4.20E-04 9.09E-05 1.70E-08
c (n=2) (n=2) (n=2) (n=5)
TRIP12
NM_001284214.1
q 0.273 1 2.35E-04 0.174 E3 ubiquitin-protein ligase involved in 
ubiquitin fusion degradation pathway. 
Guards excessive spreading of 
ubiquitinated chromatin at damaged 
chromosomes in DNA repair.
p 5.55E-05 0.003 2.05E-08 4.05E-05
c (n=2) (n=2) (n=4) (n=4)
All genes listed reached statistical significance after Benjamini–Hochberg correction for enrichment of functional and/or 
LoF DNM in the RUMC or ID cohort. For each gene the Benjamini–Hochberg corrected P-value (q), uncorrected P-value 
(p) and raw counts (c) are shown. Significant Benjamini–Hochberg-corrected P-values are depicted in bold. n.d. (not 
defined) indicates genes without observed DNMs in the RUMC or ID cohort.
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SETD2, show phenotypic similarities suggestive of a shared genetic cause consistent with 
previous case reports (Supplemental Figure 3.7 and Supplemental Note).116; 117
Studies have shown that genes involved in genetic disorders exhibit strongly reduced 
tolerance to nonsynonymous genetic variation compared to non-disease-associated genes. 
This is particularly evident for ID.46 We found that a large set of well-known dominant ID 
genes (n = 444), along with the ten candidate ID genes, are highly intolerant of LoF variation71 
(median probability of being LoF-intolerant (pLI) of 0.95, P < 1 × 10−5 and median pLI 
of 0.99, P < 1 × 10−5, respectively; Material and methods, Supplemental Figure 3.8 and 
Supplemental Table 3.8). We noted that those ID genes that harbor only missense variants 
(‘missense-only’ genes) are among the most intolerant ID genes (median pLI of 0.99, P < 1 
× 10−5; Supplemental Figure 3.8). Additionally, we found that mutations in missense-only 
genes are more likely to cluster than mutations in genes for which we also identified LoF 
mutations (P = 0.01, Fisher’s exact test; Material and methods and Supplemental Table 3.9). 
There is considerable overlap of genes and molecular pathways involved in 
neurodevelopmental disorders (NDDs), such as autism spectrum disorder, schizophrenia, 
epileptic encephalopathy and ID.45 Therefore, we performed a third analysis including 12 
published family-based sequencing studies of various NDDs (Supplemental Table 3.1 and 
Supplemental Figure 3.6). Repeating our analysis in this NDD cohort, we identified seven 
genes significantly enriched for either LoF or functional DNMs (Supplemental Figure 3.9 and 
Supplemental Table 3.10). In line with our hypothesis, five of these identified genes were also 
identified in our previous analyses with individuals with ID only, whereas two genes (SLC6A1 
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Intellectual disability (ID) and other neurodevelopmental disor-
ders are in part due to de novo mutations affecting protein-coding 
genes1–4. Large scale exome sequencing studies of patient–parent trios 
have efficiently identified genes enriched for de novo mutations in 
cohorts of individuals with ID compared to controls2 or on the basis 
of expected gene-specific mutation rates5.
Here we sequenced the exomes of 820 patients with ID and their 
parents as part of routine genetic testing at the Radboud University 
Medical Center (RUMC) in the Netherlands. We identified 1,083 
de novo mutations (DNMs) in the coding and canonical splice site 
regions affecting 915 genes (Supplementary Tables 1 and 2 and 
Supplementary Figs. 1–4). In our cohort we detected an increased 
number of loss-of-function (LoF) mutations compared to controls 
(Fisher’s exact test, P = 9.38 × 10−12; Online Methods) and enrichment 
for recurrent gene mutations (observed versus expected, P < 1 × 10−5; 
Supplementary Fig. 5).
Using an established framework of gene specific mutation rates6, 
we calculated for each gene the probability of identifying the observed 
number of LoF or functional DNMs in our cohort (Online Methods). 
To validate this approach we first performed the analysis on the com-
plete set of 820 ID patients. After Benjamini–Hochberg correction for 
multiple testing, 18 well-known ID-associated genes were significantly 
enriched for DNMs (Supplementary Tables 3 and 4). To optimize 
our analysis for the identification of new candidate genes in the 
RUMC cohort, we excluded all individuals with mutations in any of 
the known ID genes (Online Methods and Supplementary Fig. 6). 
Repeating the analysis for mutation enrichment, we identified four 
genes (DLG4, PPM1D, SOX5 and TCF20) that were not, to our 
knowledge, previously associated with ID and that were significantly 
enriched for DNMs in our cohort (Fig. 1, Table 1 and Supplementary 
Table 5). To achieve the best possible power for the identification of 
candidate ID genes, we next added data from four previously pub-
lished family-based sequencing studies (Supplementary Table 1). 
The combined cohort included 2,104 patient–parent trios and 
2,637 DNMs across 1,990 genes. After again excluding individuals 
with mutations in known ID genes, this cohort consisted of 1,471 
individuals with 1,400 DNMs in 1,235 genes (Online Methods and 
Supplementary Fig. 6). Meta-analysis on this combined cohort iden-
tified ten candidate ID genes with more LoF DNMs or more func-
tional DNMs than expected a priori. These ten genes included the 
four candidate ID genes previously identified in the RUMC cohort, 
as well as RAC1, SMAD6, SON, TLK2, TRIP12 and SYNCRIP (Fig. 1, 
Table 1 and Supplementary Table 6).
To further evaluate the identification of the ten candidate ID genes, 
we compared the phenotypes of the 18 RUMC individuals with DNMs 
in these genes. We observed strong phenotypic overlap for some of 
these genes (Fig. 2, Supplementary Table 7 and Supplementary Note). 
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To identify candidate genes for intellectual disability, we 
performed a meta-analysis on 2,637 de novo mutations, 
identified from the exomes of 2,104 patient–parent trios. 
Statistical analyses identified 10 new candidate ID genes: 
DLG4, PPM1D, RAC1, SMAD6, SON, SOX5, SYNCRIP, 
TCF20, TLK2 and TRIP12. In addition, we show that these 
genes are intolerant to nonsynonymous variation and that 
mutations in these genes are associated with specific clinical 
ID phenotypes. 
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Figure 1 Genes enriched for LoF and functional DNMs in a cohort of 2,104 
ID trios from multiple studies. The y axis shows the −log10-transformed, 
corrected P-value of the DNM enrichment as listed in Table 1. Corrected  
P-values based on LoF mutations are blue and corrected P-values based  
on functional mutations are green. Only genes with corrected P-values  
(LoF, functional, or both) less than the significance threshold (red dotted 
line, 0.05) are shown.
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Figure 3.1: Genes enriched for LoF and functional DNMs in a cohort of 2,104 ID trios from multiple studies. 
The y axis shows the −log10-transformed, corrected P-value of the DNM enrichment as listed in Table 1. Corrected 
P-values based on LoF mutations are blue and corrected P-values based on functional mutations are green. Only genes 
with corrected P-values (LoF, functional, or both) less than the significance threshold (red dotted line, 0.05) are shown.
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and TCF7L2) only reached significance in the NDD meta-analysis as a result of additional 
mutations in patients with phenotypes other than ID (Supplemental Table 3.11). Specifically, 
for two of the five candidate ID genes (TLK2 and TRIP12) additional DNMs were identified 
in individuals with autism spectrum disorder and schizophrenia, suggesting that DNMs in 
these genes may lead to a broader phenotype than ID alone. For TRIP12, a similarly broad 
phenotype has been reported previously.114
In summary, we identified ten candidate ID genes via a meta-analysis of whole exome 
sequencing data on 2,104 ID trios. The statistical framework used here differs from other 
methods based on gene-specific mutation rates by removing all trios with mutations in 
known disease genes and by applying Benjamini–Hochberg correction for multiple testing. 
Our study underscores the impact of DNMs on a continuum of neurodevelopmental 
phenotypes that impinge on a broad range of processes, including chromatin modifiers 
(TRIP12 and TLK2), Fragile X Mental Retardation Protein (FMRP) target and synaptic 
plasticity genes (DLG4; Supplemental Figure 10) and embryonically expressed genes 
(PPM1D and RAC1).31 Data from a similar systematic study of DNMs in neurodevelopmental 
disorders suggest that many, and possibly most, genes whose DNM causes severe 
developmental disorders are now known.33 Yet only TCF20 and PPM1D are shared between 
the 10 candidate genes in our study and the 14 genes identified by McRae et al.33 Thus, a 
large number of rare dominant developmental disorder genes may remain to be identified. 
Material and methods
Recruitment of individuals with ID
The Department of Human Genetics from the Radboud University Medical Center 
(RUMC) is a tertiary referral center for clinical genetics. Approximately 350 individuals 
with unexplained intellectual disability (ID) are referred annually to our clinic for diagnostic 
evaluation. Since September 2011 whole exome sequencing (WES) has been part of the 
routine diagnostic work-up aimed at the identification of the genetic causes underlying 
disease.118 For individuals with unexplained ID, a family-based WES approach is used which 
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Figure 2 TLK2 protein (Q86UE8) with DNMs 
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domain. Two individuals in the RUMC cohort 
were found to have a DNM in TLK2; they 
showed overlapping clinical features including 
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statistical framework used here differs from other methods based on 
gene-specific mutation rates by removing all trios with mutations in 
known disease genes and by applying Benjamini–Hochberg correc-
tion for multiple testing. Our study underscores the impact of DNMs 
on a continuum of neurodevelopmental phenotypes that impinge on 
a broad range of processes, including chromatin modifiers (TRIP12 
and TLK2), Fragile X Mental Retardation Protein (FMRP) target and 
synaptic plasticity genes (DLG4; Supplementary Fig. 10) and embry-
onically expressed genes (PPM1D and RAC1)2. Da  from a similar 
systematic study of DNMs in neurodevelopmental dis rders suggest 
that many, and possibly most, genes whose DNM causes severe devel-
opmental disorders are now known11. Yet only TCF20 and PPM1D are 
shared between the 10 candidate genes in our study and the 14 genes 
identified by McRae et al.11. Thus, a large number of rare dominant 
developmental disorder genes may remain to be identified.
METHODS
Methods, including statements of data availability and any as ociated 
accession codes and references, are available in the online version of 
the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Figure 3.2: TLK2 protein (Q86UE8) with DNMs localized to the serine/threonine catalytic domain.
Two individuals in the RUMC cohort were found to have a DNM in TLK2; they showed overlapping clinical features 
including facial dysmorphisms (Supplemental Note).
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allows the identification of DNMs as well as variants segregating according to other types 
of inheritance, including recessive mutations and maternally inherited X-linked recessive 
mutations in males.28 For this study, we selected all individuals with ID who had family-
based WES using the Agilent SureSelect v4 enrichment kit combined with sequencing on 
the Illumina HiSeq platform in the time period 2013–2015. This selection yielded a set of 820 
individuals, including 359 females and 461 males. The level of ID ranged between mild (IQ 
50–70) and severe–profound (IQ <30).
Families gave informed consent both for the diagnostic procedure and for forthcoming 
research that could result in the identification of new genes underlying ID by meta-analysis, 
as presented here. Explicit consent for photo-publication was sought and granted by a 
subset of families.
Diagnostic whole exome sequencing
The exomes of 820 patient–parent trios were sequenced, using DNA isolated from blood, at 
the Beijing Genomics Institute (BGI) in Copenhagen. Exome capture was performed using 
Agilent SureSelect v4 and samples were sequenced on an Illumina HiSeq instrument with 
101-bp paired-end reads to a median coverage of 75×. Sequence reads were aligned to the 
hg19 reference genome using BWA version 0.5.9-r16. Variants were subsequently called 
by the GATK unified genotyper (version 3.2-2) and annotated using a custom diagnostic 
annotation pipeline. Base-pair resolution coverage of the regions enriched by the SureSelect 
V4 kit were computed by BEDTools based on the regions as provided by the manufacturer. 
An average of 98.9% of Agilent SureSelect V4 enriched targets was covered by 10 or more 
reads for the RUMC cohort of 820 ID patients (Supplemental Figure 3.1).
Identification of DNMs in 820 individuals with ID
The diagnostic WES process as outlined above only reports (de novo) variants that can be 
linked to the individuals’ phenotypes. In this study, we systematically collected all DNMs 
located in the coding sequence (RefSeq) and/or affected canonical splice sites (canonical 
dinucleotides GT and AG for donor and acceptor sites;  Supplemental Figure 3.4), as 
identified in the 820 individuals with ID irrespective of their link to disease, to evaluate the 
potential relevance of genes for ID in an unbiased fashion using a statistical framework. 
DNMs were called as described previously.28 Briefly, variants called within parental samples 
were removed from the variants called in the child. For the remaining variants, pileups were 
generated from the alignments of the child and both parents. Based on pileup results, 
variants were then classified into the following categories: ‘maternal’ (identified in the mother 
only), ‘paternal’ (identified in the father only), ‘low coverage’ (insufficient read depth in either 
parent), ‘shared’ (identified in both parents) and ‘possibly de novo’ (absent in the parents). 
Variants classified as possibly de novo were included in this study.
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We applied various quality measures to ensure that only the most reliable variant calls were 
included in the study: (i) all samples had fewer than 25 possibly de novo calls; (ii) each 
variant had at least 10× coverage in either parent (for example, high prior probability of being 
inherited); (iii) the location was not in dbSNP version137 (for example, a possible highly 
mutable genomic location) and (iv) each variant was called in a maximum of 5 samples in our 
in-house variant database (which eliminated variants that occur too frequently to be disease-
causing given the incidence of ID in combination with the sample size of our in-house 
database); (v) each variant showed a variant read percentage >30%, or alternatively, >20% 
with >10 individual variant reads; and (vi) each variant had a GATK quality score of >400. 
For de novo variants called within a 5-bp window of each other within the same individual, 
variant calls were manually curated and merged into a single call (when occurring on the 
same allele). This set of criteria resulted in the identification of 1,083 potential DNMs in 820 
individuals with ID.
Validation and categorization of DNMs
In a separate (unpublished) in-house study, we recently determined the predictive value for 
GATK quality scores in terms of the variant being validated by Sanger sequencing. A set of 
840 variants called by the same version of GATK was retrospectively analyzed for the quality 
scores and validation statuses of each variant in the set. Based on this assessment, we 
determined that a GATK quality score ≥500 resulted in 100% of variants being validated by 
Sanger sequencing (data not shown). In addition to our in-house study, two other studies 
also found 100% Sanger validation rates for variants with GATK quality scores of ≥500.67 
Based on these results, we considered all variants with a GATK Q-score of ≥ 500 (n = 1,039) 
to be true DNMs. Nonetheless, a random set of 141 potential DNMs with GATK Q-scores 
of ≥500 were all confirmed by Sanger sequencing. All potential de novo variants with GATK 
Q-scores between 400 and 500 (n = 40) were subsequently validated by Sanger sequencing, 
and all were confirmed. All 20 DNMs of the reported candidate genes were confirmed by 
Sanger sequencing (Supplemental Table 3.2 and Supplemental Figures 3.2-3.4).
For further downstream statistical analysis (see below), DNMs were categorized by mutation 
type: (i) LoF DNM (n = 211), including nonsense (n = 77), frameshift (n = 97), canonical splice 
site (n = 27), start loss (n = 2), stop loss (n = 1) and premature stop codon resulting from an 
indel (n = 7); and (ii) functional DNM (n = 872), including all LoF mutations (n = 211), in-frame 
insertion/deletion events (n = 23) and all missense mutations (n = 638) (Supplemental Figure 
3.4). For variants within the same individual and within the same gene but more than 5 bp 
apart, the variant with the most severe functional effect was considered for the per-gene 
statistics (see below).
Evaluating the number of recurrently LoF and functional de novo mutated genes
We simulated the expected number of recurrently mutated genes by redistributing the 
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observed number of mutations at random over all genes based on their specific LoF and 
functional mutation rates (see “Statistical enrichment of DNMs” below) as described 
by Samocha et al.115 Based on results from 100,000 simulations, we calculated how 
many times the number of recurrently mutated genes was the same as or exceeded the 
observed number of recurrently mutated genes in the RUMC data set. We performed these 
simulations separately for LoF and functional DNMs (Supplemental Figure 3.5). P-values 
were then calculated by taking the number of times the number of recurrently mutated genes 
exceeded the observed number of recurrently mutated genes and dividing by the number 
of simulations. In addition, z-values were computed by subtracting the mean value of the 
simulations from the observed value and dividing by the s.d. of the simulations.
Genes previously implicated in ID etiology
To evaluate whether the genes identified by our meta-analyses had been previously 
implicated in ID, we used two publicly available repositories of genes known to be involved 
in ID. First, we used our list of 707 genes, routinely used by our diagnostic setting to 
interpret WES results of individuals with ID.119 Second, we downloaded a list of 1,424 genes 
associated with developmental disorders from the DDG2P database (http://www.ebi.ac.uk/
gene2phenotype/gene2phenotype-webcode/cgi-bin/handler.cgi#); the list was compiled and 
curated by clinicians as part of the Deciphering Developmental Disorders (DDD) study to 
facilitate clinical feedback of likely causal variants.32 In total the two lists compromised 1,537 
unique genes. In this manuscript, the list of unique gene entries is referred to as “known ID 
genes” (Supplemental Table 3.4).
Statistical enrichment of DNMs
In our meta-analysis for ID and neurodevelopmental disorders we only included studies with 
minimum of 50 trios. For each gene, and each of the functional classes (LoF and functional), 
we used the corresponding gene-specific mutation rate (GSMR) as published by Samocha 
et al.115 to calculate the probability of the number of identified DNMs in our cohort. For genes 
for which no GSMR was reported, we used the maximum GSMR of all reported genes (i.e., 
the GSMR of the gene TTN). We then calculated specific mutation rates for the two defined 
functional classes (LoF, functional). The GSMR for LoF DNMs was calculated by summing the 
individual GSMR for nonsense, splice site and frameshift variants; the GSMR for functional 
DNMs was calculated by summing the GSMR for the LoF variants with the missense 
mutation rate; and for genes for which variants from different functional classes were 
identified, we used the overall GSMR. For the stop-loss and start-loss mutations we used the 
LoF-rate and for in-frame indels, the functional rate. Null hypothesis testing was done using a 
one-sided exact Poisson test based on a sample size of 820 individuals with ID, representing 
1,640 alleles for autosomal genes and 1,179 alleles for genes on the X chromosome (461 
males).
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For DNMs on chromosome X the correct mutation rate depends on the patient’s gender as 
the mutation rate for fathers is higher than for mothers. Estimates show a 4:1 ratio of paternal 
to maternal DNMs.120 Hence, male offspring, receiving their chromosome X exclusively from 
the mother, have therefore a lower mutation rate on chromosome X than estimated by the 
GSMR. This correction could, however, only be performed for the RUMC cohort, as gender 
information was not available for all studies included in the ID cohort. Notably, not correcting 
for this bias in male individuals for DNM in genes on the X chromosome will lead to less 
significant P-values for genes on the X chromosome, thereby potentially underestimating the 
significance of candidate ID genes located on the X chromosome. When a patient was found 
to have two DNMs in the same gene we ignored one of the two DNMs for the statistical 
enrichment analysis to avoid false positive results. In such cases the severity of the DNM 
protein effect was a factor in the choice of which DNM to ignore. For example, if a patient 
had one missense and one nonsense DNM in the same gene, the missense mutation was 
ignored in the statistical analysis.
Gene specific P-values were corrected for multiple testing based on the 18,730 genes 
present in the Agilent V4 exome enrichment kit times the number of tests (2), using the 
Benjamini–Hochberg procedure with an FDR of 0.05. In our cohort of 820 individuals with ID, 
conclusive diagnoses were already made based on DNMs in genes previously implicated in 
disease. The use of a multiple testing correction with a FDR of 0.05, in combination with a 
potential large number of DNMs in known ID genes, may artificially increase the significance 
of other genes because of an increasingly lenient correction for the least significant genes.121 
To verify that the identification of candidate ID genes was not inflated by this effect, we 
performed the analysis after removing all individuals with a DNM in one of the known 
genes (potential other DNMs in such individuals were also removed for further analysis). 
Incidentally, this also increased our statistical power. The mode of inheritance was not taken 
into account when removing individuals with a DNM in a known gene (for example, samples 
with a DNM in a recessive gene were excluded). This correction left 584/820 individuals 
with ID in the RUMC cohort, with 627 DNMs across 584 genes. Similarly, for the ID and 
neurodevelopmental cohort, we removed all individuals with a DNM in a known ID gene (and 
other DNMs in these individuals). For the ID cohort, 1,471 samples remained with 1,400 
DNMs in 1,235 genes. For the neurodevelopmental cohort, 4,944 samples remained with 
4,387 DNM across 3,402 genes (for a complete overview see Supplemental Figure 3.6). We 
corrected for testing 34,386 genes (i.e., all 18,730 genes minus the 1,537 known ID genes 
multiplied by 2 for testing the LoF and functional categories).
Validation of the statistical approach by analysis of DNMs in a control cohort
To further confirm the validity of our statistical approach, we applied the same analyses 
to a set of DNMs identified in trios of healthy individuals and unaffected siblings. For this 
purpose, we downloaded and reannotated all DNMs identified in 1,911 unaffected siblings 
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of individuals with ASD from Iossifov et al.31 together with DNMs in controls (Supplementarl 
Table 3.12). In total the control set contained 2,019 coding DNMs found in 2,299 trios. 
Notably, the protein coding DNM rate in the control cohort was markedly lower than that 
observed in the individuals with ID (0.91 DNMs versus 1.32 DNMs, respectively). Additionally, 
we observed no significant enrichment of recurrently mutated genes for LoF or functional 
mutations (P = 0.60 and P = 0.12, respectively; Supplemental Figure 3.11).
For the control cohort we performed statistical analyses as described above and identified 
only one gene that was significantly enriched in functional DNMs. For YIF1A (FDR corrected 
P = 0.01) we identified a total of 3 missense DNMs and 1 frameshift DNM (Supplemental 
Tables 3.13 and 3.14). YIF1A may be involved in transport between the endoplasmic 
reticulum and the Golgi, and it has a pLI of 2.08 × 10−8 indicating this gene is a LoF-tolerant 
gene. We note that the control cohort consists mostly of healthy siblings from individuals with 
ASD, and, as such, may still have minor enrichments for mutations that lead to susceptibility 
to neurodevelopmental disorders.
Increased number of LoF mutations in RUMC cohort compared to controls
To reduce the impact of the enrichment kit used in the control set studies and RUMC cohort, 
we computed the intersection of all enrichment kits (Agilent SureSelect 37Mb - Agilent 
SureSelect 50Mb - Agilent SureSelect V4 - Nimblegen SeqCap V2; Supplemental Table 3.12) 
using the “intersect” function of BEDTools. Only the LoF DNMs present in the 28,189,737-
Mb intersection of the four enrichment kits were used in the analysis. The Fisher’s exact 
test on the enrichment kits normalized LoF DNMs yielded a significant difference with P = 
9.38 × 10−12 (RUMC: 157 LoF DNMs of a total of 805 DNMs; controls: 137 LoF DNMs of a 
total of 1,485 DNMs; OR = 2.38; CI: 1.85–3.07). The coverage and other relevant technical 
information of the control studies are listed in Supplemental Table 3.12. We note it is 
important to consider the coverage and false negative rates of all sequencing studies. So far, 
only a single study has attempted to provide a false negative rate (for example, mutations 
that are there but were not identified) for exome sequencing, and this was predicted to be 
<5%.31
Attributing pLI for all protein coding genes
To determine the intolerance to LoF variation for each gene, we used the probability of LoF 
intolerance (pLI), which is based on data from the Exome Aggregation Consortium (ExAC) 
version 0.3.1, providing exome variants from 60,706 unrelated individuals.71 The pLI is based 
on the expected versus observed variant counts to determine the probability that a gene is 
intolerant to LoF variants and is computed for a total of 18,226 genes. The closer a pLI is 
to 1, the more intolerant a gene is to LoF variants. The authors consider a pLI ≥ 0.9 as an 
extremely LoF-intolerant set of genes. The pLIs for the genes used in this study can be found 
in Supplemental Table 3.8. Intolerance to LoF variation was evaluated for the available pLIs 
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of four gene sets: (1) 170 LoF-tolerant (LoFT) genes,122 (2) 404 housekeeping genes, involved 
in crucial roles in cell maintenance,123 (3) 1,359 genes with functional DNMs from the healthy 
control data set (Supplemental Table 3.14), and (4) 444 well-known dominant ID genes 
(Supplemental Table 3.4).
Gene set based evaluation of pLI
We evaluated the pLI by computing the expected median pLI for each gene set based on 
randomly drawing n pLI values from the complete set of 18,226 pLI annotated genes and 
calculating the median (where n is the number of genes in the gene set). By repeating this 
random sampling process 100,000 times, we computed the likelihood of the observed 
median pLI of a gene set compared to the expected median pLI by calculating the empirical 
P-value:
where m is the median pLI of one simulation, mobserved is the observed median pLI and N 
is the total number of performed simulations (N = 100,000). In addition, the z-values were 
computed as described in the section “Evaluating the number of recurrently LoF and 
functional de novo mutated genes.”
Based on the simulations we identified a significantly lower median pLI for the LoFT genes, 
which is in line with the LoFT nature of this gene set (observed 9.33 × 10−9 distribution 
simulations: μ = 0.04, σ = 0.03; empirical P < 1 × 10−5; z = 1.25). For the healthy control 
set, the observed median pLI matched the simulated distribution of median pLI (observed 
0.03; distribution simulations: μ = 0.03, σ = 0.01; empirical P = 0.31; z = 0.39). For the 
housekeeping and dominant ID gene sets, the observed median pLI was significantly 
higher than the simulated distribution of median pLI (HK genes: observed: 0.87; simulated 
distribution: μ = 0.03, σ = 0.02; empirical P < 1 × 10−5; z = 54.05 and dominant ID genes: 
observed: 0.95; simulated distribution: μ = 0.03, σ = 0.01; empirical P < 1 × 10−5; z = 61.54). 
In addition, the median pLI of the housekeeping gene approximated (median pLI = 0.87) 
and the dominant ID gene set (median pLI = 0.95) surpassed the extremely LoF-intolerant 
threshold of 0.9, which is in line with the LoF-intolerant nature of housekeeping and dominant 
ID genes (Supplemental Figure 3.12).
The set of ten novel candidate ID genes has a median pLI of 0.99 (observed 0.99; simulated 
distribution: μ = 0.14, σ = 0.20; empirical P < 1 × 10−5; z = 4.28) which is, as observed for the 
dominant ID genes, above the extremely LoF-intolerant gene threshold of 0.9 (Supplemental 
Figure 3.8). For the missense-only genes (with at least three missense mutations in the 
absence of LoF mutations, all of which were known dominant ID genes), we observe the 
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820 individuals with ID, representing 1,640 alleles for autosomal genes and 1,179 
alleles for genes on the X chromosome (461 males).
For DNMs on chromosome X the correct mutation rate depends on the 
patient’s gender as the mutation rate for fathers is higher than for mothers. 
Estimates show a 4:1 ratio of paternal to maternal DNMs16. Hence, male 
offspring, receiving their chromosome X exclusively from the mother, have 
therefore a lower mutation rate on chromosome X than estimated by the GSMR. 
This correction could, however, only be performed for the RUMC cohort, as 
gender information was not available for all studies included in the ID cohort. 
Notably, not correcting for this bias in male individuals for DNM in genes on the 
X chromosome will lead to less significant P-values for genes on the X chromo-
some, thereby potentially underestimating the significance of candidate ID genes 
located on the X chromosome. When a patient was found to have two DNMs in 
the same gene we ignored one of the two DNMs for the statistical enrichment 
analysis to avoid false positive results. In such cases the severity of the DNM 
protein effect was a factor in the choice of which DNM to ignore. For example, 
if a patient had one missense and one nonsense DNM in the same gene, the 
missense mutation was ignored in the statistical analysis.
Gene specific P-values were corrected for multiple testing based on the 18,730 
genes present in the Agilent V4 exome enrichment kit times the number of 
tests (2), using the Benjamini–Hochberg procedure with an FDR of 0.05. In 
our cohort of 820 individuals with ID, conclusive diagnoses were already made 
based on DNMs in genes previously implicated in disease. The use of a multiple 
testing correction with a FDR of 0.05, in combination with a potential large 
number of DNMs in known ID genes, may artificially increase the significance of 
other genes because of an increasingly lenient correction for the least significant 
genes17. To verify that the identification of candidate ID genes was not inflated 
by this effect, we performed the analysis after removing all individuals with a 
DNM in one of the known genes (potential other DNMs in such individu ls wer  
also removed for further analysis). Incidentally, this also increased our statisti-
cal power. The mode of inheritance was not taken into account when removing 
individuals with a DNM in a known gene (for example, samples with a DNM in 
a recessive gene were excluded). This correction left 584/820 individuals with 
ID in the RUMC cohort, with 627 DNMs across 584 genes. Similarly, for the 
ID and neurodevelopmental cohort, we removed all individuals with a DNM 
in a known ID gene (and other DNMs in these individuals). For the ID cohort, 
1,471 samples remained with 1,400 DNMs in 1,235 genes. For the neurodevel-
opmental cohort, 4,944 samples remained with 4,387 DNM across 3,402 genes 
(for a complete overview see Supplementary Fig. 6). We corrected for testing 
34,386 genes (i.e., all 18,730 genes minus the 1,537 known ID genes multiplied 
by 2 for testing the LoF and functional categories).
Validation of the statistical approach by analysis of DNMs in a control cohort. 
To further confirm the validity of our statistical approach, we applied the same 
analyses to a set of DNMs identified in trios of healthy individuals and unaf-
fected siblings. For this purpose, we downloaded and reannotated all DNMs 
identified in 1,911 unaffected siblings of individuals with ASD from Iossifov 
et al.2 together with DNMs in controls (Supplementary Table 12). In total the 
control set contained 2,019 coding DNMs found in 2,299 trios. Notably, the 
protein coding DNM rate in the control cohort was markedly lower than that 
observed in the individuals with ID (0.91 DNMs versus 1.32 DNMs, respectively). 
Additionally, we observed no significant enrichment of recurrently mutated 
genes for LoF or functional mutations (P = 0.60 and P = 0.12, respectively; 
Supplementary Fig. 11).
For the control cohort we performed statistical analyses as described above 
and identified only one gene that was significantly enriched in functional DNMs. 
For YIF1A (FDR corrected P = 0.01) we identified a total of 3 missense DNMs 
and 1 frameshift DNM (Supplementary Tables 13 and 14). YIF1A may be 
involved in transport between the endoplasmic reticulum and the Golgi, and 
it has a pLI of 2.08 × 10−8 indicating this gene is a LoF-tolerant gene. We note 
that the control cohort consists mostly of healthy siblings from individuals with 
ASD, and, as such, may still have minor enrichments for mutations that lead to 
susceptibility to neurodevelopmental disorders.
Increased number of LoF mutations in RUMC cohort compared to controls. To 
reduce the impact of the enrichment kit used in the control set studies and RUMC 
cohort, we computed the intersection of all enrichment kits (Agilent SureSelect 
37Mb  Agilent SureSelect 50Mb  Agilent SureSelect V4  Nimblegen SeqCap 
V2; Supplementary Table 12) using the “intersect” function of BEDTools. Only 
the LoF DNMs present in the 28,189,737-Mb intersection of the four enrich-
ment kits were used in the analysis. The Fisher’s exact test on the enrichment 
kits normalized LoF DNMs yielded a significant difference with P = 9.38 × 10−12 
(RUMC: 157 LoF DNMs of a total of 805 DNMs; controls: 137 LoF DNMs of 
a total of 1,485 DNMs; OR = 2.38; CI: 1.85–3.07). The coverage and other rel-
evant technical information of the control studies are listed in Supplementary 
Table 12. We note it is important to consider the coverage and false negative rates 
of all sequencing studies. So far, only a single study has attempted to provide a 
false negative rate (for example, mutations that are there but were not identified) 
for exome sequencing, and this was predicted to be <5% (ref. 2).
Attributing pLI for all protein coding genes. To determine the intolerance to 
LoF variation for each gene, we used the probability of LoF intolerance (pLI), 
which is based on data from the Exome Aggregation Consortium (ExAC) 
version 0.3.1, providing exome variants from 60,706 unrelated individuals9. 
The pLI is based on the expected versus observed variant counts to determine 
the probability that a gene is intolerant to LoF variants and is computed for a 
total of 18,226 genes. The closer a pLI is to 1, the more intolerant a gene is to LoF 
variants. The authors consider a pLI q 0.9 as an extremely LoF-intolerant set of 
genes. The pLIs for the genes used in this study can be found in Supplementary 
Table 8. Intolerance to LoF variation was evaluated for the available pLIs of four 
gene sets: (1) 170 LoF-tolerant (LoFT) genes18, (2) 404 housekeeping genes, 
involved in crucial roles in cell maintenance19, (3) 1,359 genes with functional 
DNMs from the healthy control data set (Supplementary Table 14), and (4) 444 
well-known dominant ID genes (Supplementary Table 4).
G ne set based evaluation of pLI. We evaluated the pLI by computing the 
expected median pLI for each gene set based on randomly drawing n pLI 
values from the complete set of 18,226 pLI annotated genes and calculating the 
median (where n is the number of genes in the gene set). By repeating this random 
sam ling process 10 , 0 ti es, we computed the likelihood of the observed 
median pLI of a gene set compared to the expected median pLI by calculating 
the empirical P-value: 
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pLI and N is the total number of performed simulations (N = 100,000). In addi-
tion, the z-values were computed as described in the section “Evaluating the 
number of recurrently LoF and functional de novo mutated genes.”
Based on the simulations we identified a significantly lower median pLI for 
the LoFT genes, which is in line with the LoFT nature of this gene set (observed 
9.33 × 10−9 distribution simulations: M = 0.04, S = 0.03; empirical P < 1 × 10−5; 
z = 1.25). For the healthy control set, the observed median pLI matched the 
simulated distribution of median pLI (observed 0.03; distribution simulations: 
M = 0.03, S = 0.01; empirical P = 0.31; z = 0.39). For the housekeeping and 
dominant ID gene sets, the observed median pLI was significantly higher than 
the simulated distribution of median pLI (HK genes: observed: 0.87; simulated 
distribution: M = 0.03, S = 0.02; empirical P < 1 × 10−5; z = 54.05 and dominant 
ID genes: observed: 0.95; simulated distribution: M = 0.03, S = 0.01; empirical 
P < 1 × 10−5; z = 61.54). I  addition, the median pLI of the housekeeping gene 
approximated (median pLI = 0.87) and the dominant ID gene set (median pLI 
= 0.95) surpassed the extremely LoF-intolerant threshold of 0.9, which is in 
line with the LoF-intolerant nature of housekeeping and dominant ID genes 
(Supplementary Fig. 12).
The set of ten novel candidate ID genes has a median pLI of 0.99 (observed 
0.99; simulated distribution: M = 0.14, S = 0.20; empirical P < 1 × 10−5; z = 4.28) 
which is, as observed for the dominant ID genes, above the extremely LoF-intol-
erant gene threshold of 0.9 (Supplementary Fig. 8). For the missense-only genes 
(with at least three missense mutations in the absence of LoF mutations, all of 
which were known dominant ID genes), we observe the highest median pLI of 
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highest median pLI of 0.9999 (observed: 0.9999; simulated distribution: μ = 0.09, σ = 0.14; 
empirical P < 1 × 10−5; z = 6.70), illustrating that those known and candidate dominant ID 
genes that harbor only missense variants are among the most LoF-intolerant ID genes 
(Supplemental Figure 3.8).
Attributing residual variation intolerance scores (RVIS) to all genes
In addition, the residual variation intolerance score (RVIS) was assessed in the same fashion 
as described for the pLI. The RVIS ranks genes based on whether they have more or less 
common functional genetic variations relative to the genome-wide expectation. The initial 
RVIS gene scores were computed based on the NHLBI-ESP6500 data set124 and recently 
recomputed based on the ExAC v0.3 data set (http://genic-intolerance.org/). The genes from 
our study were annotated with RVIS scores based on ExAC (Supplemental Table 3.8).
RVIS scores for gene sets were compared in the same way as for the pLI (Supplemental 
Figure 3.13). Again, we found the new candidate ID genes to be significantly more intolerant 
than any random set of genes found (observed median RVIS: 8.47, distribution simulations: 
μ = 50.05, σ = 15.08; empirical P = 4.60 × 10−4; z: −2.76), like the known dominant ID genes 
(Supplemental Figure 3.13). For the dominant missense-only genes we again observed the 
lowest median RVIS of 3.56 (distribution simulations: μ = 50.02, σ = 10.42; empirical P < 1 × 
10−5; z: −4.46; Supplemental Figure 3.13).
Estimating clustering of DNMs
The spatial distributions of missense, frameshift and nonsense DNMs were analyzed for 
clustering within the respective gene they occurred in based on 100,000 simulations. The 
locations of observed DNMs were randomly sampled over the coding exons of the gene and 
the distances (in base pairs) between the mutations were normalized for the total coding size 
of the respective gene. The geometric mean (the nth root of the product of n numbers) of all 
mutation distances between the DNMs was taken as a measure of clustering. A pseudocount 
(adding 1 to all distances and 1 to the gene size) was applied to avoid a mean distance of 0 
when there were identical mutations.
Based on the prior distance distribution of the 100,000 simulations, we computed a gene-
based empirical probability of the observed distance for dominant ID genes with 3 or more 
DNMs (n = 64 genes) in the ID set of 2,104 trios. A total of 21 genes contained only missense 
mutations (“missense-only” group) and 43 genes contained frameshift, nonsense or a 
combination of frameshift, nonsense and missense DNMs (“LoF + functional” group). In 21 
genes of the missense-only group, 5 genes had empirical probabilities below the significant 
threshold of 0.05/64, whereas only 1 of the 43 LoF + functional genes had an empirical 
probability below the significance threshold (Supplemental Table 3.9). Fisher’s exact test was 
used to compute the statistical significance (P = 0.012; OR = 12.56; CI: 1.26–632.65).
526362-L-bw-Reijnders
Processed on: 20-11-2018 PDF page: 44
44 Chapter 3
3
Clinical evaluation of selected patients
All patients were referred by clinical geneticists for diagnostic evaluation and overall patient 
characteristics were comparable to those of a previously published cohort.28 To confirm 
the identification of the candidate ID genes, we compared the phenotypes of individuals 
with a DNM in any one of the ten candidate genes and in two genes (SLC6A1 and TCF7L2) 
significantly enriched in the neurodevelopmental cohort. Comparison of phenotypes was only 
possible for 8 of 12 genes in which at least 2 individuals with ID were in the RUMC cohort 
(7 of 10 candidate ID genes, and 1 of 2 candidate NDD genes). A table listing these clinical 
details is provided in Supplemental Table 3.7. Detailed clinical data for other published 
individuals is mostly not available. For TLK2 and SETD2 a more detailed phenotypic 
comparison was performed (see Supplemental Note for case studies).
Statistics
Statistical significance was calculated using R statistical computing software version 3.1.0. 
Two-tailed Fisher’s exact tests (significance level α of 0.05) were used to analyze statistical 
significance between groups for the number of LoF DNMs and number of clustered DNMs. 
The gene-specific analysis of excess numbers of LoF and functional DNMs was performed 
using one-sided exact Poisson tests with gene-specific mutation rates taken from the 
Samocha et al. study.115 The gene-specific P-values were corrected for multiple testing 
based on the 18,730 genes present in the Agilent V4 exome enrichment kit times the number 
of tests (2; LoF and functional), using the Benjamini–Hochberg procedure with an FDR of 
0.05. Data distribution was assumed to be normal, but this was not formally tested.
For the statistical testing based on random sampling we used the “sample” and “sample.
int” functions (without replacement) from R version 3.1.0 with a random sample size n of 
100,000. By comparing the observed value to the distribution of the random samples, the 
empirical P-value was computed. In addition the z-value was computed by subtracting 
the mean value of the simulations from the observed value and dividing by the standard 
deviation of the simulations.
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De novo mutations in SON disrupt RNA 
splicing of genes essential for brain 
development and metabolism, causing 
an intellectual-disability syndrome
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Abstract
The overall understanding of the molecular etiologies of intellectual disability (ID) and 
developmental delay (DD) is increasing as next generation sequencing technologies identify 
genetic variants in individuals with such disorders. However, detailed analyses conclusively 
confirming these variants, as well as the underlying molecular mechanisms explaining 
the diseases, are often lacking. Here, we report on an ID syndrome caused by de novo 
heterozygous loss-of-function (LoF) mutations in SON. The syndrome is characterized by ID 
and/or DD, malformations of the cerebral cortex, epilepsy, vision problems, musculoskeletal 
abnormalities, and congenital malformations. Knockdown of son in zebrafish resulted in 
severe malformation of the spine, brain, and eyes. Importantly, analyses of RNA from affected 
individuals revealed that genes critical for neuronal migration and cortex organization 
(TUBG1, FLNA, PNKP, WDR62, PSMD3, and HDAC6) and metabolism (PCK2, PFKL, IDH2, 
ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced 
transcripts resulting from erroneous SON-mediated RNA splicing. Our data highlight SON as 
a master regulator governing neurodevelopment and demonstrate the importance of SON-
mediated RNA splicing in human development.
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Report
Recent advances in whole-exome and whole-genome sequencing have accelerated the 
identification of the genetic etiologies of intellectual disability (ID) and developmental delay 
(DD), facilitating appropriate care and therapy for affected individuals and their families. So 
far, mutations in more than 1,500 genes have been implicated in ID and DD disorders,21; 27-29; 
32; 46; 101; 125; 126 and de novo single-nucleotide variants and copy-number variations (CNVs) 
have been identified as a major cause of severe ID and/or DD.28; 46 Recently, two independent 
studies reported on a single individual with ID and/or DD and a de novo mutation in SON 
(SON DNA binding protein [MIM: 182465]), which encodes a protein required for proper RNA 
splicing. However, the level of evidence required for securely implicating mutations in this 
gene as disease causing was lacking.46; 72; 95 Including these two individuals, we recruited a 
total of 20 unrelated individuals with mild to severe ID and/or DD (Figure 4.1A and 
Supplemental Table 4.1) and report on the delineation of an ID syndrome caused by de novo 
LoF mutations in SON. This study was approved by the local institutes under the realm of 
diagnostic testing. We compared in detail the phenotypic characteristics of all 20 individuals 
with SON LoF mutations. Clinical examination showed that all affected individuals had mild 
to moderate facial dysmorphisms, including facial asymmetry, midface retraction, low-set 
ears, downslanting palpebral fissures, deep-set eyes, horizontal eyebrows, a broad and/ or 
depressed nasal bridge, and a short philtrum (Figures 4.1B and Supplemental Figure 4.1). 
Interestingly, brain MRI, available for 19 affected individuals, revealed that 17 of them had 
significant abnormalities, including abnormal gyration patterns (polymicrogyria, simplified 
gyria, and periventricular nodular heterotopia), ventriculomegaly, Arnold Chiari malformations, 
arachnoid cysts, hypoplasia of the corpus callosum, hypoplasia of the cerebellar 
hemispheres, and loss of periventricular white matter (Figures 4.1C–E). 11 of 20 individuals 
developed seizures and/or epilepsy with an age of onset ranging from 1 to 6 years. 17 of 20 
individuals presented with musculoskeletal abnormalities, comprising hemivertebrae, 
scoliosis or kyphosis, contractures, hypotonia, and hypermobility of the joints. Vision 
problems, including cerebral visual impairment, hypermetropia, optic atrophy, and 
strabismus, were present in 15 of 20 individuals. In addition, the vast majority of individuals 
showed congenital malformations consisting of urogenital malformations (6/20), heart defects 
(5/20), gut malformations (3/20), and a high and/or cleft palate (2/20). Short stature was 
present in ten individuals, and craniosynostosis involving both the metopic (n = 1) and the 
sagittal sutures (n = 2) was noted in 3 of 20 individuals. Metabolic screening was performed 
in 9 of 20 individuals, confirming mitochondrial dysfunction in individuals 2 and 11 and an 
O-glycosylation defect in individual 20 (a clinical summary is provided in Table 4.1, and 
details are listed in Supplemental Table 4.2). Apart from individuals 13 (II-1 in family 13; 
Figure 1A), 15 (II-3 in family 15), and 20 (II-1 in family 20), none of the individuals had 
additional coding-sequence mutations that explained (part of) the phenotype (Supplemental 
Table 4.2). Individual 13 was clinically diagnosed with dyskeratosis congenita, for which a 
maternally inherited pathogenic TERT (MIM: 187270) mutation was identified (Supplemental 
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Figure 1. Pedigree Structures, Photos, and Brain MRI of Individuals with SON Mutations
(A) Family pedigrees ondividuals carrying mutations in SON .
(B) Top row from left to right: photos ondividuals 2 (at age 5 years), 4 (age 19 years), 5 (age 2 years), 6 (age 6 years), 8 (age 34 years), and
10 (age 6 years). Bottom row from left to right: photos ondividuals 11 (age 21 years), 13 (age 14 years), 15 (age 15 months), 16 (age 5
years), 18 (age 6 years), and 19 (age 10 years). Shared facial dysmorphisms include facial asymmetry, midface retraction, low-set ears,
downslanting palpebral fissures, deep-set eyes, horizontal eyebrows, a broad and/or depressed nasal bridge, and a short philtrum.
(C) Axial T2-weighted fast spin-echo MRI of the brain ondividual 1 at age 3 years. Three panels show ascending images (left to right)
revealing that the individual’s insular cortex on the right is thickened and featureless. Less impressive areas of similar change were noted
in the posterior aspect of the left insular cortex, which revealed bilateral perisylvian and parietal polymicrogyria (yellow arrowhead).
(legend continued on next page)
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Figure 4.1: Pedigree structures, photos, and brain MRI of individuals with SON mutations 
(A) Family pedigrees of individuals carrying mutations in SON. (B) Top row from left to right: photos of individuals 2 (at 
age 5 years), 4 (age 19 years), 5 (age 2 years), 6 (age 6 years), 8 (age 34 years), and 10 (age 6 years). Bottom row from 
left to right: photos of individuals 11 (age 21 ye rs), 13 (age 14 years), 15 ( ge 15 onths), 16 (age 5 years), 18 (age 6 
years), and 19 (age 10 y ars). Shared facial dysmorphisms include facial asymmetry, midface retraction, low-set ears, 
downslanting pal ebral fissures, deep-set eyes, horizontal eyebrow , a broad and/or depr ssed nasal bridge, and a 
526362-L-bw-Reijnders
Processed on: 20-11-2018 PDF page: 51
51De novo mutations in SON disrupt RNA splicing of genes essential for brain development and metabolism, causing an intellectual disability syndrome
4
Table 4.2). Individual 13 was, however, more severely affected than could be explained by a 
TERT mutation alone. Similarly, none of the other coding variants identified in individual 15 or 
the additional genes deleted by the 384 kb deletion CNV in individual 20 were likely to 
explain the phenotype of these individuals (Supplemental Table 4.2). SON (GenBank: 
NM_138927.2) is composed of 12 exons (Figure 4.2A) and encodes a protein (GenBank: 
NP_620305.2) containing an arginine/serine (RS)-rich domain and two RNA-binding motifs (a 
G-patch and a double-stranded RNA binding motif) (Figure 4.2A).127-129 17 of 20 mutations are 
frameshift mutations, including a recurrent 4-bp deletion (c.5753_5756del) in four 
independent individuals (Supplemental Table 4.1 and Figures 4.2A and 4.2B). The remaining 
mutations include a nonsense mutation, an in-frame deletion of eight amino acids, and a 
complete gene deletion (Supplemental Table 4.1). Importantly, parental DNA was available for 
testing in 19 of 20 individuals and indicated that all mutations had occurred de novo 
(Supplemental Figure 4.2 and Supplemental Table 4.1). Interestingly, de novo truncating 
mutations in SON have not been observed in over 2,000 control individuals,29; 31; 40; 130; 131 and 
SON, with a Residual Variation Intolerance Score of 1.88, belongs to the 2% most intolerant 
human protein-coding genes.124 Furthermore, interrogation of large databases (such as the 
Exome Aggregation Consortium [ExAC] Browser) has shown that, after sequence context 
and mutability are considered, SON is significantly depleted of LoF variants according to 
multiple LoF metrics (pLI = 1.00, and the false-discovery rate of the LoF depletion score is p 
= 1.68 3 106 ).71; 132 Although these population genetic signatures of intolerance cannot be 
considered sufficient evidence of causality on their own, they support the hypothesis that 
SON LoF mutations are under strong purifying selection in the human population and that 
their occurrence most likely contributes to severe clinical phenotypes. Transcripts bearing a 
premature stop codon are likely to be degraded by nonsense-mediated mRNA decay. To 
confirm that LoF mutations result in reduced dosage of SON, we used three different PCR 
primer sets (Supplemental Table 4.3) to perform qRT-PCR to determine the amounts of the 
SON transcript in peripheral-blood mononuclear cells (PBMCs) isolated from trio 1 (I-1, I-2, 
and II-2 in family 1), trio 3 (I-1, I-2, and II-1 in family 3), individual 5 (II-1 in family 5; Figure 
4.1A), and an unrelated healthy donor (Figure 4.2C). All three primer sets showed that 
compared to mRNA from the parental samples and the unrelated healthy donor, SON mRNA 
short philtrum. (C) Axial T2-weighted fast spin-echo MRI of the brain of individual 1 at age 3 years. Three panels show 
ascending images (left to right) revealing that the individual’s insular cortex on the right is thickened and featureless. 
Less impressive areas of similar change were noted in the posterior aspect of the left insular cortex, which revealed 
bilateral perisylvian and parietal polymicrogyria (yellow arrowhead). (D) Sagittal T1-weighted and axial T2-weighted 
MRI of the brain of individual 2. The two images on the left (age 1 day; gestational age 34 + 6 weeks) reveal enlarged 
lateral ventricles, cavum septum pellucidum, a hypoplastic cerebellar hemisphere, a broad cistern magna, a small 
fourth ventricle, and a thin corpus callosum. The cortex shows a simplified gyration pattern, and the perisylvian and 
frontotemporal areas are suspect for polymicrogyria (yellow arrowheads). The two panels on the right (age 2 years) 
show the fissure Sylvie with an abnormal cortical border, an Arnold Chiari malformation, and hydrocephalus. (E) Frontal 
T2-weighted, sagittal T1-weighted, axial T2-weighted, and sagittal T1-weighted MRI of the brain of individual 7 (II-1 in 
family 7) at the age of 2 months. The cortex shows deep sulci and perisylvian areas suspect for polymicrogyria (yellow 
arrowheads), as well as discrete heterotopic nodules (orange arrowheads). A thin corpus callosum, a small fourth 
ventricle, enlarged frontal horns of the lateral ventricles, and cavum septum pellucidum are present.
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Table 4.1 Clinical features of individuals with SON haploinsufficiency
   Percentage Number of affected 
individuals
Intellectual disability 100% 20/20
Brain malformation 89% 17/19
   Ventricular enlargement 74% 14/19
   Corpus callosum abnormality 53% 10/19
   Cortex malformation 37% 7/19
   White matter abnormalities 21% 4/19
   Cerebellum abnormalities 21% 4/19
   Other 11% 2/19
Neurological features 85% 17/20
   Seizures 55% 11/20
   Hypotonia 75% 15/20
Musculoskeletal abnormalities 85% 17/20
   Hypermobility 40% 8/20
   Scoliosis or kyphosis 20% 4/20
   Hemivertebrae 10% 2/20
   Contractures 10% 2/20
   Other 85% 17/20
Eye and/or vision abnormality 75% 15/20
   Strabismus 55% 11/20
   Suspicion of CVI 20% 4/20
   Hypermetropia 30% 6/20
Heart defect 25% 5/20
Gastrointestinal malformation 15% 3/20
Urogenital malformation 30% 6/20
   Horseshoe kidney 10% 2/20
   Other 20% 4/20
Facial dysmorphism 100% 20/20
Short stature 50% 10/20
Craniosynostosis 15% 3/20
Abbreviation: CVI = cortical visual impairment
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in the affected individuals was significantly downregulated (Figure 4.2C). Subsequent 
western blotting using PBMC lysates from trio 1 and two different SON antibodies 
consistently showed the reduction of SON in individual 1 (Figures 4.2D and 4.2E), indicating 
that de novo SON LoF mutations result in SON haploinsufficiency. To examine the effect of 
SON haploinsufficiency on embryonic development, we utilized Danio rerio (zebrafish), which 
Figure 4.2: SON mutations and their functional effect at the RNA and protein levels. 
(A and B) Schematic representation of SON (A) and SON (B) shows the position of the mutations identified in the 20 
affected individuals with color-coded arrowheads. The locations of the PCR primer sets are indicated by black arrows. 
(C) Real-time qPCR with three different primer pairs showed that SON mRNA from the affected individuals was overall 
downregulated in comparison to mRNA from the parents and unrelated normal individual. Error bars represent mean ± 
SD. *p < 0.001. (D and E) Western blotting demonstrated reduced expression of SON. SON-N antibody (1:1,000) was 
generated against amino acids 74–88 of the human SON (amino acid sequence DTELRYKPDLKEGSR). The cocktail 
of WU SON antibodies was a mixture of three different SON antibodies (WU09 [1:100], WU14 [1:2,000], and WU21 
[1:200]). The epitopes of WU SON antibodies were as follows: MDSQMLATSS for WU09, CEESESKTKSH for WU14, and 
SMMSAYERS for WU21. SON-N antibody (D) and the cocktail of SON WU antibodies (E) showed similar results. The 
bands indicated by the black arrow represent full-length SON. Other bands, which could represent potential isoforms, 
were also detected. Besides the bands present in samples from both normal and affected individuals, no other specific 
bands were detected in the affected individuals.stem cells. 25 Surprisingly, from these previous datasets, we
noticed that a group of genes playing pivotal roles in
neuronal cell migration, embryonic survival, metabolism,
and mitochondrial function, including TUBG1 (MIM:
191135), FLNA (MIM: 300017), PNKP (MIM: 605610),
WDR62 (MIM: 613583), PSMD3 , HDAC6 (MIM: 300272),
PCK2 (MIM: 614095), PFKL (MIM: 171860), IDH2 (MIM:
147650), ACY1 (MIM: 104620), and ADA (MIM: 608958),
showed significantly decreased expression upon SON
knockdown ( Tables S4 and S5). 13,22,25 To investigate
whether genes involved in regulating brain development
and in metabolism are also downregulated in individuals
with SON LoF mutations, we measured the levels of RNA
expression of these genes in PBMCs from trio 1, trio 3,
and individual 5, as well as from an unrelated healthy
donor (primers are listed in Table S3 ). Using qPCR analysis,
we confirmed that all 11 genes were indeed significantly
downregulated in individuals with SON haploinsufficiency
(Figures 4 A and 4B).
SON functions as a splicing co-factor that promotes
correct and efficient RNA splicing of weak splice sites and
alternative splice sites by facilitating spliceosome recruit-
ment to the elongatingRNApolymerase II complex. 13 Prom-
inent features observed upon SON knockdown in HeLa cells
Figure 2. SON Mutations and Their Functional Eect at the RNA and Protein Levels
(A and B) Schematic representation of SON (A) and SON (B) shows the position of the mutations identified in the 20 aected individuals
with color-coded arrowheads. The locations of the PCR primer sets are indicated by black arrows.
(C) Real-time qPCR with three dierent primer pairs showed that SON mRNA from the aected individuals was overall downregulated in
comparison to mRNA from the parents and unrelated normal individual. Error bars represent mean 5 SD. *p < 0.001.
(D and E) Western blotting de onstrated reduced expression of SON. SON-N antibody (1:1,000) was generated against amino acids
74–88 of the human SON (amino acid s quence DTELRYKPDLKEGSR). The cocktail of WU SON antibodies was a mixture of three
dierent SON ntibodies (WU09 [1:100], WU14 [1:2,000], and WU21 [1:200]). The epitopes of WU SON antibodies were as follows:
MDSQMLATSS for WU09, CEESESKTKSH for WU14, and SMMSAYER for WU21. SON-N antibody (D) and the cocktail of SON WU
antibodies (E) showed similar results. The bands indicated by the black arrow represent full-length SON. Other bands, which could re-
present potential isoforms, were also detected. Besides the bands present in samples from both normal and aected individuals, no other
specific bands were detected in the aected individuals.
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has a well-conserved homolog of human SON (NCBI Gene: LOC565999; Supplemental 
Figures 4.3 and 4.4).We assessed the developmental effects of SON haploinsufficiency in 
vivo with morpholino (MO)-mediated knockdown of son in zebrafish embryos. Interestingly, 
embryos injected with a son MO had a host of developmental defects that ranged from bent 
tails (63.6%) to eye malformations and microcephaly (17.1%) and shortened or gnarled tails, 
deformed body axes, and massive body curvatures (2.1%) 24 hr post-injection (hpi) (Figure 
4.3A and Supplemental Figure 4.5). Embryos that survived 72 hpi progressed to more severe 
phenotypes including extreme spinal malformations (22.2%), head and eye malformations 
with brain edema (37.2%), and profound developmental abnormalities (10.1%; Figure 4.3B), 
mimicking features observed in the affected individuals. SON is a nuclear speckle protein 
able to bind to both DNA and RNA, and its cellular functions include regulation of RNA 
splicing and gene transcription, as well as proper cell-cycle and embryonic stem cell 
maintenance.128; 133-136 To identify molecular mechanisms underlying the clinical features of 
individuals with SON haploinsufficiency, we examined global expression patterns upon SON 
knockdown in cellular systems. Hereto, we re-analyzed microarray-based RNA-expression 
profiling and RNA-sequencing datasets generated upon SON knockdown in HeLa cells128; 133 
and human embryonic stem cells.136 Surprisingly, from these previous datasets, we noticed 
and human embryonic stem cells have included intron
retention and exon skipping, which have been shown at
the gene level for TUBG1 , HDAC6 , and ADA .13,22,25 We
next sought to determine whether RNA splicing of these
11 genes is also impaired in our individuals with SON
haploinsufficiency. To this end, we analyzed the pre-mRNA
sequences of the remaining eight genes to predict weak
splice sites that could be potential targets of SON-mediated
RNA splicing ( Table S6 ). We performed RT-PCR by using
DNase-treated RNA samples isolated from trio 1, trio 3, indi-
vidual 5, and an unrelated healthy donor and using primers
designed to detect intron retention and exon skipping
(Tables S6 and S7). We not only confirmed that these sites
were indeedmis-spliced in HeLa cells upon SON knockdown
(Figure S6 ) but also found that all three aected individuals
showed significant intron retention ( TUBG1 , FLNA , PNKP ,
WDR62 , PSMD3 , PCK2 , PFKL , IDH2 , and ACY1 ) and exon
skipping ( HDAC6 and ADA ) at the predicted sites of the
target pre-mRNAs and that this resulted in the accumulation
ofmis-splicedproducts ( Figures4 Cand4D). In contrast,mis-
spliced RNA products were absent in the parents and
unrelated donor ( Figures 4 C and 4D). Together, these results
indicate that SON-mediated RNA splicing is severely
compromised in individuals with SON haploinsufficiency.
Our data have revealed that the complex neurodevelop-
mental disorder observed in these aected individuals is
due to compromised SON function, which causes insuffi-
cient production of downstream targets as a result of erro-
neous SON-mediated RNA splicing. Moreover, the roles of
several downregulated genes are well-known causes of ID
and/or DD in humans ( Tables S4 and S5). 4,6,26–35 For
instance, FLNA haploinsufficiency is the most common
cause of periventricular nodular heterotopia (MIM:
300049), 35 a rare brain malformation that we also found
among our cohort with SON LoF mutations. Similarly, de
novo LoFmutations in TUBG1 are known to result in cortical
malformations (MIM: 615412), 32 also frequently observed in
our cohort of aected individuals. Because we have shown
that a substantial number of essential developmental genes
are significantly downregulated upon SON haploinsuffi-
ciency, SON thus represents a master regulator of genes
essential for human neurodevelopmental processes.
In summary, we have identified de novo LoF mutations
in SON as a cause of a complex neurodevelopmental disor-
der associated with ID and/or DD and severe brain malfor-
mations. In addition, we have revealed the underlying
molecular mechanism by showing that SON haploinsuffi-
ciency leads to defective RNA splicing of multiple genes
critical for brain development, neuronal migration, and
metabolism. Our findings thus greatly contribute to our
understanding of how defective RNA splicing leads to
human neurodevelopmental disorders.
Supplemental Data
Supplemental Data include six figures and seven tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
2016.06.029 .
Figure 3. Targeted son Knockdown in Developing Zebrafish Causes Impaired Head Development and Spinal Malformations
(A) Zebrafish injected with a splice-blocking sonmorpholino (MO; 5 0-TGGTCCTGGATATAACAGACAGATT-3 0, 6.25 ng) that targeted the
junction between intron 9 and exon 10, a control MO (5 0-CCTCTTACCTCAGTTACAATTTATA-3 0, 6.25 ng), or no MO showed a normal
phenotype, a bent spine or tail, a head or eye defect, or a severe phenotype at 24 and 72 hpi. The percentages of embryos with each
phenotype are shown in the bar graphs, and the number of embryos examined is listed next to each bar.
(B) Representative images of the phenotype observed 72 hr after MO injection (red arrow, bent spine or tail; white arrow, eye defects; and
yellow arrow, brain edema).
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Figure 4.3: Targeted son knockdown in developing zebrafish causes impaired head development and spinal 
malformations.
(A) Zebrafish injected with a splice-blocking son morpholino (MO; 5’-TGGTCCTGGATATAACAGACAGATT-3’, 6.25 ng) 
that targeted the junction between intron 9 and exon 10, a control MO (5’-CCTCTTACCTCAGTTACAATTTATA-3’, 6.25 
ng), or no MO showed a normal phenotype, a bent spine or tail, a head or eye defect, or a severe phenotype at 24 and 
72 hpi. The percentages of embryos with each phenotype are shown in the bar graphs, and the number of embryos 
examined is listed next to each bar. (B) Representative images of the phenotype observed 72 hr after MO injection (red 
arrow, bent spine or tail; white arrow, eye defects; and yellow arrow, brain edema). 
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that a group of genes playing pivotal roles in neuronal cell migration, embryonic survival, 
metabolism, and mitochondrial function, including TUBG1 (MIM: 191135), FLNA (MIM: 
300017), PNKP (MIM: 605610), WDR62 (MIM: 613583), PSMD3, HDAC6 (MIM: 300272), 
PCK2 (MIM: 614095), PFKL (MIM: 171860), IDH2 (MIM: 147650), ACY1 (MIM: 104620), and 
ADA (MIM: 608958), showed significantly decreased expression upon SON knockdown 
(Supplemental Tables 4.4 and 4.5).128; 133; 136 To investigate whether genes involved in 
regulating brain development and in metabolism are also downregulated in individuals with 
SON LoF mutations, we measured the levels of RNA expression of these genes in PBMCs 
from trio 1, trio 3, and individual 5, as well as from an unrelated healthy donor (primers are 
listed in Supplemental Table 4.3). Using qPCR analysis, we confirmed that all 11 genes were 
indeed significantly downregulated in individuals with SON haploinsufficiency (Figures 4.4A 
and 4.4B). SON functions as a splicing co-factor that promotes correct and efficient RNA 
splicing of weak splice sites and alternative splice sites by facilitating spliceosome 
recruitment to the elongating RNA polymerase II complex.128 Prominent features observed 
upon SON knockdown in HeLa cells and human embryonic stem cells have included intron 
retention and exon skipping, which have been shown at the gene level for TUBG1, HDAC6, 
and ADA.128; 133; 136 We next sought to determine whether RNA splicing of these 11 genes is 
also impaired in our individuals with SON haploinsufficiency. To this end, we analyzed the 
pre-mRNA sequences of the remaining eight genes to predict weak splice sites that could be 
potential targets of SON-mediated RNA splicing (Supplemental Table 4.6). We performed 
RT-PCR by using DNase-treated RNA samples isolated from trio 1, trio 3, individual 5, and an 
unrelated healthy donor and using primers designed to detect intron retention and exon 
skipping (Supplemental Tables 4.6 and 4.7). We not only confirmed that these sites were 
indeed mis-spliced in HeLa cells upon SON knockdown (Supplemental Figure 4.6) but also 
found that all three affected individuals showed significant intron retention (TUBG1, FLNA, 
PNKP, WDR62, PSMD3, PCK2, PFKL, IDH2, and ACY1) and exon skipping (HDAC6 and 
ADA) at the predicted sites of the target pre-mRNAs and that this resulted in the 
accumulation of mis-spliced products (Figures 4.4C and 4.4D). In contrast, mis-spliced RNA 
products were absent in the parents and unrelated donor (Figures 4.4C and 4.4D). Together, 
these results indicate that SON-mediated RNA splicing is severely compromised in 
individuals with SON haploinsufficiency. Our data have revealed that the complex 
neurodevelopmental disorder observed in these affected individuals is due to compromised 
SON function, which causes insufficient production of downstream targets as a result of 
erroneous SON-mediated RNA splicing. Moreover, the roles of several downregulated genes 
are well-known causes of ID and/or DD in humans (Supplemental Tables 4.4 and 4.5).29; 32; 
137-146 For instance, FLNA haploinsufficiency is the most common cause of periventricular 
nodular heterotopia (MIM: 300049),146 a rare brain malformation that we also found among 
our cohort with SON LoF mutations. Similarly, de novo LoF mutations in TUBG1 are known 
to result in cortical malformations (MIM: 615412),143 also frequently observed in our cohort of 
affected individuals. Because we have shown that a substantial number of essential 
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Figure 4.4: Individuals carrying heterozygous SON LoF mutations have defective RNA splicing of genes 
associated with the pathophysiology of ID and/or DD and metabolic disorders, resulting in their reduced 
expression.
 (A and B) Multiple genes associated with the pathophysiology of ID and/or DD (A) and metabolic disorders (B) in 
the affected individuals were downregulated in comparison to genes from parents and unrelated healthy individuals. 
TUBA1A mRNA served as a negative control (unaffected transcript). Error bars represent mean ± SD. *p < 0.001. (C 
and D) Intron retention and exon skipping of genes involved in ID and/or DD when mutated (C) and genes involved in 
metabolic disorders when mutated (D) in the individuals with SON mutations. The locations of the primers used for 
PCR are marked by gray arrows above the exons. Analysis of TUBA1A pre-mRNA, which served as a negative control, 
demonstrated that splicing of this transcript is not impaired in the affected individuals. *, intron-retained products; #, 
exon-skipped products. 
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Figure 4. Individuals Carrying Heterozygous SON LoF Mutations Have Defective RNA Splicing of Genes Associated with the
Pathophysiology of ID and/or DD nd Metabolic Disorders, Resulting in Their Reduced Expression
(A and B) Mult ple genes associated wit the pathophysiology of I and/or DD (A) and metabolic disorders (B) in the aected individuals
were downregulated in comparison to genes from parents and unrelated healthy individuals. TUBA1A mRNA served as a negative control
(unaected transcript). Error bars represent mean 5 SD. * < 0.001.
(C and D) Intron retention and exon skipping of genes involved in ID and/or DD when mutated (C) and genes involved in metabolic
disorders when mutated (D) in the individuals with SON mutations. The locations of the primers used for PCR are marked by gray arrows
above the exons. Analysis of TUBA1A pre-mRNA, which served as a negative control, demonstrated that splicing of this transcript is not
impaired in the aected individuals. *, intron-retained products; #, exon-skipped products.
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developmental genes are significantly downregulated upon SON haploinsufficiency, SON 
thus represents a master regulator of genes essential for human neurodevelopmental 
processes. In summary, we have identified de novo LoF mutations in SON as a cause of a 
complex neurodevelopmental disorder associated with ID and/or DD and severe brain 
malformations. In addition, we have revealed the underlying molecular mechanism by 
showing that SON haploinsufficiency leads to defective RNA splicing of multiple genes 
critical for brain development, neuronal migration, and metabolism. Our findings thus greatly 
contribute to our understanding of how defective RNA splicing leads to human 
neurodevelopmental disorders.
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Abstract
Next generation sequencing is a powerful tool for the discovery of novel genes related 
to neurodevelopmental disorders (NDDs). Here, we report the identification of a new 
syndrome due to de novo or inherited heterozygous mutations in the Tousled-like kinase 
2 gene (TLK2) in 38 unrelated individuals and two affected mothers using whole exome 
and whole genome sequencing technologies, matchmaker databases and international 
collaborations. Affected individuals had a consistent phenotype, characterized by mild-
borderline neurodevelopmental delay (86%), behavioral disorders (68%), severe gastro-
intestinal problems (63%), and facial dysmorphism including blepharophimosis (82%), 
telecanthus (74%), prominent nasal bridge (68%), broad nasal tip (66%), thin vermilion of 
the upper lip (62%), and upslanting palpebral fissures (55%). Analysis of cell lines from three 
affected individuals showed that mutations act through a loss-of-function mechanism in at 
least two cases. Genotype-phenotype analysis and comparison of computationally modeled 
faces showed that phenotypes of these and other individuals with loss-of-function variants 
significantly overlapped with phenotypes of individuals with other variant types (missense 
and C-terminal truncating). This suggests that haploinsufficiency of TLK2 is the most likely 
underlying disease mechanism, leading to a consistent neurodevelopmental phenotype. This 
work illustrates the power of international data sharing, by the identification of 40 individuals 
from 26 different centers in seven different countries, allowing the identification, clinical 
delineation and genotype-phenotype evaluation of a novel NDD caused by mutations in 
TLK2. 
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Report
The introduction of whole exome sequencing (WES) as a diagnostic test for individuals with 
unexplained neurodevelopmental disorders (NDDs) has led to the identification of dozens 
of novel disease genes. As a recent example, statistical analysis of aggregated exome data 
uncovered variants in ten different genes as likely causes of intellectual disability, a subtype 
of NDDs characterized by deficits in both intellectual and adaptive functioning.1; 126 One such 
gene was Tousled-like kinase 2 (TLK2), which was originally named because of homology 
to the Arabidopsis gene Tousled.147  The TLK2 gene, ubiquitously expressed in all tissues 
including fetal brain, encodes a serine/threonine kinase comprising a catalytic domain and 
multiple highly conserved coiled-coil motifs.147; 148 TLK2 is known to have maximal activity 
during the S-phase of the cell cycle and is therefore tightly linked to DNA-replication.147 
DNA double-strand breaks lead to rapid and transient inhibition of TLK activity, suggesting 
a role in DNA repair.149 With the discovery of both H3-H4 chaperone Asf1 and histone H3 
as physiological substrates of TLKs, its protein function has been linked to chromatin 
assembly.150-154 
To establish the contribution of TLK2 variants to NDDs in humans, we systematically 
collected phenotypic data of the five affected individuals with TLK2 variants reported 
previously,126 derived cell lines and exploited different strategies to identify additional 
individuals with a variant in this gene. By using Genematcher88 and by sharing data with 
international collaborators, we identified a total of 38 unrelated individuals and two affected 
mothers with heterozygous variants in TLK2. Variants were detected by either family-based 
WES (research settings: n=18 probands and 2 affected parents; diagnostic settings: n=18 
probands) or whole genome sequencing (WGS) (research settings, n=2 probands) in 26 
different institutions and seven different countries (Supplemental Figure 5.1; Supplemental 
Methods, Supplemental Tables 5.1 and 5.2). Two additional individuals with de novo TLK2 
variants p.(Val505Asp) and p.(Arg724Gln), each of whom had a second likely pathogenic 
mutation in another gene, were excluded from further consideration to avoid confounding in 
the phenotypic analysis (Supplemental Methods). IRB-approved consents for WES or WGS 
in diagnostic or research settings were obtained for all individuals. 
We observed a broad spectrum of different variant types in TLK2 (NM_006852): four 
frameshift variants, ten nonsense variants (including two located in the last exon), twelve 
canonical splice-site variants, and nine missense variants (Figures 5.1A-1C; Table 5.1). 
Additionally, we identified a de novo balanced translocation in one of the WGS cases, 
resulting in a breakpoint at chromosome 17 disrupting the TLK2 intron between exons 2 and 
3 (Figure 5.1D; Supplemental Methods). Interestingly, we found recurrent mutations within 
our cohort of affected individuals. Missense variants p.(His496Arg) and p.(Arg339Trp) were 
each reported in two unrelated individuals. In addition, p.(Arg339Gln) affects the same amino 
acid residue as variants p.(Arg339Trp) (Figure 5.1C; Table 5.1). Finally, two splice variants 
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Figure 5.1: Intragenic variants and balanced translocation identified in TLK2 
(A) Location of TLK2 (NM_006852) in chromosome 17 (see Supplemental Information for discussion about different 
TLK2 spliceforms). Vertical marks in TLK2 represent the 22 exons. Green arrow indicates region enlarged in panel 
below. (B) Schematic view (not to scale) of exons 12-22 and location of identified splice site mutations (green crosses). 
The splice site mutation inherited from an affected parent is shown in bold and green. The variant subjected to cDNA 
analysis is shown in the dark green rectangle. (C) Overview of TLK2 protein with the protein kinase domain (dark green) 
and three coiled coil motifs (light green). Loss-of-function variants (13; 8 nonsense and 5 frameshift) are shown above 
the protein and other variants (23; 10 splice site variants, shown as green crosses, 11 missense variants and 2 nonsense 
variants causing a premature stop codon in the last exon). The frameshift mutation inherited from an affected parent is 
shown in bold and green. The variants subjected to cDNA analysis are shown in the dark green rectangle (D) Balanced 
translocation between chromosomes 4 and 17, with the breakpoint disrupting TLK2 between exons 2 and 3, identified in 
one individual:46,XX,t(4;17)(27;q23.2).seq[GRCh37]t(4;17)g.[chr4:pter_cen_122332907::
chr17:60,581,319_qter]g.[chr17_pter_cen_60,581,315::chr4:122,332,920_qter] (E) Pedigrees of individuals with inherited 
variants and photographs of probands and their affected mothers. Both mothers have facial dysmorphism similar to their 
child. 
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were predicted to give rise to the same affected protein product: c.1286+1G>T, p.(?) and 
1286+1G>A, p.(?) (Figure 5.1B; Table 5.1). From the nine missense variants identified in 
eleven unrelated individuals, five are located in the catalytic domain of the protein and three 
in a coiled coil motif. One variant, p.(Gly297Asp), is located outside a known functional 
domain, but affects a highly conserved amino acid and was predicted pathogenic by several 
in silico prediction programs, similar to other missense variants (Figure 5.1C; Supplemental 
Table 5.3). None of the missense variants were present in the ExAC database,71 nor in our 
in-house database of variants identified in healthy controls. The recently released gnomAD 
database, containing WGS variants identified in controls, reported only p.(Arg546Trp) in a 
single individual (allele frequency of ~0.000004). None of the other missense variants were 
present in the gnomAD database (Table 5.1). 
For all but two variants (Table 5.1), the de novo status was assessed by sequencing the 
parents of the proband. In two individuals, variants were inherited from a similarly affected 
parent, while all other variants (n=34) occurred de novo. Detailed phenotyping revealed that 
both mothers carrying a predicted loss-of-function (LOF) TLK2 variant (Table 5.1) were mildly 
affected. The first mother (c.1460+2T>G) had mild neurodevelopmental delay and speech 
delay. The second affected mother (p.Gly593fs) had low-normal IQ levels, but was diagnosed 
with bipolar disorder. Both had facial dysmorphism similar to their affected child (Figure 
5.1E). The inherited mutations illustrate that the search for a diagnosis should not always be 
restricted to de novo mutations, in particular if individuals are only mildly affected. Similar to 
the parents in this study, who were never referred for genetic testing before diagnostic testing 
in their child uncovered a TLK2 mutation, we expect mutations causing milder phenotypes 
to be present in the general population. This could explain why, although TLK2 exhibits very 
strong constraint against LOF variants (pLI = 1), five LOF variants (low-coverage variants 
excluded) have been reported in gnomAD, and a missense variant p.(Arg546Trp) reported 
here as de novo variant, was present at very low allele frequency in the population (aggregate 
minor allele frequency of LOF and missense variants ~0.000024). 
Consistent with the phenotypes of both affected mothers, mild neurodevelopmental 
phenotypes accompanied by language and motor delay, were present in the majority of 
the 38 unrelated probands: 6% of the individuals had normal IQ levels (85-100), 14% had 
borderline ID (IQ 70-85) and from the 72% diagnosed with ID (IQ<70), most had mild ID (IQ 
50-70) (Figure 5.2). Most of the affected probands (22 males and 16 females) were children 
at the time of last examination (median 8.0 years; interquartile range 4.1-13.5 years), ages 
ranged between 3 months and 29 years. Three individuals, who all had language and motor 
delay, were too young for formal assessment of their neurodevelopmental phenotype. In 
addition to this, systematic evaluation of other clinical data, scored by the referring clinician, 
showed a variety of overlapping features (Figure 5.2, Supplemental Table 4). Neurological 
problems including hypotonia (37%), epilepsy (13%), and non-specific intracranial brain 
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Table 5.1 identified intragenic variants in TLK2 (NM_006852), inheritance and presence 
in ExAC and gnomAD databases*
Subgroup cDNA position Protein position Inheritance RNA 
analysis
cMAF Exac cMAF 
gnomAD
Predicted 
LOF
c.37C>T p.(Gln13*) De novo No No LOF 
variants
5 LOF 
variants:
~0.00002
c.181C>T p.(Arg61*) De novo No
c.202G>T p.(Glu68*) De novo No
c.685_688del p.(Glu229fs) De novo No
c.777C>A p.(Tyr259*) De novo No
c.784C>T p.(Arg262*) De novo No
c.832-1G>A p.(?) De novo No
c.907C>T p.(Arg303*) De novo No
c.968+1del p.(?) De novo No
c.989C>A p.(Ser330*) De novo Yes
c.1121+1G>A p.(?) De novo No
c.1122-1G>T p.(?) De novo No
c.1286+1G>T p.(?) De novo No
c.1286+1G>A p.(?) De novo No
c.1460+2T>G p.(?) Inherited No
c.1550+1G>A p.(?) De novo No
c.1651C>T p.(Gln551*) De novo No
c.1672dup p.(Tyr558Leufs*4) De novo No
c.1720+1G>T§ p.(?) De novo Yes
c.1746delA p.(Ala583Argfs*5) De novo No
c.1776_1783delTGGTCTTT p.(Gly593Glufs*5) Inherited No
c.1860-1G>T p.(?) Unknown No
c.1972-2A>G p.(?) De novo No
c.2079+1G>A p.(?) De novo No
Other 
variant 
types
c.2092C>T§ p.(Arg698*) De novo Yes 0 0
c.2170C>T p.(Arg724*) De novo No 0 0
c.890G>A p.(Gly297Asp) De novo No 0 0
c.1015C>T p.(Arg339Trp) De novo∞ No 0 0
c.1016G>A p.(Arg339Gln) De novo No 0 0
c.1273G>A p.(Glu425Lys) Unknown No 0 0
c.1412A>G§ p.(His471Arg) De novo No 0 0
c.1487A>G§ p.(His496Arg) De novo∞ No 0 0
c.1636C>T p.(Arg546Trp) De novo No 0 ~0.000004
c.1819G>A§ p.(Asp607Asn) De novo No 0 0
c.1973C>G p.(Pro658Arg) De novo No 0 0
Abbreviations: cMAF = cumulative minor allele frequency; LOF = Loss-of-function
*    Identified balanced translocation (n=1) is not included in this table 
§   Variant reported previously126
∞  Recurrent de novo variant identified in two unrelated individuals
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Figure 5.2: Clinical spectrum associated with TLK2 variants
Overview of clinical features observed in individuals with TLK2 variants. 
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abnormalities (13%) (Supplemental Table 5) were observed. A broad range of behavioral 
disorders was present (68%), with often severely affected social functioning: tantrums (11 
individuals), autism spectrum disorder (11 individuals), attention-deficit disorder with or 
without hyperactivity (5 individuals) and severe social-emotional problems (6 individuals) were 
the most commonly reported problems. Less frequently observed were short attention span, 
pica disorder, aggression, obsessive-compulsive disorder and anxiety in eleven individuals. 
Other recurrent features included gastro-intestinal problems (constipation in 55%; severe 
diarrhea in 8%), neonatal feeding difficulties (42%), eye abnormalities (refraction abnormality 
in 29%, strabismus in 26%), musculoskeletal abnormalities (joint hypermobility in 21%; 
pes planus in 21%; toe walking in 18%; scoliosis in 8%; contractures of the hands in 8%), 
recurrent otitis media (24%), hypertrichosis (16%) and hoarse voice (8%). Abnormalities of 
skull shape were observed in 31% of probands (Figure 5.2, Supplemental Tables 4 and 6), 
with clinically proven craniosynostosis being present in four (10%) of them (Supplemental 
Table 7). However, sequence-based screening of 309 DNA samples from individuals with 
mixed, genetically undiagnosed craniosynostosis did not identify further cases, indicating 
that TLK2 mutations are only rarely associated with craniosynostosis. Growth parameters 
were frequently abnormal. Short stature was documented in 37%, microcephaly in 24% 
and low body weight in 13%. Three individuals (8%) were overweight. Features reported 
in only one or two individuals are summarized in Supplemental Table 6. In addition to the 
other clinical features, overlapping facial dysmorphisms were present (Figures 5.3A and B). 
Most frequently reported by clinicians were blepharophimosis (82%), telecanthus (74%), 
prominent nasal bridge (68%), broad nasal tip (66%), thin vermilion of the upper lip (62%), 
and upslanting palpebral fissures (55%). Pointed and tall chin (42%), epicanthal folds (42%), 
narrow mouth (32%), high palate (30%), microtia (29%), posteriorly rotated ears (29%), long 
face (27%), ptosis (21%), and asymmetric face (16%) were observed in fewer than half of the 
individuals. 
 
Analysis of data from the ExAC database demonstrates that TLK2 is extremely intolerant for 
LOF variants (pLI score = 1).71 In line with this observation, animal models with depletion of 
TLK2 have been reported to have severely disturbed cellular and developmental processes. 
Drosophila with complete LOF of TLK were associated with arrested nuclear divisions, 
Figure 5.3: Facial dysmorphism of individuals with TLK2 variants
(A) Photographs of 21 unrelated individuals with a loss-of-function variant in TLK2, showing overlapping facial 
dysmorphism. Most frequently reported by clinicians were blepharophimosis, telecanthus, prominent nasal bridge, 
broad nasal tip, thin vermilion upper lip, and upward slanted palpebral fissures. Pointed and tall chin. epicanthal folds, 
narrow mouth, high palate, microtia, posteriorly rotated ears, long face, ptosis, and asymmetric face were observed 
in less than half of the individuals. (B) Photographs of 7 unrelated individuals with a missense or C-terminal truncating 
variant in TLK2. Variant p.(Arg724*) is assigned to this subgroup, since a premature stop codon is introduced in the 
last exon. Facial dysmorphisms overlapped with dysmorphism observed in individuals with loss-of-function variants. 
(C) Computational averaging of 33 facial photographs of 22 subjects with LOF variants in TLK2 (left) compared with 
22 gender- and age-matched controls (right). (D)  Computational averaging of 11 facial photographs of 8 subjects with 
missense or C-terminal truncating variants in TLK2 (left) compared with 8 gender- and age-matched controls (right). 
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causing apoptosis of the cell.151 Tlk2 null mice were  embryonically lethal due to placental 
failure.155 In this study, we found several predicted LOF variants in affected individuals. To 
investigate whether variants resulted in an aberrant transcript, we synthesized cDNA from 
RNA extracted from fibroblast or lymphoblastoid cell lines from three individuals with different 
variants: (1) p.(Ser330*), predicted to result in a truncated product leading to nonsense-
mediated decay (NMD); (2) p.(Arg698*), with a premature stop codon in the last exon 
predicted to escape from NMD; and (3) c.1720+1G>T, a mutation predicted to affect splicing 
of exon 18. To investigate the significance of NMD for expression of TLK2 transcripts, we 
treated fibroblasts (for p.Ser330*) and lymphoblastoid cell lines (for p.(Ser330*), p.(Arg698*) 
and c.1720+1G>T) with cycloheximide, an inhibitor of NMD.156 Transcript stability of cDNA 
PCR products from p.(Ser330*)and p.(Arg698*) individuals in the presence of cycloheximide 
was analyzed using a restriction enzyme assay targeting the wild-type transcript and the 
results were confirmed using deep sequencing to quantify relative levels of wild-type and 
mutant transcripts (Supplemental Methods). For fibroblast and lymphoblastoid cell lines 
heterozygous for the p.(Ser330*) variant, the mutant allele represented 15.8% and 21.5% 
of transcripts respectively in the absence of cycloheximide, but rose to 37.7% and 48.5% 
respectively in the presence of cycloheximide, supporting that this variant is subject to 
NMD and causes haploinsufficiency of TLK2. In contrast, wild-type and mutant transcripts 
from lymphoblastoid cells of the individual heterozygous for p.(Arg698*) did not show 
significant differences between treated and untreated cells, supporting that the mutant 
transcript escapes NMD due to its location within the last coding exon of TLK2 (Figure 
5.4A). Amplification of cDNA from an individual with a splice-site variant (c.1720+1G>T) 
showed a full length wild-type product of 300 bp and an additional aberrant smaller product 
of 130 bp, consistent with skipping of exon 18. Direct sequencing of this smaller fragment 
confirmed that exon 17 spliced directly to exon 19, thereby producing an out-of-frame 
transcript predicted to introduce a premature stop codon at the next amino acid position 
(p.Ser517fs*1). Additionally, the intensity of the spliced transcript increased when treated with 
cycloheximide, indicating that the mutant transcript is subjected to NMD (Figure 5.4B).
By analyzing TLK2 transcripts in cell lines of three different individuals, we were able to 
confirm that transcripts were subjected to NMD in two of them, causing haploinsufficiency 
of TLK2. It is likely that comparable variants predicted to cause LOF of TLK2 affect the 
transcript similarly. The large number of identified individuals with TLK2 variants allowed 
us to search for underlying pathogenic mechanisms for the individuals with variants with 
unknown effect, such as p.(Arg698*). To assess this, we divided our cohort in two subgroups 
and (1) performed a structured genotype-phenotype analysis, and (2) created and compared 
computationally modeled faces. Subgroup 1 (n=25) included all probands carrying a 
predicted LOF variant (nonsense, frameshift variant or canonical splice-site, or balanced 
translocation) similar to variants p.(Ser330*) and c.1720+1G>T. Subgroup 2 (n=13) comprised 
individuals with either missense variants or variants causing a premature stop codon in the 
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last exon of TLK2, such as p.(Arg698*). Affected parents of probands with inherited mutations 
were not included in the subgroups. Next, we compared frequencies of 40 different features 
and frequencies of 15 facial dysmorphisms between the two groups using a two-tailed 
Fisher’s exact test. This showed that both clinical features and facial dysmorphisms were 
remarkably similar between the two subgroups. From the 55 different features, none differed 
significantly between the two subgroups (p<0.05), even without correction for multiple 
testing (Supplemental Table 4). Secondly, averaged visualization of facial dysmorphism 
by computational modeling of 33 photographs from 22 individuals in subgroup 1 and 11 
photographs from 8 individuals in subgroup 2 at different ages (Supplemental Methods), 
showed consistent differences from a comparable number of gender- and age-matched 
controls, including telecanthus, broad nasal tip and tall, pointed chin (Figure 5.3C and D). 
Figure 5.4: Analysis of transcripts of three different cell lines
(A) Analysis of transcripts encoding nonsense mutations p.(Ser330*) and p.(Arg698*) in cell lines of affected individuals. 
Left panel shows reverse transcriptase-PCR (RT-PCR) products of cDNA prepared from fibroblast and lymphoblastoid 
cell lines of subject with p.(Ser330*) variant, either in the presence (+C) or absence (-C) of cycloheximide and 
incubated with ApoI (digests wild-type allele). Central panel shows RT-PCR of cDNA prepared from lymphoblastoid 
cell line of subject with p.(Arg698*) variant, in the presence (+C) or absence (-C) of cycloheximide and incubated with 
Hpy99I (digests wild-type allele). Right panel shows proportion (± standard deviation) of variant alleles quantified by 
deep sequencing of triplicate samples. Statistical testing of differences: *, P=0.046; ** P=0.011; NS, not significant. 
(B) Analysis of transcripts with canonical splice-site mutation c.1720+1G>T. A wild-type fragment at 300 bp in 
c.1720+1G>T lymphoblastoid cells is observed as well as a second fragment at 130 bp, which is absent in control 
cDNA. An increase of mutant transcript in cells was present when treated with cycloheximide (+C), indicating that 
the aberrant transcript was subject to NMD. Sequencing of the 300 bp (white box) and 130 bp (green box) fragments 
demonstrated skipping of exon 18 in the lower cDNA product. Abbreviations: Fibs = fibroblasts; EBV = lymphoblastoid 
cells; C/CHX = cycloheximide; WT= control cDNA.
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Given this strong overlap in phenotypes and facial dysmorphic features between probands 
with different type of mutations, it is likely that not only LOF variants, but also the majority of 
identified missense variants and variants with a premature stop codon in the last exon only 
have a single functional copy of TLK2. Hence, we conclude that the predominant pathogenic 
mechanism of these TLK2 mutations is haploinsufficiency. 
Often mentioned together with TLK2 is its close interactor TLK1. From birth, murine Tlk2 
shows a similar expression pattern to the closely related paralog Tlk1 across many tissues.155 
Human TLK1 has 84% identity to TLK2 at the protein level,147 and it was shown that TLK1-
depletion leads to extensive chromosome segregation defects in human cells.157 Interestingly, 
TLK1 is (similarly to TLK2) intolerant for both missense and truncating mutations in healthy 
individuals (significant z-scores of 3.84 (TLK1) and 5.67 (TLK2) and pLI (constraint) scores 
of 1.00 for both TLK1 and TLK2) (ExAC database).71 In the literature, four de novo variants 
have been reported in TLK1 (NM_012290.4): p.(Pro25Leu) in an individual with intellectual 
disability,126 p.(Met566Thr) in an individual with autism,158 p.(Ala599Gly) in an individual with 
a NDD and congenital heart disease159 and p.(Lys367fs) in an individual with schizophrenia.39 
Importantly, none of these variants are present in the ExAC or gnomAD databases. Taking 
this into account, it is possible that TLK1 variants could contribute to NDDs, similar to the 
homolog TLK2. In future research, the exact role of TLK1 in NDDs should be further explored. 
In conclusion, we show that both de novo and inherited mutations in TLK2 cause a 
novel neurodevelopmental disorder, hallmarked by mild developmental delay, a variety 
of behavioral disorders, severe gastro-intestinal problems and facial dysmorphism. The 
identification of a large number of individuals (n=40, including two affected mothers) 
emphasizes the power and importance of data sharing, allowing us to delineate the clinical 
phenotype and to evaluate genotype-phenotype correlations. By analyzing three cell lines 
of affected individuals, we were able to confirm that at least two variants act through 
a heterozygous loss-of-function mechanism (haploinsufficiency). Phenotypes of these 
individuals and others with comparable loss-of-function variants significantly overlapped 
with phenotypes of individuals with other variant types, providing further evidence for the 
underlying disease mechanism of the TLK2 variants. Given the genetic and functional 
similarities between TLK2 and TLK1, further research should focus on the potential role of 
TLK1 mutations in developmental disorders. 
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Abstract
RAC1 is a widely studied Rho GTPase, a class of molecules that modulate numerous 
cellular functions essential for normal development. RAC1 is highly conserved across 
species and is under strict mutational constraint. We report seven individuals with distinct de 
novo missense RAC1 mutations and varying degrees of developmental delay, brain 
malformations, and additional phenotypes. Four individuals, each harboring one of c.53G>A 
(p.Cys18Tyr), c.116A>G (p.Asn39Ser), c.218C>T (p.Pro73Leu), and c.470G>A (p.Cys157Tyr) 
variants, were microcephalic, with head circumferences between −2.5 to −5 SD. In contrast, 
two individuals with c.151G>A (p.Val51Met) and c.151G>C (p.Val51Leu) alleles were 
macrocephalic with head circumferences of +4.16 and +4.5 SD. One individual harboring 
a c.190T>G (p.Tyr64Asp) allele had head circumference in the normal range. Collectively, 
we observed an extraordinary spread of ~10 SD of head circumferences orchestrated by 
distinct mutations in the same gene. In silico modeling, mouse fibroblasts spreading assays, 
and in vivo overexpression assays using zebrafish as a surrogate model demonstrated that 
the p.Cys18Tyr and p.Asn39Ser RAC1 variants function as dominant-negative alleles and 
result in microcephaly, reduced neuronal proliferation, and cerebellar abnormalities in vivo. 
Conversely, the p.Tyr64Asp substitution is constitutively active. The remaining mutations are 
probably weakly dominant negative or their effects are context dependent. These findings 
highlight the importance of RAC1 in neuronal development. Along with TRIO and HACE1, a 
sub-category of rare developmental disorders is emerging with RAC1 as the central player. 
We show that ultra-rare disorders caused by private, non-recurrent missense mutations 
that result in varying phenotypes are challenging to dissect, but can be delineated through 
focused international collaboration.
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Report
Developmental disorders (DDs) are etiologically extremely heterogeneous and affect 
2%–5% of individuals.20; 21 De novo mutations account for a substantial proportion of DDs 
and are thought to underlie approximately 400,000 new DD-affected case subjects world-
wide annually.33 Recently, large-scale next generation sequencing studies have led to the 
identification of several DD-associated genes that lead to clinical manifestations through 
protein truncating or recurrent missense variants.31; 32; 126 However, rare disorders caused 
by private, non-recurrent missense mutations that result in varying phenotypes remain 
challenging to dissect.72 
Several human DDs are known to result from mutations in members of the RAS superfamily 
of small GTPases.160 The RAS superfamily is further divided into smaller families, one of 
which is the 22-member Rho family. Rho GTPases cycle between active GTP-bound and 
inactive GDP-bound states. Their activity is regulated by guanine nucleotide exchange 
factors (GEFs), GTPases activating proteins (GAPs), and guanine nucleotide dissociated 
inhibitors (GDIs).161 Rho GTPases modulate essential cellular functions, including cell polarity, 
migration, vesicle trafficking, and cytokinesis and play crucial roles in neuronal development, 
neuronal survival, and neurodegeneration.162-164 However, no human DDs caused by 
mutations in genes encoding Rho GTPases are known.
One of the most widely studied Rho GTPases is the RAS-related C3 Botulinum 
Toxin Substrate 1 (RAC1).165 RAC1 is part of the RAC Rho GTPases subfamily 
that also includes RAC2, RAC3, and RhoG.166 RAC1 is an important modulator of 
the cytoskeleton, with a critical function in phagocytosis, mesenchymal-like migration, 
neuronal polarization, axonal growth, adhesion, and differentiation of multiple cell 
types.162; 167; 168 Additionally, it is involved in cellular growth and cell-cycle regulation via 
mTOR signaling.169 In mouse studies, Rac1 is required for the formation of three germ 
layers during gastrulation, with Rac1-knockout mice being embryonic lethal.170 Conditional 
forebrain-specific Rac1-knockout mice display impaired neuronal migration, 
abnormal dendritic growth and remodelling, disruption of lamellipodia formation, reduced 
neuronal proliferation, premature differentiation, and microcephaly.171-173 Here, we report de 
novo missense RAC1 (MIM: 602048) mutations in individuals with DD and divergent 
phenotypes.
All procedures followed were in accordance with the ethical standards of the institutional 
and national responsible committees on human or animal experimentation and that, where 
relevant, informed consent was obtained. Review of data from 4,293 families, who underwent 
trio whole-exome sequencing (WES) as part of the Deciphering Developmental Disorders 
study,33 led to identification of three individuals with de novo RAC1 (GenBank: NM_006908) 
missense mutations: individual 3 with c.218C>T (p.Pro73Leu), individual 5 with c.190T>G 
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Figure 1. Properties of Germline RAC1 Variants
(A) RAC1 is located on human chromosome 7p22.1. Exon-intron structure of the two protein-coding RAC1 transcripts is shown. The
ubiquitously expressed RAC1 transcript is composed of six exons (blue vertical lines). RAC1B (mainly expressed in gastrointestinal
and epithelial cells) contains an additional exon (exon 4; gray vertical line).
(legend continued on next page)
470 The American Journal of Human Genetics 101, 466–477, September 7, 2017
Figure 6.1: Properties of germline RAC1 variants
(A) RAC1 is located on human chrom some 7p22.1. Exon-intron structure of the two protein-coding RAC1 transcripts 
is shown. The ubiquitously expressed RAC1 transcript is composed of six exons (blue vertical lines). RAC1B (mainly 
expressed in gastrointestinal and epithelial cells) contains an additional exon (exon 4; gray vertical line). (B) Schematic 
of RAC1, with the coding exons shown as blue rectangles and the introns as blue lines. Exon 4 that is expressed only 
in the longer RAC1B transcript is shown as a gray rectangle. The red triangles represent the positions of the mutations 
identified in this study. The red oval within exon 4 shows the two splice donor variants detected in the ExAC database. 
The purple ovals represent the missense variants in the ExAC database. (C) Amino acid sequence of the RAC1 across 
positions p.1-p.192. Red amino acids are highly conserved in >90% of the RAS family members and blue amino acids 
represent RAS protein G box consensus residues. Positions of the identified missense mutations (in red) are marked 
526362-L-bw-Reijnders
Processed on: 20-11-2018 PDF page: 77
77RAC1 mutations in developmental disorders with diverse phenotypes 
6
(p.Tyr64Asp), and individual 6 with c.151G>A (p.Val51Met) (Table 6.1; Figures .61 and 6.2). 
Two additional individuals were independently ascertained through family-based diagnostic 
WES: individual 1 with c.53G>A (p.Cys18Tyr) and individual 2 with c.116A>G (p.Asn39Ser) 
(Table 6.1; Figures 6.1 and 6.2). While functional studies were ongoing for the five individuals, 
two additional individuals were identified via the GeneMatcher tool88 or through international 
collaboration: individual 4 with c.470G>A (p.Cys157Tyr) and individual 7 with c.151G>C 
(p.Val51Leu) (Table 6.1; Figures 6.1 and 6.2).
Human RAC1 (ENSG00000136238) encodes six transcripts, of which two are protein 
coding: RAC1 and RAC1B (Figure 6.1A). Of the two protein-coding transcripts, 
GenBank: NM_006908 (RAC1, ENST00000348035.8) lacks exon 4 and encodes the shorter 
RAC1 isoform of 192 amino acids, which is ubiquitously expressed in all tissues.174 RAC1 is 
under strict mutational constraint with only 15 missense variants observed versus 75.9 
expected in ~60,000 exomes cataloged in the ExAC database (z-score = 3.42).71 Moreover, 
7 of these 15 observed missense variants are located in exon 4, which is included only in 
RAC1B (ENST00000356142.4) that encodes the longer isoform and is mainly expressed 
in gastrointestinal and epithelial tissues.175 Of particular note, there are no missense variants 
in exons 1, 2, 3, and 5 in the ExAC database (Figure 6.1B). Six out of seven mutations 
described here are in exons 2 and 3. The p.Cys157Tyr change (p.Cys176Tyr in the longer 
RAC1B) lies in a sub-region of exon 7 with no known germline human missense variants 
(Figure 6.1B). None of the identified mutations were present in any of the in-house variant 
databases of the four centers participating in this study. All six amino acids affected 
by the seven mutations are highly conserved among different species (Figure 6.1C). All 
reported RAC1 mutations are within or in proximity to G box residues and/or conserved 
residues present in 90% of the RAS superfamily members (Figure 6.1C).176  Collectively, the 
genetic data were strongly supportive of deleteriousness for each of the seven mutations.
Informed consent for publication of photographs was obtained from legal guardians. 
Detailed clinical information was collected on all affected individuals (Table 6.1; Figure 6.2; 
see Supplemental Note). All seven individuals (age range 4.5 months–15 years) had moderate 
to severe intellectual disability (ID) and variable degrees of neurological involvement including 
hypotonia (4/7), epilepsy (3/7), behavioral problems (3/7), and stereotypic movements (2/7). 
However, their occipital frontal circumferences (OFC) were remarkably different: individuals 1, 
2, 3, and 4 were microcephalic (OFCs of −2.5, −3, −5, and −2.5 SD, respectively), individual 
with dotted lines and the high conservation among different species of these amino acids is shown in the rectangle 
below. (D) Crystal structure of human RAC1 showing the position of the identified missense variants presented in this 
study. The sites of substitution are indicated by sticks in spheres and are color coded according to their putative impact 
on guanine nucleotide binding (cyan), protein-protein interactions (yellow), and structural stability (red). For reference, 
the non-hydrolyzable GTP analog GMPPNP bound to the structure is shown in sticks. The structure was analyzed and 
this figure was generated using the program ICM-Pro v3.8 (Molsoft, LLC).
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5 with p.Tyr64Asp mutation had a normal OFC (+1 SD), and individuals 6 and 7, both with 
mutations affecting Val51, were macrocephalic (OFCs of +4.16 and +4.5 SD, respectively) 
(Table 6.1; Figure 6.2). Hypoplasia of the corpus callosum and the cerebellar vermis were the 
commonest features observed on available magnetic resonance imaging (MRI) studies of 
individuals with microcephaly. However, they all had additional abnormalities (Supplemental 
Note; Figure 6.2). Individual 5 (with normal OFC) was reported to have polymicrogyria and 
hypoplastic corpus callosum (images not available). The two individuals with macrocephaly 
(individuals 6 and 7) showed periventricular white matter lesions (Table 6.1; Figure 6.2). 
Arched eyebrows, dysplastic ears, prominent nasal bridges, and overhanging columellae 
were shared between a majority of individuals without macrocephaly (Supplemental 
Note; Figure 6.2), but their facial dysmorphism does not overlap sufficiently to make this 
condition recognizable via their gestalt. Both individuals with macrocephaly displayed 
prominent broad foreheads, open mouth appearance, and scooped out appearance on 
lateral view (Figure 6.2). Collectively, the clinical data suggested a remarkable phenotypic 
variability in our cohort.
We mapped each of the seven identified mutations onto the available crystal structure of 
human RAC1 (PDB: 3TH5) (Figure 6.1D) to gain insights into their effect on the protein 
structure and function. The amino acids affected by the seven mutations could be 
categorized into three groups. (1) Cys18 and Cys157 are located in and adjacent 
to, respectively, the guanine nucleotide binding site that binds GTP/GDP. These 
two cysteinethiols can be oxidized by glutathionylation, a post-translational modification that 
alters GTP binding and exchange activities of RAC1.177 The p.Cys18Tyr and p.Cys157Tyr 
substitutions introduce a bulky aromatic residue in place of the thiol group and are 
expected to impact GTPase activity either by directly interfering with GTP binding or 
indirectly by abolishing the post-translational modification. (2) Asn39 is part of the switch 
I motif, while Tyr64 and Pro73 are within and adjacent to, respectively, the switch II 
motif. Both switch motifs are highly conserved regions involved in the interactions with 
various GEFs and GAPs (e.g., Rex1, DOCK),178 mediating the conformational changes for 
guanine nucleotide exchange (Supplemental Figure 1), and downstream effectors. 
Missense mutations affecting these residues are likely to impact the protein-protein 
interactions directly. (3) Val51 has no obvious involvement in GTP binding or interactions 
with GEF/GAPs. Free energy calculations by FoldX (in the SNPeffect 4.0 server)179 revealed 
a reduction of protein stability for these two substitutions (ΔΔG of 2.13 and 1.94 kcal/mol for 
p.Val51Met and p.Val51Leu, respectively).
RAC1 is known to regulate the spreading of fibroblasts plated onto fibronectin.180 The 
genetic data and in silico modeling suggested that the phenotypes are unlikely to result 
from haploinsufficiency. We reasoned that the RAC1 mutations identified in this study 
could be dominant negative or acting as constitutively active. If so, these mutations 
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should result in changes in fibroblast spreading. To test this hypothesis, we introduced 
selected RAC1 mutations in NIH 3T3 fibroblasts. Mammalian expression plasmids encoding 
GFP-Rac1, GFP-Rac1-T17N, and GFP-Rac1-Q61L were obtained from Prof. Viki Allan 
(Manchester). A Quikchange Lightning kit (Agilent Technologies) was used to introduce point 
mutations in the GFP-Rac1 expression plasmid. We generated plasmids encoding 
6/7 variants identified in this study (p.Cys18Tyr, p.Asn39Ser, p.Val51Met, p.Tyr64Asp, 
p.Pro73Leu, and p.Cys157Tyr) along with p.Thr17Asn that is known to have a dominant-
negative effect181 and p.Gln61Leu which is known to result in constitutive protein 
activation.182 NIH 3T3 fibroblasts were cultured in a 24-well plate and were transfected with 
methanol, 20% DMSO) at 4C. The embryos were first re-
hydrated in progressively decreasing methanol solutions,
bleached with 10% H2O2, 0.5% KOH, and 0.1% Triton-X.
After two washes in PBS, the tissue was permeabilized
with proteinase K followed by post-fixation with 4% PFA.
PFA-fixed embryos were washed first in PBS and subse-
quently in IF buffer (0.1% Tween-20, 1% BSA in PBS) for
10 min at room temperature. The embryos were incubated
in the blocking buffer (10% FBS, 1% BSA in PBS) for 1 hr at
room temperature. After two washes in IF buffer for 10 min
each, embryos were incubated overnight at 4Cwith 1:500
phospho histone 3 (PH3, a marker for proliferating cells)
primary antibody (ser10)-R (sc-8656-R, rabbit, Santa
Cruz) in blocking solution. After two additional washes
in IF buffer for 10 min each, embryos were incubated in
the secondary antibody solution (Alexa Fluor goat anti-
mouse IgG [A21207, Invitrogen] and donkey anti-rabbit
[A21206, Invitrogen], 1:1,000) in blocking solution for
1 hr at room temperature. Proliferating cells were quanti-
fied by counting all positive cells on a dorsal view of a 48
hpf embryos, excluding the eyes from the scored area, us-
ing the ITCN ImageJ plugin that counts cells with 10 pixel
width and 5 pixel minimum distance between them in
order to be considered as separate cells. Statistical
A
B
Figure 2. Facial Dysmorphism and Brain Abnormalities Observed in Individuals with RAC1 Mutations
(A) Frontal and lateral photographs of the faces of individuals 1–3 and 5–7. Individuals 1, 2, and 3 weremicrocephalic, individual 5 had a
normal occipital-frontal circumference, and individuals 6 and 7 had macrocephaly. Variable degrees of arched eyebrows, dysplastic ears,
prominent nasal bridge, and overhanging columella were noted. Individuals with macrocephaly have prominent broad foreheads,
slightly up-slanted palpebral fissures, open mouths, and ‘‘scooped out’’ appearance on lateral view.
(B) Panel 1 shows brain MRI images of individual 1: axial T2 images showing dysgenetic vermis and right cerebellar hemisphere (left),
cystis lesions in the right frontal deep white matter (middle, arrow), and sagittal T1 images (right) showing enlarged cisterna magna
(arrow). Panel 2 shows brain MRI images of individual 2: axial T2 images showing hypoplastic cerebellar vermis (left), slightly enlarged
lateral ventricles (middle), and sagittal T1 images (right) showing hypoplastic corpus callosum, pons (arrow head), hypoplastic lower
vermis, enlarged 4th ventricle, and cisterna magna (arrow). Panel 6 shows brain MRI image of individual 6: axial T2 image showing
non-specific white matter changes in the frontal and parietal lobes. No hydrocephalus or extra-axial fluid was observed. Panel 7 shows
brainMRI of individual 7: T2 weightedMRI images. Left: axial image showing very discrete bilateral patchy high intensity signal changes
in the deep white matter of the frontal and parietal lobes; right: mid-sagittal section showing, except for megalencephaly, normal brain
structures.
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Figure 6.2: Facial dysmorphism and brain abnormalities observed in individuals with RAC1 mutations.
(A) Frontal nd lateral photographs of the faces of individuals 1–3 and 5–7. Individuals 1, 2, and 3 were microcephalic, 
individual 5 had a normal occipital-frontal circumference, and individuals 6 and 7 had macrocephaly. Variable degrees 
of arched eyebrows, dysplastic ears, prominent nasal bridge, and overhanging columella were noted. Individuals with 
macrocephaly have prominent broad foreheads, slightly up-slanted palpebral fissures, open mouths, and “scooped out” 
appearance on lateral view. (B) Panel 1 shows brain MRI images of individual 1: axial T2 images showing dysgenetic 
vermis and right cerebellar hemisphere (left), cystis lesions in the right frontal deep white matter (middle, arrow), and 
sagittal T1 images (right) showing enlarged cisterna magna (arrow). Panel 2 shows brain MRI imag s of individual 2: 
axial T2 images showing hypoplastic cerebellar v rmis (left), slightly enl rged lateral ventricles (middle), and sagittal T1 
images (right) showing hypoplastic corpus callosum, pons (arrow head), hypoplastic lower vermis, enlarged 4th ventricle, 
and cisterna magna (arrow). Panel 6 shows brain MRI image of individual 6: axial T2 image showing non-specific white 
matter changes in the frontal and parietal lobes. No hydrocephalus or extra-axial fluid was observed. Panel 7 shows 
brain MRI of individual 7: T2 weighted MRI images. Left: axial image showing very discrete bilateral patchy high intensity 
signal changes in the deep white matter of the frontal and parietal lobes; right: mid-sagittal section showing, except for 
megalencephaly, normal brain structures.
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the Rac expression plasmids 24 hr after plating using Fugene 6 reagent (Promega). 48 hr 
after transfection, the fibroblasts were trypsinized then replated onto fibronectin-coated 
coverslips. 30 min after re-plating, the coverslips were rinsed with PBS and fixed with 4% 
paraformaldehyde (PFA). The fixed cells were then permeabilized with 0.1% Triton X-100 
in PBS followed by blocking with 1% BSA in PBS. The cells were stained with a rabbit 
anti-GFP (Invitrogen) antibody (1:500), followed by an Alexa 488 anti-rabbit secondary 
antibody (Invitrogen) and Alexa568-phalloidin (Invitrogen) before mounting in Prolong Gold 
(Invitrogen). Cells were imaged on a Nikon A1R confocal microscope, using a 60× 1.4NA oil 
objective.
Cell circularity values were obtained using ImageJ software. Cell perimeters were identified 
using the ImageJ “threshold” function and then circularity index (4π × area/perimeter2) 
was calculated using the “analyze particles” function. Circularity datasets were statistically 
analyzed using one-way ANOVA with Dunnett’s correction for multiple comparisons. At least 
50 cells were analyzed for each dataset except p.Asn39Ser, p.Tyr64Asp, p.Cys157Tyr (>40 
cells), and p.Gln61Leu (25 cells). Data were pooled from three independent experiments 
and highly expressing cells were excluded. Morphology was also assessed qualitatively 
by classifying cells according to their predominant actin protrusion type. Three categories 
were used: (1) >50% of cell perimeter occupied of filopodia, (2) >50% of perimeter occupied 
by lamellipodia/ruffles, and (3) mixed protrusions, with neither type occupying 50% of the 
perimeter.
The majority (51%) of cells transfected with wild-type Rac1 exhibited mixed protrusions, 
with the remaining cells split almost equally between those in which >50% the perimeter 
was occupied by filopodia or lamellipodia/ruffles (Figure 6.3A). As observed previously, 
transfection of the known dominant-negative p.Thr17Asn variant resulted in a filopodia-rich 
cell perimeter and a significantly reduced circularity index (Figures 6.3A–6.3C).180 By contrast, 
expression of the known constitutively active p.Gln61Leu variant resulted in virtually all cells 
exhibiting large lamellipodia or membrane ruffles and a significantly increased circularity 
index.183 Expression of the p.Cys18Tyr and p.Asn39Ser variants (seen in individuals 1 and 
2 with microcephaly) resulted in a phenotype reminiscent of dominant-negative Rac1, 
with an increase in the proportion of cells rich in filopodia and a reduction in cells rich in 
lamellipodia/ruffles (Figures 6.3A and 6.3C). Consistently, these mutations exhibited a 
significantly decreased circularity index (Figure 6.3B). By contrast, cells transfected with 
the p.Tyr64Asp substitution resulted in a phenotype more reminiscent of constitutive active 
Rac1, with significantly increased circularity index and a greater proportion of cells exhibiting 
lamellipodia or ruffles (Figures 6.3A–6.3C). Cells expressing p.Val51Met, p.Pro73Leu, and 
p.Cys157Tyr all showed a tendency toward increased filopodia and reduced lamellipodia 
but did not result in a significant change in circularity index relative to cells expressing wild-
type Rac, suggesting at most a modest impact on Rac function in these assays (Figures 
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6.3A–6.3C). All the Rac1 mutant proteins exhibited similar cellular localization to wild-type 
Rac1 with the exception of p.Tyr64Asp, which appeared to localize strongly to the leading 
edge of ruffles and lamellipodia (Figure 6.3C).
Next, we sought to explore the in vivo effects of RAC1 mutations in zebrafish embryos. 
Toward this, we identified rac1a as the sole zebrafish ortholog with highest degree of 
homology to the human RAC1 (90% similarity, 90% identity) and used the CRISPR/
significance for this assay was established using Student’s
t test. This assay showed significantly reduced cellular pro-
liferation for bothmutants (p¼ 0.0012 for p.Cys18Tyr and
p ¼ 0.0018 for p.Asn39Ser when compared to WT RAC1;
Figures 4C and 4D).
Finally, armed with prior knowledge that RAC1 has a
known role in cerebellar development36 together with
the observation that cerebellar abnormalities were re-
ported in 3/7 individuals in our cohort, we sought to study
the effect of the p.Cys18Tyr and p.Asn39Ser variants on
cerebellar development of our zebrafish model. For the
assessment of the cerebellum, embryos were fixed at 72
hpf in Dent’s fixative and subsequently whole-mount
stained following the same staining protocol as for
neuronal proliferation and usi g a primary antibody
against acetylated tubulin (1:1,000; Thr7451, mouse,
%
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Figure 3. Distinct RAC1 Mutations Genocopy Dominant-Negative or Constitutively Active Variants
(A) NIH 3T3 fibroblasts transfected with 500 ng of DNA per coverslip expressing the indicated Rac1 mutants and were fixed 30 min after
plating onto fibronectin and stained with Alexa-568 phalloidin to reveal the actin cytoskeleton and anti-GFP to reveal the expressed
construct. Cells were imaged by confocal microscopy and divided into the three indicated categories. At least 50 cells were analyzed
for each dataset except p.Asn39Ser, p.Tyr64Asp, p.Cys157Tyr (40 cells), and p.Gln61Leu (25 cells). Data were pooled from three
independent experiments.
(B) Graph showing mean circularity index of cells expressing indicated Rac1 mutants. Error bars indicate SEM. Datasets statistically
analyzed using ANOVA test with Dunnett’s correction for multiple comparisons. Asterisks indicate datasets significantly different to
WT (*p < 0.05, **p < 0.01, ***p < 0.001).
(C) Images of cells expressing the indicated RAC1 mutation. In each case the cell is a representative example of the most common
morphological category for that mutation (see A). Top panels show Alexa-568 phalloidin staining to reveal F-actin distribution, while
the panels immediately below show a magnified view of the boxed region from the top panels to highlight the morphology of actin
protrusions at the cell periphery. The third row of panels show the GFP channel of the same cells to reveal the distribution of the
expressed RAC1 mutation, and the bottom panels show a merge of the F-actin (red) and GFP (green) channels. All scale bars indicate
10 mm.
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Figure 6.3: Distinct RAC1 mutations genocopy dominant-N gative or constitutively active va iants.
(A) NIH 3T3 fibroblasts transfected with 500 ng of DNA per coverslip expressing the indicated Rac1 mutants and were 
fixed 30 min after plating onto fibronectin and stained with Alexa-568 phalloidin to reveal the actin cytoskeleton and 
a ti-GFP to rev al the expressed construct. Cells were imaged by confocal microscopy and divided into the three 
indicated categories. At least 50 cells were analyzed for each dataset except p.Asn39Ser, p.Tyr64Asp, p.Cys157Tyr 
(40 cells), and p.Gln61Leu (25 cells). Data were pooled from three independent experiments. (B) Graph showing mean 
circularity index of cells expressing indicated Rac1 mutants. Error bars indicate SEM. Datasets statistically analyzed 
using ANOVA test with Dunnett’s c rrection f r multiple comparisons. Asterisk  indicate dat sets significantly differ nt 
to WT (*p < 0.05, **p < 0.01, ***p < 0.001). (C) Images of cells expressing the indicated RAC1 mutation. In each case the 
cell is a representative example of the most common morphological category for that mutation (see A). Top panels show 
Alexa-568 phalloidin staining to reveal F-actin distribution, while the panels immediately below show a magnified view of 
the boxed region from the top panels to highlight the morphology of actin protrusions at the cell periphery. The third row 
of panels show the GFP channel of the same cells to reveal the distribution of the expressed RAC1 mutation, and the 
bottom panels show a merge of the F-actin (red) and GFP (green) channels. All scale bars indicate 10 μm.
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Figure 6.4: Overexpression of human RAC1 p.Cys18Tyr and p.Asn39Ser cause microcephaly, while p.Gln61Leu 
causes the mirror phenotype in zebrafish embryos.
Functional assessment of de novo variants in RAC1 by in vivo complementation in zebrafish larvae. (A) Dorsal view 
of 5 days post fertilization (dpf) control and overexpressant larvae. For each experiment, embryos were injected with 
either WT or mutant RAC1 human mRNA message. The embryos were allowed to grow to 5 dpf and imaged live for 
head size. The midbrain area between the eyes highlighted with the dashed red line was measured for every imaged 
embryo, to produce a quantitative score. (B) Bar graph of normalized values showing the quantification of the head size 
phenotype in control embryos and embryos injected with either WT or mutant human RAC1 message, from two plotted 
experiments. Statistical analyses were performed by Student’s t test. (C) Dorsal view of 2 dpf control and overexpressant 
larvae, fixed in Dent’s fixative and whole-mount immuno-stained with an anti-phospho histone 3 (PH3) antibody that 
marks proliferating cells. For each experiment, embryos were injected with either WT or mutant RAC1 human mRNA 
message. The embryos were allowed to grow to 2 dpf and subsequently were fixed, stained, and imaged. Embryos 
were imaged dorsally and z stacks were acquired every 100 nm. The z stacks were collapsed to produce an extended 
depth of focus (EDF) image that was then processed for scoring. The PH3-positive cells were counted for every 
embryo imaged using the ITCN plugin from ImageJ, to produce a quantitative score. (D) Bar graph of normalized 
values showing the quantification of the proliferating cell count phenotype, across three biological replicas. Statistical 
analyses for the neuronal proliferation experiments were performed by Student’s t test. (E) Dorsal view of 3 dpf 
A B
C D
E F
Figure 4. Overexpression of Human RAC1 p.Cys18Tyr and p.Asn39Ser Cause Microcephaly, while p.Gln61Leu Causes the Mirror
Phenotype in Zebrafish Embryos
Functional assessment of de novo variants in RAC1 by in vivo complementation in zebrafish larvae.
(A) Dorsal view of 5 days post fertilization (dpf) control and overexpressant larvae. For each experiment, embryos were injected with
either WT or mutant RAC1 human mRNA message. The embryos were allowed to grow to 5 dpf and imaged live for head size. The
midbrain area between the eyes highlighted with the dashed red line was measured for every imaged embryo, to produce a quantitative
score.
(B) Bar graph of normalized values showing the quantification of the head size phenotype in co trol embryos and embryos injected with
either WT or mutant human RAC1 message, from two plotted experiments. Statistical analyses were performed by Student’s t test.
(C) Dorsal view of 2 dpf control and overexpressant larvae, fixed in Dent’s fixative andwhole-mount immuno-stainedwith an anti-phos-
pho histone 3 (PH3) antibody thatmarks proliferating cells. For each experiment, e bryos were injected with eitherWTormutant RAC1
human mRNA message. The embryos we allowed to grow to 2 dpf and subsequently were fixed, stained, and imaged. Embryos w re
imaged dorsally and z stacks were acquired every 100 nm. The z stacks were collapsed to produce an extended depth of focus (EDF) image
(legend continued on next page)
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Cas9 system to introduce deletions, as a way to explore the phenotypic effects induced by 
loss of function of RAC1. Guide RNAs targeting the Danio rerio coding region of rac1 were 
generated as previously described.184; 185 We observed sequence aberrations in 30% of the 
evaluated rac1 clones (Supplemental Figure 2A). Assessment of mosaic F0 embryos injected 
with a guide against exon 2 did not result in statistically different head size counts between 
F0 CRISPR and control embryos (Supplemental Figure 2B). No overt morphological changes 
were observed in the genetically edited embryos.
We next considered a dominant effect of the RAC1 alleles. To test this hypothesis, we cloned 
the human wild-type RAC1 mRNA (GenBank: NM_018890) into the pCS2+ vector and 
transcribed in vitro using the SP6 Message Machine kit (Ambion). The mouse fibroblast 
spreading assays had indicated that dominant-negative effects could be a common 
mechanism for RAC1 mutations. We therefore introduced the two variants (p.Cys18Tyr 
and p.Asn39Ser) that were shown to be the strongest genocopies of the known dominant-
negative mutation using Phusion high-fidelity DNA polymerase (New England Biolabs) and 
custom-designed primers. Additionally, for sake of comparison, we also introduced the 
known dominant-negative (p.Thr17Asn) and constitutively active (p.Gln61Leu) mutants. 
Based on the dose-curve for the titration of the effect that WT RAC1 had on the head-size 
phenotype (Supplemental Figure 3), we injected 50 pg of WT or mutant RNA into wild-
type zebrafish embryos at the 1- to 4-cell stage. The injected larvae were grown to 5 dpf 
and imaged live on dorsal view. The area of the head was traced excluding the eyes from 
the measurements and statistical significance was calculated using Student’s t test. All 
experiments were repeated three times and scored blind to injection cocktail. Injection 
of RNA encoding p.Thr17Asn, p.Cys18Tyr, or p.Asn39Ser in zebrafish embryos induced 
a significant decrease in head-size (p < 0.0005) compared to controls (Figures 6.4A and 
6.4B). Injection of RNA encoding p.Gln61Leu induced a significant increase in head-size 
(p < 0.0001) compared to controls (Figures 6.4A and 6.4B). Importantly, the head-size 
could not be rescued by co-injection of mutant RAC1 with WT message (Supplemental 
Figure 4) arguing further in favor of these RAC1 mutations acting as dominant alleles in vivo, 
consistent with our results of mouse fibroblast spreading assay.
Driven by the fact that RAC1 is involved in neuronal proliferation,173 we next assessed 
neuronal proliferation in the brain of embryos injected with WT or a subset of 
mutant RAC1 (encoding p.Cys18Tyr or p.Asn39Ser). To do this, the injected embryos were 
control and overexpressant larvae for RAC1 WT and mutant conditions. The area of the cerebellum consisting of the 
neuronal axons that cross the midline is highlighted with a green dashed box. At least 50 embryos per condition were 
imaged live and evaluated at 3 dpf for the depletion of axons within the area highlighted. (F) Bar graph of cumulative 
plotted experiments across three biological replicas showing percentages of embryos with cerebellar defects. Statistical 
analyses for the cerebellar integrity assay using a χ2 test. Error bars define 95% confidence interval.
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fixed overnight at 48 hr post fertilization (hpf) in Dent’s fixative (80% methanol, 20% DMSO) 
at 4°C. The embryos were first rehydrated in progressively decreasing methanol solutions, 
bleached with 10% H2O2, 0.5% KOH, and 0.1% Triton-X. After two washes in PBS, the tissue 
was permeabilized with proteinase K followed by post-fixation with 4% PFA. PFA-fixed 
embryos were washed first in PBS and subsequently in IF buffer (0.1% Tween-20, 1% BSA 
in PBS) for 10 min at room temperature. The embryos were incubated in the blocking buffer 
(10% FBS, 1% BSA in PBS) for 1 hr at room temperature. After two washes in IF buffer for 
10 min each, embryos were incubated overnight at 4°C with 1:500 phospho histone 3 (PH3, 
a marker for proliferating cells) primary antibody (ser10)-R (sc-8656-R, rabbit, Santa Cruz) 
in blocking solution. After two additional washes in IF buffer for 10 min each, embryos were 
incubated in the secondary antibody solution (Alexa Fluor goat anti-mouse IgG [A21207, 
Invitrogen] and donkey anti-rabbit [A21206, Invitrogen], 1:1,000) in blocking solution for 1 hr 
at room temperature. Proliferating cells were quantified by counting all positive cells on a 
dorsal view of a 48 hpf embryos, excluding the eyes from the scored area, using the ITCN 
ImageJ plugin that counts cells with 10 pixel width and 5 pixel minimum distance between 
them in order to be considered as separate cells. Statistical significance for this assay 
was established using Student’s t test. This assay showed significantly reduced cellular 
proliferation for both mutants (p = 0.0012 for p.Cys18Tyr and p = 0.0018 for p.Asn39Ser 
when compared to WT RAC1; Figures 6.4C and 6.4D).
Finally, armed with prior knowledge that RAC1 has a known role in cerebellar development186 
together with the observation that cerebellar abnormalities were reported in 3/7 individuals 
in our cohort, we sought to study the effect of the p.Cys18Tyr and p.Asn39Ser variants 
on cerebellar development of our zebrafish model. For the assessment of the cerebellum, 
embryos were fixed at 72 hpf in Dent’s fixative and subsequently whole-mount stained 
following the same staining protocol as for neuronal proliferation and using a primary 
antibody against acetylated tubulin (1:1,000; Thr7451, mouse, Sigma-Aldrich). The embryos 
were then scored qualitatively assaying the integrity of the cerebellum by scoring for the 
presence and organization of axons along the midline of the structure (highlighted with a 
green dashed box; Figure 6.4E) and statistical significance was determined using a χ2 test. 
Structural defects in the integrity of the cerebellum consisted of depletion of the axons that 
cross the midline were observed only upon overexpression of RAC1 p.Cys18Tyr (p = 0.01) 
but not RAC1 p.Asn39Ser (p = 0.2) (Figures 6.4E and 6.4F). The latter is likely consistent with 
the more pronounced cerebellar defect observed in individual 1 (who harbors the p.Cys18Tyr 
variant) (Figure 6.2B).
In summary, we report seven individuals with de novo missense RAC1 mutations and 
variable developmental delay with additional features. Remarkably, the OCFs observed 
in this study ranged from −5 SD to +4.5 SD. Previously, some chromosomal regions have 
been associated with both microcephaly (deletions) and macrocephaly (duplications).187-189 
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However, it is extremely rare that point mutations within the same gene can cause differences 
of such magnitude (~10 SD) in head size of affected individuals. It is interesting to note 
that RAC1 is involved in mTOR signaling and other disorders in this pathway also result 
in significant alterations in head size.169; 190; 191 The variability of RAC1 phenotypes appear 
to be dependent on specific mutations, although the contribution of genetic background 
cannot be ruled out. In silico modeling, mouse fibroblasts spreading assays, and zebrafish 
experiments demonstrate that some RAC1 mutations (those encoding p.Cys18Tyr and 
p.Asn39Ser) genocopy a known dominant-negative mutant (p.Thr17Asn) and result in 
reduced neuronal proliferation, microcephaly, and cerebellar abnormalities in vivo. On 
the other hand, the in vitro effects of p.Tyr64Asp, seen in affected individual 5 with OFC 
within the normal range, are similar to the known constitutively active RAC1 mutation. Of 
note, in vitro expression of dominant-negative and constitutively active Rac1 have been 
previously shown to cause opposite effects on dendritic growth and morphology.170 However, 
the link between the human mutations and the resultant phenotypes is likely to be 
complex depending on the balance between interactors, regulators, and effectors of RAC1 
signaling.192 This is likely to be especially true for other RAC1 mutations identified in this 
study that could not be clearly classed as being either dominant negative or constitutively 
active (those encoding p.Val51Met, p.Pro73Leu, and p.Cys157Tyr). Further studies will be 
required in the future to uncover the precise underlying mechanisms of phenotypic variability 
of RAC1 mutations.
Our findings show that mutations in genes encoding members of the RhoGTPases-family 
can cause DDs. Of note, mutations in TRIO (MIM: 601893), a gene that encodes a RAC1 
GEF, have been shown to result in mild intellectual disability.193; 194 Interestingly, missense 
mutations in RAC-GEF domain of TRIO result in a more severe phenotype with global 
developmental delay, microcephaly, and reduced RAC1 activity.193 Furthermore, bi-allelic 
mutations in HACE1 (MIM: 610876), a known interactor of RAC1, have been recently shown 
to result in an autosomal-recessive syndrome with macrocephaly.195 Notably, overexpression 
of a WAVE mutant has been demonstrated to partially rescue axon growth in Rac1 knock-
out neurons,171 suggesting that some of the conditions in this group could be potentially 
treatable. Overall, a potentially treatable sub-category of rare DDs appears to be emerging 
with RAC1 as the central player.
Finally, our results show that ultra-rare disorders caused by private, non-recurrent missense 
mutations, resulting in varying phenotypic effects severity and degrees of severity, are 
challenging to dissect but can be delineated through focused international collaborations.
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Abstract
De novo mutations in specific mTOR pathway genes cause brain overgrowth in the context 
of intellectual disability (ID). By analyzing 101 mTOR-related genes in a large ID patient 
cohort and two independent population cohorts, we show that these genes modulate brain 
growth in health and disease. We report the mTOR activator gene RHEB as an ID gene that 
is associated with megalencephaly when mutated. Functional testing of mutant RHEB in 
vertebrate animal models indicates pathway hyperactivation with a concomitant increase 
in cell and head size, aberrant neuronal migration, and induction of seizures, concordant 
with the human phenotype. This study reveals that tight control of brain volume is exerted 
through a large community of mTOR-related genes. Human brain volume can be altered, by 
either rare disruptive events causing hyperactivation of the pathway, or through the collective 
effects of common alleles.
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Introduction
Many aspects of brain homeostasis, among which are measures of total brain volume, 
are highly heritable.196 Genome-wide association studies (GWAS) of brain volume have 
shown a polygenic architecture in the general population, with individual common genetic 
variants explaining <1% of phenotypic variance.197 Neurodevelopmental disorders, such 
as intellectual disability (ID) and autism spectrum disorder (ASD), have been associated 
with significant brain overgrowth. In ID, up to 6% of the patients are macrocephalic.28 One 
of the key regulators of normal brain development is the evolutionarily conserved Ser/Thr 
protein kinase Mammalian Target Of Rapamycin (mTOR). The role of the mTOR pathway in 
brain development and function has been intensively studied both in vitro and in vivo using 
different mouse models. In these models, mutations in either the downstream effectors of 
mTOR, or the most important upstream regulators of mTOR, such as Ras homolog enriched 
in brain (Rheb), tuberous sclerosis 1 (Tsc1), and Tsc2, have been tested.198; 199 Collectively, 
all studies provide strong evidence that proper mTOR signaling is involved in key aspects 
of brain development, such as neuronal progenitor maintenance and differentiation 
(including regulation of neuronal polarity, soma size and neurite outgrowth) and neuronal 
migration.200-211 In the mature brain, mTOR is an important regulator of synapse formation 
and synaptic function,212-215 in particular through its role in regulating protein translation and 
elongation.216-219 Not surprisingly, hyperactivity of the mTOR pathway in mice can lead to a 
myriad of phenotypes such as macrocephaly, seizures, and behavioral abnormalities.200; 220-225 
In contrast, sustained downregulation of the mTOR pathway appears to have little effect on 
neuronal function and behavior.226 Findings that the epilepsy and behavioral deficits in mice 
can be rescued by mTOR inhibitors, offers a broad therapeutic window in which patients can 
potentially be treated. Indeed, recent studies indicated that mTOR inhibition is a promising 
treatment for epilepsy in tuberous sclerosis complex (TSC) patients.227-231
Given the large body of evidence implying mTOR function in key aspects of brain 
development, it is not surprising that hyperactivating, somatic, and germline mutations in 
components of the PI3K-AKT3-mTOR pathway have been linked with rare ID syndromes 
associated with (hemi)megalencephaly, focal cortical dysplasia, and epilepsy.190; 232-234 We 
were struck by the apparent recurrence of mTOR-related mutations in ID, the persistent co-
morbid megalencephaly and the absence of studies investigating the overall contribution of 
the mTOR pathway to ID and brain growth. Considering this knowledge gap, we sought to 
identify deleterious germline mutations in mTOR-related genes, and assess their contribution 
to the development of ID and megalencephaly. Next, assuming that our findings are not only 
relevant to rare diseases such as ID, we hypothesized that the pathology of syndromic ID 
patients represents the extreme end of a more continuous contribution of the mTOR pathway 
to human brain development and neuroanatomical variance in the population. Our data 
indeed indicate that mTOR variation significantly contributes to megalencephaly in a large ID 
cohort and brain size in the population. Furthermore, we present that de novo mutations in a 
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key regulator of mTOR, RHEB, causes severe ID, epilepsy and megalencephaly in humans. 
By functionally testing the RHEB mutations in vertebrate animal models, we show that the 
specific mutations cause hyperactivation of mTOR, with a concomitant increase in cell and 
head size, aberrant neuronal migration and induction of seizures, concordant with the human 
phenotype. The extent of mTOR activation likely affects brain volume in humans. In extreme 
cases, highly deleterious mutations can lead to profound pathology. For such patients, 
functional restoration of the pathway through treatment with selective mTOR inhibitors might 
be of direct clinical utility.
Results
mTOR-related mutations are associated with macrocephaly
To assess the overall burden of mTOR defects to ID, we performed whole-exome 
sequencing (WES) in a cohort of 826 patients with ID cataloguing de novo mutations 
(Supplemental Data 7.1) in a set of 101 mTOR-related genes (Supplemental Data 7.2, 
Figure 7.1). We identified 17 de novo mutations affecting 10 different mTOR-related 
genes, providing a possible genetic diagnosis in 2.1% of our cohort. Five of the identified 
genes were known ID genes (PIK3R1, PIK3R2, RAF1, PPP2R5D, MTOR) and five 
(RHEB, RAC1, PPP2R5E, PPP2CA, ERK1) were not associated with ID previously (Figure 7.1, 
Table 7.1, Supplemental Data 7.3). Three of the five novel genes (RHEB, RAC1, and PPP2CA) 
showed a significant enrichment for de novo mutations in our patient cohort (Table 7.1, 
Supplemental Table 7.1). Combining the gene-specific mutation rates of all individual mTOR-
related genes, we found a significant enrichment for de novo mutations in mTOR-related 
genes (p = 3.50e−04) (Supplemental Table 7.1). Additionally, we found significant spatial 
clustering of de novo missense variants for a single gene (PPP2R5D: p < 1e−07; permutation 
test) and a general pattern of spatial clustering across the five genes with recurrent de novo 
missense variants (p = 0.0057, Fisher’s combined probability test; Supplemental Table 7.2).
To investigate the contribution of mTOR-related mutations on brain overgrowth, we 
performed a literature analysis of the 101 mTOR genes. This search showed that 23 genes 
had been previously reported to cause syndromic ID, with the majority (18/23; 78%) being 
associated with varying degrees of macrocephaly or relative macrocephaly (Supplemental 
Table 7.3). Motivated by this observation, we collected occipital frontal circumference (OFC) 
data from 732/826 patients (Supplemental Data 7.4). Macrocephaly was present in 6% of 
patients in our cohort (47/732 ID patients), a rate comparable to previous reports from an 
independent cohort3. De novo mutations were identified in 76% of our cohort (553/732 
patients; Table 7.2). Among the 35 patients presenting with ID, macrocephaly, and a de novo 
mutation, we found a significant enrichment (p = 9.084e−09) for de novo mutations within 
genes of the mTOR pathway (9/14) compared to genes that operate in mTOR independent 
pathways (26/539) (Table 7.2). In contrast, microcephaly was not enriched among patients 
with de novo mutations in mTOR-related genes (p = 0.4228).
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mTOR pathway contributes to intracranial volume
Driven by the high frequency of brain overgrowth described in the literature and the 
strong enrichment of macrocephaly in patients with mutations in mTOR-related genes 
in our cohort, we tested our set of 101 mTOR pathway genes for an association with 
intracranial volume (ICV) in the general population (Figure 7.1, Supplemental Table 7.2). 
Many aspects of brain homeostasis, among which aremeasures of total brain volume, are highly heritable1.Genome-wide association studies (GWAS) of brain
volume have shown a polygenic architecture in the general
population, with individual common genetic variants explaining
<1% of phenotypic variance2. Neurodevelopmental disorders,
such as intellectual disability (ID) and autism spectrum disorder
(ASD), have been associated with signiﬁcant brain overgrowth. In
ID, up to 6% of the patients are macrocephalic3. One of the key
regulators of normal brain development is the evolutionarily
conserved Ser/Thr protein kinase Mammalian Target Of
Rapamycin (MTOR). The role of the mTOR pathway in brain
development and function has been intensively studied both
in vitro and in vivo using different mouse models. In these
models, mutations in either the downstream effectors of mTOR,
or the most important upstream regulators of mTOR, such as Ras
homolog enriched in brain (Rheb), tuberous sclerosis 1 (Tsc1),
and Tsc2, have been tested4, 5. Collectively, all studies provide
strong evidence that proper mTOR signaling is involved in key
aspects of brain development, such as neuronal progenitor
maintenance and differentiation (including regulation of neuro-
nal polarity, soma size and neurite outgrowth) and neuronal
migration6–17. In the mature brain, mTOR is an important reg-
ulator of synapse formation and synaptic function18–21, in par-
ticular through its role in regulating protein translation and
elongation22–25. Not surprisingly, hyperactivity of the mTOR
pathway in mice can lead to a myriad of phenotypes such as
macrocephaly, seizures, and behavioral abnormalities6, 26–31.
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Fig. 1 Schematic overview of selected mTOR-related genes. Schematic representation of the genes (n= 101) included in our mTOR-related gene-set based
on three different authorative publications59–61. Both proteins acting upstream of mTOR and proteins acting downstream of mTOR were included.
Additionally, we subdivided the total set in two subsets: the RAS-MAPK-mTOR subset and the PI3K-AKT-mTOR subset. In both subsets, downstream
genes are included as well. Genes in which we identiﬁed de novo mutations in this study were marked with a yellow star, and genes previously reported to
cause ID and (relative) macrocephaly are shown in bolt and dark green
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00933-6
2 NATURE COMMUNICATIONS |8: 1052 |DOI: 10.1038/s41467-017-00933-6 |www.nature.com/naturecommunications
Figure 7.1: Schematic overview of selected mTOR-related genes. 
Schematic representation of the genes (n = 101) included in our mTOR-related gene-set based on three different 
authorative publication.249-251 Both proteins acting upstream of mTOR and proteins acting downstream of mTOR were 
included. Additionally, we subdivided the total set in two subsets: the RAS-MAPK-mTOR subset and the PI3K-AKT-
mTOR subset. In both subsets, downstream genes are included as well. Genes in which we identified de novo mutations 
in this study were marked with a yellow star, and genes previously reported to cause ID and (relative) macrocephaly are 
shown in bolt and dark green.
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The final data set contained 76,746 SNPs in 96 autosomal genes (data were unavailable 
for X-chromosomal ARAF, RPS6KA3, RPS6KA6, RRAGB, and PPP2R3B). Using the 
ENIGMA2 data set (n = 13,171) we found a significant association of the entire mTOR 
gene set with ICV for the self-contained test (p self-contained = 0.0029088) and a suggestive 
association for the competitive test (p competitive = 0.054742). Data from the CHARGE 
consortium (n = 12,803) similarly revealed a significant association of the mTOR 
gene set with ICV for the self-contained test, but not for the competitive test (p self-
contained = 0.00076589 and p competitive = 0.22105, respectively). Meta-analysis of the two 
data sets, confirmed the significant association of the mTOR gene set with ICV both 
for self-contained and competitive tests (p self-contained = 1.3895e−05, p competitive = 0.025764). 
Post hoc testing of the two major branches of the mTOR pathway separately (RAS-
MAPK-mTOR, 76 genes; PI3K-AKT-mTOR, 60 genes; Figure 7.1, Supplemental 
Table 7.1 Identified mutations with bonferroni corrected p-value and occipital frontal 
circumference (OFC) of patients with de novo mutations in mTOR-related genes
Patient key Gene c.DNA Protein 
change
Known 
ID gene
OFC Bonferroni corrected 
p-value
1 RHEB c.202T>C p.(S68P) No > +2.5 SD 4.514e-03*
2 RHEB c.110C>T p.(P37L) No > +2.5 SD
3 RHEB c.110C>T p.(P37L) No > +2.5 SD
4 RAC1 c.53G>A p.(C18Y) No < -2.5 SD 7.657e-03
5 RAC1 c.116A>G p.(N39S) No < -2.5 SD
6 PPP2R5E c.605T>G p.(V202G) No No data 1
7 PPP2CA c.882dup p.(R295*) No No data 1.696e-02
8 PPP2CA c.572A>G p.(H191R) No > +2.5 SD
9 ERK1 c.569T>C p.(I190T) No < -2.5 SD 1
10 PIK3R1 c.1359C>G p.(N453K) Yes Normal 7.662e-02
11 PIK3R1 c.1692C>G p.(N564K) Yes > +2.5 SD
12 PIK3R2 c.1117G>A p.(G373R) Yes > +2.5 SD 1
13 RAF1 c.1082G>C p.(G361A) Yes Normal 1
14 PPP2R5D c.1258G>A p.(E420K) Yes No data 7.832e-04
15 PPP2R5D c.598G>A p.(E200K) Yes > +2.5 SD
16 PPP2R5D c.592G>A p.(E198K) Yes > +2.5 SD
17 MTOR c.4555G>A p.(A1519T) Yes > +2.5 SD 1
Abbreviations: OFC = occipital frontal circumference; SD = standard deviation 
*In the statistical enrichment analysis, the RHEB p.(P37L) variant was considered as a single event. 
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Table 7.4) showed stronger association of PI3K-AKT-mTOR than RAS-MAPK-mTOR 
with ICV (PI3K-AKT-mTOR: p self-contained = 0.00092471, p competitive = 0.0079133; RAS-MAPK-
mTOR: pself-contained = 2.2885e−07, p competitive = 0.068983). The role of the PI3K-AKT-mTOR 
pathway in volumetric variation of the brain was further strengthened by testing the 
previously described Reactome_PI3K_AKT_activation gene-set235 (35 genes; p self-
contained = 3.8649e−13; p competitive = 0.00028957; Supplemental Table 7.5). Not all 96 genes in the 
gene-set analysis showed significant association with ICV individually. The most strongly 
associated individual gene was AKT3 (P = 2.22E−05) and in total, 18 genes of the mTOR gene 
set including APC (P = 0.00042), and the new ID gene RHEB (P = 0.0041), showed nominally 
significant association with ICV (Supplemental Figure 7.1; Supplemental Table 7.6).
RHEB mutations cause increased neuronal cell and head size
Two of the three individuals with de novo RHEB mutations were siblings and carried 
the same heterozygous p.(Pro37Leu) mutation, while a sporadic individual carried the 
p.(Ser68Pro) allele. The p.(Pro37Leu) mutation was not identified in either parent, suggesting 
parental gonadal mosaicism (Figure 7.2A). The RHEB mutations are located in the RAS 
domain (Figure 7.2B and C) and are absent from ExAC, EVS, or our internal clinical exome 
databases. All three individuals (Figure 7.2D) with de novo RHEB mutations had short stature 
(−2 to −3 SD) and early brain overgrowth with pronounced macrocephaly during childhood 
(+2.5/+3 SD). They had severe to profound ID with hypotonia, as well as autism spectrum 
disorder. Two of three individuals were reported to have epilepsy. No epileptic episodes 
were noted for the third patient, but EEG recordings were suggestive of epileptic discharges 
(Supplementary Note, Supplemental Table 7.7). Brain magnetic resonance imaging (MRI) 
evaluation of the patient with the p.(Ser68Pro) allele, confirmed megalencephaly with broad 
frontal lobes and mild dilatation of the lateral ventricles. The MRI scan further showed a 
thickened rostrum of the corpus callosum and small splenium, and mild hypoplasia of the 
lower cerebellar vermis (Figure 7.2E).
We selected the RHEB mutations to obtain experimental evidence for our hypothesis 
that de novo changes in mTOR-related genes are likely due to a gain-of-function 
Table 7.2 Number of patients with macrocephaly, normal OFC and microcephaly
Macrocephaly Normal OFC Microcephaly
Patients with clinical data (n=732) 47 580 105
Patients with de novo mutation(s) (n=553) 35 442 76
Patients with de novo mutation in mTOR-related gene (n=14) 9 2 3
Patients with de novo mutation in gene not related to MTOR (n=539) 26 440 73
Abbreviation: OFC = occipital frontal circumference 
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mechanism, resulting in hyperactivation of mTOR, as previously shown for other syndromic 
neurodevelopmental cases associated with macrocephaly. We first tested in vitro whether 
the RHEB de novo changes have an impact on overall mTOR activity levels. Given that 
mTORC1 regulates cell size,205; 236 we used primary hippocampal neuron soma size as a 
readout to assess differences between RHEB-WT overexpressing vs. RHEBp.P37L and 
p< 1e−07; permutation test) and a general pattern of spatial
clustering across thefive genes with recurrent de novo missense
variants (p= 0.0057, Fisher’s combined probability test; Supple-
mentary Table2).
To investigate the contribution of mTOR-related mutations
on brain overgrowth, we performed a literature analysis of the
101 mTOR genes. This search showed that 23 genes had
been previously reported to cause syndromic ID, with the
majority (18/23; 78%) being associated with varying degrees of
macrocephaly or relative macrocephaly (Supplementary Table3).
Motivated by this observation, we collected occipital frontal
circumference (OFC) data from 732/826 patients (Supplementary
Data 4). Macrocephaly was present in 6% of patients in our
cohort (47/732 ID patients), a rate comparable to previous reports
from an independent cohort3. De novo mutations were identified
in 76% of our cohort (553/732 patients; Table2). Among the
35 patients presenting with ID, macrocephaly, and a de novo
mutation, we found a significant enrichment (p= 9.084e−09) for
de novo mutations within genes of the mTOR pathway (9/14)
compared to genes that operate in mTOR independent pathways
(26/539) (Table 2). In contrast, microcephaly was not enriched
among patients with de novo mutations in mTOR-related genes
(p= 0.4228).
mTOR pathway contributes to intracranial volume . Driven by
the high frequency of brain overgrowth described in the literature
and the strong enrichment of macrocephaly in patients with
mutations in mTOR-related genes in our cohort, we tested our set
of 101 mTOR pathway genes for an association with intracranial
volume (ICV) in the g neral population (Fig.1, Supplementary
Table 2). The final data set contained 76,746 SNPs in 96 auto-
somal genes (data were unavailable for X-chromosomalARAF ,
RPS6KA3 , RPS6KA6 , RRAGB , and PPP2R3B). Using the
ENIGMA2 data set ( n= 13,171) we found a significant associa-
tion of the entire mTOR gene set with ICV for the self-contained
test (pself-contained= 0.0029088) and a suggestive association for
the competitive test (pcompetitive= 0.054742). Data from the
CHARGE consortium ( n= 12,803) similarly revealed a significant
association of the mTOR gene set with ICV for the self-contained
test, but not for the competitive test (pself-contained= 0.00076589
and pcompetitive= 0.22105, respectively). Meta-analysis of the two
data sets, confirmed the significant association of the mTOR
gene set with ICV both for self-contained and competitive tests
(pself-contained= 1.3895e−05, pcompetitive= 0.025764). Post hoc
testing of the two major branches of the mTOR pathway sepa-
rately (RAS-MAPK-mTOR, 76 genes; PI3K-AKT-mTOR, 60
genes; Fig.1, Supplementary Table4) showed stronger association
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Fig. 2 De novo mutations inRHEB cause an ID syndrome associated with megalencephaly.a Pedigree structure, disease status and genotype information
for patients with changes inRHEB. b Schematic of the RHEB protein and the RAS domain.c Schematic of the N-terminal portion of the human RHEB protein.
G-box residues characteristic of RAS superfamily proteins’ are shown in blue; highly conserved residue conserved in 90% of the RAS superfamily members
are shown in red. Dotted lines are showing the amino-acid residues mutated in patients described in the context of this study.d Photographs of the
probands carrying de novo variants inRHEB. e MRI images (left: axial, T2-weighted; right: sagittal midline, T1-weighted) of the proband (age 1 year,
9 months) carrying the de novoRHEBp.S68P variant, showing macrocephaly, megalencephaly, broad frontal lobes, mild dilatation oateral ventricles, large
rostrum of corpus callosum and mild hypoplasia of the lower cerebellar vermis. No cortical malformations have been observed
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Figure 7.2: De novo mutatio s in RHEB caus  an ID syndrome associated with megalencephaly. 
(A) Pedigree stru ture, disease status and genotype information f r patients with changes in RHEB. (B) Schematic of 
the RHEB protein and the RAS domain. (C) Schematic of the N-terminal portion of the human RHEB protein. G-box 
residues characteristic of RAS superfamily proteins’ are shown in blue; highly conserved residue conserved in 90% of 
the RAS superfamily members are shown in red. Dotted lines are showing the amino-acid residues mutated in patients 
described in the context of this study. (D) Photographs of the probands carrying de novo variants in RHEB. (E) MRI 
images (left: axial, T2-weighted; right: sagittal midline, T1-weighted) of the proband (age 1 year, 9 months) carrying 
the de novo RHEBp.S68P variant, showing macrocephaly, megalencephaly, broad fr ntal lobe , mild dilatation of 
lateral ventricles, large rostrum of corpus callosum and mild hypoplasia of the lower cerebellar vermis. No cortical 
malformations have been observed.
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RHEBp.S68P overexpressing neurons. A significant increase in soma size was detected 
already in RHEB-WT transfected neurons, suggesting that RHEB is a highly dosage sensitive 
gene, likely causing hyperactivation of the mTOR pathway.237 Overexpression of the RHEB 
mutant proteins caused an increase in soma size, confirming that these mutations do not 
cause a loss of function (Figures 7.3A and B, one-way ANOVA, p < 0.0001, F(3,260) = 50.35; 
control vector vs. RHEB-WT: p < 0.0001; control vector vs. RHEBp.P37L: p < 0.0001; 
control vector vs. RHEBp.S68P: p < 0.0001 by Tukey’s multiple comparisons test). Notably, 
overexpression of RHEBp.P37L had the strongest effect inducing a significantly pronounced 
increase in soma size compared to RHEB-WT (p < 0.05) and RHEBp.S68P (p < 0.05).
We next sought to evaluate the relevance of these variants in the development of 
neuroanatomical phenotypes in a developing zebrafish in vivo model. Toward this, 
we identified the sole zebrafish rheb ortholog (96% similarity, 91% identity). First, we 
corroborated that the variants identified are not acting through a loss of function mechanism 
by generating a CRISPR-Cas9 system to introduce deletions. Assessment of head size 
in mosaic F0 embryos injected with a guideRNA against exon 3 showed microcephaly in 
two biological replicates, which was opposite to the phenotype observed in the patients 
(Supplemental Figure 7.2). We next evaluated the effect of the rheb alleles on head size 
under a gain of function and mTOR hyperactivating paradigm, as suggested through our in 
vitro studies. To test this hypothesis, we injected human WT or mutant RHEB mRNA into 
1- to 4-cell stage zebrafish embryos. Expression of WT human RHEB induced a significant 
increase in the headsize area of 5 dpf larvae (p = 0.0013). Overexpression of either RHEBp.
P37L or p.S68P, also resulted in significantly increased headsize, reminiscent of the 
megalencephaly seen in our patients (p < 0.0001 for either mutant allele when compared to 
WT RHEB; Figures 7.3D and E). This finding was reproducible across three independent 
biological replicates.
Rapamycin rescues neuronal soma and head size defects
Antagonists of the mTOR pathway, such as rapamycin, can ameliorate some of neurological 
deficits associated with mTOR hyperactivity227-231. To evaluate whether this is true for 
the RHEB activating mutations described here, we treated the neurons with 20 nM 
rapamycin or vehicle 1 day after transfection for 3 days and assessed neuronal soma 
size. We found that while the soma size of RHEB-WT overexpressing neurons nominally 
decreased, a statistically significant reduction of neuronal soma size was observed for both 
RHEBp.P37L and RHEBp.S68P and a trend in the same direction was seen for RHEB-
WT (Figure 7.3C, two-way ANOVA, effect of treatment p < 0.0001, F(1,89) = 16.29; RHEBp.
P37L vehicle vs. RHEBp.P37L Rapamycin p < 0.01; RHEBp.S68P vehicle vs. RHEBp.S68P 
Rapamycin: p < 0.05; RHEB-WT vehicle vs. RHEB-WT Rapamycin: p = 0.1; by Bonferroni’s 
multiple comparisons test). Taken together, these data show that overexpression of either 
wild-type or mutant RHEB induces an mTOR-dependent increase in soma size and that 
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this phenotype can be rescued through the administration of the known mTOR antagonist 
rapamycin. Grounded on the in vitro observations, we next explored the possibility of 
rapamycin serving as a putative therapeutic agent in vivo. Toward this, we co-injected 
rapamycin together with WT or mutant RHEB mRNA in zebrafish embryos and we 
compared the embryos’ head size at 5 dpf. Rapamycin alone did not induce any appreciable 
neuroanatomical pathologies, or indeed any other overt morphological phenotype(s) 
(Figure 7.3E). In contrast, rapamycin sufficiently and reproducibly rescued the macrocephalic 
phenotype induced by both RHEBp.P37L and RHEBp.S68P, suggesting that suppression 
of mTOR hyperactivity might present a therapeutic target for disease ammelioration 
(Figure 7.3E).
of PI3K-AKT-mTOR than RAS-MAPK-mTOR with ICV (PI3K-
AKT-mTOR: pself-contained= 0.00092471, pcompetitive= 0.0079133;
RAS-MAPK-mTOR: pself-contained= 2.2885e−07, pcompetitive=
0.068983). The role of the PI3K-AKT-mTOR pathway in volu-
metric variation of the brain was further strengthened by testing
the previously described Reactome_PI3K_AKT_activation gene-
set42 (35 genes; pself-contained= 3.8649e−13; pcompetitive=
0.00028957; Supplementary Table 5). Not all 96 genes in the
gene-set analysis showed signiﬁcant association with ICV indi-
vidually. The most strongly associated individual gene was AKT3
(P= 2.22E−05) and in total, 18 genes of the mTOR gene
set including APC (P= 0.00042), and the new ID gene RHEB
(P= 0.0041), showed nominally signiﬁcant association with ICV
(Supplementary Fig. 1; Supplementary Table 6).
RHEB mutations cause increased neuronal cell and head size.
Tw of the three individuals with de novo RHEB mutations
were siblings and carried the same heterozygous p.(Pro37Leu)
mutation, while a sporadic individual carried the p.(Ser68Pro)
allele. The p.(Pro37Leu) mutation was not identiﬁed in either
parent, suggesting parental gonadal mosaicism (Fig. 2a). The
RHEB mutations are located in the RAS domain (Fig. 2b, c) and
are absent from ExAC, EVS, or our internal clinical exome
databases. All three individuals (Fig. 2d) with de novo RHEB
mutations had short stature (−2 to −3 SD) and early brain
overgrowth with pronounced macrocephaly during childhood
(+2.5/+3 SD). They had severe to profound ID with hypotonia, as
well as autism spectrum disorder. Two of three individuals were
reported to have epilepsy. No epileptic episodes were noted for
the third patient, but EEG recordings were suggestive of epileptic
discharges (Supplementary Note, Supplementary Table 7). Brain
magnetic resonance imagi g (MRI) evaluation of the patient with
the p.(Ser68Pro) allele, conﬁrmed megalencephaly with broad
frontal lobes and mild dilatation of the lateral ventricles. The MRI
scan further showed a thickened rostrum of the corpus callosum
and small splenium, and mild hypoplasia of the lower cerebellar
vermis (Fig. 2e).
We selected the RHEB mutations to obtain experimental
evidence for ur hypothesis that de novo changes in mTOR-
related genes are likely due to a gain-of-function mechanism,
resulting in hyperactivation of mTOR, as previously shown for
other syndromic neurodevelopmental cases associated with
macrocephaly. We ﬁrst tested in vitro whether the RHEB de
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Fig. 3 De novo mutations in RHEB increase soma size and headsize, phenotypes that can be rescued by rapamycin. a Representative confocal images of
hippocampal neurons transfected with control vector, RHEB-WT, RHEBp.P37L or RHEBp.S68P. b Summary bar graph of soma size measured for each
condition and normalized to the control vector. c Summary bar graph of soma size measured with and without rapamycin. Data are presented as mean±
SEM. Numbers depicted in the bar graph in b represent the number of independent cultures/total number of cells analyzed and in c number of cells
analysed. Statistical signiﬁcance was assessed by one-way ANOVA followed by Tukey’s post hoc test (*p< 0.01). d Dorsal view of 5 dpf control and
overexpressant zebraﬁsh larvae. For each experiment, embryos were injected with either WT or mutant RHEB human mRNA message. The area between
the eyes was measured for every embryo, to produce a quantitative score. e Bar graph showing the quantiﬁcation of the headsize phenotype in control
embryos and embryos injected with either WT or mutant human RHEB with and without rapamycin. The graph represents cumulative plotted experiments
across three biological replicas. Statistical analyses were performed by Student’s t-test
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Figure 7.3: De novo mutations in RHEB increase soma size and headsize, phenotypes that can be rescued by 
rapamycin. 
(A) Representative co foc l images of hippocampal neur ns transf cted with control vector, RHEB-WT, RHEBp.P37L 
o  RHEBp.S68P. (B) Summary bar g aph of soma size m asured for ach condition and normalized to the control 
vector. (C) Summary bar graph f soma size measured with and without rapamycin. Dat  are presented as mean ± SEM. 
Numbers depicted in the bar graph in b represent the number of independent cultures/total number of cells analyzed 
and in c number of cells analysed. Statistical significance was assessed by one-way ANOVA followed by Tukey’s post 
hoc test (*p < 0.01). (D) Dorsal view of 5 dpf control and overexpressant zebrafish larvae. For each experiment, embryos 
were injected with either WT or mutant RHEB human mRNA message. The area between the eyes was measured for 
every embryo, to produce a quantitative score. (E) Bar graph showing the quantification of the headsize phenotype in 
control embryos and embryos injected with either WT or mutant human RHEB with and without rapamycin. The graph 
represents cumulative plotted experiments across three biological replicas. Statistical analyses were performed by 
Student’s t-test.
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RHEB mutations affect neuronal migration and induce seizures
Previous studies have shown that mTOR signaling is not only involved in cell morphology 
and growth, but also plays a role in neuronal migration. Increased mTOR activity in 
vivo, induced either by overexpression of a constitutively active RHEB or by inactivating 
mutations in the Tsc1 or Tsc2 genes, two negative regulators of RHEB, causes neuronal 
migration defects206-211. We performed in utero electroporation at E14.5 to induce the in 
vivo overexpression of RHEB-WT, RHEBp.P37L, and RHEBp.S68P, and tested the effect 
of the RHEB mutations on neuronal migration in the still developing somatosensory cortex 
of P0 pups.238; 239 Although in neuronal cultures overexpression of RHEB-WT and RHEB 
mutants increased soma size equally, the results obtained in vivo showed notable differences 
between these proteins. We observed that while cells transfected with the control vector 
efficiently migrated to the cortical plate (CP), cells transfected with RHEB-WT could be 
found in all the layers of the cortex (Figure 7.4A). Strikingly, the majority of cells transfected 
with either RHEBp.P37L or RHEBp.S68P remained in the subplate (SP), indicating more 
severe migration deficits compared to RHEB-WT overexpression (Figure 7.4A). At P7, when 
the cortical layers are more defined, the difference between RHEB-WT and RHEBp.P37L 
or RHEBp.S68P was even more striking (Figure 7.4B). Analysis of the number of tdTomato-
positive cells present in the different cortical layers showed a significant difference between 
the four different conditions (two-way repeated measure ANOVA, effect of interaction: 
F(27,180) = 13.73, p < 0.0001), consistent with our previous in vitro and in vivo studies that 
the mutations in RHEB are gain-of-function hyperactivating mutations. Consistent with 
our findings in primary neuronal cultures, post hoc analysis revealed that the RHEBp.P37L 
mutation yielded the strongest effects among evaluated conditions (Figure 7.4C).
Neuronal migration deficits are often linked with seizures and ID.240 Additionally, the link 
between an epileptogenic phenotype and hyperactivity of the mTOR pathway has been 
established from studies in both human and mice.222; 224; 241 Interestingly, knockdown of 
the TSC1 gene, a negative regulator of the mTOR pathway, in just a subset of cortical 
neurons reduces the threshold for seizure induction.206 Careful monitoring of the in utero 
electroporated mice, revealed that overexpression of RHEB-WT, RHEBp.P37L, and RHEBp.
S68P resulted in spontaneous tonic–clonic seizures starting at P20 (Supplemental Movie 7.1). 
Seizures were particularly common in mice expressing mutant RHEB: whereas 20% (2/10) of 
mice expressing RHEB1-WT developed epilepsy, all (7/7) mice expressing RHEBp.P37L and 
83% (5/6) of mice expressing RHEBp.S68P developed spontaneous seizures (Figure 7.4D). 
Consistent with our findings from primary neuronal cultures and neuronal migration following 
in utero electroporation, the RHEBp.P37L allele was shown to have the strongest effect, as 
the mice expressing this allele also showed a significantly earlier onset of seizures (log-
rank (Mantel–Cox) p < 0.01 compared to RHEBp.S68P; Figure 7.4D). Taken together, our in 
vivo results further corroborate the conclusion that the missense mutations in RHEB act as 
dominant activating mutations.
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Discussion
Here we studied the contribution of mTOR-related genes to ID and brain overgrowth in 826 
ID patients unselected for any other phenotypic features and found 17 germline de novo 
mutations in genes related to mTOR, providing a possible genetic diagnosis for 2.1% of our 
cohort. We show that genes encoding components of the mTOR pathway, contribute to rare 
and common alleles that impact brain volume and provide insight into neurodevelopmental 
processes mediated through mTOR hyperactivity and outlook to potential treatment options 
for a subset of patients with ID.
A significant fraction of patients harboring a de novo mutation in mTOR-related genes was 
novo changes have an impact on overall mTOR activity
levels. Given that mTORC1 regulates cell size11, 43, we used
primary hippocampal neuron soma size as a readout to assess
differences between RHEB-WT overexpressing vs. RHEBp.P37L
and RHEBp.S68P overexpressing neurons. A signiﬁcant increase
in soma size was detected already in RHEB-WT transfected
neurons, suggesting that RHEB is a highly dosage sensitive
gene, likely causing hyperactivation of the mTOR pathway44.
Overexpression of the RHEB mutant proteins caused an
increase in soma size, conﬁrming that these mutations do not
cause a loss of function (Fig. 3a, b, one-way ANOVA, p< 0.0001,
F(3,260)= 50.35; control vector vs. RHEB-WT: p< 0.0001;
control vector vs. RHEBp.P37L: p< 0.0001; control vector
vs. RHEBp.S68P: p< 0.0001 by Tukey’s multiple comparisons
test). Notably, overexpression of RHEBp.P37L had the strongest
effect inducing a signiﬁcantly pronounced increase in soma
size compared to RHEB-WT (p< 0.05) and RHEBp.S68P
(p< 0.05).
We next sought to evaluate the relevance of these variants in
the development of neuroanatomical phenotypes in a developing
zebraﬁsh in vivo model. Toward this, we identiﬁed the sole
zebraﬁsh rheb ortholog (96% similarity, 91% identity). First, we
corroborated that the variants identiﬁed are not acting through a
loss of function mechanism by generating a CRISPR-Cas9 system
to introduce deletions. Assessment of head size in mosaic F0
embryos injected with a guideRNA against exon 3 showed
microcephaly in two biological replicates, which was opposite to
the phenotype observed in the patients (Supplementary Fig. 2).
We next evaluated the effect of the rheb alleles on head size under
a gain of function and mTOR hyperactivating paradigm, as
suggested through our in vitro studies. To test this hypothesis, we
injected human WT or mutant RHEB mRNA into 1- to 4-cell
stage zebraﬁsh embryos. Expression of WT human RHEB
induced a signiﬁcant increase in the headsize area of 5 dpf larvae
(p= 0.0013). Overexpression of either RHEBp.P37L or p.S68P,
also resulted in signiﬁcantly increased headsize, reminiscent of
the megalencephaly seen in our patients (p< 0.0001 for either
mutant allele when compared to WT RHEB; Fig. 3d, e). This
ﬁnding was reproducible across three independent biological
replicates.
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Fig. 4 Overexpression of RHEB mutants in vivo causes deﬁcits in neuronal migration and seizures in mouse. a, b Representative images of E14.5 in utero
electroporated P0 brains (a) or P7 brains (b), with an enlargement showing the migratory pathway of the transfected cells (tdTomato+) from the
intermediate zone (IZ) and subplate (SP) to the more superﬁcial layers of the cortex (CP= cortical plate and MZ=marginal zone). c Quantiﬁcation of the
neuronal migration pattern observed in different conditions. Data are presented as mean± SEM. Statistical signiﬁcance was assessed by two-way repeated
measure ANOVA followed by Bonferroni’s post hoc test (for bins 2–4: *indicates signiﬁcant difference between control vector and the different RHEB
conditions (p< 0.0001); #indicates signiﬁcant difference between the RHEB-WT and all other conditions (p< 0.0001); for bins 9 and 10: *indicates
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RHEBp.P37L and RHEBp.S68P (p< 0.001). d Kaplan–Meier graph representing onset of tonic–clonic seizures in successfully targeted mice. The insert
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Figure 7.4: Overexpression of RHEB mutants in vivo causes deficits in neuronal migra ion and seizures in ouse. 
(A,B) Repr sent tive im ges of E14.5 in utero electroporated P0 brains (a) or P7 brains (b), with an e largement showing 
the igratory pathway of the transfected cells (tdTomato+) from the intermediate zone (IZ) and subplate (SP) to the more 
superficial layers of the cortex (CP = cortical plate and MZ = marginal zone). (C) Quantification of the neuronal migration 
pattern observed in different conditions. Data are presented as mean ± SEM. Statistical significance was assessed by 
two-way repeated measure ANOVA followed by Bonferroni’s post hoc test (for bins 2–4: *indicates significant difference 
between control vector and the different RHEB conditions (p < 0.0001); #indicates significant difference between the 
RHEB-WT and all other conditions (p < 0.0001); for bins 9 and 10: *indicates significant difference between control 
vector and RHEBp.P37L and RHEBp.S68P; #indicates significant difference between RHEB-WT and RHEBp.P37L and 
RHEBp.S68P (p < 0.0001)); §indicates significant difference between RHEB-WT and RHEBp.P37L (p < 0.0001); £indicates 
significant difference between RHEBp.P37L and RHEBp.S68P (p < 0.001). (D) Kaplan–Meier graph representing 
onset of tonic–clonic seizures in successfully targeted mice. The insert legends of the graph show Npictures/N mice (c) 
or N seizure/N total (d).
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observed to be macrocephalic. The link between mTOR mutations and ID and/or head 
size differences has already been established through numerous studies that identified 
genes such as AKT3, PIK3CA, PPP2R5D, and recently MTOR itself.190; 232; 233; 242 In fact, from 
the 23 genes previously reported to cause ID among our gene-set of 101 mTOR-related 
genes, most (18/23, 78%) have been associated in the literature with macrocephaly or 
relative macrocephaly. Our study significantly extends these findings: of the 35 patients 
with macrocephaly in the complete cohort, 9 patients (26%) harbored a de novo mutation 
in mTOR-related genes. As such, genes in this pathway should be carefully evaluated in 
patients with ID and macrocephaly.
Motivated by the high frequency of brain overgrowth in previous reports of mTOR-related 
syndromes, and in patients with mutations in mTOR-related genes in our cohort, we 
reasoned that the highly penetrant activating alleles that we identified de novo might 
represent only a fraction of alleles associated with severe neurocognitive disorders, and that 
more common and less penetrant alleles might be associated with head and brain growth in 
the general population. Indeed, a combined analysis of common variants of all 96 autosomal 
genes in the mTOR-related gene-set showed significant association with ICV in two large 
imaging genetics samples from the CHARGE and ENIGMA consortia, confirming our initial 
hypothesis. Interestingly, the PI3K-AKT-activation pathway (35 genes from the reactome 
gene-set) was recently shown to be among the most strongly associated pathways for ICV 
in an enrichment analysis testing 671 Reactome gene-sets using the same cohorts.235 Our 
analyses support and expand this conclusion by testing a different, carefully selected gene-
set (only 15 out of 96 genes overlapping). Taken together, our data support a model by which 
mTOR-related genes, including the newly discovered ID gene RHEB, contribute to variation 
in brain growth, through common and rare genetic variants, in health and disease. Our 
observations corroborate, how rare disorders can inform biological mechanisms underlying 
common traits in the general population.
There is ongoing debate on the precise genetic composition of gene-sets. Gene-set 
databases, such as KEGG, Ingenuity, and others, all differ in their coverage of specific 
biological pathways and their functional annotations. In line with this observation, the 
number of genes mapped to pathways may also vary greatly across the databases.243 
For mTOR-related gene-sets, inclusion in databases is incomplete, with key proteins and 
protein complexes such as RAC1, RAG, MEK, and PP2A missing. For this reason, we used 
three authorative reviews on mTOR signaling describing both upstream and downstream 
interactors of mTOR and then used additional evidence from the literature to subdivide 
various protein complexes into their constituent proteins and genes. Therefore, our selection 
of 101 mTOR-related genes might be incomplete and additional genes are likely to be 
involved in mTOR signaling. For this reason and because of limitation of our methods to 
detect reliably somatic mosaicism, a mechanism thought to be a significant contributor to 
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mutation burden in this pathway,190; 232; 233 we postulate that the diagnostic rate within our 
cohort (2.1%) might represent the lower bound of the estimate.
In this study, we identified de novo mutations in both known ID genes 
(PIK3R1, PIK3R2, RAF1, PPP2R5D, MTOR) and novel candidate ID genes 
(RHEB, RAC1, PPP2R5E, PPP2CA, ERK1). For the most frequently mutated gene, RHEB, 
we show that hyperactivating mutations cause an ID syndrome with brain overgrowth and 
epilepsy. The finding that these mutations are hyperactivating, is in line with the observation 
that loss of RHEB activity does not result in overt neurological phenotypes in Rheb mutant 
mice.226 Several mechanisms, such as increased proliferation, increased soma size and 
reduced apoptosis are known to have a role in the development of megalencephaly.244 We 
observed a significant increase in soma size upon overexpressing WT and mutant RHEB 
alleles in vitro. Since RHEB is the canonical activator of mTOR, this finding is consistent with 
other reports that have highlighted mTOR as a main regulator of cell size.200; 205; 209; 245 In vivo, 
we postulate that the increased soma size might represent one of the mechanisms through 
which macrocephaly occurs, as the zebrafish embryos injected with mutant RHEB were 
phenotypically concordant with the human patients. Further dissecting the 
pathomechanism(s) underlying RHEB-associated ID, we showed severe neuronal migration 
defects in mouse embryos electroporated with mutant RHEB and an increased incidence 
of epileptogenic activity postnatally. These findings are reminiscent to what has been 
observed for mutations of MTOR itself. Constitutive activation of mTORC1 causes enlarged 
neuronal somata in rodent neurons, and focal cortical expression of MTOR mutations has 
been reported to disrupt neuronal migration and to cause spontaneous seizures by in utero 
electroporation in mice.233; 234; 246 This observation shows that activating mutations in different 
genes of the mTORC1 branch of the mTOR pathway act through convergent mechanisms 
and have similar phenotypic outcomes.
Based on these observations, we reasoned that patients with activating RHEB changes 
might be able to benefit from therapies that result in a reduction of mTOR activity, such 
as rapamycin. Indeed, we here showed that suppression of mTOR levels through the 
administration of the mTOR antagonist rapamycin can significantly and reproducibly prevent 
both the neuronal soma size phenotype in vitro and the macrocephalic phenotype in vivo. 
Recent studies have reported successful implementation of mTOR inhibitor treatment in 
individuals with TSC-associated epilepsy and brain tumors.227-231 In a conceptually similar 
paradigm, fibroblasts from a patient with an mTOR activating PIK3CA change, were 
treated successfully with the PI3K inhibitors wortmannin or LY294002, which abrogated the 
overactivation of the pathway.247 It is premature to advocate the use of rapamycin in patients 
with ID and mutations in all mTOR-related genes, not least because of the potentially adverse 
effects induced by prolonged exposure to this agent.248 However, we speculate that targeted 
administration of mTOR inhibitors (rapamycin, wortmannin, everolimus as well as currently 
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emerging second-generation drugs), perhaps during critical postnatal neurodevelopmental 
windows, might be of significant benefit to patients. In that context, rapid molecular 
diagnosis in both known ID genes and candidate ID genes, would be a critical component of 
the treatment decision process.
In conclusion, our data show that a large number of mTOR-related genes together modulate 
human brain volume in the population. Severe disruption of such mTOR-related genes can 
cause intellectual disability and brain overgrowth, most likely through mTOR hyperactivation.
Material and methods
Subjects and mutation analysis
We evaluated a cohort of 826 patients with ID, who had undergone diagnostic trio WES 
at Radboud University Medical Center (Radboudumc). We included 820 simplex patients 
described previously, as well as three sib pairs excluded from the earlier study.126 Diagnostic 
WES was approved by the medical ethics committee of the Radboud University Medical 
Center (Commissie Mensgebonden Onderzoek), Nijmegen, The Netherlands (registration 
number 2011-188).Written informed consent was obtained from all individuals or their legal 
guardians. We collected all available clinical information and performed deep phenotyping 
of individuals with a de novo mutation in RHEB. Consent for publication of photographs was 
obtained. Brain images were re-evaluated where available.
Selection of mTOR-related genes
We focused on the two well-described, convergent pathways in which mTOR acts as 
key regulator: the PI3K-AKT-mTOR pathway and the RAS-MAPK-mTOR pathway. We 
defined a list of 101 mTOR-related genes based on three authorative reviews on the mTOR 
regulators.249-251 Protein complexes were mapped to single proteins and genes based on 
information available in the literature. The final list contains 101 mTOR-related genes: 96 map 
on autosomes and five map on the X-chromosome.
Identification of mutations and collection of OFC data
From our cohort of 826 patients with ID, we selected all de novo mutations that affect 
mTOR-related genes. All mutations were confirmed by Sanger sequencing. mTOR-related 
genes were considered to be known ID genes, if present in our recently published list 
containing over 1500 known ID genes.126 We performed a literature search by querying 
Pubmed to investigate which of the known mTOR-related ID genes have been associated 
with large or small head size. Within our cohort of 826 patients, individuals were classified as 
microcephalic (OFC < −2.5 SD), macrocephalic (OFC >  +2.5 SD), normocephalic (OFC between 
−2.5 SD and +2.5 SD) or unknown. We used Fisher’s Exact test to calculate enrichment 
of macrocephaly in mTOR-related mutation carriers. The significance threshold was set 
at p < 0.05.
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Gene-based enrichment
To assess whether mTOR-related genes were significantly enriched for functional de novo 
mutations in our cohort, we tested each of the 101 genes using a statistical model as 
described previously.126 For this statistical enrichment analysis, the RHEB p.(P37L) variant 
was considered as one single event. Multiple testing correction was performed by the 
Bonferroni procedure based on 101 tested genes. Additionally, we tested whether the 
mTOR pathway as a whole was enriched for functional de novo mutations in our cohort by 
combining the gene-specific mutation rates of all individual genes in the pathway.
Clustering analysis
Clustering analysis was performed by generating the full cDNA for the respective RefSeq 
genes. To increase the statistical power of the spatial clustering of the recurrently mutated 
genes, we added de novo missense variants from the denovo-db252 annotated by our 
in-house pipeline (Supplemental Data 7.5). The locations of observed de novo missense 
mutations were randomly sampled 100,000 times over the cDNA of the gene after which 
the distances (in base pairs) between the mutations were normalized for the total coding 
size of the respective gene. The geometric mean (the nth root of the product of n numbers) 
of all mutation distances between the mutations was taken as a measure of clustering. 
A pseudocount (adding 1 to all distances and 1 to the gene size) was applied to avoid a 
mean distance of 0 when there were identical mutations. To assess overall clustering of 
the set of genes, we used Fisher’s combined probability test to combine the 5 p-values of 
individual genes. To avoid a possible bias introduced by highly significant p-values (e.g., 
gene PPP2RD5), we calculated the combined p-value on deflated p-values where all values 
smaller than 0.05 were set to 0.05.
ENIGMA and CHARGE study populations and data description
This study reports data on 25,974 subjects of Caucasian ancestry from 46 study 
sites that are part of the Enhancing NeuroImaging Genetics through Meta-Analysis 
(ENIGMA)253 consortium (13,171 subjects) and Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE; 12,803 subjects).254 Briefly, the ENIGMA consortium 
brings together numerous studies, mainly with case–control design, which performed 
neuroimaging in a range of neuropsychiatric or neurodegenerative diseases, as well as 
healthy normative populations. The CHARGE consortium is a collaboration of predominantly 
population-based cohort studies that investigate the genetic and molecular underpinnings 
of age-related complex diseases, including those of the brain. An overview of the 
demographics and type of contribution for each cohort is provided in Supplemental Table 
7.8 (Table adapted from original publication by Adams et al.235). Written informed consent 
was obtained from all participants. The study was approved by the institutional review 
board of the University of Southern California and the local ethics board of Erasmus MC 
University Medical Center. Procedures of whole-genome genotyping, imputation, MRI, 
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GWAS, and meta-analysis are summarized in Supplemental Methods (adapted from original 
publication235). The meta-analysis data from the recent ENIGMA2 and CHARGE studies of 
ICV were available as genome-wide summary statistics, including genome-wide single-
nucleotide polymorphism (SNP) data with corresponding p-values. The ENIGMA consortium 
has completed a meta-analysis of site-level GWAS in a discovery sample of 13,171 subjects 
of European ancestry.197; 253 Access to the summary statistics of ENIGMA can be requested 
via their website (http://enigma.ini.usc.edu/download-enigma-gwas-results/). The CHARGE 
consortium has completed meta-analysis of site-level GWAS in a discovery sample of 
12,803 subjects of European ancestry.235 Genome-wide summary statistics of the CHARGE 
consortium has been requested by the principal investigator of the study described by 
Adams et al.235 For both data sets, only SNPs with an imputation quality score of RSQ ≥ 0.5 
and a minor allele frequency ≥0.005 within each site were included. Procedures of whole-
genome genotyping, imputation, magnetic resonance imaging (MRI), GWAS, and meta-
analysis of the cohorts are summarized in the Supplemental Methods.
Gene-based and gene-set analyses
Gene-based and gene-set analyses were performed using the Multi-marker Analysis 
of GenoMic Annotation (MAGMA) software package (version 1.02).255 First, gene-
based p-values were calculated using a symmetric 100 kb flanking region for each cohort 
separately for the 96 autosomal genes in the mTOR pathway. Genome-wide SNP data 
from a reference panel (1000 Genomes, v3 phase1)256 was annotated to NCBI Build 37.3 
gene locations using a symmetric 100 kb flanking window, and both files were downloaded 
from http://ctglab.nl/software/magma. Next, the gene annotation file was used to map the 
genome-wide SNP data from the different studies (ENIGMA2 and CHARGE), to assign SNPs 
to genes and to calculate gene-based p-values for each cohort, separately. Since data from 
the genome-wide association analyses only included autosomal SNPs, five genes located 
on the X-chromosome were omitted from the analysis. For the gene-based analyses, single 
SNP p-values within a gene were transformed into a gene-statistic by taking the mean of 
the χ 2-statistic among the SNPs in each gene. To account for linkage disequilibrium (LD), 
the 1000 Genomes Project European sample was used as a reference to estimate the LD 
between SNPs within (the vicinity of) the genes (http://ctglab.nl/software/MAGMA/ref_data/
g1000_ceu.zip). Gene-wide p-values were converted to z-values reflecting the strength of 
the association of each gene with the phenotype (ICV), with higher z-values corresponding 
to stronger associations. Subsequently, we tested, whether the genes in the mTOR gene-
set were jointly associated with ICV in the ENIGMA2 data set, using self-contained and 
competitive testing.257 For the gene-set analyses, we used an intercept-only linear regression 
model including a subvector corresponding to the genes in the gene-set. This self-contained 
analysis evaluating, whether the regression coefficient of this regression was larger than 0, 
tests whether the gene-set shows any association with ICV at all. Next, we tested whether 
genes in each gene-set were more strongly associated with ICV than all other genes in the 
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genome. Therefore, the regression model was then expanded including all genes outside the 
gene-set. With this competitive test, the differences between the association of the mTOR 
gene-set to genes outside this gene-set is tested, accounting for the polygenic nature of a 
complex trait like ICV. To account for the potentially confounding factors of gene size and 
gene density, both variables as well as their logarithms were included as covariates in the 
competitive gene-set analysis. Since self-contained tests do not take into account the overall 
level of association across the genome, gene-size (number of principal components, or 
SNPs) and gene density, we were interested in the competitive test for the current analysis. 
The same procedure was followed for analysis of the CHARGE cohort. In addition to the 
gene-set analyses within the individual cohorts, we meta-analyzed data of both cohorts 
on the gene-level followed by gene-set analysis. Post hoc, the potential effects of the two 
separate mTOR pathways in the gene-set (the PI3K-AKT-mTOR pathway (60 genes) and the 
RAS-MAPK-mTOR pathway (76 genes)) as well as the individual genes were investigated, by 
reviewing their gene test-statistics. Moreover, the Reactome_PI3K_AKT_activation gene-
set, consisting of 38 genes, was tested for its association with ICV (downloaded from http://
software.broadinstitute.org/gsea/msigdb/genesets.jsp). Genes were considered gene-wide 
significant, if they reached the Bonferroni correction threshold adjusted for the number of 
genes within the total gene-set (N = 96; p < 0.000521).
Generation of zebrafish rheb mutants
All animal experiments were carried out with the approval of the Institutional Animal 
Care and Use Committee (IACUC). Guide RNAs targeting the Danio rerio coding region 
of rheb were generated as described.185 Subsequently, rheb guide oligonucleotide 
sequences (rheb_ex3_g1F: 5′-TAGGGTCGTGGAACGCAGCGTTCA-3′ and rheb_ex3_g1R: 
5′-AAACTGAACGCTGCGTTCCACGAC-3′) were ligated into the pT7Cas9sgRNA vector 
(Addgene) into Bsm BI sites. For the generation of gRNA, the template DNA was linearized 
with Bam HI, purified by phenol/chloroform extraction and in vitro transcribed using the 
MEGAshortscript T7 kit (Invitrogen). To generate F0 CRISPR mutants we injected 1 nl 
containing 100 pg rheb guide RNA and 200 ng Cas9 protein (PNA bio, CP01) to 1-cell stage 
embryos. To determine the efficiency of the guide RNA, embryos were allowed to grow 
to 5 days post fertilization (dfp), at which time they were killed and subjected to digestion 
with proteinase K (Life Technologies) to extract genomic DNA. The targeted locus was PCR 
amplified using the drrheb_g1test_1 F 5′-GAGTGATCAGCTGTGAAGAAGG-3′ and drrheb_
g1test_1 R 5′-GAACAGCGACAGGAGCTACA-3′ primer pair. PCR amplicons were digested 
using T7 endonuclease I (New England Biolabs) at 37 °C for 1 h and were visualized on a 
2% agarose gel. For Sanger sequencing of individual products from the rheb locus, PCR 
fragments from four embryos with a positive T7assay were cloned into the pCR4/TOPO TA 
cloning vector (Life Technologies), and 40 colonies from each cloned embryo were Sanger 
sequenced. We observed sequence aberrations in ~75% of the evaluated rheb clones.
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In vivo modeling in zebrafish embryos
The human wild-type258 mRNA of RHEB (NM_005614) was cloned into the pCS2+ vector 
and transcribed in vitro using the SP6 Message Machine kit (Ambion). The variants identified 
in RHEB in our patient cohort (RHEBp.P37L, RHEBp.S68P) were introduced using Phusion 
high-fidelity DNA polymerase (New England Biolabs) and custom-designed primers. We 
injected 50 pg of WT or mutant RNA into wild-type zebrafish embryos at the 1- to 4-cell 
stage. For the experiments with rapamycin treatment we added 2.7 nM of ready-made 
rapamycin solution in DMSO (R8781, Sigma-Aldrich) in each of the injection cocktails. For 
the headsize assay, the injected larvae were grown to 5 dpf and imaged live on dorsal view. 
The area of the head was traced excluding the eyes from the measurements and statistical 
significance was calculated using Student’s t-test. All experiments were repeated three times 
and scored blind to injection cocktail.
Generation of constructs for mouse studies
The cDNA sequences from human RHEB-WT (NM_005614), and the variants found in 
the patient cohort (RHEBp.P37L and RHEBp.S68P) were synthesized by GeneCust, and 
cloned into our dual promoter expression vector. The dual promoter expression vector was 
generated from the pCMV-tdTomato vector (Clonetech), in which the CMV promoter was 
replaced with a CAGG promoter followed by a multiple cloning site (MCS) and transcription 
terminator sequence. To assure expression of the tdTOMATO independent from the gene of 
interest, a PGK promoter was inserted in front of the tdTomato sequence (for a schematic 
overview of the expression vector see Supplemental Figure 7.3). For all the in vivo and in 
vitro experiments, the vector without a gene inserted in the MCS was used as control (control 
vector).
Mice used for the in vitro and in vivo studies
For the neuronal cultures, FvB/NHsD females were crossed with FvB/NHsD males (both 
ordered at 8–10 weeks old from Envigo). For the in utero electroporation female FvB/NHsD 
(Envigo) were crossed with male C57Bl6/J (ordered at 8–10 weeks old from Charles River). 
All mice were kept group-housed in IVC cages (Sealsafe 1145T, Tecniplast) with bedding 
material (Lignocel BK 8/15 from Rettenmayer) on a 12/12 h light/dark cycle in 21 °C (±1 °C), 
humidity at 40–70% and with food pellets (801727CRM(P) from Special Dietary Service) 
and water available ad libitum. All animal experiments were approved by the Erasmus 
MC institutional Animal Care and Ethical Committee, in accordance with European and 
Institutional Animal Care and Use Committee guidelines.
In vitro modeling in mouse primary hippocampal neurons
Primary hippocampal neuronal cultures were prepared from FvB/NHsD wild-type mice 
according to the procedure described in Goslin and Banker.259 Briefly, hippocampi were 
isolated from brains of E16.5 embryos and collected altogether in 10 ml of neurobasal 
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medium (NB, Gibco) on ice. After two washes with NB, the samples were incubated in 
pre-warmed trypsin/EDTA solution (Invitrogen) at 37 °C for 20 min. After two washes in 
pre-warmed NB, the cells were resuspended in 1.5 ml NB medium supplemented with 2% 
B27, 1% penicillin/streptomycin and 1% glutamax (Invitrogen), and dissociated using a 5 ml 
pipette. Following dissociation, neurons were plated on poly-d-lysine (25 mg/ml, Sigma) 
coated 15 mm glass coverslips at a density of 3×104 or 5×104 cells per coverslip for the 
axon length measurements and 1×106cells per coverslip for all the other experiments. The 
plates were stored at 37 °C/5% CO2 until the day of transfection. Neurons were transfected 
at 3 days in vitro (DIV3, DIV7, and DIV14) with the following DNA constructs: control vector 
(1.8 µg per coverslip), RHEB-WT, RHEBp.P37L, and RHEBp.S68P (all 2.5 µg per coverslip). 
Plasmids were transfected using Lipofectamine 2000 according to the manufacturer’s 
instructions (Invitrogen). For the rescue experiments, 20 nM Rapamycin (dissolved in 0.01% 
Ethanol) was applied to the culture 1 day post transfection for 3 days. Neurons were 
fixed 4 days (Rapamycin experiment) or 5 days (for soma size) post transfection with 4% 
paraformaldehyde (PFA)/4% sucrose and incubated overnight at 4 °C with primary antibodies 
in GDB buffer (0.2% BSA, 0.8 M NaCl, 0.5% Triton X-100, 30 mM phosphate buffer, pH 7.4). 
The following primary antibodies were used: guinea-pig anti MAP2 (1:500, catalogue number: 
188004, Synaptic System) to stain for dendrites, and rabbit anti-RHEB (1:100, catalogue 
number: 4935, Cell Signaling). Donkey anti-guinea-pig-Alexa647- and donkey anti-rabbit-
Alexa488-conjugated were used as secondary antibodies (all 1:200, catalogue numbers: 706-
605-148 and 711-545-152, respectively, Jackson ImmunoResearch). Slides were mounted 
using mowiol-DABCO mounting medium. Confocal images were acquired using a LSM700 
confocal microscope (Zeiss). For the analysis of the neuronal transfections, at least ten 
distinct confocal images (×20 objective, 0.5 zoom, 1024 × 1024 pixels; neurons were identified 
by the red immunostaining signal) were taken from each coverslip for each experiment. 
ImageJ software was used for the analysis of the soma size, by drawing a line around the 
soma of the cell. For each coverslip, the area of the transfected cells was normalized against 
the area of the non-transfected cells (five cells per coverslips). These values were then 
normalized against the mean value of the control (control vector).
In vivo modeling in mice
The in utero electroporation was performed as described before.260 Pregnant FvB/NHsD 
mice at E14.5 of gestation were used to target the progenitor cells giving rise to pyramidal 
cells of the layer 2/3.261 The DNA construct (1.5–3 µg/µl) was diluted in fast green (0.05%) 
and injected in the lateral ventricle of the embryos while still in utero, using a glass pipette 
controlled by a Picospritzer ® III device. To ensure proper electroporation of the injected 
DNA constructs (1–2 µl) into the progenitor cells, five electrical square pulses of 45 V with a 
duration of 50 ms per pulse and 150 ms inter-pulse interval were delivered using tweezer-type 
electrodes connected to a pulse generator (ECM 830, BTX Harvard Appartus). The positive 
pole was targeting the developing somatosensory cortex. The following plasmids were 
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injected: control vector, RHEB-WT, RHEBp.P37L and RHEBp.S68P. After birth, pups were 
sacrificed at P0 or P7 for histochemical processing (to investigate neuronal migration) or 
used to monitor seizure development.
For the migration analysis, confocal images (×10 objective, 0.5 zoom, 1024 × 1024 pixels) 
were taken from 2 to 3 non-consecutive sections from 2 and 3 electroporated animals 
per control and RHEB-containing plasmids, respectively. Images were rotated to correctly 
position the cortical layers, and the number of cells in different layers were counted using 
ImageJ using the analyze particles plugin. The results were exported to a spreadsheet for 
further analysis. Cortical areas from the pia to the ventricle were divided in 10 equal-sized 
bins and the percentage of tdTOMATO-positive cells per bin was calculated.
For immunofluorescence, mice were deeply anesthetized with an overdose of Nembutal 
and transcardially perfused with 4% PFA. Brains were extracted and post-fixed in 4% PFA. 
Brains were then embedded in gelatin and cryoprotected in 30% sucrose in 0.1 M phosphate 
buffer (PB), frozen on dry ice, and sectioned using a freezing microtome (40/50 μm thick). 
Free-floating coronal sections were washed in 0.1 M PB and a few selected sections were 
counterstained with 4′,6-diamidino-2-phenylindole solution (DAPI, 1:10,000, Invitrogen) 
before being mounted with mowiol® (Sigma-Aldrich) on glass. Overview images of the 
coronal sections were acquired by tile scan imaging using a LSM700 confocal microscope 
(Zeiss) with a ×10 objective. Zoom-in images of the targeted area were taken using a ×20 
objective. For seizure observations, mice obtained after in utero electroporation were 
observed daily starting at P18. General behavior was observed by looking for abnormal 
behaviors such as hyperactivity, the presence of stereotypical behaviors and the presence 
of tonic–clonic seizures, either spontaneous or induced upon mild handling. Weaned mice 
were video-monitored for 24 h per day in the Phenotyper (Noldus), to assess seizure onset. 
Abnormal behaviors and onset of seizures were scored and analysed for each mouse by an 
expert experimentalist who had been blinded to the identity of samples (i.e., which plasmid 
had been transfected).
Statistical analysis used for the mouse studies
Statistical difference in soma size between the RHEB WT and mutants was determined 
using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test for multiple 
comparisons. The effect of Rapamycin treatment on soma size was determined using 
two-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc test for multiple 
comparisons. For the analysis of the in utero electroporation data, a two-way ANOVA 
repeated measure was performed, followed by the Bonferroni’s multiple comparisons test. 
For the analysis of epilepsy onset, the log-rank Mantel–Cox test was used. The significance 
threshold was set at p < 0.05. Data are presented as mean ± standard error of the mean (SEM).
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Abstract
The Rab GTPase family comprises ~70 GTP-binding proteins, functioning 
in vesicle formation, transport and fusion. They are activated by a conformational 
change induced by GTP-binding, allowing interactions with downstream effectors. Here, we 
report five individuals with two recurrent de novo missense mutations in RAB11B; c.64G>A; 
p.Val22Met in three individuals and c.202G>A; p.Ala68Thr in two individuals. An overlapping 
neurodevelopmental phenotype, including severe intellectual disability with absent speech, 
epilepsy, and hypotonia was observed in all affected individuals. Additionally, visual 
problems, musculoskeletal abnormalities, and microcephaly were present in the majority of 
cases. Re-evaluation of brain MRI images of four individuals showed a shared distinct brain 
phenotype, consisting of abnormal white matter (severely decreased volume and abnormal 
signal), thin corpus callosum, cerebellar vermis hypoplasia, optic nerve hypoplasia and mild 
ventriculomegaly. To compare the effects of both variants with known inactive GDP- and 
active GTP-bound RAB11B mutants, we modeled the variants on the three-dimensional 
protein structure and performed subcellular localization studies. We predicted that both 
variants alter the GTP/GDP binding pocket and show that they both have localization 
patterns similar to inactive RAB11B. Evaluation of their influence on the affinity of RAB11B to 
a series of binary interactors, both effectors and guanine nucleotide exchange factors (GEFs), 
showed induction of RAB11B binding to the GEF SH3BP5, again similar to inactive 
RAB11B. In conclusion, we report two recurrent dominant mutations in RAB11B leading to a 
neurodevelopmental syndrome, likely caused by altered GDP/GTP binding that inactivate the 
protein and induce GEF binding and protein mislocalization.
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Report
The application of whole-exome sequencing (WES) as a genetic test for intellectual 
disability (ID) and developmental delay has increased the number of genetic causes to more 
than 1,500.32; 126 This has significantly enhanced our knowledge of molecular processes 
that regulate learning and memory as well as brain development, although the roles of 
many genes involved in these processes have not yet been defined. Using trio-based 
WES in diagnostic and research settings,32; 126 we identified two different heterozygous de 
novomissense mutations in RAB11B (GenBank: NM_004218.3; MIM: 604198), c.64G>A; 
p.Val22Met and c.202G>A; p.Ala68Thr, in five unrelated individuals with severe ID 
(Figures 8.1A and B; Table 8.1). Written consent was obtained from the legal guardians 
for all individuals and the study was given IRB approval. Following identification of 
the RAB11B mutations of the first two individuals at Radboud University Medical Center, 
Nijmegen (individual 1: p.Val22Met; individual 4: p.Ala68Thr), a query via GeneMatcher88 
so resulted in the identification of individual 2 at Haukeland University Hospital, Bergen, 
and individual 3 at Seoul National University College of Medicine, Seoul. Both individuals 
harbored the variant p.Val22Met, similar to individual 1. A fifth individual (individual 
5; DECIPHER ID: 263643), reported before as part of a study sequencing a large ID 
cohort,33 was identified through international collaboration. Interestingly, this individual 
had the same variant, p.Ala68Thr, as individual 4 (Figure 8.1B). Neither identified missense 
mutation was present in the ExAC database or in-house control databases and both 
variants affect highly conserved amino acids in 90% of Rab family members176 and among 
different species (Figure 8.1B). Additionally, the ExAC database has shown that RAB11B is 
significantly depleted of rare missense variants (Z score 3.48) in healthy controls.71 
RAB11B is a member of the large Rab GTPase protein subfamily of RAS GTPases, consisting 
of almost 70 small ~21 kDa monomeric GTP-binding proteins. They serve as molecular 
switches that function in vesicle formation, transport, tethering, and fusion.262; 263 The tightly 
regulated spatiotemporal activity of Rabs is controlled by guanine nucleotide exchange 
factors (GEFs) that catalyze the GDP/GTP-exchange and GTPase activating proteins, 
which catalyze the hydrolysis of GTP into GDP.264-266 Rabs mainly interact with downstream 
GTPase effector proteins in their GTP-bound active conformation.265; 267 Rab GTPases and 
their effector proteins have been described to play a role in neuronal development and 
the shaping of cognitive functions.268 Several genes within this Rab GTPase family have 
been associated with neurodevelopmental disorders and micro- or macrocephaly, for 
example RAB18 [MIM: 602207] and RAB3GAP1 [MIM: 602536] are associated with Warburg 
micro syndrome [MIM: 600118], and RAB39B [MIM: 300774] is associated with Waisman 
syndrome [MIM: 311510] and Mental Retardation, X-linked 72 [MIM: 300271].
All five individuals that carried de novo mutations in RAB11B showed severe ID with 
motor delay and absent speech. A variety of neurological problems were present in all 
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Table 8.1 Clinical features of individuals with de novo mutations in RAB11B
  Individual 1 
(Nijmegen)
Individual 2 
(Bergen)
Individual 3 
(Seoul)
Individual 4 
(Nijmegen)
Individual 5 
(DDD)
Gender Female Female Male Male Female
Age of 
examination
13 years 4.5 years 8 years, 5 months 11 years 8 years, 8 months
Mutation (NM_004218.3)
Chromosome 
position (Hg19)
g.8464770G>A g.8464770G>A g.8464770G>A g.8464908G>A g.8464908G>A
cDNA change c.64G>A c.64G>A c.64G>A c.202G>A c.202G>A
Amino acid 
change
p.(Val22Met) p.(Val22Met) p.(Val22Met) p.(Ala68Thr) p.(Ala68Thr)
Growth
Height 152 cm (-1 SD) -2 SD 112 cm (-1.9 SD) 141 cm (- 1.5 SD) 121 cm  (-1.5 SD)
Weight 47.8 kg (+1.5 SD) NR 34.1 kg  (+1.7 SD) 34.5 kg (+0.7 SD) 25.7 kg (-0.5 SD)
Head 
circumference
49 cm (-3 SD) -4 SD 52 cm (+0.6 SD) 50 cm (-2.2 SD) 48 cm (-3 SD)
Development
Intellectual 
disability
Yes – severe/
profound
Yes Yes Yes – severe/
profound
Yes- severe/
profound
First words Absent speech Absent speech Absent speech Absent speech Absent speech
First steps with 
support
3 years 3 years 6 years Unknown 8 years
Neurological
Epilepsy Possibly – to 
investigate
No Yes Yes Single generalized 
seizure
Hypotonia Yes – childhood Yes Yes Yes No
Spasticity NR No No Yes Yes
Dystonia NR No No Yes Yes
Abnormal gait Yes – ataxic; 
broad-based
NR NR Yes – ataxic; 
broad-based
Yes – broad-
based
Nystagmus Yes NR NR No Yes - horizontal
Opthalmological abnormalities
Refraction 
abnormality
Hypermetropia 
– Mild
NR No Hypermetropia No
Strabismus Yes NR No No Yes
Other Delayed visual 
maturation
Reduced vision None None Optic atrophy
Musculoskeletal abnormalities
Developmental 
hip dysplasia
Yes – mild, non-
progressive
Yes – right-sided, 
non-progressive
Yes No Yes – requiring 
surgery
Tapering fingers Yes Yes Yes Yes Yes
Other Pes cavus; 
shortened 
achilles tendons; 
prominent 
steloideus ulnae
2 cm anisomelia; 
adducted thumbs; 
bilateral club foot
None No Long fingers
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affected individuals, including hypotonia (4/5), epilepsy (3/5), spasticity (2/4), dystonia (2/4), 
broad-based (3/3), and ataxic gait (2/3) and nystagmus (2/3) (Table 8.1). Re-evaluation 
of brain MRI images of four individuals showed similar brain imaging abnormalities 
(Figure 8.2 and Supplemental Table 8.1). All had severely decreased white matter volume 
(cerebral cortex more severely affected than cerebellum), thin corpus callosum, and mild ex 
vacuo lateral ventriculomegaly affecting the frontal horns and body of the ventricles more 
than the occipital and temporal horns. Other features that were scorable in a subset of 
images included cerebellar vermis hypoplasia (3/3), thin brainstem (3/3), early global white 
matter signal abnormalities consistent with delayed myelination (2/2), later patchy white 
matter signal abnormalities consistent with injury (4/4), optic nerve hypoplasia (2/2), and 
what appears to be atypical partial rhombencephalosynapsis (1/3). Although two other 
affected individuals did not have rhombencephalosynapsis (partial or complete absence of 
the cerebellar vermis with fusion of the cerebellar hemispheres), the width of the cerebellar 
vermis was subjectively narrower than typical. Besides the neurological phenotype, 
ophthalmological and musculoskeletal abnormalities were present in the majority of 
individuals. Microcephaly was observed in three individuals (Table 8.1).
To study the effects of the identified mutations on the well described three-dimensional 
protein structure of RAB11B, we modeled the substitutions on Protein Data Bank 
entry PDB: 2F9M269 using YASARA software,270 and compared to the described active, 
GTP-locked RAB11B mutant p.Gln70Leu and inactive, GDP-locked RAB11B mutant 
p.Ser25Asn (Figure 8.1C).271 The p.Ser25Asn variant was shown to disrupt the binding of 
a magnesium molecule which is essential for GTP binding, consequently locking the GTPase 
in an inactive GDP bound, non-membrane-associated state.272-274 In contrast, the p.Gln70Leu 
variant affects a conserved residue in the flexible switch II region, which is essential for 
catalysis, and therefore this variant is predicted to fix the GTPase in a GTP-bound state, 
which is constitutively active (Figures 8.1B and C).274; 275 Both mutations identified in this 
study are situated in close proximity to the binding pocket for GTP/GDP and specifically 
on the side where the phosphate groups of GTP/GDP are positioned (Figure 8.1C). 
The valine residue at position 22 is located at the base in the middle of the GTP/GDP 
binding pocket, thereby being responsible for its shape (Figures 8.1B and D). Substitution 
Other
Drooling; Simean 
crease; neonatal 
feeding difficulties
Bilateral palsy 
nervus laryngeus 
recurrens, 
Diabetes 
Mellitus Type 1, 
hydrocephalus
Acanthotic skin, 
Epidermal nevus in 
face, neck, trunk;
Short neck; 
Obstructive 
sleep apnea; 
cryptorchidism
Simean crease Bruxism.
Abbreviations: NR, Not Reported; SD, Standard Deviation.
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into methionine brings in a larger amino acid which causes a predicted reorganization of 
the region around this residue, altering the shape of the binding pocket. This likely disrupts 
binding of GDP and GTP, resulting in a nucleotide-free, inactive state of RAB11B. The second 
mutation affects an alanine at position 68 and is located within a flexible loop of the switch II 
region (Figures 8.1B and E), which together with the switch I region specifically interacts with 
effector proteins when GTP is bound.267 This flexible loop provides more space for a bigger 
amino acid residue, however, the mutant residue is positioned closely to the magnesium 
molecule, as well as the phosphate groups of GTP/GDP, and thereby alters the binding 
pocket and is predicted to disrupt nucleotide binding. Furthermore, the location within the 
switch region suggests that the mutation causes altered binding with effector proteins. Taken 
together, both identified mutations are predicted to alter the GTP/GDP binding pocket of 
RAB11B, hence it is likely that the functionality of the protein is affected.
RAB11B is one of three genes in the Rab11 GTPase subfamily, together 
with RAB11A [MIM: 605570] and RAB25 [MIM: 612942], and this subfamily specifically 
associates with recycling endosomes.262; 276 RAB11A is the best-characterized family member 
and is ubiquitously expressed,277 in contrast to specific expression of RAB25 and RAB11B in 
epithelial tissue278 or in heart, testis, and brain,279 respectively. The proteins have been 
implicated in the regulation of vesicular trafficking between the recycling endosome 
compartment and early endosomes to the trans Golgi network and plasma membrane.272; 
280 Furthermore, it has been shown that RAB11 is essential for ciliogenesis,281-283 and that the 
proteins are localized to peri-centrosomal recycling endosomes concentrated at the base of 
the cilium.284
To evaluate whether the identified mutations affect the sub-cellular localization of RAB11B, 
potentially at the cilium, we transfected human TERT-immortalized retinal pigment epithelium 
1 (hTERT RPE1) cells with cDNA expression constructs encoding WT (UniProt: Q15907) 
or mutant RAB11B, fused to an N-terminal 3xFLAG tag. A marker for the peri-centrosomal 
region (Pericentriolar Material 1; PCM1) was used to assess the effect on the peri-
centrosomal localization (Figures 8.3A–F), and the marker acetylated tubulin to assess 
cilium morphology (Supplemental Figure 8.1). Wild-type RAB11B localization was scattered 
throughout the cell with a punctuated pattern as shown in Figure 8.3A. For some cells, 
puncta were enriched, as expected, at the peri-centrosomal region. We observed that 
the constitutively active mutant RAB11B-p.Gln70Leu had a strong organization in puncta 
throughout the cytoplasm and a consistent localization at the peri-centrosomal region in 
all cells (Figure 8.3B). In contrast, GDP-bound inactive RAB11B-p.Ser25Asn showed a 
generally dispersed cytosolic localization, losing its association with the peri-centrosomal 
region, but with enrichment near the nucleus suggesting Golgi localization (Figure 8.3C). 
This was confirmed using Golgi marker GM130 (Figure 8.3G–L). Our results upon expression 
of recombinant WT, p.Ser25Asn, and p.Gln70Leu RAB11B confirmed earlier studies 
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RAB11B is a member of the large Rab GTPase protein
subfamily of RAS GTPases, consisting of almost 70 small
21 kDa monomeric GTP-binding proteins. They serve
as molecular switches that function in vesicle formation,
transport, tethering, and fusion.7,8 The tightly regulated
spatiotemporal activity of Rabs is controlled by guanine
nucleotide exchange factors (GEFs) that catalyze the
GDP/GTP-exchange and GTPase activating proteins,
which catalyze the hydrolysis of GTP into GDP.9–11 Rabs
mainly interact with downstream GTPase effector proteins
in their GTP-bound active conformation.10,12 Rab GTPases
and their effector proteins have been described to play a
role in neuronal development and the shaping of cognitive
functions.13 Several genes within this Rab GTPase family
have been associated with neurodevelopmental disorders
and micro- or macrocephaly, for example RAB18 [MIM:
602207] and RAB3GAP1 [MIM: 602536] are associated
with Warburg micro syndrome [MIM: 600118], and
RAB39B [MIM: 300774] is associated with Waisman syn-
drome [MIM: 311510] and Mental Retardation, X-linked
72 [MIM: 300271].
All five individuals that carried de novo mutations in
RAB11B showed severe ID with motor delay and absent
speech. A variety of neurological problems were present
in all affected individuals, including hypotonia (4/5), epi-
lepsy (3/5), spasticity (2/4), dystonia (2/4), broad-based
(3/3), and ataxic gait (2/3) and nystagmus (2/3) (Table 1).
Re-evaluation of brain MRI images of four individuals
showed similar brain imaging abnormalities (Figure 2
and Table S1). All had severely decreased white matter vol-
ume (cerebral cortex more severely affected than cere-
bellum), thin corpus callosum, and mild ex vacuo lateral
ventriculomegaly affecting the frontal horns and body of
the ventricles more than the occipital and temporal horns.
Other features that were scorable in a subset of images
included cerebellar vermis hypoplasia (3/3), thin brain-
stem (3/3), early global white matter signal abnormalities
consistent with delayed myelination (2/2), later patchy
white matter signal abnormalities consistent with injury
(4/4), optic nerve hypoplasia (2/2), and what appears
to be atypical partial rhombencephalosynapsis (1/3).
Although two other aff cted individuals did not have
rhombencephalosynapsis (partial or complete absence of
the cerebellar vermis with fusion of the cerebellar hemi-
spheres), the width of the cerebellar vermis was subjec-
tively narrower than typical. Besides the neurological
phenotype, ophthalmological and musculoskeletal abnor-
malities were present in the majority of individuals. Micro-
cephaly was observed in three individuals (Table 1).
To study the effects of the identified mutations on
the well described three-dimensional protein structure of
RAB11B, we modeled the substitutions on Protein Data
Bank entry PDB: 2F9M14 using YASARA software,15 and
compared to the described active, GTP-locked RAB11B
A
B
C D
E
Figure 1. RAB11B Mutations in Five Indi-
viduals with Severe ID
(A) cDNA composition of RAB11B and
location of exons (dark gray) and identi-
fied mutations (green stars).
(B) Amino acid sequence of exon 2 of
RAB11B. Both identified variants (green)
localize at one of the two GTP binding
sites (red stripes) and p.Ala68Thr also in-
volves the switch 2 region (black stripe).
Both identified mutations affect highly
conserved amino acid residues among
different species (light gray box). The
known inactive variant p.Ser25Asn and
known active variant p.Gln70Leu are
marked orange.
(C–E) Structural characterization of muta-
tions. In all panels, the overall Protein
DataBank structure 2f9m of RAB11B14
is colored gray and shown in ribbon rep-
resentation, GNP (phosphoaminophos-
phonic acid-guanylate ester, a non-hydro-
lyzable analog of GTP) is multicolored in
a spacefill representation with the guani-
dine ring in blue shades and the phos-
phates in red and yellow. The magnesium
molecule is represented as a purple sphere.
The side chains of the affected amino acids
in the affected individuals are green and
for the GDP/GTP-locked mutants are or-
ange. (C) Overview of RAB11B bound to
GNP and magnesium and the affected
amino acids are highlighted. (D) Close up
of the p.Val22Met variant shows the side chains of valine at position 22 in green and the methionine in red. (E) Close up of the
p.Ala68Thr variant shows the side chains of alanine at position 68 in green and threonine in red, and themutated glutamine at position
70 which is mutated in the GTP-locked mutant is in orange.
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on the effect of these variants on the localization of this GTPase.272; 273 Localization of 
both RAB11B-p.Val22Met (Figure 8.3D) and RAB11B-p.Ala68Thr (Figure 8.3E) showed 
homogeneous localization in the cytoplasm, no association with the peri-centrosomal 
Figure 8.1: RAB11B Mutations in five individuals with severe ID.
(A) cDNA composition of RAB11B and location of exons (dark gray) and identified mutations (green stars). (B) Amino 
acid sequence of exon 2 of RAB11B. Both identified variants (green) localize at one of the two GTP binding sites (red 
stripes) and p.Ala68Thr also involves the switch 2 region (black str pe). B th identified mutations affect highly 
conserved amino acid residues among different species (light gray box). The known inactive variant p.Ser25Asn and 
known active variant p.Gln70Leu are marked orange. (C–E) Structural characterization of mutations. In all panels, 
the overall Protein DataBank structure 2f9m of RAB11B269 is colored gray and shown in ribbon representation, GNP 
(phosphoaminophosphonic acid-guanylate ester, a non-hydrolyzable analog of GTP) is multicolored in a spacefill 
representation with the guanidine ring in blue shades and the phosphates in red and yellow. The magnesium molecule 
is represented as a purple sphere. The side chains of the affected amino acids in the affected individuals are green and 
for the GDP/GTP-locked mutants are orange. (C) Overview of RAB11B bound to GNP and magnesium and the affected 
amino acids are highlighted. (D) Close up of the p.Val22Met variant shows the side chains of valine at position 22 in 
green and the methionine in red. (E) Close up of the p.Ala68Thr variant shows the side chains of alanine at position 68 
in green and threonine in red, and the mutated glutamine at position 70 which is mutated in the GTP-locked mutant is in 
orange.
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region and co-localization with Golgi marker GM130 (Figures 8.3J and K), similar to the 
GDP-bound inactive mutant p.Ser25Asn. Quantification of the co-localization patterns 
with PCM1 and GM130 confirmed our observations (Figure 8.3F and L). The morphology 
of the cilium appeared normal in cells transfected with each of the four mutant constructs 
(Supplemental Figure 8.1). We reproduced the localization patterns at the base of the 
cilium or at the Golgi for all RAB11B variants in a different cell line: mouse inner medullary 
collecting duct 3 (IMCD3) cells (Supplemental Figure 8.2). In short, introduction of either 
one of the identified RAB11B variants results in a similar localization pattern as the GDP-
bound inactive form, without an obvious difference between the two. Interestingly, previous 
Figure 8.2: Brain imaging features and facial photographs of individuals with RAB11B-related intellectual 
disability.
(A, F, G, J) Markedly decreased cortical white matter volume in individuals 1, 3, 4, and 5. (B, H, K) Markedly thin corpus 
callosum (arrows), mildly thin brainstem, and mildly small, atrophic-appearing cerebellar vermis (bracket) in individual 1, 
4, and 5. (C) Increased T2/FLAIR signal in the cortical white matter (asterisks) in individual 1. (D and E) Atypical partial 
rhombencephalosynapsis in individual 1 (arrowheads). (A, D, F, G, and H) are T2-weighted axial images. (B and H) are 
T1-weighted sagittal images. (C) is a T2/FLAIR-weighted axial image. (E) is a reformatted inversion-recovery coronal 
image. (K) is a T2-weighted sagittal image. (I and L) Facial photographs show upward slanted palpebral fissures, 
periorbital fullness, full nasal tip, and hypotonic face in individual 4 and upward slanted palpebral fissures, deep set 
eyes, and short philtrum in individual 5.
mutant p.Gln70Leu and inactive, GDP-locked RAB11B
mutant p.Ser25Asn (Figure 1C).16 The p.Ser25Asn variant
was shown to disrupt the binding of a magnesium mole-
cule which is essential for GTP binding, consequently
locking the GTPase in an inactive GDP bound, non-mem-
brane-associated st te.17–19 In contrast, the p.Gln70Leu
variant affects a conserved residue in the flexible switch
II region, which is essential for catalysis, and therefore
this variant is predicted to fix the GTPase in a GTP-bound
state, which is constitutively active (Figures 1B and
1C).19,20 Both mutations identified in this study are situ-
ated in close proximity to the binding pocket for GTP/
GDP and specifically on the side where the phosphate
groups f GTP/GDP are positioned (Figure 1C). The valine
residue at position 22 is located at the base in themiddle of
the GTP/GDP binding pocket, thereby being responsible
for its shape (Figures 1B and 1D). Substitution into methi-
onine brings in a larger amino acid which causes a pre-
dicted reorganization of the region around this residue,
altering the shape of the binding pocket. This likely dis-
rupts binding of GDP and GTP, resulting in a nucleotide-
free, inactive state of RAB11B. The second mutation affects
an alanine at position 68 and is located within a flexible
loop of the switch II region (Figures 1B and 1E), which
together with the switch I region specifically interacts
with effector proteins when GTP is bound.12 This flexible
loop provid s more space for a bigger amino acid residue,
however, the mutant residue is positioned closely to the
magnesium molecule, as well as the phosphate groups of
GTP/GDP, and thereby alters the binding pocket and is pre-
dicted to disrupt nucleotide binding. Furthermore, the
location within the switch region suggests that the muta-
tion causes altered binding with effector proteins. Taken
together, both identified mutations are predicted to alter
A B C D E
F
G H I
J K L
Figure 2. Brain Imaging Features and Facial Photographs of Individuals with RAB11B-Related Intellectual Disability
(A, F, G, J) Markedly decreased cortical white matter volume in individuals 1, 3, 4, and 5.
(B, H, K) Markedly thin corpus callosum (arrows), mildly thin brainstem, and mildly small, atrophic-appearing cerebellar vermis
(bracket) in individual 1, 4, and 5.
(C) Increased T2/FLAIR signal in the cortical white matter (asterisks) in individual 1.
(D and E) Atypical partial rhombencephalosynapsis in individual 1 (arrowheads). (A, D, F, G, and H) are T2-weighted axial images. (B and
H) are T1-weighted sagittal images. (C) is a T2/FLAIR-weighted axial image. (E) is a reformatted inversion-recovery coronal image. (K) is a
T2-weighted sagittal image.
(I and L) Facial photographs show upward slanted palpebral fissures, periorbital fullness, full nasal tip, and hypotonic face in individual 4
and upward slanted palpebral fissures, deep set eyes, and short philtrum in individ al 5.
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studies showed that GDP-locked GTPases lose their membrane association.272; 274 For the 
p.Ser25Asn mutant of RAB11B, we indeed observe a localization pattern that is similar to 
that of the published RAB11B-ΔC mutant where five C-terminal amino acids were substituted 
to abolish prenylation, and consequently disturbed vesicular membrane association.273 The 
fact that both identified variants result in a comparable RAB11B localization pattern as the 
p.Ser25Asn mutant, suggests that in the affected individuals, the association of RAB11B with 
(vesicular) membranes is affected, contributing to the pathogenic effects of the identified 
variants.
To further assess the effect of the identified variants on the functionality of RAB11B, we 
screened for binary interaction partners of RAB11B by using a GAL4-based yeast two-
hybrid screen of cDNA libraries from neuronal tissues (brain and retina) as previously 
described.285 In physiological conditions, RAB11B is either GDP or GTP bound. Therefore 
we used both p.Ser25Asn and p.Gln70Leu mutant constructs as baits to screen for potential 
interactors, which identified two (p.Ser25Asn) and eight (p.Gln70Leu) different potential 
interactors (Figure 8.4 and Supplemental Figure 8.3). All interactions were confirmed using 
independent co-transformation assays with validation of reporter gene activity (Supplemental 
Figure 8.3). The identified interactors were all previously reported as Ral/Rac or Rab11 
specific interacting partners (Supplemental Table 8.2), validating our assay. Interestingly, three 
direct interactors identified in our yeast screen are encoded by genes where loss of function 
mutations are associated with neurodevelopmental disorders: CNKSR2 [MIM: 300724] 
with X-linked Intellectual Disability,286-288 MYO5A [MIM: 160777] with Griscelli syndrome 
type 1 [MIM: 214450], and TRAPPC9 [MIM: 611966] with Recessive Mental Retardation 13 
[MIM: 613192] (Table S2).
To assess whether the identified variants affect the affinity of RAB11B to any of the 
interactors, we co-expressed p.Val22Met and p.Ala68Thr mutant constructs with 
each interactor and compared the binding affinities semiquantitatively by evaluation of the 
reporter gene-activation levels (Figure 8.4 and Supplemental Figure 8.3, and Supplemental 
Table 8.2). Wild-type, GDP-, and GTP-bound RAB11B were taken along as controls. Because 
GTP is more abundantly present in the cytosol than GDP, the WT RAB11B construct is 
expected to be predominantly GTP-bound. We indeed observed that the interaction pattern 
of the WT was comparable to the constitutively active mutant (Figure 8.4 and Supplemental 
Figure 8.3). When either one of the identified variants was introduced, the binding 
pattern was mostly similar to that of WT RAB11B, but one important difference could be 
distinguished: both mutant proteins were able to bind to the one bona fide GEF identified in 
our screen, SH3BP5, while WT RAB11 could not (Figure 8.4 and Supplemental Figure 8.3).
The affinity of the p.Val22Met mutant protein to SH3BP5 was strong and comparable to the 
GDP-locked mutant protein p.Ser25Asn, while the affinity of the p.Ala68Thr mutant protein 
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Figure 8.3: Localization of wild-type and mutant RAB11B in hTERT-RPE1 cells.
Shown in green is the expression of recombinant 3xFLAG-RAB11B wild-type (A and G) and 3xFLAG-RAB11B variants 
p.Gln70Leu (B and H), p.Ser25Asn (C and I), p.Val22Met (D and J), p.Ala68Thr (E and K) in hTERT RPE1 cells, detected 
using anti-FLAG antibodies (rabbit polyclonal, #F7425, Sigma Aldrich; dilution 1:500 in PBS). N-terminal tagging 
was performed to not disturb the prenylation of the C terminus of RAB11B, which is required for membrane 
association.265; 273 Recombinant protein expression, immunocytochemistry, and image capture was performed 
as described previously.299 All secondary antibodies were Alexa Fluor conjugates (Thermo Fisher Scientific). The 
following transfection efficiencies were obtained per 3xFLAG-RAB11B construct: wild-type, 14%; p.Gln70Leu, 
19%; p.Ser25Asn, 9%; p.Val22Met, 10%; p.Ala68Thr, 14%. Staining of Pericentriolar Material 1 (PCM1) using anti-
PCM1 antibodies (goat polyclonal, #SC-50164, Santa Cruz Biotechnology; dilution 1:250 in PBS) was used to mark 
the peri-centrosomal region (red) and magnifications are shown in the insets (A–E). Staining of GM130 using anti-
GM130 antibodies (mouse monoclonal, #610822, BD Biosciences; dilution 1:250 in PBS) was used to mark the Golgi 
Figure 3. Localization of Wild-Type and Mutant RAB11B in hTERT-RPE1 Cells
Shown in green is the expression of recombinant 3xFLAG-RAB11B wild-type (A and G) and 3xFLAG-RAB11B variants p.Gln70Leu
(B and H), p.Ser25Asn (C and I), p.Val22Met (D and J), p.Ala68Thr (E and K) in hTERT RPE1 cells, detected using anti-FLAG antibodies
(rabbit polyclonal, #F7425, Sigma Aldrich; dilution 1:500 in PBS). N-terminal tagging was performed to not disturb the prenylation of
the C terminus of RAB11B, which is required for membrane association.10,18 Recombinant protein expression, immunocytochemistry,
and image capture was performed as described previously.44 All secondary antibodies were Alexa Fluor conjugates (Thermo Fisher
Scientific). The following transfection efficiencies were obtained per 3xFLAG-RAB11B construct: wild-type, 14%; p.Gln70Leu, 19%;
p.Ser25Asn, 9%; p.Val22Me , 10%; p.Ala68Thr, 14%. Staining of Pericentriolar Material 1 (PCM1) using anti-PCM1 tibodies (goat
polyclonal, #SC-50164, Santa Cruz Biotechnology; dilution 1:250 in PBS) was used to ark the peri-centrosomal region (red) and
(legend continued on next page)
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was somewhat lower. Based on the 3D modeling and our localization assay, we already 
suggested that the p.Val22Met variant results in a nucleotide-free state by the inability of 
the protein to bind GDP or GTP. The interaction data support our hypothesis that variant 
p.Val22Met causes a nucleotide-free state, because GEFs are required for the stabilization 
of a GTPase if not bound to GTP or GDP.266; 274 A somatic substitution affecting the adjacent 
conserved glycine residue (RAB11B position 23; Supplemental Figure 8.4) has been 
described in RAS-GTPase RHOA (p.Gly17Val),289-291 resulting in a nucleotide-free state of 
RHOA. As a result, mutant RHOA acts in a dominant-negative manner because it sequesters 
GEFs, which prohibits that these GEFs are available to activate wild-type RHOA.292 With 
(1) the position of the p.Val22Met variant adjacent to this reported RHOA substitution, (2) 
the 3D modeling suggesting a nucleotide-free state of RAB11B (Figure 8.1C), and (3) the 
strong affinity of the mutant to bind the RAB11B GEF SH3BP5 (Figure 8.4 and Supplemental 
Figure 8.3), it is likely that the identified p.Val22Met variant acts in a dominant-negative 
manner as described for RHOA. Interestingly, we observed that this mutant RAB11B 
is still able to interact with effectors as well as GEFs (Figure 8.4 and Supplemental 
Figure 8.3). Also, for the p.Ala68Thr variant, the binding to SH3BP5 is much less 
pronounced and only detectable under less stringent assay conditions (-LWH + 5mM 
3AT, Figure 8.4 and Supplemental Figure 8.3). It has been described that a specific dominant-
negative mutant of Ras (Ras15A), member of the RAS-GTPase family as well, has stronger 
affinities for GEFs with more defective nucleotide binding, compared to another dominant-
negative mutant of Ras (Ras17N) where a neighboring residue is affected.292 This highlights 
the possibility of variable effects between variants in the GTP/GDP binding pocket on the 
affinity for GEFs and nucleotides. We argue that, despite these slight differences in affinity, 
both variants have similar consequences on RAB11B function, since individuals who 
harbor the p.Ala68Thr variant display strong phenotypic overlap with individuals carrying 
the p.Val22Met variant. Furthermore, both variants caused a similarly disturbed localization 
(Figure 8.3). Therefore, we hypothesize that p.Ala68Thr could act in a dominant-negative 
manner as well, with the same phenotypic consequences as the p.Val22Met variant.
The second GEF for RAB11B identified in our screen is TRAPPC9, member of the TRAPP II 
complex. This group of proteins is involved in intracellular membrane trafficking processes265; 
293 and acts as a GEF for RAB11B orthologs in yeast.294-296 The fact that the p.Val22Met and 
p.Ala68Thr mutant proteins are not able to associate with TRAPPC9 seems to contradict 
apparatus (in red; G-K). Co-localization with PCM1 (F) or GM130 (L) was quantified by calculating the Pearson’s 
correlation coefficient (PCC) using the JACoP plugin in ImageJ (N = 12 cells for each construct, mean in red and error 
bars represent the SD).300-302 The significance of difference with WT was calculated with a Student’s t test (ns: not 
significant (p > 0.05); *: p < 0.05; **: p < 0.005; ***: p < 0.0005). Wild-type and GTP-bound active RAB11B (p.Gln70Leu) 
are showing punctuated localization with an enrichment at the peri-centrosomal region. Both identified variants 
p.Val22Met and p.Ala68Thr show similar localization as GDP-bound inactive RAB11B (p.Ser25Asn) with dispersed 
localization throughout the cytoplasm and enrichment at the Golgi apparatus. In all pictures, nuclei were stained 
with DAPI (blue). Scale bars represent 10 μm.
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the results with the GEF SH3BP5. However, SH3BP5 was shown to be a bona fide GEF for 
RAB11,297 while TRAPPC9 requires the other subunits of the TRAPP II complex to act as 
a GEF. As the identified RAB11B mutations do not induce the TRAPPC9 binding, our data 
also suggest that TRAPPC9, as a single protein, does not act as a RAB11 GEF in contrast to 
SH3BP5.
It is likely that RAB11B disruption also has molecular consequences other than disturbed 
protein interactions that might alter several cellular mechanisms such as calcium influx, 
synaptic function, and neuronal migration,268 that could contribute to the underlying 
pathology. One explanation could be found in the mislocalization of RAB11B mutant 
proteins, which were able to bind effector proteins based on our yeast two-hybrid data. As a 
result of the membrane unbound situation suggested by the localization data, mislocalization 
of mutant RAB11B might therefore result in mislocalization of bound effectors, sequestering 
them from their usual sites of function.292 Our data also show that RAB11B localization is 
altered at the basal body of the cilium (Supplemental Figure 8.1), and RAB11B is a direct 
interactor of the ciliary RAB Rabin8 (Figure 8.4 and Supplemental Table 8.2),298 although we 
observed no morphological changes of the cilium in hTERT-RPE1 cells. More subtle changes 
in cilium morphology could have been missed in our assay or cilia might have an altered 
signaling function without morphological abnormalities. Although speculative at this point 
without an animal model, cilia could be mainly affected in brain tissue, given the predominant 
expression of RAB11B in the brain.268; 279
Figure 8.4: Identified interactors of RAB11B using yeast two-hybrid cDNA library screening and their affinity for 
RAB11B variants.
Co-transformations were performed in PJ69-4α yeast strains with the identified clones from the library screens fused 
to pAD together with WT or mutant RAB11B constructs fused to pBD. The clones are sorted according to the library 
in which they have been identified, as indicated in the far left column. The quantification of the selection of the growth 
of two-hybrid clones grown on medium lacking leucine, tryptophan and histidine with 3mM 3AT is quantified in the 
“growth” column. α-Galactosidase reporter gene activation (α-gal column) or β-galactosidase reporter gene activation 
(β-gal column) are quantified as well. Quantifications are on a scale from 0-3; with 0 for no reporter gene activation and 
3 for highest reporter gene activation. Details of the identified clones in the cDNA library screens can be found in Table 
S2, including quantification of reporter gene activation on –LWHA medium. Original images are shown in Figure S2.
semiquanti atively by valuation of the reporter g ne-ac -
vation levels (Figure 4 and Figure S3, and Table S2). Wild-
type, GDP-, and GTP-bound RAB11B were taken along as
controls. Because GTP is more abundantly present in the
cytosol than GDP, the WT RAB11B construct is expected
to be predominantly GTP-bound. We indeed observed
that the interaction pattern of the WT was comparable to
the constitutively active mutant (Figure 4 and Figure S3).
When either one of the identified variants was introduced,
the binding pattern was mostly similar to that of WT
RAB11B, but one important difference could be distin-
guished: both mutant proteins were able to bind to the
one bona fide GEF identified in our screen, SH3BP5, while
WT RAB11 could not (Figure 4 and Figure S3).
The affinity of the p.Val22Met mutant protein to
SH3BP5 was strong and comparable to the GDP-locked
mutant protein p.Ser25Asn, while the affinity of the
p.Ala68Thr mutant protein was somewhat lower. Based
on the 3D modeling and our localization assay, we already
suggested that the p.Val22Met variant results in a nucleo-
tide-free state by the inability of the protein to bind GDP
or GTP. The interaction data support our hypothesis that
variant p.Val22Met causes a nucleotide-free state, because
GEFs are required for the stabilization of a GTPase if not
bound to GTP or GDP.11,19 A somatic substitution affecting
the adjacent conserved glycine residue (RAB11B position
23; Figure S4) has been described in RAS-GTPase RHOA
(p.Gly17Val),34–36 resulting in a nucleotide-free state of
RHOA. As a result, mutant RHOA acts in a dominant-nega-
tive manner because it sequesters GEFs, which prohibits
that these GEFs are available to activate wild-type
RHOA.37 With (1) the position of the p.Val22Met variant
adjacent to this reported RHOA ubstitution, (2) the 3D
modeling suggesti g a nucleotide-free state of RAB11B
(Figure 1C), and (3) the strong affinity of the mutant to
bind the RAB11B GEF SH3BP5 (Figure 4 and Figure S3), it
is likely that the identified p.Val22Met variant acts in a
dominant-negative manner as described for RHOA. Inter-
estingly, we observed that this mutant RAB11B is still
able to interact with effectors as well as GEFs (Figure 4
and Figure S3). Also, for the p.Ala68Thr variant, the bind-
ing to SH3BP5 is much less pronounced and only detect-
able under less stringent assay conditions (-LWH þ 5mM
3AT, Figure 4 and Figure S3). It has been described that
a specific dominant-negative mutant of Ras (Ras15A),
member of the RAS-GTPase family as well, has stronger af-
finities for GEFs with more defective nucleotide binding,
compared to another dominant-negative mutant of Ras
(Ras17N) where a neighboring residue is affected.37 This
highlights the possibility of variable effects between vari-
ants in the GTP/GDP binding pocket on the affinity for
GEFs and nucleotides. We argue that, despite these slight
differences in affinity, both variants have similar conse-
quences on RAB11B function, since individuals who
harbor the p.Ala68Thr variant display strong phenotypic
overlap with individuals carrying the p.Val22Met variant.
Furthermore, both variants caused a similarly disturbed
localization (Figure 3). Therefore, we hypothesize that
p.Ala68Thr could act in a dominant-negative manner
as well, with the same phenotypic consequences as the
p.Val22Met variant.
The second GEF for RAB11B identified in our screen
is TRAPPC9, member of the TRAPP II complex. This
group of proteins is involved in intracellular membrane
Figure 4. Identified Interactors of RAB11B Using Yeast Two-Hybrid cDNA Library Screening and Their Affinity for RAB11B Variants
Co-transformations were performed in PJ69-4a yeast strains with the identified clones from the library screens fused to pAD together
with WT or mutant RAB11B constructs fused to pBD. The clones are sorted according to the library in which they have been identified,
as indicated in the far left column. The quantification of the selection of grow h of tw -hybrid clones grown on m dium lacking
leucine, tryptophan and histidine with 3mM 3AT is quantified in the ‘‘growth’’ column. a-Galactosidase reporter gene activation
(a-gal column) or b-galactosidase reporter gene activation (b-gal column) are quantified as well. Quantifications are on a scale from
0-3; with 0 for no reporter gene activation and 3 for highest reporter gene activation. Details of the identified clones in the cDNA library
screens can be found in Table S2, including quantification of reporter gene activation on –LWHAmedium. Original images are shown in
Figure S2.
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In conclusion, we identified two recurrent de novo missense mutations in RAB11B in five 
unrelated individuals with severe ID and specific brain abnormalities. We show that (1) both 
mutations affect the GDP/GTP binding pocket of this small GTPase, (2) the association of 
the mutant proteins with (vesicular) membranes is affected in localization studies, and (3) 
both mutations have limited effect on RAB11B effector protein binding, but can enhance 
the affinity to the GEF SH3BP5. We propose that these effects together cause distinct 
defects in several neuronal developmental processes, a combination that results in a 
neurodevelopmental syndrome in human.
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Abstract
Mutations in more than a hundred genes have been reported to cause X-linked recessive 
intellectual disability (ID) mainly in males. In contrast, the number of identified X-linked 
genes in which de novo mutations specifically cause ID in females is limited. Here, we 
report 17 females with de novo loss-of-function mutations in USP9X, encoding a highly 
conserved deubiquitinating enzyme. The females in our study have a specific phenotype 
that includes ID/developmental delay (DD), characteristic facial features, short stature, and 
distinct congenital malformations comprising choanal atresia, anal abnormalities, post-axial 
polydactyly, heart defects, hypomastia, cleft palate/bifid uvula, progressive scoliosis, and 
structural brain abnormalities. Four females from our cohort were identified by targeted 
genetic testing because their phenotype was suggestive for USP9X mutations. In several 
females, pigment changes along Blaschko lines and body asymmetry were observed, 
which is probably related to differential (escape from) X-inactivation between tissues. 
Expression studies on both mRNA and protein level in affected-female-derived fibroblasts 
showed significant reduction of USP9X level, confirming the loss-of-function effect of the 
identified mutations. Given that some features of affected females are also reported in known 
ciliopathy syndromes, we examined the role of USP9X in the primary cilium and found that 
endogenous USP9X localizes along the length of the ciliary axoneme, indicating that its loss 
of function could indeed disrupt cilium-regulated processes. Absence of dysregulated ciliary 
parameters in affected female-derived fibroblasts, however, points toward spatiotemporal 
specificity of ciliary USP9X (dys-)function.
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Report
X-linked intellectual disability (ID) with presumed recessive inheritance pattern is shown to 
be caused by mutations in more than a hundred genes 303; 304 Most families display a clear 
X-linked segregation pattern, in which males are affected while females are unaffected or 
mildly affected carriers.305-307 In contrast, the number of identified X-linked genes in which de 
novo mutations cause ID specifically in females is limited. 
Using whole-exome sequencing (WES), SNP array, array CGH, and CytoScan HD 
array in a diagnostic setting as described before,19; 28; 99; 308-310 we identified 13 de novo 
loss-of-function mutations in USP9X (Ubiquitin-specific protease 9 [MIM: 300072; 
GenBank: NM_001039590.2]) in females with ID/developmental delay (DD) and multiple 
congenital malformations (Figures 9.1A and B; Supplemental Table 9.1). Female 7 was 
previously reported as part of a large study sequencing individuals with ID, congenital 
anomalies, and/or autism with a targeted gene panel.309 Written consent was obtained from 
the legal guardians for all females and the study was given IRB approval. We recognized a 
similar pattern of facial characteristics, congenital malformations, and brain abnormalities 
in these females. Four additional affected females were identified because their phenotype 
was suggestive for USP9X mutations. Subsequently, de novo protein-truncating mutations 
and intragenic USP9X deletions were duly demonstrated by Sanger sequencing, WES, or 
CytoScan HD array (Figures 9.1A and B; Supplemental Table 9.1), illustrating the clinical 
recognizability of this new syndrome. All females (age ranging 2 years, 7 months to 23 
years) with de novo mutations shared a distinct phenotype. They showed mild to moderate 
ID with motor and language delay, short stature, hearing loss, and distinct congenital 
malformations, notably choanal atresia, asymmetric hypomastia, cleft palate/bifid uvula, 
heart defects, progressive scoliosis, post-axial polydactyly, and anal abnormalities (Tables 
9.1 and Supplemental Table 9.2; case studies in Supplemental Note). Shared facial 
characteristics included prominent forehead, low nasal bridge, prominent nose with flared 
alae nasi, thin upper lip, smooth and long philtrum, and ears that were low set, posteriorly 
rotated, and dysplastic (Figure 9.2A). In addition to the USP9X variant, female 5 also 
harbored a de novo variant in PTPN11 (MIM: 176876), which has previously been reported 
to cause Noonan syndrome (MIM: 163950).311 Though all features that were observed in this 
female could potentially be explained by the USP9X variant itself (Supplemental Table 9.2), a 
contribution of aberrant PTPN11 to phenotypic features such as intellectual disability, short 
stature, and heart defect in this female is likely. Neuroimaging reports were available for 13 
out of 17 females (Supplemental Table 9.2). Detailed evaluation of brain images of five of 
these females (females 1, 2, 3, 7, and 16) showed asymmetric hypoplasia of the cerebellar 
vermis and hemisphere with a retrocerebellar cyst, short and thin corpus callosum, thin 
brainstem, and mildly abnormal frontal gyration pattern (Figure 9.3). Notably, we observed 
thyroid hormone abnormalities in six of the females, requiring medical treatment in three of 
them.
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Figure 1. Identified De Novo USP9X Loss-of-Function Mutations
(A) Detailed view of the USP9X (GenBank: NM_001039590.2) region and the reported deletions.
(B) Overview of USP9X includingUBL and catalytic domain and the location of reportedmutations according to their relative position at
the protein level. The reported amino acid substitution is located within the catalytic domain.
(C) RNA was extracted from both control and affected female (c.30282A>G [p.(?)]) fibroblasts cultured under normal conditions
or in the presence of cycloheximide (CHX) to inhibit NMD. After cDNA synthesis and PCR, agarose gel analysis showed two
different product sizes generated from the c.30282A>G transcript but only one from the control fibroblast transcript. Excision
and sequencing of the additional band revealed that the aberrant USP9X transcript lacked exon 21. The level of the aberrant transcript
was increased 4-fold when fibroblasts were treated with cycloheximide, confirming that the aberrant transcript was indeed subjected
to NMD.
(legend continued on next page)
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Figure 9.1: Identified de novo USP9X loss-of-function mutations.
(A) Detailed view of the USP9X (GenBank: NM_001039590.2) region and the reported deletions. (B) Overview of 
USP9X including UBL and catalytic domain and the location of reported mutations according to their relative position 
at the protein level. The reported amino acid substitution is located within the catalytic domain. (C) RNA was extracted 
from both control and affected female (c.3028−2A>G [p.(?)]) fibroblasts cultured under normal conditions or in the 
presence of cycloheximide (CHX) to inhibit NMD. After cDNA synthesis and PCR, agarose gel analysis showed two 
different product sizes generated from the c.3028−2A>G transcript but only one from the control fibroblast transcri t. 
Excision and sequencing of the additional band revealed that the aberrant USP9X transcript lacked exon 21. The level 
of the aberrant transcript was increased 4-fold when fibroblasts were treated with cycloheximide, confirming that the 
aberrant transcript was indeed subjected to NMD. (D) USP9X expression is depleted in female cell lines harboring loss-
of-function alleles. Relative qPCR analysis of USP9X mRNA and relative quantification of immunoblot analysis of USP9X 
protein derived from female and male control cell lines and from affected female cell lines. n = the number of individual 
cell lines analyzed. Each cell line analyzed in quadruplicate. Error bars represent SDs. Asterisk (*) indicates significantly 
different to female controls, p < 0.05 by Student’s t test.
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Table 9.1 Clinical features of females with de novo USP9X loss 
of function mutations
Percentage Number 
Development
Intellectual disability or developmental delay 100% 17/17
Growth
Short stature 53% 9/17
Congenital abnormalities
Eye abnormality 59% 10/17
Choanal atresia 35% 6/17
Cleft palate/bifid uvula 29% 5/17
Dental abnormality 71% 12/17
Asymmetric hypomastia 29% 5/17
Heart defect 44% 7/16
Urogenital abnormality 29% 5/17
Sacral dimple 29% 5/17
Scoliosis 65% 11/17
Hip dysplasia 47% 8/17
Post-axial polydactyly 53% 9/17
Abdominal wall abnormality 12% 2/17
Anal atresia 53% 9/17
Neurology
Seizures 24% 4/17
Hypotonia 47% 8/17
Brain abnormalities
Dandy walker malformation (variant) 38% 5/13
Hypoplastic corpus callosum 62% 8/13
(Asymmetric) cerebellar hypoplasia 55% 6/11
(Asymmetric) enlarged ventricles 73% 8/11
Thin brain stem 30% 3/10
Abnormal gyration pattern frontal lobe 50% 5/10
Other
Hearing loss 65% 11/17
(Blaschko) pigment abnormality 65% 11/17
Hypertrichosis 29% 5/17
Leg length discrepancy 41% 7/17
Malignancy 12% 2/17
Recurrent respiratory tract infections 53% 9/17
Thyroid hormone abnormality 35% 6/17
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The X-linked USP9X encodes a structurally and functionally highly conserved 
deubiquitinating enzyme, containing a UBL (ubiquitin-like) and a catalytic ubiquitin 
specific protease (USP) domain.312-314 It is known to play an important role in neural 
development of both humans and mice and is required for fetal development.315-317 USP9X is 
highly expressed during embryogenesis and expression declines as cell fates become 
restricted.316 The USP9X ortholog in Drosophila, fat facets (faf), has been shown to be 
important in cell polarity and cell fate of the developing eye in Drosophila.318 A range of 
signaling proteins involved in different neurodevelopmental pathways including Notch, Wnt, 
TGF-β, and mTOR have been shown to interact with USP9X.313; 319-326 USP9X also has been 
described to act as both an oncogene and tumor-suppressor gene and is frequently found to 
be dysregulated in human cancer.313; 327; 328 Two of the affected females developed malignancy 
at a young age (22 and 8 years). Both acute lymphoblastic leukemia and osteosarcoma were 
treated successfully and have not reoccurred. To determine the risk and nature of particular 
malignancies in this new syndrome, further studies are required.
We observed pigment abnormalities along Blaschko lines and facial asymmetry, asymmetric 
abnormalities of the brain and breast, and asymmetric length of the legs (Figures 9.2A, 
9.2D, and  9.3), all suggestive of a pattern of post-zygotic mosaicism or differential 
X-inactivation (XCI) between tissues (functional mosaicism).62 USP9X is one of the genes 
shown to escape XCI.329; 330 However, it is known that most of the genes that escape 
from XCI are not fully expressed from the inactivated X chromosome and instead show 
a partial escape.331-333 Moreover, there is accumulating evidence for tissue-specific and 
developmental-stage-dependent differences in XCI and variability of escape of USP9X.332; 
334-337 In the partial escaping genes, non-random XCI or skewing, as observed often in female 
carriers of an X-linked mutation, will only partially restore a normal phenotype.333 Consistent 
with this hypothesis, XCI was found to be skewed >90% in fibroblasts in three of the five of 
the tested females, but skewing was not related to disease severity (Supplemental Table 9.3). 
We note that a similar skewing pattern of XCI was observed recently in females with de novo 
mutations in DDX3X (MIM: 300160), another X-chromosomal gene that has been suggested 
to escape XCI and in which de novo mutations cause ID specifically in females.338
In one of the affected females, a predicted splice site mutation was identified. To evaluate 
whether this mutation indeed results in an aberrant transcript, we synthesized cDNA from 
RNA extracted from primary skin fibroblasts of both the affected female and a control. 
We amplified a fragment of 576 base pairs (bp) covering exon 20 to exon 22 by PCR. 
Electrophoretic separation showed two products of 576 and 455 bp in the sample from 
the affected female, and a single 576-bp product in the control. Sequencing of the smaller 
product revealed that this cDNA transcript from the affected female indeed lacked exon 
21, confirming the truncating effect of the splice site mutation. Importantly, the level of the 
transcript was increased 4-fold when fibroblasts were treated with cycloheximide, strongly 
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both qRT-PCR and immunoblot analysis of fibroblasts
(n ¼ 4) and lymphoblastoid cell lines (LCLs; n ¼ 1)
derived from affected females and both female and
male controls (Figures 1D and S1). We found that expres-
ion of USP9X in affected females was reduced compared
to control females in both fibroblasts and LCLs at both
mRNA expression and protein levels. Although some
cellular variability was evident, on average this decrease
was significant (p < 0.05 by Student’s t test) (Figures 1D
and S1). There was no correlation between skewing of
XCI and expression of mRNA and protein level. Whether
the cells in affected tissue have benefit from the skewed
XCI remains uncertain. The escape from XCI was sup-
ported by the fact that the average expression of USP9X
mRNA in both control male fibroblasts and control
male LCLs was ~50% of that in female controls. After
quantification of protein levels in male control LCLs,
similar levels were observed. The USP9X protein level in
male control fibroblasts was increased to ~80% of that
in female controls, but was still significantly less than
the protein level in female controls. Intriguingly, these
data thus reveal that affected females displayed reduced
levels of USP9X compared to female controls but compa-
rable levels to that in healthy control males. It will be
important to expose whether these trends extend to
other tissues, where the level of escape from XCI might
Figure 3. Representative MRI Images
from Females 1, 2, 3, 7, and 16 with De
Novo USP9X Loss-of-Function Mutations
(A–D) Female 1 (2 years): MRI T2 axial
(A, B) and sagittal (C) and T1 axial (D) sec-
tions show brachycephaly, mild enlarge-
ment of the lateral and 3rd ventricles;
mild hypoplasia of cerebellar vermis and
left cerebellar hemisphere; enlarged IV
ventricle and cisterna magna with small
retrocerebellar cyst; thin brain stem and
mesencephalon; relatively small frontal
lobes with somewhat simplified gyration;
and short hypoplastic corpus callosum
(both rostrum and splenium).
(E–H) Female 2 (1.5 years): MRI T2 axial
(E, F) and T1 sagittal (G) and coronal (H)
sections show enlargement of the lateral
ventricles, mild hypoplasia of cerebellar
vermis and left cerebellar hemisphere;
enlarged cistern magna; thin corpus cal-
losum, pons, mesencephalon, and brain
stem; and broader and underdeveloped
frontal gyri.
(I–L) Female 3 (11 years): MRI T2 axial (I, J)
and T1 sagittal (K) and axial (L) sections
show asymmetric enlargement of the
lateral ventricles; simplified convolutions
of the frontal lobe gyri; hypoplasia of cere-
bellar vermis and left hemisphere; large
cisterna magna and retrocerebellar cyst;
and thin corpus callosum with hypoplasia
of the rostrum.
(M–P) Female 7: MRI T2 axial (M), T1 axial
(N), T1 sagittal (O), and coronal FLAIR (P)
sections show macrocephaly; enlargement
of the lateral and 3rd ventricles with an
interhemispheric cyst; dysplastic cerebellar
hemispheres; dysplasia of the cerebellar
vermis which is uplifted, with a high posi-
tion of the tentorium and a large posterior
fossa, typical of Dandy-Walker malforma-
tion; and thin and hypoplastic corpus
callosum.
(Q–T) Female 16 (2 years): MRI T2 axial
(Q, R, S) and T1 coronal (T) sections show
enlarged lateral ventricles; irregular gyri of
the cerebral cortex with irregular depth of
the sulci in frontal and perisylvian areas;
small heterotopic nodule of gray matter (arrow) and thin and hypoplastic corpus callosum (both rostrum and splenium); hypoplasia
of the anterior cerebellar vermis and left cerebellar hemisphere; enlarged cisterna magna and arachnoidal cyst surrounding the cere-
bellum, especially at the left side; and mild hypoplasia of pons and brain stem. This female was identified with Sanger sequencing based
on these brain abnormalities in combination with ID, dysmorphic features, and congenital abnormalities.
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suggesting that the aberrant transcript was subjected to nonsense-mediated mRNA decay 
and as such leads to loss of function of this USP9X allele (Figure 9.1C). To study the effect 
of the heterozygous loss-of-function USP9X alleles on their mRNA expression and protein 
levels, we performed both qRT-PCR and immunoblot analysis of fibroblasts (n = 4) and 
lymphoblastoid cell lines (LCLs; n = 1) derived from affected females and both female 
and male controls (Figures 9.1D and Supplemental Figure 9.1). We found that expression 
of USP9X in affected females was reduced compared to control females in both fibroblasts 
and LCLs at both mRNA expression and protein levels. Although some cellular variability 
was evident, on average this decrease was significant (p < 0.05 by Student’s t test) (Figures 
9.1D and Supplemental Figure 9.1). There was no correlation between skewing of XCI and 
expression of mRNA and protein level. Whether the cells in affected tissue have benefit from 
the skewed XCI remains uncertain. The escape from XCI was supported by the fact that the 
average expression of USP9X mRNA in both control male fibroblasts and control male LCLs 
was ~50% of that in female controls. After quantification of protein levels in male control 
LCLs, similar levels were observed. The USP9X protein level in male control fibroblasts 
was increased to ~80% of that in female controls, but was still significantly less than the 
protein level in female controls. Intriguingly, these data thus reveal that affected females 
displayed reduced levels of USP9X compared to female controls but comparable levels to 
that in healthy control males. It will be important to expose whether these trends extend to 
other tissues, where the level of escape from XCI might not be comparable. Furthermore, 
characterization of different expression patterns between sexes (described for USP9X in 
brain thus far339) and/or that of protein levels of USP9X substrates will be important to 
ascertain as well.
Figure 9.3: Representative MRI images from females 1, 2, 3, 7, and 16 with de novo USP9X loss-of-function 
mutations.
(A–D) Female 1 (2 years): MRI T2 axial (A, B) and sagittal (C) and T1 axial (D) sections show brachycephaly, mild 
enlargement of the lateral and 3rd ventricles; mild hypoplasia of cerebellar vermis and left cerebellar hemisphere; 
enlarged IV ventricle and cisterna magna with small retrocerebellar cyst; thin brain stem and mesencephalon; relatively 
small frontal lobes with somewhat simplified gyration; and short hypoplastic corpus callosum (both rostrum and 
splenium). (E–H) Female 2 (1.5 years): MRI T2 axial (E, F) and T1 sagittal (G) and coronal (H) sections show enlargement 
of the lateral ventricles, mild hypoplasia of cerebellar vermis and left cerebellar hemisphere; enlarged cistern magna; 
thin corpus callosum, pons, mesencephalon, and brain stem; and broader and underdeveloped frontal gyri. (I–L) Female 
3 (11 years): MRI T2 axial (I, J) and T1 sagittal (K) and axial (L) sections show asymmetric enlargement of the lateral 
ventricles; simplified convolutions of the frontal lobe gyri; hypoplasia of cerebellar vermis and left hemisphere; large 
cisterna magna and retrocerebellar cyst; and thin corpus callosum with hypoplasia of the rostrum. (M–P) Female 7: MRI 
T2 axial (M), T1 axial (N), T1 sagittal (O), and coronal FLAIR (P) sections show macrocephaly; enlargement of the lateral 
and 3rd ventricles with an interhemispheric cyst; dysplastic cerebellar hemispheres; dysplasia of the cerebellar vermis 
which is uplifted, with a high position of the tentorium and a large posterior fossa, typical of Dandy-Walker malformation; 
and thin and hypoplastic corpus callosum. (Q–T) Female 16 (2 years): MRI T2 axial (Q, R, S) and T1 coronal (T) sections 
show enlarged lateral ventricles; irregular gyri of the cerebral cortex with irregular depth of the sulci in frontal and 
perisylvian areas; small heterotopic nodule of gray matter (arrow) and thin and hypoplastic corpus callosum (both 
rostrum and splenium); hypoplasia of the anterior cerebellar vermis and left cerebellar hemisphere; enlarged cisterna 
magna and arachnoidal cyst surrounding the cerebellum, especially at the left side; and mild hypoplasia of pons and 
brain stem. This female was identified with Sanger sequencing based on these brain abnormalities in combination with 
ID, dysmorphic features, and congenital abnormalities.
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In contrast to the severely disruptive de novo mutations in females, three milder mutations 
in USP9X have been reported in males without multiple congenital malformations. The 
mutations were transmitted by phenotypically normal females and resulted in ID, hypotonia, 
and behavioral problems in the males.340 An additional two missense mutations were 
identified after resequencing of USP9X in a cohort of 284 males with epilepsy.341 For two 
de novo mutations reported in large autism cohorts, no specific gender information was 
described.31 The phenotype of the males differs notably from the observed phenotype 
in the affected females described here. They had ID and short stature, but lacked the 
multiple congenital malformations observed in affected females. Besides four missense 
mutations, one frameshift mutation has been reported in the males. This single frameshift 
mutation occurred within the last 50 nucleotides upstream of the last 3′-exon-exon junction, 
presumably escaping nonsense-mediated mRNA decay (NMD), and therefore results in 
a truncated protein lacking the last exon.342; 343 Because no truncating variants have been 
described in healthy controls in the ExAC database and no mutations causing loss of 
function of USP9X have been reported in males, we suspect that loss-of-function mutations 
could be lethal in males. This hypothesis is further supported by the fact that the absence of 
Usp9X in male mice is embryonically lethal.344 In contrast, all but one of the affected females 
we report here have protein-truncating mutations and deletions. In one female, we identified 
a de novo missense mutation, located in the catalytic domain of the protein. Given the fact 
that this female was phenotypically comparable with the other females, it is likely that this 
specific missense mutation leads to loss of function of the protein. We hypothesize that in 
addition to complete loss-of-function mutations, such as protein-truncating mutations and 
deletions, a small subset of specific missense mutations will also lead to disease in females.
Figure 9.4: USP9X localizes to the primary cilium.
To induce ciliogenesis, control and affected female fibroblasts, matched for gender and age, were starved for 48 hr 
prior to immunofluorescence labeling. Endogenous USP9X is detected along the length of the axoneme of primary 
cilia, using an antibody against its N terminus (N-Term, shown in green) as compared to the ciliary markers RPGRIP1L 
(pink, denoting the ciliary transition zone at the base of the cilium) and acetylated alpha-tubulin (red, marking the ciliary 
axoneme). DAPI (blue) stains the nuclei; scale bars represent 10 μm. Ciliated fibroblasts derived from affected females 
are shown here, USP9X localization in control fibroblasts is shown in Supplemental Figure 9.2.
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Affected females presented with symptoms that overlap with CHARGE syndrome 
(MIM: 214800) (CHD7 [MIM: 608892] tested in four of the females) and with the clinical 
spectrum of some known ciliopathy syndromes, such as Bardet-Biedl, Meckel-Gruber, and 
Joubert syndromes.345 Therefore, we investigated whether heterozygous protein-truncating 
mutations result in the disruption of ciliary structure, formation, or trafficking in fibroblasts of 
four of the affected females we had available (females 1, 3, 14, and 15). First, we determined 
subcellular localization of endogenous USP9X in both controls and affected-female-
derived fibroblasts under serum starvation to induce ciliogenesis, as well as in serum-rich 
conditions.346; 347 USP9X showed diffuse cytoplasmic staining with areas enriched with puncta 
consistent with its described association with protein and vesicle trafficking.348 Importantly, 
upon the induction of ciliogenesis in the fibroblasts, USP9X was indeed found to localize to 
the cilium. This ciliary localization was observed along the length of the ciliary axoneme of 
most fibroblasts, and comparable in cells from affected females and from age- and gender-
matched controls (Figure 9.4). This localization was significantly decreased with siRNA 
knockdown of USP9X indicating specificity of the signal (Supplemental Figure 9.2). We were 
unable to observe any significant differences in ciliogenesis, ciliary length, or ciliary trafficking 
between fibroblasts from affected females when compared to controls (Supplemental 
Figure 9.3), and siRNA knockdown of USP9X did not impair ciliogenesis in fibroblasts. 
This suggests that USP9X dosage is not critical to the generation of primary cilia in these 
fibroblasts, despite localization of USP9X in their cilia. It is therefore more likely that USP9X-
regulated signal transduction pathways mediated by the primary cilium are more subtly 
disturbed, and/or that this disturbance is spatiotemporally restricted to the tissues affected in 
this specific phenotype, possibly due to tissue-specific and developmental-stage-dependent 
differences in XCI and variability of escape of USP9X. Future studies utilizing dedicated cell-
based or animal models will be necessary to evaluate these mechanisms.
In conclusion, this study defines a recognizable X-linked ID/DD syndrome with associated 
multiple congenital malformations and brain abnormalities specific to females, caused by 
de novo loss-of-function mutations in USP9X, a gene known to escape X-inactivation. The 
phenotypic characteristics overlap with ciliopathy conditions and USP9X localization along 
the length of the ciliary axoneme of fibroblasts indicates a role in de-ubiquitination of ciliary 
proteins, which could contribute to the disease pathogenesis of this specific syndrome.
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Abstract
Recently WAC was reported as a candidate gene for intellectual disability (ID) based on 
the identification of a de novo mutation in an individual with severe ID. WAC regulates 
transcription-coupled histone H2B ubiquitination and has previously been implicated in the 
10p12p11 contiguous gene deletion syndrome. In this study, we report on 10 individuals 
with de novo WAC mutations which we identified through routine (diagnostic) exome 
sequencing and targeted resequencing of WAC in 2326 individuals with unexplained ID. All 
but one mutation was expected to lead to a loss-of-function of WAC. Clinical evaluation 
of all individuals revealed phenotypic overlap for mild ID, hypotonia, behavioral problems 
and distinctive facial dysmorphisms, including a square-shaped face, deep set eyes, long 
palpebral fissures, and a broad mouth and chin. These clinical features were also previously 
reported in individuals with 10p12p11 microdeletion syndrome. To investigate the role 
of WAC in ID, we studied the importance of the Drosophila WAC orthologue (CG8949) 
in habituation, a non-associative learning paradigm. Neuronal knockdown of Drosophila 
CG8949 resulted in impaired learning, suggesting that WAC is required in neurons for 
normal cognitive performance. In conclusion, we defined a clinically recognizable ID 
syndrome, caused by de novo loss-of-function mutations in WAC. Independent functional 
evidence in Drosophila further supported the role of WAC in ID. On the basis of our data 
WAC can be added to the list of ID genes with a role in transcription regulation through 
histone modification.
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Introduction
Intellectual disability (ID) is a heterogeneous disorder, both clinically and genetically. To 
date, 4650 genes have been associated with ID and novel genes are still being identified. 
The introduction of triobased whole-exome sequencing (WES) in individuals with ID has 
proven to be a valuable approach for the identification of novel ID genes, especially for 
those individuals who do not show a clinical recognizable syndrome.28; 29 In addition to the 
identification of mutations in known disease genes, WES has facilitated the identification 
of candidate ID genes. To establish the pathogenicity of mutations in such candidate ID 
genes, it is essential to identify additional individuals with an overlapping phenotype and a 
mutation in the same gene.349-351 With increasing availability of WES in routine diagnostics6 
as well as technological advances facilitating targeted resequencing of candidate ID genes 
in larger cohorts of samples,352 chances of finding such additional individuals are increasing. 
Furthermore, supporting evidence and insights into underlying mechanisms can be obtained 
from functional studies in cell or animal models.353; 354 Previously, we and others separately 
reported on an individual with a de novo mutation in the ‘WW domain-containing adapter 
with coiled-coil’ (WAC) gene using trio-based exome sequencing.28; 355 The mutations were 
reported as potential cause of disease, based on mutation severity, protein function, its 
expression in fetal stages and high expression in adult brain.28; 355; 356 WAC encodes a protein- 
regulating transcription-coupled histone H2B ubiquitination and contains two evolutionary 
conserved domains, including an N-terminal WW domain interacting with RNA polymerase 
II and a C-terminal coiled-coil domain promoting the RNF20/RNF40’s E3 ligase activity for 
ubiquitination at active transcription sites.357; 358 Furthermore, the RNF20/40/WAC complex 
may have a role in cell cycle checkpoint activation upon genotoxic stress.357 In addition, WAC 
has previously been implicated in ID based on the finding that deletions of chromosome 
10p12p11 result in a contiguous gene deletion syndrome, for which the shortest deleted 
region contains two genes, WAC and BAMBI. All individuals with a deletion of at least these 
two genes were reported to have a similar phenotype including ID, behavior problems and 
dysmorphic features, supporting a disease cause of WAC heterozygous loss-offunction.359-362 
Although it may well be hypothesized that WAC haploinsuffiency may explain the ID 
phenotype observed in the 10p12p11 contiguous gene syndrome, and ID in individuals 
with mutations in this gene, detailed evidence to support this hypothesis is lacking. In the 
present study we aimed to identify additional individuals with de novo mutations in WAC by 
using different sequencing strategies to define the clinical spectrum associated with WAC 
haploinsufficiency. Finally, to address the role of WAC in cognition, we investigated the role of 
the Drosophila WAC orthologue in habituation, a form of nonassociative learning.
Results
Identification of individuals with de novo CNVs affecting WAC
After the identification of the de novo mutation c.139C>T (NM_016628.3) leading to nonsense 
mutation p.(Arg47*) in Individual 1 (as reported before28), we set out to find additional 
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Figure 1 Individuals with WAC mutations. (a) Frontal and lateral photographs of individuals with de novo mutations in WAC. All individuals shared
overlapping facial dysmorphisms including a square-shaped face, long palpebral ﬁssures, broad mouth and broad chin. Additional features included deep set
eyes, epicanthal folds and short philtrum in Individual 1 (photograph at the age of 19 years); low posterior hairline, broad forehead, simple ears,
hypertelorism, deep set eyes, low-set full eyebrows, synophrys, deep nasal bridge, ﬂat nose, biﬁd tongue and broad gums in Individual 2 (photographs at the
age of 12 years and 23 years); brachycephaly, posterior ear creases, broad forehead, prominent antihelix, low-set full eyebrows, synophrys and prominent
teeth in Individual 3 (photographs at the age of 4 years and 9 years); prominent antihelix, frontal bossing, dental crowding, broad teeth and high palate in
Individual 6 (photographs at the age of 3 years and 20 years) and prominent antihelix and deep set eyes in Individual 9 (photographs at the age of 3 years).
Photographs were published with consent. (b) The genomic region involved in the 10p12p11 contiguous gene deletion region with the previously published
microdeletions, represented by gray horizontal bars.14–16 (c) Detailed view of the smallest region of overlap (SRO) and the deletion described in this study,
represented by a red horizontal bar. In addition, de novo mutations in WAC (NM_016628.3) reported in this study are shown according to their relative
position at protein level.
WAC haploinsufﬁciency causes an ID syndrome
D Lugtenberg et al
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individuals with mutations affecting WAC to obtain more evidence for its involvement in 
ID. Systematic analysis of DECIPHER and ECARUCA, two databases collecting clinically 
relevant copy number variants (CNVs), for CNVs affecting WAC yielded one small deletion 
(Individual 2; Figure 10.1). This deletion, hg19 chr10:g.(?_288422777)_(28929097_?)del, 
disrupted the coding sequence of WAC by deletion of exons 5-14 (NM_016628.3). The 
shortest region of deletion overlap of the chromosome 10p12p11 contiguous gene deletion 
syndrome was previously determined by nine deletions ranging in size between 0.99 and 
10.66 Mb.359-362 Comparison of the deletion in Individual 2 to the shortest region of deletion 
overlap indicates WAC as a only remaining candidate gene for the ID phenotype (Figure 
10.1B).
Diagnostic exome sequencing in individuals with neurodevelopmental disorders to 
identify de novo point mutations in WAC
In routine diagnostic trio-based exome sequencing for individuals with unexplained ID, 
performed as described before,28 we identified four additional individuals with de novo 
loss-of-function mutations in WAC (NM_016628.3): c.329C>A, p.(Ser110*) in Individual 3; 
c.1885_1886del, p.(Leu629fs) in Individual 4; c.356dup, p.(Asn119fs) in Individual 5 and 
c.1648C>T, p.(Arg550*) in Individual 6 (Figure 10.1C). In addition, two more individuals with 
de novo mutations were identified by trio-based exome sequencing of a large cohort of 
individuals with autism spectrum disorder:31; 114 c.523_524del, p.(Lys175fs) in Individual 7 and 
c.1209_1212del, p.(His404fs) in Individual 8. Whereas exome sequencing had identified a 
second de novo mutation in Individual 1 (MIB1; NM_020774.2:c.521G>A; p.(Arg174His)),28 no 
further clinically relevant de novo mutations were identified in Individuals 3–8, leaving WAC 
haploinsufficiency as the most likely candidate to explain disease.
Targeted resequencing of WAC in an ID cohort identifies additional de novo muta-
tions
On the identification of multiple de novo loss-of-function mutations in WAC, we performed 
targeted resequencing of this gene in a cohort of over 2300 individuals with unexplained ID 
Figure 10.1: Individuals with WAC mutations. 
(A) Frontal and lateral photographs of individuals with de novo mutations in WAC. All individuals shared overlapping 
facial dysmorphisms including a square-shaped face, long palpebral fissures, broad mouth and broad chin. Additional 
features included deep set eyes, epicanthal folds and short philtrum in individual 1 (photograph at the age of 19 years); 
low posterior hairline, broad forehead, simple ears, hypertelorism, deep set eyes, low-set full eyebrows, synophrys, deep 
nasal bridge, flat nose, bifid tongue and broad gums in individual 2 (photographs at the age of 12 years and 23 years); 
brachycephaly, posterior ear creases, broad forehead, prominent antihelix, low-set full eyebrows, synophrys and prom-
inent teeth in individual 3 (photographs at the age of 4 years and 9 years); prominent antihelix, frontal bossing, dental 
crowding, broad teeth and high palate  in individual 6 (photographs at the age of 3 years and 20 years) and prominent 
antihelix and deep set eyes in individual 9 (photographs at the age of 3 years). Photographs were published with con-
sent. (B) The genomic region involved in the 10p12p11 contiguous gene deletion region with the previously published 
microdeletions, represented by gray horizontal bars.359-361 (C) Detailed view of the smallest region of overlap (SRO) 
and the deletion described in this study, represented by a red horizontal bar. In addition, de novo mutations in WAC 
(NM_016628.3) reported in this study are shown according to their relative position at protein level.
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using MIPs as described before.352 This cohort was selected from the in-house collection 
of the Department of Human Genetics of Radboud University Medical Center containing 
individuals with unexplained ID. All candidate loss-of-function mutations as well as highly 
conserved missense mutations (PhyloP>5) were validated by standard Sanger sequencing 
approaches. For assessing the de novo occurrence of validated mutations, DNA from 
the parents was tested. This targeted screen identified two additional de novo truncating 
mutations: c.1415del, p.(Pro472fs) in Individual 9 and c.1648C>T, p.(Arg550*) in Individual 10 
(Figure 10.1C).
WAC mutation spectrum in control individuals
Of all ten de novo mutations identified, nine are predicted to directly result in nonsense-
mediated decay of the RNA transcripts; the de novo frameshift in Individual 4 is located in 
the last exon, suggesting it may skip nonsense-mediated RNA decay. None of the de novo 
mutations are reported in our in-house variant database containing Exome sequencing 
variants detected in 5031 individuals, nor in ExAC, a large database collecting NGS variants 
in over 60 000 exomes as proxy for variant allele frequencies in the general population.363 The 
latter, however, does contain three other, presumable loss-of-function, variants (by insertion–
deletion events), each observed only once in ~100 000 alleles. Whereas these three variants 
have not been validated by Sanger sequencing, thereby possible being sequencing artefacts 
rather than true mutations, this observation may also reflect the very mild end of the ID 
spectrum in the general population.
Clinical spectrum associated with WAC haploinsuffiency
Clinical evaluation of all individuals with de novo loss-of-function mutations in WAC showed 
distinct phenotypic overlap (Table 10.1; Supplemental Information (clinical descriptions); 
and Supplementary Table 1.1). All, but one individual, had ID. The range of ID observed 
ranged from mild-to-severe and was accompanied by language and motor delay. In addition, 
individuals showed a variety of neurological problems including hypotonia (6/9), with 
remarkable manifestation in the oral region resulting in dysarthria, and behavioral problems 
(10/10). The latter recurrently included autism (4/9), anxiety (3/10), concentration disorder 
(4/10) and/or sleep disturbance (6/10). Other overlapping features consisted of unexplained 
reduced vision (3/9) and respiratory problems (7/9) with recurrent respiratory infections 
reported most often (5/7). Notably, all individuals had overlapping facial dysmorphisms 
consisting of a square shape of the face, deep set eyes, long palpebral fissures, broad mouth 
and broad chin (Figure 10.1A).
Panneuronal knockdown of the Drosophila WAC orthologue results in learning  
deficit
To obtain independent evidence for the involvement of WAC in the ID phenotype of the 
described individuals, we decided to study the functional consequences of WAC knockdown 
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using Drosophila as a model. The Drosophila genome contains a previously uncharacterized 
WAC orthologue named CG8949, not be confused with the unrelated Drosophila WAC (wee 
Augmin) gene. CG8949 codes for several protein isoforms, the longest one consisting of 
876 amino acids, and shows the highest expression in adult ovaries and the larval central 
nervous system.364; 365 WAC is 26% identical and 39% conserved over the C-terminal 588 
amino acids of the fly protein, with sequence similarity distributed over the whole protein, 
further characterized by clusters of short sequences of high conservation for the important 
functional motifs of the protein.358 We investigated the role of the Drosophila WAC orthologue 
in lightoff jump reflex habituation paradigm. Habituation is a simple form of non-associative 
learning, in which an initial strong behavioral response towards a repeated, non-threatening 
stimulus gradually wanes. It provides a filtering mechanism, which is an important 
prerequisite for higher cognitive functioning.366; 367 Using the light-off jump reflex habituation, 
we have previously identified learning deficits in number of Drosophila ID models.354; 368; 369 
Two independent inducible RNAi lines targeting the Drosophila WAC orthologue CG8949 
(vdrc48307 and vdrc107328) and their corresponding genetic background control lines 
(vdrc60000 and vdrc60100) were obtained (Vienna Drosophila RNAi Center370) and fly stocks 
were kept under standard conditions. Expression of CG8949 was specifically downregulated 
in neurons using the UAS-Gal4 system. The efficiency of ubiquitous RNAi knockdown 
was measured using qPCR on RNA isolated from Drosophila brains of third instar larvae, 
representing the tissue and developmental stage with the highest expression of CG8949 
Flies were exposed to series of 100 short (15 ms) light-off stimuli
with 1 s interval between stimuli. Both control and CG8949vdrc48307
knock-down ﬂies showed good initial jump response; there
was no signiﬁcant difference between the initial startle
response of CG8949vdrc48307 and control ﬂies (t-test, P= 0.469).
Whereas, control ﬂies quickly habituated to the repeated light-off
stimuli, CG8949vdrc48307 knock-down animals failed to adapt their
behavioral response and retained high average jump response
throughout the whole experiment (Figure 2). This defect was
statistically signiﬁca t (fol -change= 5.93; P= 5.21 × 10 − 12). No
habitation defects were seen in the CG8949vdrc107328 knock-down
ﬂies (data not shown), as was to be expected based on the
insufﬁcient RNA knockdown.
DISCUSSION
Here, we report the identiﬁcation of a novel clinically recognizable
syndrome caused by haploinsufﬁciency of WAC. All but one
patient showed mild ID, with speech and motor delay, whereas
one had an overall more severe ID phenotype, epilepsy and
an absence, rather than delay, of speech. All patients had
neurological problems including hypotonia and a variety of
behavioral problems including autism, anxiety, concentration
problems, sleep disturbance and/or self-mutilation. Notably, all
patients had overlapping facial dysmorphisms consisting of square
shape of the face, deep set eyes, long palpebral ﬁssures, broad
mouth and broad chin. Complementary experimental evidence in
Drosophila showed a role of the evolutionarily conserved WAC
proteins in cognitive processes and a role for the Drosophila WAC
orthologue in non-associative lear ing.
Previously, another individual was reported with a truncating
mutation in WAC10 who shows a phenotype similar to the
individuals report d in this study (Supplementary Table S1). Also,
a large-scale study aiming at the identiﬁcation of genetic causes
underlying developmental disorders recently reported the identi-
ﬁcation of one de novo nonsense mutation in WAC but further
clinical details of this individual were lacking, hampering detailed
phenotypic comparison.33 Interestingly, three of our patients were
negative tested for RAI1, known to cause Smith–Magenis
syndrome.34 The coarse facial appearance as well as the ID with
variable behavior problems of the individuals with WAC mutations
have similarities with individuals reported with Smith–Magenis
syndrome.35
Interstitial deletions including WAC were previously described and
associated with ID.14–17 Wentzel et al.14 presented six individuals with
an interstitial deletion at 10p12p11, all sharing a region of overlap
including two genes: BAMBI and WAC. All individuals were reported
to have developmental delay, abnormal behavior and facial dys-
morphic features including a bulbous nasal tip, deep set eyes,
synophrys/thick eyebrows and full cheeks. This phenotype is highly
similar to the phe otype observed in the current individuals and
consistent with our ﬁnding that loss of WAC causes ID and the
characteristic facial dysmorphisms in 10p12p11 microdeletion syn-
drome (Supplementary Table S1). In this 10p12p11 microdeletion
syndrome, cardiac abnormalities have frequently been reported (7/9
individuals) and heterozygosity of two other genes, LYZL1 and SVIL,
has been suggested to contribute to the development of these cardiac
abnormalities.14 This is in line with the fact that in none of our
individuals cardiac abnormalities were present. Epilepsy has been
reported in two out of nine individuals with deletion of 10p12p11 and
is present in on y one of ur individuals (Individual 1). This more
severely affected individual carried also a de novo MIB1 mutation. This
variant has been reported twice in ExAC, containing NGS variants in
healthy c ntrols of several ethnicities.28 Moreover, one missense and
one nonsense mutations in MIB1 were identiﬁed previously and
segregated each in two large dominant families with affected indivi-
duals with cardiomyopathy, but without ID.36 Therefore, a contribu-
tion of the second mutation in MIB1 as potential modiﬁer of the more
severe phenotype is unlikely. The more severe phenotype may be
caused by other yet unknown potential genetic modiﬁer(s) or reﬂects
the severe end of the clinical spectrum caused by WAC
haploinsufﬁciency.
Figure 2 Knockdown of the Drosophila WAC orthologue CG8949 affects non-associative learning in the light-off jump reﬂex habituation paradigm. Jump
responses of 3–7-day-old individual male ﬂies were induced by repeated light-off pulses (100 trials) with a 1 s inter-trial interval. CG8949 knockdown ﬂies
(CG8949vdrc48307; genotype: 2xGMR-wIR/+; UAS-CG8949vdrc48307/elav-Gal4, UAS-Dicer-2) are plotted in red and genetic background control ﬂies are plotted
in dark gray. Habituation was scored as the mean number of trials required to reach the non-jump criterion (TTC). Main effects of genotype (mutant vs
control), day and test system on log-transformed TTC values were tested using linear model regression analysis.27 (a) Average jump response across 100
light-off trials. (b) Mean TTC of CG8949vdrc48307 (TTC=38.39, n=54) vs mean TTC of control ﬂies (TTC=6.47, n=49). Quantiﬁcation of average jump
responses revealed that ﬂies with pan-neuronally induced CG8949 knockdown habituated signiﬁcantly slower (***Po0.001, linear model regression
analysis).
WAC haploinsufﬁciency causes an ID syndrome
D Lugtenberg et al
7
European Journal of Human Genetics
Figure 10.2: Knockdown of the Drosophila WAC orthologue CG8949 affects non-associative learning in the light-
off jump reflex habituation paradigm. 
Jump responses of 3-to-7-day-old individual male flies were induced by repeated light-off pulses (100 trials) with a 1s 
inter-trial interval. CG8949 knockdown flies (CG8949vdrc48307; genotype: 2xGMR-wIR/+; UAS-CG8949vdrc48307/elav-Gal4, 
UAS-Dicer-2) are plotted in red and genetic background control flies are plotted in dark grey. Habituation was scored as 
the mean number of trials required to reach the non-jump criterion (Trials To Criterion, TTC). Main effects of genotype 
(mutant vs control), day and test system on log-transformed TTC values were tested using linear model regression analy-
sis.380 (A) Average jump response across 100 light-off trials. (B) Mean TTC of CG8949vdrc48307 (TTC=38.39, n=54) vs mean 
TTC of control flies (TTC=6.47, n=49). Quantification of average jump responses revealed that flies with pan-neuronally 
induced CG8949 knockdown habituated significantly slower (*** P<0.001, linear model regression analysis).
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allowing for an efficient detection of expression differences. There was no significant 
CG8949vdrc107328-mediated knockdown on CG8949 expression levels (88% remaining gene 
expression; P=0.16, student’s t-test; Supplemental Table 10.2). In contrast, CG8949vdrc48307-
mediated RNAi reduced levels of CG8949 to 58% remaining gene expression (P<0.01, 
Student’s t-test; Supplemental Table 10.2).
Flies were exposed to series of 100 short (15 ms) light-off stimuli with 1 s interval between 
stimuli. Both control and CG8949vdrc48307 knock-down flies showed good initial jump response; 
there was no significant difference between the initial startle response of CG8949vdrc48307 
and control flies (t-test, P = 0.469). Whereas, control flies quickly habituated to the repeated 
light-off stimuli, CG8949vdrc48307 knock-down animals failed to adapt their behavioral response 
and retained high average jump response throughout the whole experiment (Figure 10.2). 
This defect was statistically significant (fold-change = 5.93; P = 5.21 × 10-12). No habitation 
defects were seen in the CG8949vdrc107328 knock-down flies (data not shown), as was to be 
expected based on the insufficient mRNA knockdown.
Discussion
Here, we report the identification of a novel clinically recognizable syndrome caused by 
haploinsufficiency of WAC. All but one patient showed mild ID, with speech and motor 
delay, whereas one had an overall more severe ID phenotype, epilepsy and an absence, 
rather than delay, of speech. All patients had neurological problems including hypotonia and 
a variety of behavioral problems including autism, anxiety, concentration problems, sleep 
disturbance and/or self-mutilation. Notably, all patients had overlapping facial dysmorphisms 
consisting of square shape of the face, deep set eyes, long palpebral fissures, broad mouth 
and broad chin. Complementary experimental evidence in Drosophila showed a role of the 
evolutionarily conserved WAC proteins in cognitive processes and a role for the Drosophila 
WAC orthologue in non-associative learning.
Previously, another individual was reported with a truncating mutation in WAC355  who shows 
a phenotype similar to the individuals reported in this study (Supplemental Table 10.1). Also, 
a large-scale study aiming at the identification of genetic causes underlying developmental 
disorders recently reported the identification of one de novo nonsense mutation in WAC 
but further clinical details of this individual were lacking, hampering detailed phenotypic 
comparison.32 Interestingly, three of our patients were negative tested for RAI1, known to 
cause Smith–Magenis syndrome.371 The coarse facial appearance as well as the ID with 
variable behavior problems of the individuals with WAC mutations have similarities with 
individuals reported with Smith–Magenis syndrome.372 
Interstitial deletions including WAC were previously described and associated with ID.359-362 
Wentzel et al.359 presented six individuals with an interstitial deletion at 10p12p11, all sharing 
a region of overlap including two genes: BAMBI and WAC. All individuals were reported to 
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have developmental delay, abnormal behavior and facial dysmorphic features including a 
bulbous nasal tip, deep set eyes, synophrys/thick eyebrows and full cheeks. This phenotype 
is highly similar to the phenotype observed in the current individuals and consistent with our 
finding that loss of WAC causes ID and the characteristic facial dysmorphisms in 10p12p11 
microdeletion syndrome (Supplemental Table 10.1). In this 10p12p11 microdeletion 
syndrome, cardiac abnormalities have frequently been reported (7/9 individuals) and 
heterozygosity of two other genes, LYZL1 and SVIL, has been suggested to contribute to the 
development of these cardiac abnormalities.359 This is in line with the fact that in none of our 
individuals cardiac abnormalities were present. Epilepsy has been reported in two out of nine 
individuals with deletion of 10p12p11 and is present in only one of our individuals (Individual 
1). This more severely affected individual carried also a de novo MIB1 mutation. This variant 
has been reported twice in ExAC, containing NGS variants in healthy controls of several 
ethnicities.363 Moreover, one missense and one nonsense mutations in MIB1 were identified 
previously and segregated each in two large dominant families with affected individuals with 
cardiomyopathy, but without ID.373 Therefore, a contribution of the second mutation in MIB1 
as potential modifier of the more severe phenotype is unlikely. The more severe phenotype 
may be caused by other yet unknown potential genetic modifier(s) or reflects the severe end 
of the clinical spectrum caused by WAC haploinsufficiency.
Human WAC encodes a protein containing a WW domaincontaining adapter and a 
coiled-coil region. WAC is an evolutionary conserved protein, but its exact function is still 
unknown. Protein–protein interaction studies suggest a role in the regulation of histone 
H2B ubiquitination and gene transcription.357 Interaction of WAC via the coiled-coil domains 
with RNF20 and RNF40 activates UBE2A-mediated H2B ubiquitination. On the basis of this 
interaction, RNF20 and RNF40 could be considered as candidate genes for ID. Interestingly, 
de novo mutations in both genes have been described in individuals with autism and 
unrelated unaffected siblings.31 A clear relation to a clinical phenotype, if any, remains to be 
established. RNA polymerase II recruits WAC to active transcription sites by binding to the 
WW domain. On the basis of sequence homology it has also been suggested that WAC is 
involved in RNA processing or transcription.358 Besides co-localization of WAC with splicing 
factor SC35 in nuclear speckles, there is, however, currently no further evidence for a role in 
RNA splicing. The localization of WAC in the nucleus supports its suggested function in gene 
transcription via UBE2A histone H2B ubiquitination. Although WAC and UBE2A lack a direct 
interaction, they are both likely to function within a protein complex important for histone 
H2B ubiquitination and transcription regulation.357 Interestingly, for UBE2A, microdeletions 
and point mutations have been associated in males with an X-linked inherited clinical 
syndrome characterized by ID, seizures, absent speech, urogenital and skin anomalies. 
Recent work on Drosophila has uncovered a novel role of UBE2A in clearance of defective 
mitochondria from the synaptic compartment and in synaptic plasticity.374 On the basis of 
the suggested interaction of WAC and UBE2A being part of the same complex, and their 
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clinical phenotypes both including ID, we experimentally addressed whether CG8949, like fly 
UBE2A, is required for synaptic vesicle cycling, mitochondrial functioning and morphology.374 
We found all these processes unperturbed in our Drosophila model (Supplemental Figure 
10.1). Despite the unavailability of the second CG8949 knockdown fly as an independent 
confirmation of the habituation phenotype, our data supports the role of WAC in cognition by 
the deficit in nonassociative learning. 
In summary, we describe a clinically recognizable syndrome owing to loss-of-function 
mutations in WAC, which is characterized by mild ID, hypotonia, behavioral problems and 
facial dysmorphisms consisting of square shape of the face, deep set eyes, long palpebral 
fissures, broad mouth and broad chin. Complementary experimental evidence in Drosophila 
showed a role of the evolutionarily conserved WAC proteins in cognitive processes and a role 
for the Drosophila WAC orthologue in nonassociative learning. WAC is a component of the 
evolutionary conserved histone H2B ubiquitination complex, regulating gene transcription. 
On the basis of our results, WAC can be added to the growing list of genes involved the H2B 
ubiquitination complex leading to cognitive defects.
Material and methods
Diagnostic exome sequencing
Individuals 1, 3, 4, 5 and 6 were ascertained through family-based WES in a diagnostic 
setting using techniques as described before.28 All clinically relevant candidate de novo 
mutations were validated using Sanger sequencing, and subsequently tested for absence 
in parental DNA samples. Individual 1 was previously reported as part of a large study 
assessing the clinical utility of WES, in which she was also identified to have a second de 
novo mutation in MIB1.28 Individuals 7 and 8 were identified in a large multicenter study 
to establish the contribution of de novo coding mutations to autism spectrum disorder.31; 
114 Apart from the de novo mutation in WAC these two patients were not reported to have 
additional de novo mutations.31
Database searches for copy number variations disrupting WAC
We systematically searched for individuals with small deletions including WAC in our 
in-house database and international databases such as the database of the European 
Cytogeneticists Association Register of Unbalanced Chromosome Aberrations (ECARUCA) 
and the Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl 
Resources (DECIPHER).375; 376
Targeted resequencing of WAC
Upon identification of the de novo mutation in Individual 1, targeted resequencing was 
performed on a cohort of 2326 patients with unexplained ID using molecular inversion probes 
(MIPs) as described previously.352 This cohort was selected from the in-house collection of 
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the Department of Human Genetics of Radboud University Medical Center (Nijmegen, The 
Netherlands) containing patients with unexplained ID. Candidate loss-of-function mutations 
as well as highly conserved missense mutations (PhyloP>5) were validated by standard 
Sanger sequencing approaches on DNA extracted from peripheral blood. For assessing the 
de novo occurrence of validated mutations, DNA from the parents was tested. This study 
was approved by the institutional review board ‘Commissie Mensgebonden Onderzoek Regio 
Arnhem-Nijmegen’.
Deposition of genotypes and phenotypes in a locus-specific database.
All mutations and phenotypes reported in this publication are deposited in the locus-specific 
database for WAC, under the realm of the Leiden Open Variation Database (LOVD; http://
databases.lovd.nl/shared/genes/WAC). Variant information and phenotypes can be retrieved 
using the following submission entries: Individual 1: #00054835; Individual 2: #00054836; 
Individual 3: #00054837; Individual 4: #00054838; Individual 5: #00054839; Individual 6: 
#00054848; Individual 7: #00054849; Individual 8: #00054850; Individual 9: #00054851; and 
Individual 10: #00054852.
Drosophila lines and maintenance
Fly stocks were kept on standard Drosophila diet (cornmeal/sugar/yeast) at 25 °C and 
45–60% humidity at 12 h:12 h light/dark cycle. Inducible RNAi lines targeting the Drosophila 
WAC orthologue CG8949 (vdrc48307, vdrc107328) and corresponding genetic background 
control lines (vdrc60000, vdrc60100) were obtained from the Vienna Drosophila RNAi 
Center.370 The s19 value, which refers to the specificity of the dsRNA hairpin construct,377 
is 1.00 for vdrc48307 with no off-target and 0.99 for vdrc107328 (two possible off-targets, 
CG11122 and CG11354). 
RNAi was induced using the UAS-Gal4 system and the panneuronal driver lines: elav-
Gal4 w1118; 2xGMR-wIR; elav-Gal4, UAS-Dicer-2 or nSyb-Gal4 w1118, UAS-Dicer-2; nSyb-
Gal4.354; 368 Flies were reared and tested at 25°C (elav-Gal4) and 28°C (nSyb-Gal4) and 70% 
humidity. The ubiquitous actin-Gal4 driver w1118; P(w[+mC]=Act5c-Gal4)/CyO obtained from 
Bloomington Drosophila Stock Center,378 was used to generate RNAi-mediated knockdown 
for quantitative PCR (qPCR).
Analysis of CG8949 mRNA levels from larval brains by qPCR
RNA isolations (three biological replicates) from third instar larvae brains were performed 
using Arcturus Picopure RNA Isolation Kit (Life Technologies, Bleiswijk, The Netherlands). 
RNA was treated with DNase (DNAfree Kit, Ambion, Bleiswijk, The Netherlands). First-strand 
cDNA synthesis was performed using iScript cDNA Synthesis Kit (Biorad, Veenendaal, 
The Netherlands). Gene expression was analysed by real-time PCR (7900HT Fast Real-
Time PCR system, Applied Biosystems, Bleiswijk, The Netherlands). PCR reactions were 
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performed in a volume of 25 μl containing 150 nM primers and GoTag Green Mastermix 
(Promega, Leiden, The Netherlands). Primer sequences used for amplification of CG8949: 
5’-TGGAATTACGACAACGATGG-3’and 5’-TAACTGGCTTCCGAGGTAGG-3’. BetaCop 
was used as reference gene, primer sequences: 5’-AACTACAACACCCTGGAGAAGG-3’, 
5’-ACATCTTCTCCCAATTCCAAAG-3’.
Light-off jump reflex habituation
The light-off jump reflex habituation assay was performed as previously described.369 
Habituation of the startle jump response towards repeated lightoff stimuli of 3–7-day-
old individual male flies was tested in two independent 16-unit light-off jump habituation 
systems. A total of 32 flies (16 flies/system) were simultaneously exposed to series of 100 
short (15 ms) light-off pulses with a 1 s inter-pulse interval. The noise amplitude of wing 
vibrations following every jump response was recorded for 500 ms after the start of light-off 
pulse and an appropriate threshold was applied to filter out the background noise. Data were 
collected and analysed by a custom-made Labview Software (National Instruments). High 
initial jumping responses to light-off pulse decreased with the growing number of trials and 
flies were considered habituated when they failed to jump in five consecutive trials (non-
jump criterion). Habituation was scored as the mean number of trials required to reach the 
non-jump criterion (trials to criterion, TTC). Main effects of genotype (mutant vs control), day 
and test system on log-transformed TTC values were tested using linear model regression 
analysis (lm) in R statistical software (R version 3.0.0 (2013-04-03)).379
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Abstract 
Background
De novo mutations in PURA have recently been described to cause PURA syndrome, a 
neurodevelopmental disorder characterised by severe intellectual disability (ID), epilepsy, 
feeding difficulties and neonatal hypotonia.
Objectives
To delineate the clinical spectrum of PURA syndrome and study genotype-phenotype 
correlations.
Methods
Diagnostic or research-based exome or Sanger sequencing was performed in individuals 
with ID. We systematically collected clinical and mutation data on newly ascertained PURA 
syndrome individuals, evaluated data of previously reported individuals and performed a 
computational analysis of photographs. We classified mutations based on predicted effect 
using 3D in silico models of crystal structures of Drosophila-derived Pur-alpha homologues. 
Finally, we explored genotype-phenotype correlations by analysis of both recurrent mutations 
as well as mutation classes.
Results
We report mutations in PURA (purine-rich element binding protein A) in 32 individuals, the 
largest cohort described so far. Evaluation of clinical data, including 22 previously published 
cases, revealed that all have moderate to severe ID and neonatal-onset symptoms, including 
hypotonia (96%), respiratory problems (57%), feeding difficulties (77%), exaggerated 
startle response (44%), hypersomnolence (66%) and hypothermia (35%). Epilepsy (54%) 
and gastrointestinal (69%), ophthalmological (51%) and endocrine problems (42%) were 
observed frequently. Computational analysis of facial photographs showed subtle facial 
dysmorphism. No strong genotype-phenotype correlation was identified by subgrouping 
mutations into functional classes.
Conclusion
We delineate the clinical spectrum of PURA syndrome with the identification of 32 additional 
individuals. The identification of one individual through targeted Sanger sequencing points 
towards the clinical recognisability of the syndrome. Genotype-phenotype analysis showed 
no significant correlation between mutation classes and disease severity.
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Introduction
Deletions in the 5q31.2q31.3 region have been reported to cause a syndrome comprising 
severe developmental delay, profound hypotonia, feeding difficulties, abnormal breathing 
pattern and seizures.381 382-385 Within this region, haploinsufficiency of the purine-rich 
element binding protein A (PURA) has been suggested as responsible for the observed 
neurodevelopmental features by narrowing the region of overlap to three genes.384 Further 
evidence for the essential role of PURA in development came from two articles describing 
15 individuals with intellectual disability (ID) and de novo mutations in PURA.386; 387 The 
pathogenicity of mutations in PURA was further supported by publication of a cohort of six 
additional individuals with ID and de novo mutations in PURA and two case reports.388-390
The functionality of PURA is dependent on three PUR motifs, PUR I, PUR II and PUR 
III.391; 392 The ubiquitously expressed PURA protein, Pur-alpha, has multiple regulatory 
functions in processes such as DNA replication and transcription, mRNA transport and 
DNA repair.392; 393 Several studies have shown that Pur-alpha has an important role in 
neuronal development and differentiation.394 In animal models, Pur-alpha is involved in 
postnatal brain development.395; 396 The Pur-alpha deficient knockout mouse model has a 
severe neurological phenotype, including tremor and spontaneous seizures.396 Recently, 
heterozygous PURA knockout mice have been reported to develop gait abnormalities, 
hypotonia and memory deficits. Immunohistochemical assays displayed a reduced number 
of neurons in cerebellum and hippocampus of these animals, which is in line with their 
neurological, behavioural and cognitive phenotypes.397
Mental retardation, autosomal dominant type 31 [MIM616158], or ‘PURA syndrome’, 
the name of the syndrome adopted by the parents and clinical community alike, is 
phenotypically hallmarked by a wide spectrum of neurodevelopmental problems, including 
severe neurodevelopmental delay, epilepsy, abnormal movements, hypotonia and brain 
abnormalities. Additionally, neonatal respiratory insufficiency and feeding difficulties have 
been reported. Outside of this core phenotype, a broad variability in clinical severity has been 
observed within PURA syndrome.386-389 Different types of mutations have been identified so 
far and mutations occur throughout the gene. It has been suggested that disruption of PUR 
repeat III possibly results in a more severe phenotype, but additional studies are needed to 
better understand the genotype-phenotype correlation of PURA mutations.387
We present 32 individuals with de novo mutations in PURA. With this large cohort, we 
delineate the clinical spectrum of PURA syndrome. Computational modelling shows that 
subtle overlapping facial dysmorphism is present. Additionally, we present an approach for 
genotype-phenotype analysis of identified mutations and associated phenotypes, revealing 
that observed phenotypic variability is probably not associated with type and localisation of 
mutations.
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Results
Identification of 32 individuals
We report 32 individuals with mutations in PURA (Figure 11.1). All, but two, were identified 
using WES in a diagnostic setting (individuals 1–10, 20–27, 30 and 32) or research setting 
(individuals 12–19, 29 and 31). Individual 28 was identified using targeted MPS of a 
severe childhood epilepsy gene panel. Individual 11 was clinically suspected to have 
106 Reijnders MRF, et al. J Med Genet 2018;55:104–113. doi:10.1136/jmedgenet-2017-104946
Phenotypes
causing feeding difficulties (81%). Apnoeas and congenital 
hypoventilation were reported in 48% of the neonates. Both 
feeding and respiratory problems often required monitoring 
in hospital: in 20 neonates, tube feeding, oxygen supple-
mentation and/or mechanical ventilation were needed. 
Hypersomnolence (66%) and hypothermia (37%) were 
observed in a significant number of neonates. In about half 
of the neonates (58%) an exaggerated startle response was 
noted.
Development
All individuals with PURA mutations have moderate to severe 
ID with severe language and motor delay. Most individuals 
remain non-verbal (29/32, 91%), but many have better recep-
tive language than expressive language and can follow simple 
instructions. Severalnever achieved independent ambulation 
(10/24 with age >5 years, 42%). For those who did, the age 
of first steps ranged from 28 months to 7 years. Regression of 
achieved skills due to the onset of seizures has been reported 
in six individuals.
Neurological abnormalities
A variety of neurological problems were observed in individuals 
with PURA mutations. Hypotonia, often more prominent in the 
trunk, was present from birth. Spasticity of extremities at older 
age was reported in three individuals, and Babinski response 
was reported in another two. Gait, if achieved, was often 
unstable and broad based. Stereotypic hand movements, in 
some cases such as described for Rett syndrome [MIM312750], 
were observed in several individuals (36%). Six out of 30 
(20%) were mentioned to have a movement disorder, including 
dystonia, chorea-like movements, seizure-like movements with 
normal EEG and ataxic movements. Delayed myelination is the 
most frequently reported brain abnormality observed on MRI 
images (28%). Other, mostly a-specific, observed brain abnor-
malities (in 31% of individuals) include white matter abnor-
malities, prominent periventricular spaces, mild parenchymal 
atrophy, widening of lateral ventricles and underdeveloped 
rostrum of the corpus callosum. Peripheral neuropathy was 
measured in five individuals at young age (online supplemen-
tary table 1).
Figure 1 localisation of PURA mutations and subdivision in classes. Mutations of individuals identified in our cohort are marked in bold. (a) Homology 
models of n-terminal and c-terminal PUr domains (grey and blue, respectively) from human Pur-alpha. residues with single amino acid exchanges are 
depicted in red with side chains. (B) location of reported PURA frameshift and non-sense mutations. class a1 mutations are located in the n-terminal PUr 
domain that affect both n-terminal and c-terminal domains and class a2 mutations occur in the c-terminal domain, affecting only this domain and the 
c-terminus. (c) identified point mutations in one of the PUr domains, predicted to cause local folding defects. (D) Four mutations of amino acids located on 
the protein surface. three mutations are predicted to affect nucleic acid binding (class c) and one mutation (class D) likely affects a surface-exposed residue, 
which is not predicted to impair protein folding or nucleic acid binding. this mutation is possibly involved in not yet understood functions such as  
protein–protein interactions. (e) Deletion (red) caused by mutation p.(Met1?) (class e), which disrupts the start codon. the protein is likely expressed from the 
next in-frame start codon at amino acid 104, causing loss of a functional n-terminal PUr domain, but has an intact c-terminal PUr domain. (F) localisation 
of mutations reported in healthy controls in the exac database. all these mutations are predicted to have no effects on the folding and the function of the  
Pur-alpha protein. PUr, purine-rich element.
Figure 11.1: Localisation of PURA mutations and subdivision in classes. 
Mutations of individuals ident fied in our cohort a  marked in b ld. (A) Homology models of N-terminal and C-terminal 
PUR domains (grey and blue, respectively) from human Pur-alpha. Residues with single amino acid exchanges are 
depicted in red with side chains. (B) Location of reported PURA frameshift and non-sense mutations. Class A1 
mutations are located in the N-terminal PUR domain that affect both N-terminal and C-terminal domains and class A2 
mutations occur in the C-terminal domain, affecting only this domain and the C-terminus. (C) Identified point mutations 
in one of the PUR domains, predicted to cause local folding defects. (D) Four mutations of amino acids located on 
the protein surfac . Three mutations are predicted to affect nucleic acid binding (class C) a d one mutation (class D) 
likely affects a surface-exposed r sidue, which is not predicted to impair protein folding or nu leic acid binding. This 
mutation is possibly involved in not yet understood functions such as protein–protein interactions. (E) Deletion (red) 
caused by mutation p.(Met1?) (class E), which disrupts the start codon. The protein is likely expressed from the next in-
frame start codon at amino acid 104, causing loss of a functional N-terminal PUR domain, but has an intact C-terminal 
PUR domain. (F) Localisation of mutations reported in healthy controls in the ExAC database. All these mutations are 
predicted to have no effects on the folding and the function of the Pur-alpha protein. PUR, purine-rich element.
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PURA syndrome based on post-term birth, severe neonatal hypotonia, hypersomnolence, 
exaggerated startle, persistent apnoeic episodes requiring continuous SpO2 monitoring 
and supplementary oxygen, and feeding difficulties warranting nasogastric tube placement. 
Targeted Sanger sequencing revealed a PURA mutation. Mutations were de novo in 29 
individuals. For the remaining three individuals, no parental blood was available for testing. 
None of the individuals had a second, likely pathogenic, genetic variant in WES data. All 
identified missense mutations localised in one of the PUR repeat sequences (Figure 11.1).
Clinical delineation of 32 individuals
Clinical features observed in individuals reported in this study are summarised in Table 11.1. 
Numbers and percentages of features were corrected for the number of individuals without 
available information on a specific feature. More extensive and detailed clinical information is 
available in Supplemental Table 11.1.
Gestation and neonatal problems
More than half (56%) of individuals were born after >41 weeks’ gestation. Induction of 
labour and/or caesarian section were reported in 14 individuals. In 55% (6/11), excessive 
hiccups were mentioned in utero. Neonatal problems were evident in all children immediately 
after birth. Hypotonia was present in all but one of the neonates, often causing feeding 
difficulties (81%). Apnoeas and congenital hypoventilation were reported in 48% of the 
neonates. Both feeding and respiratory problems often required monitoring in hospital: in 20 
neonates, tube feeding, oxygen supplementation and/or mechanical ventilation were needed. 
Hypersomnolence (66%) and hypothermia (37%) were observed in a significant number of 
neonates. In about half of the neonates (58%) an exaggerated startle response was noted.
Development
All individuals with PURA mutations have moderate to severe ID with severe language 
and motor delay. Most individuals remain non-verbal (29/32, 91%), but many have better 
receptive language than expressive language and can follow simple instructions. Several 
never achieved independent ambulation (10/24 with age >5 years, 42%). For those who did, 
the age of first steps ranged from 28 months to 7 years. Regression of achieved skills due to 
the onset of seizures has been reported in six individuals.
Neurological abnormalities
A variety of neurological problems were observed in individuals with PURA mutations. 
Hypotonia, often more prominent in the trunk, was present from birth. Spasticity of 
extremities at older age was reported in three individuals, and Babinski response was 
reported in another two. Gait, if achieved, was often unstable and broad based. Stereotypic 
hand movements, in some cases such as described for Rett syndrome [MIM312750], 
were observed in several individuals (36%). Six out of 30 (20%) were mentioned to have a 
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Table 11.1 Percentage of clinical features reported in individuals in this article (n=32) 
and meta-analysis with previously published PURA individuals (n=22) 386-389
Clinical feature This article (n = max. 32) Literature (n = max. 22)386-389 Total (n = max. 54)
Percentage Number Percentage Number Percentage Number
Growth
   Short stature (≤-2.5 SD) 19% 5/27 14% 3/22 16% 8/49
Pregnancy/delivery
   Gestational age > 41 weeks 56% 18/32 60% 3/5 57% 21/37
Neonatal problems
   Hypotonia 97% 31/32 94% 15/16 96% 46/48
   Feeding difficulties 81% 25/31 73% 16/22 77% 41/53
   GORD 28% 8/29 17% 1/6 26% 9/35
   Breathing problems 48% 15/31 68% 15/22 57% 30/53
   Hypersomnolence 66% 19/29 NR NR 66% 19/29
   Hypothermia 37% 10/27 25% 1/4 35% 11/31
   Excessive hiccups in utero  55%                             6/11 NR NR 55% 6/11
Neurological abnormality
   Moderate to severe ID 100% 32/32 100% 22/22 100% 54/54
   Hypotonia 97% 31/32 80% 4/5 95% 35/37
   Stereotypic hand movements 36% 8/22 NR NR 36% 8/22
   Exaggerated startle response 58% 11/19 27% 4/15 44% 15/34
   Epilepsy 50% 16/32 59% 13/22 54% 29/54
   Delayed myelination 28% 9/32 24% 5/21 26% 14/53
   Movement disorder 20% 6/30 30% 3/10 22% 9/40
   Other brain abnormalities 31% 10/32 29% 6/21 30% 16/53
Skeletal abnormality
   Scoliosis 28% 9/32 18% 2/11 26% 11/43
   Hip dysplasia 23% 7/31 0% 0/11 17% 7/42
   Hyperlaxity 43% 9/21 9% 1/11 31% 10/32
Gastrointestinal abnormality
   Constipation 62% 18/29 50% 3/6 60% 21/35
   Drooling 66% 20/30 83% 5/6 69% 25/36
Respiratory abnormality 26% 8/31 27% 4/15 26% 12/46
Cardiac abnormality 13% 4/32 25% 2/8 15% 6/40
Urogenital abnormality 26% 8/31 9% 1/11 21% 9/42
Ophthalmological abnormality 40% 12/30 67% 14/21 51% 26/51
Endocrine abnormality
   Vitamin D deficiency 47% 7/15 25% 1/4 42% 8/19
   Other 26% 5/19 50% 2/4 30% 7/23
Skin abnormality
   Soft skin 46% 6/13 NR NR 46% 6/13
Abbreviations: GORD = gastro-oesophageal reflux disease; ID = intellectual disability; NR = not reported;  
PURA = purine-rich element binding protein A
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movement disorder, including dystonia, chorea-like movements, seizure-like movements 
with normal EEG and ataxic movements. Delayed myelination is the most frequently reported 
brain abnormality observed on MRI images (28%). Other, mostly a-specific, observed 
brain abnormalities (in 31% of individuals) include white matter abnormalities, prominent 
periventricular spaces, mild parenchymal atrophy, widening of lateral ventricles and 
underdeveloped rostrum of the corpus callosum. Peripheral neuropathy was measured in five 
individuals at young age (Supplemental Table 11.1).
Half of the individuals (50%) were diagnosed with epilepsy. For most of them, seizures 
started at the age of 2–4 years, but the age of onset ranged from 6 months to 15 years. 
Different seizure types were reported, including generalised tonic-clonic seizures, focal 
seizures, absence seizures, epileptic spasms, tonic seizures, drop attacks and over time, 
evolution to Lennox-Gastaut syndrome. The epilepsy is often refractory to medical treatment 
and some individuals have never been seizure free. A longer follow-up period will be required 
to determine the true prevalence of epilepsy, how refractory it is and what treatments are 
most effective.
Ophthalmological abnormalities
Eye abnormalities and visual problems were described frequently in PURA syndrome 
individuals (40%). Strabismus (often oesotropia) was the most commonly reported finding 
along with strabismus-associated refractive errors (often hypermetropia). Cortical visual 
impairment was reported in three individuals; however, it is important to note that diagnostic 
criteria for this condition are highly variable. One individual was treated successfully for a 
congenital retinoblastoma. Nystagmus was also described in a small number of cases (4/29; 
14%) but details of the phenotype are missing in reported cases.
Skeletal abnormalities
Progressive hip dysplasia and scoliosis were present in respectively 23% and 28% of 
the cases and could possibly be related to chronic truncal hypotonia (with or without 
abnormalities of limb tone), joint laxity and delayed or incomplete motor development. 
Surgical correction was required in five individuals in this cohort to date. The oldest individual 
was 18 years at time of surgery. Longer follow-up might show a larger number of surgical 
interventions, since the majority of included individuals (27/32) had an age of examination 
below 18 years. Individuals showed a tendency to short stature with five having a height ≤2.5 
SD, and six others with a height between −2 and −2.5 SD. From the remaining 16 individuals, 
only 2 had a height >0 SD. Low bone density (z-score −4; 57%) was identified in a single 
case. Pes planus was present in 11 individuals.
Gastrointestinal abnormalities
Due to severe hypotonia, swallowing problems and excessive drooling were observed in 
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more than half of the individuals (66%). Constipation was often present (62%) and may be 
severe, requiring the use of laxatives from early age.
Endocrine abnormalities
A diverse range of endocrine problems were reported, with low vitamin D most commonly 
reported (47%), and less frequently observed abnormalities including aberrant sex hormone 
levels, abnormal cortisol response and aberrant thyroid hormone levels (26%) (Supplemental 
Table 11.1). It is likely that these problems are more common than observed, since not all 
individuals have been tested for endocrine abnormalities.
Congenital structural malformations
Although not frequently reported, some individuals had congenital malformations of the 
heart, urogenital and/or respiratory tract. Cardiac malformations included a ventricular septal 
defect in two individuals, and an aberrant left subclavian artery, pulmonary stenosis and 
mild, spontaneously closed persistent ductus arteriosus each in one individual. Abnormalities 
of the urogenital tract were described in five individuals: cryptorchidism in three, kidney 
stones in two, and congenital hydronephrosis with megaureter and urinary reflux each in one 
individual. Laryngeal cleft was reported in a single case.
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stature with five having a height ≤2.5 SD, and six others 
with a height between −2 and −2.5 SD. From the remaining 
16 individuals, only 2 had a height >0 SD. Low bone density 
(z-score −4; 57%) was identified in a single case. Pes planus 
was present in 11 individuals.
Gastrointestinal abnormalities
Due to severe hypotonia, swallowing problems and excessive 
drooling were observed in more than half of the individuals 
(66%). Constipation was often present (62%) and may be severe, 
requiring the use of laxatives from early age.
Endocrine abnor alities
A diverse range of endocrine problems were reported, with low 
vitamin D most commonly reported (47%), and less frequently 
observed abnormalities including aberrant sex hormone levels, 
abnormal cortisol respo se and aberrant thyroid hormone levels 
(26%) (online supplementary table 1). It is likely that these prob-
lems are more common than observed, since not all individuals 
have been tested for endocrine abnormalities.
Congenital structural malforma ions
Although not frequently reported, some individuals had congen-
ital malformations of the heart, urogenital and/or respiratory 
tract. Cardiac malformations included a ventricular septal defect 
in two individuals, and an abe rant left subclavi n artery, pulmo-
nary stenosis and mild, spontaneously closed persistent ductus 
arteriosus each in one individual. Abnormalities of the urogen-
ital tract were described in five individuals: cryptorchidism in 
three, kidney stones in two, and congenital hy ronephrosis with
megaureter and urinary reflux each in one individual. Laryngeal 
cleft was reported in a single case.
Facial dysmorphisms
Photographs of 21 n ividuals are shown in figure 2. No striking 
similarities were observed, but a myopathic face, high anterior 
hairline, almond-shaped palpebral fissures and full cheeks were 
reported recurrently by clinicians. The presence of these features 
was confirmed by a panel of five independent dysmorphologists, 
all being asked to analyse photographs of PURA syndrome indi-
viduals from figure 2. They also mentioned eversion of lower 
lateral eyelids, prominent, well-defined philtrum and retrog-
nathia as features present in a subset of individuals.
expansion of the cohort with 22 previously published cases
We structurally analysed mutational and clinical data of 22 
previously published individuals.6–9 An overview of published 
mutations is present in figure 1 and summarised clinical infor-
mation is availabl  in online supple entary table 2.
Recurrence of mutations
We found four recurrent mutations: p.(Lys97Glu) in individual 
20 and subject #4 in Lalani et al6; p.(Phe271del) in individual 
28 and subject #1 in Lalani et al6; p(Arg245Pro) in individuals 
1 and 15; p.(Phe233del) in individuals 4, 5 and 14, patient 4 
in Tanaka et al8 and patient 4 in Hunt et al.7 In addition, indi-
viduals 24 and 31 had two distinct mutations (c.153delA and 
c.155delG, respectively) that were both predicted to give rise to 
the same truncated protein product (p.(Leu54Cysfs*24)). There 
were six individuals between whom two distinct missense muta-
tions were identified at each of three different amino acid posi-
tions: p.(Leu100Arg) and p.(Leu100Pro) in individual 21 and 
subject #1 in Lalani et al6; p.(Ile206del) and p.(Ile206Phe) in 
individual 25 and patient 3 in Hunt et al7; p.(Val226Serfs*68) 
and p.(Val226Glyfs*67) in individuals 6 and 10.
Clinical valuation
Clinical features such as neurodevelopmental delay, epilepsy, 
and brain and ophthalmological abnormalities have been 
reported in all previously published cohorts. But for the majority 
of features, no clinical information is available across all previ-
ously published cohorts. For example, hypersomnolence, 
Figure 2 Photographs of 21 individuals with PURA mutations. Shared facial dysmorphism includes high anterior hairline, almond-shaped palpebral 
fissures, full cheeks and hypotonic face. Strabismus is present in several of the PUra (purine-rich element binding protein a) individuals. additionally, 
independent dysmorphologists also observed eversion of lower lateral eyelids, prominent, well-defined philtrum and retrognathia in a subset of the 
individuals.
Figure 11.2: Photographs of 21 individuals with PURA mutations. 
Shared facial dysmorphism includes high anterior hairline, almond-shaped palpebral fissures, full cheeks and hypotonic 
face. Strabismus is pres nt in several of th  PURA (purine-rich element binding protein A) individuals. Addition lly,
independent dysmorphologists also observed eversion of lower lateral eyelids, prominent, well-defined philtrum and 
retrognathia in a subset of the individuals.
526362-L-bw-Reijnders
Processed on: 20-11-2018 PDF page: 161
161PURA syndrome: clinical delineation and genotype-phenotype study in 32 patients with review of published literature
11
Facial dysmorphisms
Photographs of 21 individuals are shown in Figure 11.2. No striking similarities were 
observed, but a myopathic face, high anterior hairline, almond-shaped palpebral fissures 
and full cheeks were reported recurrently by clinicians. The presence of these features was 
confirmed by a panel of five independent dysmorphologists, all being asked to analyse 
photographs of PURA syndrome individuals from Figure 11.2. They also mentioned eversion 
of lower lateral eyelids, prominent, well-defined philtrum and retrognathia as features present 
in a subset of individuals.
Expansion of the cohort with 22 previously published cases
We structurally analysed mutational and clinical data of 22 previously published 
individuals.386-389 An overview of published mutations is present in Figure 11.1 and 
summarised clinical information is available in online Supplemental Table 11.2.
Recurrence of mutations
We found four recurrent mutations: p.(Lys97Glu) in individual 20 and subject #4 in Lalani et 
al386; p.(Phe271del) in individual 28 and subject #1 in Lalani et al386; p(Arg245Pro) in 
individuals 1 and 15; p.(Phe233del) in individuals 4, 5 and 14, patient 4 in Tanaka et al388 and 
patient 4 in Hunt et al.387 In addition, individuals 24 and 31 had two distinct mutations 
(c.153delA and c.155delG, respectively) that were both predicted to give rise to the same 
truncated protein product (p.(Leu54Cysfs*24)). There were six individuals between whom two 
distinct missense mutations were identified at each of three different amino acid positions: 
p.(Leu100Arg) and p.(Leu100Pro) in individual 21 and subject #1 in Lalani et al;386 p.(Ile206del) 
and p.(Ile206Phe) in individual 25 and patient 3 in Hunt et al;387 p.(Val226Serfs*68) and 
p.(Val226Glyfs*67) in individuals 6 and 10.
Clinical evaluation
Clinical features such as neurodevelopmental delay, epilepsy, and brain and 
ophthalmological abnormalities have been reported in all previously published cohorts. But 
for the majority of features, no clinical information is available across all previously published 
cohorts. For example, hypersomnolence, stereotypic hand movements and excessive 
hiccups in utero have not been reported in literature before. Using the summarised clinical 
information (Supplemental Table 11.2), we calculated the frequency of clinical features in all 
54 individuals (Table 11.1).
Computational analysis of facial dysmorphism
Since no striking overlap in facial dysmorphism was observed, but similarities between 
several individuals have been reported by clinicians, we performed an objective 
computational analysis in this paper presented and previously published photographs, 
and compared it to the average image based on healthy controls (Figure 11.3). Ages 
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at photographs ranged from 2 months to 19 years. A panel of five independent 
dysmorphologists agreed that a myopathic face with typically open mouth appearance 
and full cheeks was visible on the computational modelled PURA face. Additionally, two 
dysmorphologists reported a slightly abnormal shape of the eyes as (1) shorter palpebral 
fissures and (2) eversion of lower lateral eyelids. The high anterior hairline observed in a 
subset of individuals (6,7,8,9,11,13,14,16,17,28) was not visible on the computational model 
of the PURA face.
Modelling of all reported mutations into structural homology models of human 
Pur-alpha
Using the previously reported crystal structures of the N-terminal and C-terminal PUR 
domains from the fruit fly D. melanogaster391; 392 as templates, we generated structural 
homology models for the corresponding domains of the human Pur-alpha paralogue. Based 
on these homology-modelled structures, all 46 reported mutations were analysed and 
classified according to their predicted effects on domain folding and function.
The identified frameshift and non-sense mutations affecting the entire protein C-terminal to 
the site of mutation were defined as class A mutations. Depending on whether mutations 
occurred in the N-terminal PUR domain and thus affect N-terminal and C-terminal PUR 
domains or in the C-terminal PUR only affecting this very domain plus C-terminus, we 
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stereotypic hand movements and excessive hiccups in utero have 
not been reported in literature before. Using the summarised 
clinical information ( nline supplementary table 2), we cal u-
lated the frequency of clinical features in all 54 individuals 
(table 1).
Computational analysis of facial dysmorphism
Since no striking overlap i  facial dysmorphism was observed  
but similarities between several individuals have been reported by 
clinicians, we performed an objective computational analysis in 
this paper presented and previously published photographs, 
and compared it to th  average image based on he l hy contr ls 
(figure 3). Ages at photographs ranged from 2 months to 19 
years. A panel of five independent dysmorphologists agreed that 
a myopathic face with typically open mouth appearance and full 
cheeks was visible on the c putational modelled PURA face. 
Additionally, two dysmorphologists reported a slightly abnormal 
shape of the eyes as (1) shorter palpebral fissures and (2) ever-
sion of lower lateral eyelids. The high anterior hairline observed 
in a subset of individuals (6,7,8,9,11,13,14,16,17,28) was not 
visible on the computational model of the PURA face.
Modelling of all reported mutations into structural homology 
models of human Pur-alpha
Using the previ usly reported crystal structures of the N-ter-
minal and C-terminal PUR domains from the fruit fly D. mela-
nogaster11 12 as templates, we generated structural homology 
models for the corresponding domains of the human Pur-alpha 
paralogue. Based on these homology-modelled structures, all 46 
reported mutations were analysed and classified according to 
their predicted effects on domain folding and function.
The identified frameshift and non-sense mutations affecting 
the entire protein C-terminal to the site of mutation were 
defined as class A mutations. Depending on whether muta-
tions occurred in the N-terminal PUR domain and thus affect 
N-terminal and C-terminal PUR domains or in the C-terminal 
PUR only affecting this very domain plus C-terminus, we subclas-
sified them as A1 and A2 mutations, respectively (figure 1B). 
Mutations that were predicted to affect folding only locally, for 
instance, via amino acid exchange of a buried residue or short 
amino acid deletions in a folded region, were defined as class B 
mutations (figure 1C). Since the RNA and DNA-binding mode of 
Drosophila Pur-alpha has been structurally analysed,12 the human 
homology model could also be used to predict mutations that 
affect nucleic acid binding. Such mutations were found in four 
individuals and were defined as class C mutations (figure 1D). We 
also found one mutation likely affecting a surface-exposed residue 
that was neither predicted to impair protein folding nor nucleic 
acid binding. We suggest that this residue is involved in not yet 
understood functions such as protein–protein interactions and we 
defined this as class D mutation (figure 1D). Finally, we classified 
one mutation as class E: p.(Met1?), causing loss of the start codon. 
Translation is therefore likely to start at the next in-frame start 
codon, which is locat d at protein position 104. As a result, the 
protein will lack part of the N-terminal PUR domain, while it will 
have an intact C-terminal PUR domain (figure 1E). As control, we 
analysed variants reported by ExAC, a database containing vari-
ants of healthy co trols (figure 1F). All of these variants resulted 
in single amino acid exchanges that are either located outside the 
globular domains or were exchanged against residues with similar 
side chain properties. Variant p.(Gln136Pro) is the only exception 
to this rule. It is located in t e large loop region between repeats 
I and II and thus likely allows to compensate the changes in back-
bone conformation upon mutation into proline.
Genotype-phenotype analysis
Remarkable clinical variability has been observed within the 
total cohort of PURA syndrome individuals. To assess whether 
this variability could be explained by the type and/or localisa-
tion of the identified mutations, we compared (1) phenotypes 
of individuals with the same mutation and (2) phenotypes of 
individuals with a mutation of the same class.
Recurrent mutations
We observed four recurrent mutations and two mutations with 
a similar protein effect within the cohort, and compared their 
Figure 3 computational analysis of photographs of PUra (purine-rich element binding protein a) syndrome individuals. result of an objective 
computational analysis on photographs of 34 individuals with PURA mutations (ages at photographs ranging from 2 months to 19 years; right image) 
compared with the average image based on 301 age-matched, healthy controls (left image). the computational modelled PUra face showed a hypotonic 
face with typically open mouth appearance and full cheeks. additionally, two independent dysmorphologists reported a slightly abnormal shape of the eyes 
as (1) shorter palpebral fissures and (2) eversion of lower lateral eyelids. the high anterior hairline observed in a subset of individuals is not visible on this 
computational model of the PUra face.
Figure 11.3: Computati nal analysis of photograp s of PURA syndrome individuals. 
Result of an bjective computational analysis on photographs of 34 individuals with PURA mutations (ages at 
photographs ranging from 2 months to 19 years; right image) compared with the average image based on 301 age-
matched, healthy controls (left image). The computational modelled PURA face showed a hypotonic face with typically 
open mouth appearance and full cheeks. Additionally, two independent dysmorphologists reported a slightly abnormal 
shape of the eyes as (1) shorter palpebral fissures and (2) eversion of lower lateral eyelids. The high anterior hairline 
observed in a subs t of individuals is not visible on this computational model of the PURA face.
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subclassified them as A1 and A2 mutations, respectively (Figure 11.1B). Mutations that were 
predicted to affect folding only locally, for instance, via amino acid exchange of a buried 
residue or short amino acid deletions in a folded region, were defined as class B mutations 
(Figure 11.1C). Since the RNA and DNA-binding mode of Drosophila Pur-alpha has been 
structurally analysed,392 the human homology model could also be used to predict mutations 
that affect nucleic acid binding. Such mutations were found in four individuals and were 
defined as class C mutations (Figure 11.1D). We also found one mutation likely affecting a 
surface-exposed residue that was neither predicted to impair protein folding nor nucleic acid 
binding. We suggest that this residue is involved in not yet understood functions such as 
protein–protein interactions and we defined this as class D mutation (Figure 11.1D). Finally, 
we classified one mutation as class E: p.(Met1?), causing loss of the start codon. Translation 
is therefore likely to start at the next in-frame start codon, which is located at protein position 
104. As a result, the protein will lack part of the N-terminal PUR domain, while it will have an 
intact C-terminal PUR domain (Figure 11.1E). As control, we analysed variants reported by 
ExAC, a database containing variants of healthy controls (Figure 11.1F). All of these variants 
resulted in single amino acid exchanges that are either located outside the globular domains 
or were exchanged against residues with similar side chain properties. Variant p.(Gln136Pro) 
is the only exception to this rule. It is located in the large loop region between repeats I and II 
and thus likely allows to compensate the changes in backbone conformation upon mutation 
into proline.
Genotype-phenotype analysis
Remarkable clinical variability has been observed within the total cohort of PURA syndrome 
individuals. To assess whether this variability could be explained by the type and/or 
localisation of the identified mutations, we compared (1) phenotypes of individuals with the 
same mutation and (2) phenotypes of individuals with a mutation of the same class.
Recurrent mutations
We observed four recurrent mutations and two mutations with a similar protein effect within 
the cohort, and compared their phenotypes. For all mutations, remarkable differences 
between individuals with the same mutation were present (Table 11.2). For example, drug-
resistant epilepsy was present in three out of five individuals with mutation p.(Phe233del) and 
a cardiac abnormality in two out of five individuals. The older of the two individuals without 
epilepsy could walk, in contrast to the three individuals with epilepsy, who were not able to 
walk or speak. For mutation p.(Leu54Cysfs*24), individuals had more features in common, 
such as epilepsy, scoliosis and short stature, but variation in ability to walk and heart 
abnormality was also observed.
Comparison of mutation classes
We compared phenotypes of individuals subdivided by mutation class (Supplemental 
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Table 11.2 Recurrent PURA mutations and phenotype of affected individuals
Mutation Individual/Age Reference Phenotype
p.(Leu54Cysfs*24) Individual 24
17 years
This article Hypotonia, feeding difficulties requiring TF, GORD, apnoeas, 
hypersomnolence, hypothermia, severe ID, no speech, walking 
at age 4 years, short stature (-5 SD), epilepsy, mild PDA, mild 
strabismus, scoliosis, hip dysplasia, small hands and feet.
Individual 31
16 years
This article Hypotonia, feeding difficulties requiring TF, hypersomnolence, 
severe ID, no speech, not able to walk, short stature (-2.75 SD), 
epilepsy, scoliosis, epilepsy, long fingers
p.(Lys97Glu) Individual 20
2.5 years
This article Hypotonia, mild feeding difficulties, hypersomnolence, no 
speech, not able to walk, mild constipation, pes planus
Subject #4
21 months
Lalani et al 386 Hypotonia, feeding difficulties, respiratory difficulties, seizures, 
ID, non-verbal, non-ambulatory, short stature (1%), strabismus, 
duplex left kidney, hydronephrosis
p.(Phe233del) Individual 4
14 years
This article Hypotonia, feeding difficulties, apnoeas, hypersomnolence, 
severe ID, no speech, able to walk, ASD, stereotypic hand 
movements, delayed myelination, swallow problems, severe 
hypermetropia, strabismus, low vitamin D, low ferritin, pes 
planus, abnormal peripheral nerve testing
Individual 5
19 years
This article Hypotonia, feeding difficulties, apnoeas, hypersomnolence, 
hypothermia, severe ID, no speech, not able to walk, 
stereotypic hand movements, epilepsy, nystagmus, delayed 
myelination, drooling, constipation, strabismus, CVI, scoliosis, 
hip dysplasia, low bone mineralization, low vitamin D, anaemia, 
delayed puberty, small hands, pes planus
Individual 14
9 years
This article Hypotonia, severe ID, no speech, first steps age 7 years, 
epilepsy, delayed myelination, aberrant left subclavian artery, 
VSD, drooling, refraction abnormality, strabismus, low vitamin D, 
high cholesterol
Patient 4
6 months
Tanaka et al 388 Hypotonia, CVI, periventricular leukomalacia
Patient 4
6 years, 9 
months
Hunt et al 387 Hypotonia, feeding difficulties requiring TF, apnoeas, 
hypothermia, severe ID, not able to walk, essentially non-verbal, 
exaggerated startle response, dystonia, dyskinesia, epilepsy, 
CVI, delayed myelination, excessive extra-axial fluid spaces, 
cerebral atrophy, hyperprolactinaemia, blunted cortisol stress 
response, low vitamin D
p.(Arg245Pro) Individual 1
19 years
This article Hypotonia, feeding difficulties, severe ID, no speech, not able 
to walk, autistic-like traits, chorea-like movements, Babinski 
response, delayed myelination, scoliosis, low vitamin D, 
hypogonadotropic hypogonadism
Individual 15
9 years
This article Hypotonia, feeding difficulties requiring TF, apnoeas, 
hypersomnolence, hypothermia, severe ID, no speech, first 
steps at age 4 years, epilepsy, drooling, constipation, pes 
planus
p.(Phe271del) Individual 28
11 months
This article Hypotonia, neonatal convulsions, moderate ID
Subject #1
6 months
Lalani et al 386 Hypotonia, feeding difficulties, respiratory difficulties, seizures, 
ID, pedal edema 
Abbreviations: ASD = autism spectrum disorder; CVI = cortical visual impairment; GORD = gastro-oesophageal reflux 
disease; ID = intellectual disability; PDA = persistent ductus arteriosus; TF = tube feeding; VSD = ventricular septum 
defects
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Table 11.3). Overall, no significant differences in percentage of observed features between 
mutation classes were present. One exception is mutation p.(Glu283Argfs*45), which we 
classified as class D. This mutation affects only the very C-terminus (all three PUR domains 
are intact) and it is unlikely that this mutation interrupts protein folding or nucleic acid binding 
(Supplemental Table 11.4; Figure 11.1). Clinical features in this individual are less severe than 
observed in other individuals: the 14-year-old girl could walk independently from the age of 2 
years and could speak in sentences. Furthermore, no neonatal problems, hypotonia, epilepsy 
or brain abnormalities were present.387 The clinical presentation of this girl is remarkably 
milder than other individuals, and could possibly be explained by the localisation of the 
mutation at the C-terminus.
Discussion
We report 32 individuals with PURA syndrome, the largest cohort so far. We systematically 
collected mutation and clinical data on these and previously published individuals. With 
information on a total of 54 individuals, we were able to delineate the clinical spectrum of this 
recently discovered syndrome.
The detailed and systematic collection of phenotypic data allowed us to observe less 
frequently reported features related to PURA syndrome. Clinical problems such as excessive 
hiccups in utero (55% in our cohort), hypersomnolence (66% in our cohort), stereotypic hand 
movements (36% in our cohort), regression since onset of seizures (38% of individuals with 
epilepsy in our cohort), soft skin (46% in our cohort) and short stature (19% in our cohort) 
have not been reported before in published studies. Post-term birth (56% in our cohort), 
gastro-oesophageal reflux disease (28% in our cohort), hypothermia (37% in our cohort), 
hypotonia after the neonatal period (97% in our cohort), constipation (62% in our cohort) and 
endocrine abnormalities (47% in our cohort) only have been mentioned in one other study. 
Similar to many other recently discovered novel syndromes for which only a small subset of 
individuals have been described initially, frequencies of features related to PURA syndrome 
were difficult to estimate based on reported numbers. By expanding the cohort, we were 
able to report a significant number of features not formally associated with PURA syndrome 
before. These features could be helpful for diagnosis and management of PURA syndrome 
individuals.
The phenotype of PURA syndrome has been reported as difficult to recognise in daily clinical 
practice. Here, we show with the identification of one individual using targeted Sanger 
sequencing in a neonate, that it is possible to recognise PURA syndrome based on clinical 
features. Severe neonatal problems including hypotonia, respiratory and feeding difficulties, 
hypersomnolence and hypothermia, in the majority combined with post-term birth, could 
point towards the early diagnosis of PURA syndrome. Although not a consistent feature, 
the presence of myoclonic jerks in a neonate with other features of PURA syndrome may 
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be a useful feature to distinguish from Prader-Willi syndrome or peripheral neuromuscular 
disorders such as spinal muscular atrophy (SMA). Known syndromes such as congenital 
hypoventilation syndrome [MIM209880], Prader-Willi syndrome [MIM176270], Rett syndrome, 
Angelman syndrome [MIM160900], myotonic dystrophy [MIM160900] and SMA [MIM253300] 
have been tested often in PURA syndrome individuals. We recommend to considerPURA 
syndrome in the differential diagnosis of any child tested for one or more of the above 
syndromes, especially in the context of the aforementioned neonatal problems and/or 
unexplained developmental delay.
After diagnosis of PURA syndrome, careful management of existing medical problems and 
evaluation of health issues associated with PURA syndrome is essential. Our phenotypic 
overview shows that different organ systems could be affected. Therefore, we recommend 
routine care in a multidisciplinary team, with at least a (child) neurologist, ophthalmologist, 
orthopaedic surgeon and paediatrician for children aged below 18 years involved. Epilepsy, 
present in half of the cohort, is a major problem. Some individuals have never been seizure 
free and regression of achieved developmental milestones since onset of seizures has been 
reported. In future, studies focusing on epilepsy will be important to optimise treatment of 
seizures related to PURA syndrome.
In general, individuals with epilepsy were more severely affected than individuals without 
epilepsy. However, this explained only partially the variation in developmental phenotypes 
observed between individuals. To assess whether the clinical variability could be related to 
the type and localisation of the identified mutations, we performed a genotype-phenotype 
study by analysing recurrent mutations and classifying mutations based on a homology 
model derived from a crystal structure of the Drosophila PUR-alpha homologue. Interestingly, 
remarkable differences, such as the presence or absence of epilepsy or congenital 
malformations, were observed between individuals with the same mutation. For the 
remaining mutations, class D mutations with localisation at the very end of the C-terminus 
could possibly be correlated with a less severe phenotype. But for the other mutations, 
phenotypic variability and severity could not be related to the localisation and type of 
mutation. Based on these results, we suggest that other genetic and biological mechanisms 
contribute to the phenotypic variability. Further studies are needed to obtain insight into 
these underlying pathological mechanisms.
With the identification of 54 individuals within 2.5 years of the initial description of the 
condition, PURA syndrome appears to be a relatively frequent cause of ID. Previously, 
frequencies between 0.3% and 0.5% in neurodevelopmental cohorts have been 
reported.386-388 Within our cohort, 10 individuals were identified in the diagnostic lab facility 
of the Radboudumc, Nijmegen. These were found in a total of 4700 individuals (~0.2%) 
with ID referred for WES. This frequency is probably an underestimate. It has been reported 
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that PURA, a single-exon gene rich in guanine-cytosine content, could be challenging to 
capture, similar to the first exon of multiexonic genes.106 Furthermore, all 10 mutations have 
been identified after the introduction of PURA as an ID gene in diagnostic gene panels at the 
end of 2014, while WES had already been in use in the diagnostic lab of the Radboudumc 
from 2013. Therefore, to more accurately gauge the frequency within this population, a 
targeted re-evaluation of all available exome data would be necessary.
In conclusion, we present a detailed overview of the clinical spectrum of PURA syndrome 
and a computational modelled PURA face, which is essential for better recognition of this 
newly recognised disorder and surveillance and management of symptoms after initial 
diagnosis. Our suggested approach for genotype-phenotype analysis by modelling of 
identified PURA mutations into human homology models of experimentally determined 
crystal structures from Drosophila Pur-alpha, showed that clinical variation observed between 
individuals is probably not related to type and localisation of mutations, but should be sought 
in other genetic and biological mechanisms.
Material and methods
Identification of PURA syndrome individuals and collection of clinical and mutational 
data
Whole exome sequencing (WES) was performed in individuals with ID in either diagnostic 
(n=20) or research (n=10) settings (Supplemental Methods). In one individual, targeted 
massively parallel sequencing (MPS) of a severe childhood epilepsy gene panel was used, 
and in a second individual, clinically suspected to have PURA syndrome, PURA [NM_005859] 
was investigated with targeted Sanger sequencing. Parental samples were tested to assess 
de novo state. A questionnaire with clinical and mutational details was completed by 
clinicians. Written consent for publication of photographs was obtained from legal guardians.
Evaluation of previously published cases
Twenty-two individuals with PURA mutations have been described in four different 
publications.386-389 We used the same questionnaire to collect clinical and mutation data from 
individuals (n=22) reported in the literature.
Computational analysis of facial photographs
To visualise the characteristic facial features of PURA syndrome individuals, we generated 
a realistic, deidentified average based on 34 photographs of individuals (in this paper 
presented and previously published photographs) at different ages. A control average was 
created from 301 age-matched, healthy individuals. We used a fully automated algorithm 
that (1) annotated a constellation of 68 facial landmark points on the face, (2) created an 
average face mesh and (3) warped faces of each individual onto the average face mesh. The 
face averaging algorithm was inspired by previous work398; 399 and improved upon with better 
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deidentification of individuals (Supplemental Methods). Interpretation of the composite PURA 
face was performed by a panel of five independent dysmorphologists.
Functional assessment of PURA mutations in structural homology models
For homology modelling of mutations, the crystal structures of the N-terminal PUR domain 
(PDB-ID: 3K44) and of the C-terminal PUR domain (PDB-ID: 5FGO) from Drosophila 
melanogaster were used as template. Homology structures of human PUR domains were 
calculated using the PHYRE2 program.400 In the case of the C-terminal PUR domain, the 
sequences of two repeat IIIs were merged into one peptide chain to allow for modelling of the 
entire domain. The human homology models showed high confidence scores and were used 
for in silico mutational analyses using the program Coot.401 All mutations identified in our 
cohort and previously published cohorts386-389 were included. Variants in PURA reported in 
the Exome Aggregation Consortium (ExAC) database71 were included as controls. Deletions, 
frameshift, non-sense and missense mutations were manually classified depending on 
the position, size and function of the affected amino acids. Point mutations were in silico 
introduced using the standard rotamer library of Coot and analysed for the appearance 
of steric clashes or repulsive forces of side chains. They were classified based on the 
orientation of mutated side chains and on our knowledge of functionally important surface 
regions. Figures were prepared using the program Pymol (www.pymol.org).
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12.1 Neurodevelopmental disorders: a next generation
12.1.1 Next generation NDDs & genetics: discovery of rare NDDs  
In 2010, the first gene for a Mendelian disorder was discovered using next generation 
sequencing.402 NGS techniques have steadily improved, and large numbers of novel genes 
and NDD syndromes, denoted here as ‘next generation NDDs’, have been discovered.101 
Currently, ~30%  of all NDD patients referred for WES analysis can be conclusively 
diagnosed by molecular analysis of ‘known NDD genes’ (Chapter 1). Yet, a significant 
proportion of patients remains undiagnosed. For these patients, it is important that 
identification of novel NDD genes continues. In this thesis, I aimed to discover rare novel 
NDDs by (1) WES testing of patients with unexplained NDDs on large scale, (2) using different 
approaches to interpret WES data, and (3) inclusion of patients with mild ID, a less frequently 
investigated subset of patients (Figure 12.1). 
Whole Exome
Sequencing  
1
3
2
Large-scale testing
to increase power 
Alternative analyses 
of WES-data
Inclusion of 
patients with
mild ID 
1. 2. 3.
Figure 12.1: Discovery of rare NDDs using three different strategies. To discover rare NDDs, a large cohort of 
patients (yellow arrow) is tested by WES (the sieve), and mutations causing novel NDDs (gold nuggets) can be filtered 
out using different approaches to interpret WES data. 
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By using these strategies, 14 genes were added to the NDD gene list (Table 1): DLG4, 
PPM1D, SMAD6, SOX5, SYNCRIP, TCF20 and TRIP12 as candidate NDD genes (Chapter 
3) and SON, TLK2, RAC1, RHEB, USP9X, RAB11B and WAC as novel NDD genes. (Chapter 
4-10) The identification and publication of candidate and novel NDD genes is important 
and enables the initiation of follow-up studies. In this thesis, I showed that three initial 
candidate genes could be confirmed as novel genes in additional studies (RAC1, SON and 
TLK2; Chapter 4-6). Three other candidate genes (PPM1D, TCF20 and TRIP12) have in the 
meantime been confirmed as ID/NDD genes by others.403-405  For both TRIP12 and USP9X, 
clinical follow-up studies were published recently (Table 12.1).406; 407
Increasing power to detect rare NDDs
In the absence of a clinically distinct phenotype, discovery of novel dominant disorders 
is difficult. Different strategies have been proposed to find more genes involved in the 
pathogenesis of these non-specific syndromes. One of these strategies is based on the 
search for different patients with recurrence of mutations within the same gene.412 However, 
recurrence of mutations is difficult to achieve if patient cohorts are small and the prevalence 
of disorders is low. Next generation NDDs are almost always extremely rare. ARID1B and 
ANKRD11, causing Coffin-Siris syndrome and KBG syndrome respectively,413; 414 are among 
the most frequently mutated genes in undiagnosed patients referred for WES.33 Yet, together 
they explain only for ~1.6% of patients the neurodevelopmental delay. Many other NDDs 
have an even lower prevalence. For example, mutations in KMT2D (Kabuki syndrome)415 
Table 12.1 Overview of next generation (candidate) NDD genes described in this thesis 
(in yellow), with confirmation in literature (in grey).
Gene Candidate NDD gene Novel NDD gene    Follow-up NDD gene
This thesis Literature This thesis Literature This thesis Literature
DLG4 Chapter 3
PPM1D Chapter 3 Jansen et al.403
RAC1 Chapter 3 Chapter 6
SMAD6 Chapter 3
SON Chapter 3 Chapter 4 Tokita et al.408
SOX5 Chapter 3 Nesbitt et al.409
SYNCRIP Chapter 3
TCF20 Chapter 3 Babbs et al.410 Schafgen et al.404
TLK2 Chapter 3 Chapter 5
TRIP12 Chapter 3 O’Roak et al.114 Bramswig et al.405 Zhang et al.406
RHEB Chapter 7
USP9X Brett et al.309 Chapter 9 Au et al.407
RAB11B Chapter 8
WAC Hamdan et al.,355
De Ligt et al.28
Chapter 10 DeSanto et al.411
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account for ~0.19% of diagnoses, and mutations in SETBP1 (Schinzel-Giedion)416 are even 
rarer with a prevalence of ~0.07%.33 Inspired by other large studies investigating patients 
with ASD,31; 417 we collected for the studies reported in this thesis a cohort of 826 patients 
with unexplained ID, a well-investigated subtype of NDDs, in an attempt to identify novel 
ultra-rare NDDs. In our cohort, we were able to find a mutation in a known NDD gene in 
28,6% of patients. Additionally, a significant proportion of patients (386/826, 46.7%) had 
at least one de novo mutation in a gene not previously associated with ID. Several of those 
genes were mutated in more than one patient in our cohort: the 628 de novo mutations 
comprised only 586 genes. Genes with recurrence included the novel genes TLK2, RAC1, 
RHEB, and USP9X, presented in this thesis, which each occurred at a frequency of 0.24%. 
Interestingly, even lower frequencies of de novo mutations in these genes were observed in 
the largest NDD cohort published so far consisting of 4,293 patients (0.09% - TLK2, 0.07% 
- RAC1, 0% - RHEB, and 0.16% - USP9X),33 showing that these novel NDD syndromes are 
ultra-rare. The chance that recurrence of mutations in such genes occurs, decreases when 
testing smaller cohorts of patients, and is heavily dependent on the gene-specific mutation 
rate. Further discovery of these ultra-rare novel disorders thus requires much larger datasets 
and combined datasets in meta-analysis, as shown in Chapter 3.
 
Alternative analysis of WES data to reveal candidate NDD genes 
A large cohort size not only increases the chance to identify recurrence for mutations in the 
same gene, but also allows alternative analyses on WES data to find novel NDD genes and 
additional evidence for the pathogenicity of variants. In 2014, Samocha et al. developed 
a statistical framework, along the line of previous metrics such as the residual variation 
intolerance score (RVIS),124 to investigate excesses of de novo loss-of-function and missense 
mutations per gene and per gene-set. They hypothesized that genes associated with disease 
would contain more de novo mutations than expected by chance, given a certain cohort 
size.115 In their study, a lack of power was present, since only limited WES data of both 
control and patient cohorts were available. The Deciphering Developmental Disorders (DDD) 
study was the first to show that gene-specific mutation rates were helpful for the detection 
of genes involved in NDDs by using large number of patients (n=~4,000) and controls.32 In 
the DDD study, the diagnostic yield was increased with 3% by the discovery of 12 novel 
NDD genes that showed significantly more de novo mutations than expected. In this thesis, 
we were able to further increase the number of candidate genes associated with ID/NDD 
by 10, using a similar approach and by adding data of additional patients from our cohort 
to previously available datasets (Chapter 3). The immense power of this methodology is 
further underscored by the fact that from these 10 candidate genes we described, six have 
already been confirmed as novel NDD genes in articles including specific phenotypes and/
or functional data. But limited cohort size can still a limiting factor and combined with the 
rigid statistical correction for multiple testing performed, it might be expected that genes with 
p-values only slightly below the significance threshold may still be true novel NDD genes. 
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In our study, two (CSNK2A1 and KCNQ5) out of the firrst four borderline significant genes, 
CSNK2A1, CHD3, CNOT3, and KCNQ5, have been confirmed as NDD genes by others.418; 
419 The two other two genes, CHD3 and CNOT3, remain interesting candidate genes, given 
their significant intolerance scores (z-scores=7.15 and 3.89, pLI scores = 1.00 for CHD3 and 
CNOT3, respectively) and large number of patients with NDD and de novo mutations in these 
genes in the de novo database (13 for CHD3 and 11 for CNOT3).252 Clearly, their confirmation 
as novel NDD gene awaits publication; in fact, such a manuscript was recently submitted for 
CHD3 [L. Snijders Blok, et al. personal communication]. 
One appealing approach, already proposed many years ago,420 is to study not all genes as 
separate entities, but to evaluate the contribution of functionally related genes in gene-sets 
(one-entity). So far, a search for mutations and novel NDD genes in biological pathways has 
been performed mainly on cohorts of patients with specific syndromic phenotypes. Examples 
include targeted sequencing of ciliary genes in Joubert syndrome patients,421 genes in the 
mTOR pathway in patients with focal cortical dysplasia or megalencephaly,233 chromatin-
modifiers in patients with features within the Kleefstra phenotypic spectrum,422 and genes 
interacting with known RASopathy genes in patients suspected to have Noonan syndrome.423 
With the current availability of large WES data sets, in particular WES data linked to HPO 
terms describing the patient’s phenotype,424 time-consuming selection and inclusion 
procedures to compile specific patient cohorts can be diminished. In Chapter 7, I used a 
pathway approach combined with statistical analyses to discover (possible) pathogenic 
mutations in our WES data set of 826 patients. Mutations in five candidate NDD genes 
related to mTOR were present and statistical enrichment analysis showed that significantly 
more de novo mutations were present than expected by chance. Further analysis showed 
that in aggregate, patients with a mTOR pathway de novo mutation had an increased head 
size, which is in agreement with previous phenotypic observations in patients with mutations 
in other genes from this pathway.190; 232; 233 Based on these results, it is likely that the identified 
mutations are disease-causing, although individual confirmation of each mutation is still 
required to unambiguously define them as pathogenic, similar to what we did for mutations 
in RHEB. It would be interesting to perform a similar analysis on different pathways linking 
specific clinical features that have already been reported to occur with gene mutations in 
selected pathways. For example, cardiac abnormalities for RASopathy genes, and cerebellar 
abnormalities for ciliary genes. The feasibility of this approach clearly depends on the 
availability of detailed phenotype data. 
Gene discovery in patients with mild ID 
Patients with severe phenotypes are most likely to be referred for genetic testing, since 
the diagnostic yield is historically considered to be much higher for patients with moderate 
or severe ID than for patients with mild ID.101 For example, examining subtle structural 
rearrangements as cause for unexplained ID, revealed a diagnosis in 7.4% of patients with 
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moderate/severe ID, and only in 0.5% of patients with mild ID.425 For WES, the diagnostic 
yields of different severity levels are less well documented.101 In the cohort of 826 patients 
described in this thesis (Chapter 2), 219 patients (28%) had mild ID. A de novo mutation 
in a known NDD was present in 61/219 (27.9%) (Figure 12.2). A comparable percentage 
(p = 0.924; Pearson’s chi-square test) was present for patients with more severe ID: in 104 
patients with moderate or severe ID (27.2%) a de novo mutation in a known NDD gene was 
identified (Figure 12.2). In this thesis, mutations in genes such as TLK2, WAC and USP9X 
were mainly present in patients with mild ID. These results demonstrate that WES should not 
be restricted to patients with more severe phenotypes, and that also for patients with mild ID, 
novel syndromes can be discovered.
The majority of studies aiming to identify potentially pathogenic mutations in patients with 
NDDs using NGS, including the study reported in Chapter 3, have focused on the search 
for de novo mutations.27-33; 417 This strategy has been developed based on ‘the genetic 
paradox’: de novo mutations can explain theoretically why severe disorders such as NDDs 
remain relatively frequently in the population, despite negative reproductive selection.426; 427 
The success of this de novo approach is demonstrated by the large number of novel NDDs 
that have been identified over the last years. By the same token, mild phenotypes in the 
patients give less reproductive disadvantages, resulting in transmission of a pathogenic 
mutation to children. In Chapter 5, I present an example of a next generation NDD that is not 
only caused by de novo mutations in TLK2, but can also develop as a result of an inherited 
mutation. This has been reported in literature as well for other NDDs such as KBG syndrome 
(ANKRD11 mutations), Noonan syndrome, Weaver syndrome (EZH2 mutations), and Kabuki 
syndrome (KMT2D mutations).428-431 So, in particular if (one of the) parents have a history of 
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Figure 12.2: Percentage of patients identified with a de novo mutation in a known NDD gene in the cohort of 
826 patients described in this thesis. Percentages are, in contrast to what has been published for other genetic tests, 
comparable for different severity levels of ID (p=0.924, Pearson’s chi-square test). 
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learning difficulties or behavioral problems and cognitive deficits are mild, there is a higher 
change that a Mendelian genetic cause is inherited from a mildly affected parent who was 
previously undiagnosed. Structured collection of clinical data not only from the patient but 
also the parents is therefore essential. 
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Figure 12.3: Strategies described in this thesis to confirm and delineate next generation NDDs. 
12.1.2 Next generation NDDs & clinic: confirmation and delineation by 
matchmaking 
Next generation NDDs have at least one characteristic in common: due to their rarity, and 
the novelty of the syndromes, limited clinical information is available. Most publications 
reporting the identification of candidate NDD genes based on large cohort analyses, lack 
detailed phenotypic description of patients.30-32; 417 But the identification of mutations in 
recurrent genes needs more support than statistics alone to confirm pathogenicity. Detailed 
phenotypic characterization of patients to investigate phenotypic overlap is an important step 
to collect further evidence.412 Therefore, I aimed to confirm newly discovered NND genes and 
delineate the associated phenotypes by (1) the expansion of patient numbers with specific 
next generation NDDs using matchmaking systems and (inter)national collaborations, and 
1
2
Matchmaking systems to
increase patient numbers 
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resulted in the clinical characterization and confirmation of seven novel syndromes and 
detailed phenotypic delineation of the in 2014 discovered PURA syndrome (Figure 12.4).386; 387 
Increasing patient numbers with next generation NDDs by matchmaking
The importance of data sharing for rare disorders has been underscored by multiple studies, 
organizations and consortia.22; 33; 432; 433 The International Rare Diseases Research Consortium 
(IRDiRC), established in 2011, stated that the lack of a widely adopted data-sharing 
Figure 12.4: Heatmap of recurrent clinical features, representing associated phenotypes of the eight reported 
next generation NDDs in this thesis. Numbers indicate percentages of patients showing the feature. Abbreviations: 
ADHD = attention-deficit hyperactivity disorder, ASD = autism spectrum disorder, GI = gastrointestinal, ID = intellectual 
disability
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framework and lack of common data sharing standards, currently acts as a bottleneck in 
the gene-discovery pipeline.22 This thesis confirms that the use of matchmaker systems and 
international collaborations is an effective and successful strategy: from the seven novel 
NDDs reported in this thesis, I was able to enlarge the cohort size in six of them (Figure 
12.5). For TLK2, which is an ultra-rare disorder with an estimated prevalence between 0.09% 
and 0.24%, data-sharing finally resulted in a total number of 40 patients (Chapter 5). This 
relatively large dataset allowed confirmation of the TLK2 gene as responsible for a non-
specific form of NDD. At decreasing next generation NDD prevalence, even more extensive 
data-sharing will be required as shown for mutations in RHEB: I found no additional patients 
with mutations in this gene, despite worldwide data sharing and presenting of this novel 
NDD gene at international conferences. The three patients, including two siblings, reported 
in this thesis (Chapter 7) are to the best of my knowledge the only patients identified with 
de novo pathogenic mutations in this gene worldwide. For RHEB, it is likely that the extreme 
rarity of disease-causing mutations partly reflects a specific dominant mechanism and 
hence a very restricted mutational target. This hypothesis is probably also applicable to 
RAB11B and RAC1, which both have specific pathogenetic mechanisms with a similarly 
restricted repertoire of possible pathogenic mutations, and hence a very small effective 
mutational target.434 Thus, for ultra-rare NDD syndromes representing specific mutational and 
pathogenetic mechanisms, more extensive data-sharing will be required.  
Figure 12.5: Overview of identified number of patients within the cohort of 826 patients, additional patients 
identified in house (n= ~4700), and additional patients identified by matchmaking and (inter)national 
collaborations.
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Phenotypic spectrum of next generation NDDs
Most studies reporting novel NDD genes have a maximum of 15 patients included, due 
to limited data-availability and restricted time for patient inclusion. A few exceptions are 
novel NDD genes such as DDX3X (38 patients), YY1 (23 patients), STAG1 (17 patients), 
and SYNGAP1 (17 patients).338; 435-437 But even though these numbers are relatively high 
for publications presenting novel syndromes, cohort sizes are still too small to have an 
overview about all clinical features associated with these NDDs. This makes it difficult to 
provide management recommendations to parents and physicians involved in the care of 
the diagnosed patient. Furthermore, most patients are children and only a small percentage 
of patients undergo WES at adult age, causing a lack of information on long term outlook, 
and prognostic aspects of the disorder. More longitudinal studies, and more extensive and 
detailed phenotypic data are needed to gain insight into the full clinical spectrum associated 
with the next generation NDD syndromes. For the most frequently mutated genes ARID1B 
and ANKRD11, there are already dozens of follow-up publications, including several 
studies reporting or summarizing clinical information on larger cohorts of patients.429; 438-441 
In this thesis, I collected a large, international cohort of patients with mutations in PURA 
(Chapter 11), discovered as NDD gene in 2014.386; 387 Two years after the identification of 
this syndrome, the total number of patients published in literature was 22, with information 
distributed over five different articles. By reviewing all available clinical data and by adding a 
larger cohort of patients (n = 32), I was able to better delineate the clinical spectrum of PURA 
syndrome, providing thereby a helpful document for the counseling of PURA patients and 
their parents. One important factor in gathering clinical information on such a large cohort of 
patients with PURA mutations was the involvement of a very active parental interest group 
for this syndrome (PURA syndrome foundation at www.purasyndrome.org). To fully delineate 
the very rare features of the disorder, and to find answers on specific questions about 
features such as epilepsy (Type? Frequency? Age of onset? Treatment options?), endocrine 
abnormalities (Hormone levels? Clinical relevance? Pituitary gland abnormalities? Treatment 
needed?), or skeletal abnormalities (Severity? Age of onset? Surgery needed?), will probably 
require the collection of hundreds of patients and prospective studies. For ultra-rare next 
generation NDDs caused by mutations in genes such as RHEB or RAB11B, these numbers 
may remain difficult to achieve in future. 
 
The neurodevelopmental spectrum of the next generation NDD syndromes reported in this 
thesis is broad (summary in figure 12.6). Discovery of next generation NDD syndromes 
initially started with the search for de novo mutations in patients with ID, but subsequent 
sharing of these mutations with (inter)national colleagues revealed that mutations in the 
same genes were also identified in patients diagnosed with other NDD subtypes. Therefore, 
while ID is part of all syndromes, it is not universally present. For NDDs caused by mutations 
in TLK2, USP9X or WAC, some patients had borderline ID or intelligence profiles within 
the normal range. In several of these patients, prevalence of other subtypes including 
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ASD and ADHD was reported (Figure 12.6). Genetic overlap between ID, ASD, epileptic 
encephalopathy and schizophrenia has already been shown in literature,101 and the overlap 
with ADHD is particularly interesting. The association of ADHD with ID is an ongoing debate: 
while large GWAS studies suggest a similar biological etiology, a small number of studies 
investigating the contribution of de novo mutations to non-familiar ADHD concluded that it 
appears to be independent from ID and ASD in the genetic pathogenesis.36; 442 Studies on 
the genetic basis of other subtypes of NDDs have been performed only sporadically. In this 
thesis, almost all reported patients were known to have significant language delay. Though, 
the presence of a formal communication disorder diagnosis was not In contrast to more 
mildly affected patients with TLK2, USP9X or WAC mutations, the neurodevelopmental 
phenotypes of the patients with RAB11B and RHEB mutations are the most severe end of 
the NDD spectrum (Figure 12.6). They are, also, the smallest cohorts in this thesis. While 
this likely can be explained by a restricted mutational target, it should also be considered 
that mutations in these genes can result in miscarriage during pregnancy, and therefore 
reduce the number of patients born with these syndromes. For Down syndrome and Turner 
syndrome it is well established that the majority of affected fetuses do not make it to term. 
Figure 12.6: Novel next generation NDD syndromes in this thesis are associated with a variable severity of 
developmental delay. Disorders with milder ID levels seem to have more overlap with other NDD subtypes ASD and 
ADHD. Some of these patients have normal intelligence or borderline ID, but are known to have behavioral problems. 
Unknown is whether the syndromes are associated with NDD subtypes communication disorder, specific learning 
disorder and motor disorder. Clinical information about official diagnoses of these subtypes was often not available. 
Abbreviations: ADHD = attention deficit hyperactivity-disorder; ASD = autism spectrum disorder; ID = intellectual 
disability
Borderline Mild Moderate Severe Profound
 
WAC 
USP9X
 
SON  
RAB11B 
RHEB  
 A
SD
 A
D
H
D
ID severity scale 
PURA  
RAC1
TLK2
526362-L-bw-Reijnders
Processed on: 20-11-2018 PDF page: 183
183General discussion and future perspective: Neurodevelopmental disorders: a next generation
12.1
Recently, first studies investigating deceased fetuses by WES have been published.110-112 
In Yates et al, mutation p.(Gly13Asp) in HRAS was identified in a deceased fetus with a 
hydrops. Exactly this mutation has been reported in a patient with Costello syndrome, a 
syndrome hallmarked by severe ID, macrocephaly and a variety of congenital abnormalities 
including heart malformations.443 This example shows that the neurodevelopmental 
spectrum of NDDs can be very broad, even if patients carry exactly the same variant, and 
can result in pregnancy loss in some cases, but in severely affected live births in others. 
Differences in timing of mutations can contribute to such phenotypic variation: postzygotic 
mutations (~6.5% - 7.5%)92; 93  can sometimes result in less severe phenotypes than germline 
mutations.70 
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12.1.3 Next generation NDDs & biology: unraveling underlying biological 
mechanism
In addition to phenotypic data, functional studies on the identified mutations can be used 
to provide additional support for their pathogenicity.412 Furthermore, the discovery of novel 
genes enables the investigation of underlying biological mechanisms that may ultimately 
be used for the development of new therapeutics.433; 444 I was very fortunate to collaborate 
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Figure 12.7: Overview of insights into underlying biological mechanisms of novel identified next generation 
NDDs. Abbreviations: CA = constitutively active; DN = dominant-negative; NMD = nonsense-mediated decay.
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with expert groups who conducted functional experiments to elucidate clues towards the 
underlying pathophysiological mechanism. These experiments contributed to interesting 
insights for all seven novel NDD genes (Figure 12.7).
Confirmation of novel NDD genes using model systems
Combining statistical evidence, recurrence of mutations, overlapping phenotypes and/
or molecular findings on function collectively confirm novel NDD genes. If phenotypes are 
distinct and strongly overlap between patients, such as for females with USP9X mutations 
(Chapter 9), functional studies to prove mutation pathogenicity may be less essential. The 
fact that we found a localization of USP9X to the primary cilium is interesting information to 
further understand disease mechanisms, but was not essential evidence to confirm USP9X 
as novel NDD gene in females. Similarly, finding large numbers of patients with mutations 
in the same gene reduces the need for extensive functional validation. The best example in 
this thesis is TLK2 (Chapter 5). With the identification of 40 patients with de novo mutation 
in this gene, TLK2 could be added to the list of NDD genes, beyond reasonable doubt. 
However, the majority of novel next generation syndromes have less distinct phenotypes 
and much smaller patient cohorts. For these genes, functional confirmation is more 
important, in particular if missense mutations predominate. In general, interpretation of 
missense mutations, comprising more than 60% of de novo mutations identified by WES, 
is more challenging than truncating mutations such as nonsense, frameshift or splice site 
mutations.412 Missense mutations within the same gene can result in different outcomes, 
depending on the localization of the mutation and the potential to modify protein function, 
as we showed for mutations in RAC1 (Chapter 6).412; 445 Given that functional work, as 
performed for the with missense associated genes RAB11B, RAC1 and RHEB, is time-
consuming, it may be difficult to provide functional evidence for every mutation in a novel 
next generation NDD gene. Nevertheless, there are initiatives aiming to do just this. For 
example, the Undiagnosed Disease Network (UDN) in the United-Stated has set up an 
extensive workflow for patients with undiagnosed rare disease, including NDDs. In this 
workflow, clinical characteristics of patients without a mutation in a known NDD gene 
are sent to researchers, who compare variants of unknown pathogenicity with existing 
information on the gene/variant in model systems. For interesting variants in candidate NDD 
genes, zebrafish and Drosophila models are developed to confirm variants and novel NDD 
genes.444 Similarly, large-scale government funded projects such as Care4Rare in Canada, 
and more recently EU-funded projects within the European Reference Networks (SOLVE-RD), 
are setting up broker services to link-up genomics researchers with laboratories performing 
functional experiments with the aim of speeding up and promoting functional valiation of 
novel disease genes and their mutations. Confirmation of novel NDD genes would make 
headway if comparable workflows are available for all patients with undiagnosed NDDs. 
But since most countries have no sponsors such as the National Institutes of Health (NIH; 
sponsor of UDN), the initiation and maintenance of such large structural collaborations and 
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infrastructures is difficult. Techniques accelerating the ability to measure and interpret the 
functional consequences of identified variants, such as saturation genome editing, can be 
thereby helpful.446
Further insights into underlying biological mechanisms
Biological findings reported in this thesis can act as model for other genes, proteins and 
pathways. As an example, loss-of-function mutations in SON, encoding a protein with 
an important role in gene transcription and RNA splicing,128; 133-136 disturb the function of 
multiple other cortical developmental and metabolic proteins by accumulation of mis-spliced 
transcripts (Chapter 4). Pur-Alpha or PURA (Chapter 11), is involved in similar cellular 
processes as SON: PURA is known to play a role in DNA replication and transcription, but 
also in RNA splicing.392; 393; 447 Recently, a case report was published describing a patient 
with a pathogenic PURA mutation.448 In this patient, hypoglycorrhagia was observed in 
addition to the typical PURA syndrome features. This clinical feature is a rare metabolic 
finding often caused by SLC2A1 point mutations or deletions.449-451 The authors indeed 
demonstrated significant downregulation of SLC2A1 in patient cells, likely explaining the 
patient’s unusual phenotype. But contrary to expectations, no point mutation in or deletion 
of SLC2A1 was identified. Therefore, the authors proposed that SLC2A1 might be a target 
of PURA.448 Interestingly, in at least one other PURA patient, borderline-low CSF glucose 
levels have been measured, and again the patient tested negative for a SLC2A1 mutation 
[personal observation]. Taken into account this observation, and the reported function(s) 
of PURA, including essential cellular processes such as DNA replication, transcription and 
RNA splicing, it would be interesting to perform systematic transcriptome studies in patient-
derived cells, using the SON study as a model, to investigate whether PURA mutations lead 
to downregulation of SLC2A1 and possible other neurodevelopmental and/or metabolic 
genes. 
In this thesis, missense mutations were identified in five genes: TLK2, RAC1, RHEB, USP9X 
and RAB11B. In three of these, RAC1, RHEB and RAB11B, in silico modeling and functional 
experiments showed that mutations likely act through gain-of-function or dominant-negative 
mechanisms (Chapters 6-8). Interestingly, all three genes belong to the same human RAS 
superfamily of small GTPases, which all are activated by a similar biochemical activity: GTP 
binding and hydrolysis.176 If bound to GTP, the proteins display a binding surface, formed 
by the two switch regions, that have high affinity for downstream effectors. In contrast, if 
GTP is hydrolyzed, the protein is mainly inactive, since effector proteins are released due 
to reduced affinity, thereby attenuating downstream signaling.176 Both the GTP binding 
and switch regions are highly conserved among RAS proteins and different species.176 The 
missense mutations in RAC1, RHEB and RAB11B all occurred within, or close to, these 
regions (Figure 12.8A). In literature, de novo missense mutations in RAB11A, homologue of 
RAB11B, were recently identified in two patients with epilepsy and moderate-severe ID.42 
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Meta-analysis revealed that three additional de novo missense mutations were reported by 
the DDD study. Also another RAB protein, RAB18 (RAB subfamily), has been associated with 
NDD452, as well as KRAS, HRAS, RRAS, NRAS, and RIT1 (RAS subfamily)423; 443; 453-455, and the 
recently published CDC42 protein (RHO subfamily). Similar to RHEB, RAC1 and RAB11B, the 
majority of reported missense mutations in RAB11A, RAB18, NRAS, KRAS, RRAS, HRAS, 
RIT1 and CDC42 are located within such GTP binding and swith regions (Figure 12.8B).443; 452; 
454; 456-466 Interestingly, when aligning the mutations in these genes observed in NDD patients, 
mutations seem to cluster: reported pathogenic missense mutations in genes encoding RAS 
proteins often affect the same, highly conserved regions, which represent a limited number 
of amino acids. Even more striking is the fact that some mutations affect exactly the same 
amino acid (for example: the proline in both RHEB and KRAS; the tyrosine in both RAC1 and 
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Figure 12.8: Alignment of parts of human RAS protein members known to be associated with NDDs. Reported 
affected amino acids are shown in red, conserved amino acids in more than five proteins have a yellow background. 
Blue lines indicate either a GTP binding site (dark blue) or Switch region (light blue), as reported in Chapter 6 (RAC1) and 
Chapter 8 (RAB11B). The small arrows pointing the colums indicate amino acids that are mutated in different proteins 
(‘recurrent mutations’) and show the clustering of mutations between different proteins in often highly conserved 
amino acids. Other observed mutations affect amino acids that are often very close to the amino acids with recurrent 
mutations. (A) Alignment of the three RAS protein identified in this thesis as novel NDD genes. (B) Alignment of eight 
RAS proteins reported in literature as NDD genes. 
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CDC42; the valine in both RAB11B and KRAS; Figures 12.8A and B). Recently, a study has 
been published suggesting that the use of ‘meta-domains’ can improve the interpretation of 
genetic variation. 
Authors found that genetic tolerance is consistent across protein domain homologues, and 
that patterns of genetic (in)tolerance mimic patterns of evolutionary conservation.467 Other 
studies reported that spatial clustering of mutations can lead to gene identification.468; 469 In 
one of these studies, both RAB11A and RAB11B were found to have significant clustering of 
missense mutations at protein level relative to population controls.469 It would be interesting 
to investigate whether these statistical models can be combined and expanded: mutations 
in other RAS proteins could potentially be discovered by combining clustering and meta-
domains, since mutations in genes encoding RAS proteins seem to cluster.
It is not unlikely that subsets of pathogenic mutations in different RAS proteins disrupt 
RAS protein mechanisms in a similar way. Some will disturb the nucleotide binding pocket, 
resulting in either reduced or increased GTP binding. For example, missense mutations in 
RAB11B likely impaired RAB11B GTP binding (Chapter 8), given the mis-localization within 
the cell that mimicked the inactive state of the protein, and the abnormal high binding affinity 
towards a GEF. A mutation in another gene, HRAS, is only two amino acids away from 
mutated amino acid 22 in RAB11B (Figures 12.8A and B), and has been reported to have 
decreased GTPase activity.470 On the other hand, mutations disturbing exactly the same 
amino acid (tyrosine) in both RAC1 and CDC42, are both thought to have the opposite effect: 
in Chapter 6 I showed that RAC1 mutation p.Tyr64Asp had a constitutively active effect, and 
Martinelli et al.466 reported an increased amount of active, GTP-bound protein for CDC42 
mutation p.Tyr64Cys. Mutations in HRAS causing such a hyperactive state of the protein 
have been reported to act as ‘selfish mutations’: mutations that cause a higher self-renewal 
than surrounding wild-type cells and expand clonally in testis with higher paternal age.471; 472 
The mutations lead to relative enrichment of mutant sperm over time, resulting in a higher 
risk for the father to pass the mutation to one or more children. It would be interesting to 
investigate whether activating mutations in other RAS proteins similarly have a paternal age 
effect. Inclusion of information on the age of the parents at birth of each child in articles will 
be therefore important in future studies.471 
In contrast to rare disorders caused by mutations with major effect sizes (monogenic), 
common diseases such as hypertension, diabetes, obesity, and scoliosis are mostly due 
to multiple genetic factors each contributing with smaller effects. Common diseases often 
include a small subset of individuals with a monogenic form of the disease.433 Although 
these variants explain only a small fraction, they make a significant contribution to our 
understanding of biological mechanisms underlying common disease and, ultimately, the 
development of therapy.433; 473; 474 It is estimated that approximately 20% of genes implicated 
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in monogenic forms of common disorders, also contain a variant responsible for a GWAS 
signal that achieves genome-wide significance for a complex trait.433 In this thesis, I showed 
that rare, monogenic causes of syndromic NDDs are not only relevant to find genetic causes 
of complex traits, but can also be used to find associations between gene sets or pathways 
and normal variation in the population. In Chapter 7, I reported that NDD syndromes 
caused by disruptive mutations in genes related to MTOR, were strongly associated with 
megalencephaly in NDD patients. In line with this, common variation in these genes was 
found to be significantly associated with intracranial volume in the population, thereby 
showing that disruptive mutations causing rare NDD syndromes can lead to an extreme 
phenotype beyond a continuing phenotypic spectrum in the population that can be explained 
by common variation in a similar gene set. This finding raises the question if other phenotypic 
extremes in NDD syndromes can be associated with other forms of phenotypic variation in 
the population. For example, NDD syndromes caused by mutations in genes involved in the 
bromodomain family III, such as EP300, CREBBP, BRWD3 and PHIP, frequently co-occur 
with obesity.475-477 One might investigate whether common variation in genes related to this 
bromodomain family III are associated with body weight in population, a characteristic known 
to have a high heritability and to have genes involved in the central nervous system as critical 
regulators.478-481  
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12.2 Neurodevelopmental disorders: what’s next?
12.2.1 Diagnostic and research strategies for undiagnosed NDD patients
Larger patient cohorts, increasing power (Figure 12.9)
Approximately 50% of patients referred for next generation sequencing remain undiagnosed 
at molecular level.22 Also in the cohort described in this thesis, a significant percentage of 
patients received no molecular diagnosis. For these patients, the ‘diagnostic odyssey’ is 
not yet finished. The importance of a continued search for a diagnosis in these patients is 
supported by large (international) consortia, such as the IRDiRC, the UDN, and the European 
Reference Network (ERN) ITHACA:22; 432; 482 “Exact disease recognition, an element of the 
concept of precision in medicine, requires new infrastructure that spans geography and 
institutional boundaries”.432 An universally accepted and implemented system of international 
Figure 12.9: Strategies to enlarge patient cohorts, thereby increasing the power for the discovery of novel NDDs.
1
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large-scale data-sharing, in this thesis shown to be successful on a small scale, will be a 
major challenge to achieve over the next years. But if established, it will lead to enlarged 
cohort sizes, thereby further increasing the power to find recurrence of mutations and to find 
novel NDD genes. The contribution of parents to data collection and datasharing should not 
be underestimated: where clinicians and researchers are more often reluctant in sharing data, 
parents can be much more proactive, partly because data sharing is sometimes the only 
possibility to receive a diagnosis for their child.
To further enlarge patient cohorts and the corresponding WES datasets, it will be important 
to include and test more mildly affected patients, as shown in this thesis. In addition, it 
would be interesting to systematically collect data of deceased fetuses, who may sometimes 
represent the most severe end of the NDD phenotypic spectrum. For example, in Vora et al., 
a de novo nonsense mutation in MAP4K4 was identified in a fetus with multiple congenital 
abnormalities, which often co-occur with NDDs. Authors concluded that this mutation could 
not be classified as disease causing, since it was not associated with disease before.112 
But, inspection of the international de novo database252 shows that two other truncating 
mutations in MAP4K4 have been reported in literature in patients with NDD.33 Additionally, 
four de novo missense mutations were present: three in NDD patients and one in a patient 
with a syndromic congenital heart defect.33; 483 In ExAC, MAP4K4 is classified as gene highly 
intolerant for both loss-of-function and missense variation in the population (z-score of 4.01 
and pLI score of 1.00). Based on this information, it is not unlikely that mutations in MAP4K4 
indeed cause a syndromic NDD, of which intra-uterine death is the end of the phenotypic 
spectrum. I expect that increasing the NDD cohort size by adding WES data of deceased 
fetuses to large NDD WES datasets, will facilitate the discovery of more NDDs, in particular 
those associated with congenital malformations.  
Finally, wider availability of WES will increase the collective power of the community to 
identify novel NDDs. An illustrative example can be observed in the origin of patients 
with PURA syndrome: ten patients included in the study reported in Chapter 11 were 
patients tested in the Netherlands, but no patients were identified in European countries 
such as Belgium and Germany. An important difference is that in the Netherlands the 
costs of WES are covered by the national health insurance, which is not the case in many 
other European countries. For this reason, most NDD patients in these countries remain 
untested. This currently also applies to the majority of (large) non-Western countries such as 
China.484 Accessibility of WES for all NDD patients in Europe, an important goal of the ERN 
ITHACA,482 but also worldwide as envisioned by IRDiRC, will contribute on large scale to the 
enlargement of patient cohorts and datasets, thereby raising power to discover novel rare 
next generation NDDs. 
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Improved interpretation of WES data (Figure 12.10)
Recent re-evaluation of WES data already has shown that the diagnostic yield of WES was 
increased up to 15.4% within a few years.100; 103-108 In the future, a further increase can be 
obtained by improved interpretation of WES data, leading to more diagnoses and discovery 
of more next generation NDDs. Besides the four suggestions (Figure 12.10A-D) mentioned in 
the first part of the discussion, other strategies can be considered. 
Incorporation of standardized clinical data in the diagnostic process (Figure 12.10E)
Incorporation of clinical information on the patient, preferably in HPO terms424, in the 
diagnostic process will lead to better interpretation of WES data. In this thesis I reported that 
26% of patients with macrocephaly had a de novo mutation in a gene related to mTOR. This 
is a high percentage of patients with a distinct overlapping phenotype harboring mutations in 
a small subset of genes. In diagnostics, this information can be used for better interpretation 
of WES data. If a patient has macrocephaly, and this information is available in the diagnostic 
pipeline, special attention could be paid to variants within the set of mTOR-related genes. 
This example illustrates the need for a direct link between clinical and diagnostic settings.
Implementation of improved statistical and computational models and expansion of control 
databases (Figures 12.10F and G)
Computational models currently develop fast and will further improve data interpretation.22 
Prioritizing genetic variants by tissue-specific prediction models485, assessing the likelihood 
for a gene to harbor dominant changes by the machine-learning approach DOMINO486, and 
prioritizing synonymous SNVs based on a computational algorithm487 are just a few ex-
amples of recently published models developed as useful components to NGS pipelines. 
Although such models should be carefully reviewed before implemented, it will probably lead 
to increased possibilities to filter out the (possibly) pathogenic variants, which previously re-
mained unrecognized. The use of appropriate databases containing genomic data of healthy 
controls is thereby essential. Databases such as ExAC71 and GnomAD provide these data, 
but one should bear in mind that variants in these databases are often not validated. Addi-
tionally, while these databases focus on ‘healthy’ controls, they may still contain a limited 
amount of data from mildly affected individuals. Variant interpretation is also more challeng-
ing for patients from non-European/North-American ancestry: due to relatively small numbers 
of patients from these populations in the control databases, it is harder to separate patho-
genic variants from rare benign background genetic variation.65; 104 Initiatives from organiza-
tions such as the Global Alliance for Genomics and Health have been established to include 
more samples from such underrepresented populations.488
More attention for X-linked variants in females (Figure 12.10H)
Current research mainly focuses on the identification and analysis of de novo mutations, 
which has been very successful so far. However, pathogenicity of de novo variants on the 
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Figure 12.10: Summary of strategies to improve interpretation of WES data, thereby enabling the discovery of 
novel NDDs. Strategies A – D were mentioned in Chapter 12.1, whereas strategies E – I are further explained below. 
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Figure 12.11: NDD genes USP9X and DDX3X, as well as SMC1A and (candidate) NDD genes KDM5C and IQSEC2 
are known to cluster into the same Topological Associating Domain and all (partially) escape X-inactivation.
X-chromosome in females is sometimes not appreciated. Historically, X-linked disorders 
occurred mainly in recessive form in males, with unaffected or mildly affected heterozygous 
females transmitting the mutation to their son(s). Since females have two X-chromosomes of 
which one can be preferably inactivated, they are sometimes thought to be protected against 
X-linked disorders. Mutations in X-linked MECP2, causing Rett syndrome in females,489 is a 
clear exception to this rule. The identification of de novo variants in USP9X in females (Chap-
ter 9), as well as some other next generation genes such as DDX3X338, SMC1A490, HUWE1491, 
KIAA2022492 constitute an expanding list of dominantly inherited NDDs caused by de novo 
mutations on the X-chromosome. Also the DDD study reported a genome-wide significance 
excess of de novo mutations in females in a few genes, including USP9X.33 Interestingly, 
the majority of newly identified genes are known to (partially) escape X-inactivation. These 
escaping genes appear to cluster in a few Topological Associating Domains (TADs).330; 493; 494 
Indeed, USP9X and DDX3X are located directly next to each other in a TAD, whereas SCM1A 
is located in another TAD together with KDM5C and IQSEC2, both marked as (candidate) 
NDD genes in females (Figure 12.11).495-498 With more research on and improved interpreta-
tion of X-linked  variants in females, particularly in genes clustering in these TADs associated 
with escaping genes, more X-linked genes could be discovered.
Alternative analyses of WES data using CNV data (Figure 12.10I). 
Currently, a combination of SNV and CNV analysis in WES data is the most cost-effective 
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genetic test with the highest diagnostic yield.49; 53 Previously, micro-arrays enabling 
the detection of CNVs were the first-tier test for patients with NDDs or congenital 
abnormalities.499; 500 In 2014, Coe et al. showed that micro-array data could be combined 
with WES data to successfully discover new syndromes and genes involved in NDDs.501 In 
this thesis, some of the discovered genes were implicated in genomic regions associated 
with structural variants causing NDDs: SON at 21q22.11; WAC at 10p11.23 and PURA 
at 5q31.2q31.3. Nevertheless, studies structurally investigating combined CNV- and 
SNV datasets are lagging behind on studies focusing on WES data only. I hypothesize 
that interpretation of WES data can be improved by (1) the search for de novo variants in 
genes associated with single-gene deletions, (2) the combination of WES and array data 
to systematically evaluate regions and genes associated with specific phenotypes, and (3) 
the comparison of large CNV- and SNV datasets, including CNVs identified in WES data. 
Supporting evidence for this hypothesis comes from literature. First, several studies focusing 
on the analysis of array-data mentioned the identification of deletions encompassing only 
one gene. In these studies, singe-gene deletions were found in genes such as TRIO and 
TRIP12.19; 502 TRIO has since been confirmed to be a true NDD gene by the identification 
of de novo point mutations, similar to TRIP12, in this thesis reported as candidate NDD 
gene and confirmed by others.193; 194; 405 Secondly, a high-resolution map of pathogenic 
phenotypes associated with their respective genomic regions has been published recently.503 
Such regions associated with specific phenotypes can be used for the identification of 
novel NDD genes and syndromes with specific phenotypes. As an example, Conte et al. 
used overlapping CNVs associated with the specific phenotype ‘oral facial cleft’ to define 
candidate genes for this phenotype.504 These candidate genes would be an ideal starting 
point to search for point mutations in patients with a comparable phenotype. For NDDs, 
specific phenotypes such as megalencephaly, cortical brain malformations, or epilepsy, that 
often co-occur with NDD, can be used for a similar analysis. Finally, literature reporting on 
successful CNV analysis on WES data has been published.102; 505 Results of these analyses 
should be added to and combined with datasets containing micro-array data and WES data 
on SNVs. 
 
Implementation of Whole Genome Sequencing in diagnostics (Figure 12.12)
Although WES has proven successful for the identification of NDD disorders, it also has 
limitations. In the first years of WES in diagnostics, fluctuation in coverage of any of the three 
samples from the trio analysis could influence the reliable detection of de novo variants.506 
Currently, in particular the first exons and single-exon genes remain difficult to capture due 
to high GC content, and mutations here can be easily missed.106; 507 In addition, CGG repeat 
expansions, such as in Fragile X syndrome, cannot be mapped because of the high repeat 
content of the expansion.53 It also has been mentioned that existing exome sequencing 
kits have limitations, since knowledge of all protein-coding exons in the genome is still 
incomplete.97 Finally, mutations located in non-coding regions such as regulatory- or deep 
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intronic regions and complex structural variants cannot be detected by WES.55 Whole 
genome sequencing (WGS) and long-read sequencing technologies have been shown 
to (partially) overcome these limitations.508 Recent studies reported a diagnostic yield of 
WGS between 41% and 77% in patients with undiagnosed NDDs, which were negatively 
tested with WES.46-48 Positive results included pathogenic non-exonic sequence variants 
and structural variants which were not detected by WES. Although these percentages are 
promising, in particular for patients without any identified de novo mutation by WES, there 
are disadvantages delaying the implementation in diagnostic settings. High costs for WGS 
(WES costs are 30-40% of WGS costs), which are not covered by health insurances yet, is 
the most important disadvantage.22; 33 Lowering costs will pave the way to implement WGS 
as diagnostic test for undiagnosed NDD patients, thereby increasing diagnostic possibilities 
for these patients. 
Whole Exome
Sequencing  
Whole Genome
Sequencing  
Figure 12.12: Strategy to discovery novel NDDs by implementation of WGS.
526362-L-bw-Reijnders
Processed on: 20-11-2018 PDF page: 197
197General discussion and future perspective: Neurodevelopmental disorders: what’s next?
12.2
12.2.2 Improved patient care for next generation NDDs
The massive identification of next generation NDD syndromes already has a significant 
impact on patient care. The next challenge is to translate the discovered NDDs in clinic 
and to improve care for patients and their parents. Only then, the ultimate goal of gene 
identification can be achieved: precision medicine for the NDD population.22 Projects such as 
gene-specific leaflets from Unique (www.rarechromo.org), Dutch national expertisecenters for 
rare diseases including rare NDDs (www.nfu.nl), and virtual multidisciplinary teams across EU 
centers, accessable by Telehealth technology (www.ernithaca.org) are just a few examples 
of initiatives attempting to improve care for patients with rare disorders, including next 
generation NDDs. 
Parent empowerment: the tale of the PURA Foundation
Soon after the discovery of de novo mutations in PURA as cause of a novel NDD by the 
end of 2014,386; 387 I became as researcher and physician involved in this syndrome. In the 
meta-analysis study (Chapter 3) we were working on at that time, we found four patients 
with a de novo mutation in PURA. Contact with the Southampton group, who published one 
of the first two reports,386; 387 about our patients was easily made. Soon after our first contact, 
I was introduced to a small, but enthusiastic group of parents of recently discovered ‘PURA 
children’. They had ambitious plans to set up a foundation for the support and education of 
patients and their families, and to fund research related to PURA syndrome. During the long 
process of official registration of the foundation, they created a website (www.purasyndrome.
org) and initiated a parental Facebook group. An official management board was formed 
and clinicians from different countries were asked to form a medical advisory team. After 
being officially registered as foundation, fund raising events could be started. Because of the 
growing numbers of patients identified with PURA syndrome, the plan was raised to organize 
the first official PURA Syndrome Foundation conference. In June 2016, only 1.5 years after 
the discovery of the syndrome, the first international conference took place in London, UK. 
Besides patients, parents, and clinicians, researchers from different continents with interest 
in the PURA protein were present. During the conference, a research plan was drafted, finally 
resulting in the first PURA research team publication, in this thesis presented in Chapter 
11. Currently, more functional studies are ongoing (www.purasyndrome.org/rdd2018), and 
elaboration of plans to start a global patient registry are in advanced stage, funded by the 
PURA Foundation. The establishment of a research team and medical team in different 
countries, the registration as an official foundation, the organization of two international 
conferences, funding of research and a global patient registry: parents of PURA children 
showed that is all possible within 3 years after discovery of a novel NDD gene. The PURA 
Foundation is a unique example that parents can achieve what is impossible for physicians 
and researchers, due to a lack of research time and money.  
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The PURA story as an example for other next generation NDDs
Although I realize that it often takes much more time to achieve what parents of PURA 
children did within three years, I believe that the organizational structure of the PURA 
Foundation, summarized in Figure 12.13, ideally can function as an example for other rare 
next generation NDDs. By involving parents in the organization and bundling of knowledge 
in expertise teams (both clinical and research), a lot can be achieved with the use of minimal 
time and money, which is often the limiting factor in follow-up research. A regular conference 
where patients, parents, clinicians and researchers meet, will bridges the gap between 
different disciplines and will inspire everyone involved. Important to note is that expertise 
teams should contain members from different countries, since patients with the rare NDDs 
are diagnosed worldwide. Not only referring clinicians, but also parents should have a role in 
the collection of clinical data, to keep registered clinical information up to date.
Figure 12.13: Proposed organizational structure for the care of patients with next generation NDDs.
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Nederlandse samenvatting
Neurobiologische ontwikkelingsstoornissen of ‘Neurodevelopmental disorders (NDDs)’ 
zijn een groep van stoornissen die gekenmerkt worden door een verstoorde ontwikkeling 
op jonge leeftijd.  Daardoor ontstaan problemen met persoonlijk, sociaal, academisch 
of beroepsmatig functioneren. Aandoeningen binnen de groep NDDs zijn onder andere 
verstandelijke beperking en een stoornis in het autistisch spectrum. Het is bekend dat 
genetische afwijkingen met regelmaat bijdragen aan het ontstaan van NDDs, met name als 
de ontwikkelingsstoornissen gepaard gaan met andere symptomen zoals hersenafwijkingen, 
epilepsie, aangeboren afwijkingen of bijzondere gelaatskenmerken. Door een onderliggende 
genetische aandoening te diagnosticeren kan meer inzicht worden verkregen in de 
prognose en het te volgen behandeltraject. Daarnaast verschaft het duidelijkheid over het 
herhalingsrisico voor ouders op het krijgen van een tweede kind met de aandoening. Tot 
slot moet de emotionele impact van een genetische diagnose niet worden onderschat: veel 
ouders van kinderen met ontwikkelingsstoornissen zijn al jarenlang op zoek naar een oorzaak 
van de problemen en kunnen dankzij een diagnose de situatie beter accepteren.
Genetisch testen stamt uit de jaren ’70. Echter, met de beperkte technische mogelijkheden 
bleven veel patiënten met NDD nog lange tijd zonder diagnose. Nieuwe technologische 
ontwikkelingen hebben hierin verandering gebracht. Na de introductie van array-technieken 
werd in 2010 Next Generation Sequencing (NGS) voor het eerst succesvol gebruikt om 
genen op te sporen die betrokken zijn bij een Mendeliaans overervende ziekte. Anno 2018 
zijn NGS-technieken, en dan met name Whole Exome Sequencing (WES), steeds beter 
geworden. Grote aantallen nieuwe genen - en daarmee de genetische diagnoses – zijn 
hiermee geïdentificeerd. Dit geldt ook voor genen geassocieerd met NDDs, welke in dit 
proefschrift ‘next generation NDDs’ worden genoemd. Verandering in deze genen, mutaties 
genoemd, gaan vaak gepaard met het voorkomen van verschillende andere symptomen. Al 
deze symptomen samen vormen een syndroom. 
Toch kent ook NGS zijn beperkingen. Met NGS kan nog steeds niet bij alle patiënten een 
diagnose worden gesteld: bij ~50% van de NDD-patiënten bij wie NGS wordt toegepast, 
wordt een (mogelijke) genetische oorzaak gevonden. Daarnaast is er voor patiënten 
gediagnosticeerd met een next generation NDD beperkte informatie beschikbaar over 
klinische, prognostische en eventuele behandel adviezen. Tot slot worden soms mutaties 
gevonden in genen waarover vooralsnog weinig bekend is. Het blijft dan onduidelijk of de 
mutaties daadwerkelijk pathogeen (ziekmakend) zijn. Deze beperkingen zijn voor artsen 
en hun patiënten en hun ouders lastig. Daarom is dit proefschrift erop gericht om meer 
inzicht te verkrijgen in de genetische, klinische en biologische aspecten van next-generation 
NDDs. Om dit te verwezenlijken is een groot cohort (onderzoeksgroep) van 826 patiënten 
526362-L-bw-Reijnders
Processed on: 20-11-2018 PDF page: 237
237
A
Nederlandse samenvatting
met onbegrepen NDDs samengesteld. Kenmerkend aan de patiënten is dat zij allemaal een 
verstandelijke beperking hebben. Daarnaast komt een verscheidenheid aan andere klinische 
kenmerken voor, zoals aangeboren afwijkingen, epilepsie of een afwijkende groei.  
Genetische aspecten 
Bij alle patiënten in het cohort werd NGS gedaan. Dankzij de grote hoeveelheid patiënten bij 
wie dit werd toegepast en door gebruik te maken van alternatieve manieren om de NGS-
data te interpreteren, konden mutaties in nieuwe genen en daarbij behorende syndromen 
worden ontdekt. Zo werden in hoofdstuk 3 met behulp van een statistische benadering en 
vergelijking met de literatuur tien nieuwe kandidaat genen gevonden. In een ander hoofdstuk, 
hoofdstuk 7, werd een andere benadering gebruikt: door te kijken naar een honderdtal 
genen die coderen voor eiwitten die nauw met elkaar samenwerken binnen een zogenaamde 
‘pathway’, werd de aandacht gevestigd op een gen dat voorheen nooit werd geassocieerd 
met NDDs: het RHEB-gen. Patiënten met een mutatie in dit gen hadden allemaal een 
abnormaal groot hoofd (macrocefalie), een kenmerk dat reeds sterk geassocieerd was met 
de onderzochte pathway.
Klinische aspecten
Door de klinische (medische) kenmerken van de patiënten – de fenotypes – met elkaar te 
vergelijken, is in dit proefschrift verder bewijs gevonden dat de ontdekte kandidaat genen 
daadwerkelijk kunnen worden gerekend tot de next generation NDDs. Daarnaast is zowel 
nationaal als internationaal gezocht naar extra patiënten. Meer patiënten leverde niet alleen 
meer bewijs voor de NDD-kandidaat genen, maar zorgde er ook voor dat meer inzicht 
verworven kon worden in het klinisch beeld passend bij de nieuwe syndromen. Zo werd 
in hoofdstuk 9 duidelijk dat mutaties in het USP9X-gen bij meisjes geassocieerd zijn met 
niet alleen een ontwikkelingsstoornis, maar ook met een verscheidenheid aan herkenbare 
aangeboren afwijkingen. Het TLK2-gen in hoofdstuk 5 daarentegen wordt in verband 
gebracht met een minder specifiek en minder herkenbaar fenotype. Echter, doordat een 
relatief grote hoeveelheid patiënten (40) in de wereld werd ontdekt, was er voldoende bewijs 
om ook het syndroom geassocieerd met dit gen aan te merken als next generation NDD. 
Biologische aspecten
Voor sommige kandidaat genen bleef de hoeveelheid patiënten, ondanks het wereldwijd 
delen van data, beperkt: slechts drie patiënten hadden mutaties in het RHEB-gen (hoofdstuk 
7) en vijf hadden mutaties in het RAB11B-gen (hoofdstuk 8). Verder bewijs voor deze genen 
als next generation NDDs werd niet alleen geleverd door de fenotypes van de patiënten met 
elkaar te vergelijken, maar ook door aan te tonen dat de mutaties leidden tot verstoring van 
(cel)biologische processen. Ook voor andere nieuwe genen werden aanvullende functionele 
studies in dier- en cel-modellen gedaan. Dit leverde nieuwe inzichten in (verstoorde) 
onderliggende cel-processen op. Zo hadden zebravissen met specifieke mutaties in het 
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RAC1-gen een verminderde deling van cellen in de hersenen (hoofdstuk 6) en liet onderzoek 
in cellen van patiënten met mutaties in het SON-gen zien dat niet alleen het SON-eiwit, maar 
ook andere belangrijke eiwitten verstoord waren (hoofdstuk 4). In hoofdstuk 7 werd binnen 
het set aan genen die zijn gerelateerd aan het MTOR-gen, een relatie gelegd tussen de 
hoofdomtrek van de algemene bevolking en de opvallende hoeveelheid patiënten met een 
macrocefalie. 
Neurodevelopmental disorder: a next generation – what’s next?
In dit proefschrift konden uiteindelijk 14 genen worden toegevoegd aan de NDD-gen lijst: 
zeven genen als kandidaat genen (hoofdstuk 3) en 7 genen met bijbehorende syndromen 
als nieuwe next generation NDDs (hoofdstuk 4-10). Deze nieuwe syndromen hebben, net 
als andere next generation NDDs tenminste één kenmerk gemeen: ze zijn allemaal zeer 
zeldzaam. De beschreven aantallen patiënten blijven daarom, ondanks uitgebreide (inter)
nationale samenwerkingen, beperkt. Naast het verder verbeteren van mogelijkheden om 
data te delen, zullen toekomstige klinische vervolgstudies, zoals in hoofdstuk 11 van dit 
proefschrift voor PURA syndroom is gedaan, van groot belang zijn. Hiermee kan meer inzicht 
worden verworven in het klinisch spectrum dat past bij de nieuwe syndromen. Tevens zullen 
steeds grotere cohorten van patiënten nodig zijn om ook de nóg zeldzamere syndromen te 
kunnen opsporen. 
Een tweede opvallende overeenkomst tussen de verschillende syndromen beschreven 
in dit proefschrift, is de variabiliteit in ernst van symptomen binnen de syndromen. Bij 
de selectie van het cohort voor dit proefschrift is er bewust voor gekozen niet alleen de 
ernstiger aangedane patiënten te includeren, maar ook patiënten met een milder fenotype. 
Door ook deze patiënten te selecteren werd in dit proefschrift niet alleen aangetoond dat de 
NGS-opbrengst voor deze patiënten vergelijkbaar was met ernstiger aangedane patiënten, 
maar ook dat mutaties in bepaalde genen bij sommige patiënten kunnen resulteren in zeer 
ernstige ontwikkelingsstoornissen en bij anderen tot veel mildere problemen. Juist voor de 
patiënten met een milder fenotype moet in de toekomst rekening worden gehouden met een 
overervingspatroon dat anders is dan bij patiënten met een ernstige ontwikkelingsstoornis. 
Mutaties zullen niet altijd meer ‘de novo’ zijn (nieuw ontstaan in de patiënt, niet aanwezig in 
beide ouders), maar zullen soms ook worden teruggevonden bij een vader of moeder die, net 
als hun kind, milde problemen heeft. 
Functionele experimenten zijn van essentieel belang om de zeldzame nieuwe next-generation 
NDDs te bevestigen en onderliggende ziektemechanismen te begrijpen. Uiteindelijk zal 
deze kennis nodig zijn om het ultieme doel te behalen: de ontwikkeling van therapeutische 
middelen. Veel werk werd door collegae verzet om te komen tot de resultaten in dit 
proefschrift getoond. Om dit in de toekomst voor alle next-generation NDDs tot in detail 
te kunnen doen, zal veel geld en tijd nodig zijn: zaken waar helaas grote tekorten in zijn. 
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Opnieuw zullen goede (inter)nationale samenwerkingen essentieel zijn. In landen zoals de 
VS en Canada, maar meer recenter ook in de EU, zijn middels samenwerkingsverbanden 
hiervoor de eerste stappen gezet. 
Aankomende jaren zal de zoektocht naar nieuwe next-generation NDDs verder gaan. Het 
verbeteren van WES en het analyseren van data op alternatieve manieren zal waarschijnlijk 
leiden tot de ontdekking van meer next-generation NDDs. Daarnaast zal de implementatie 
van Whole Genome Sequencing (WGS) in de diagnostiek tekortkomingen van WES kunnen 
wegnemen. Echter, de focus zal niet alleen moeten liggen in het vinden van diagnoses 
voor patiënten die vooralsnog geen diagnose hebben. Het zal een hele klus zijn om goede 
patiëntenzorg op te zetten voor patiënten gediagnosticeerd met next-generation NDDs. De 
rol van ouders in dit proces zal daarbij zeer belangrijk zijn.  
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Dankwoord
Bijna vijf jaar geleden leek dit moment nog zo ver weg: het schrijven van een dankwoord voor 
mijn proefschrift. Een perfect moment om te reflecteren op de afgelopen tijd en mezelf te 
realiseren hoeveel mensen hebben bijgedragen aan niet alleen dit proefschrift, maar ook aan 
de fantastische onderzoekstijd die ik heb gehad.
 
Promoveren – de (co)promotoren
Januari 2014 begon ik, net terug van mijn laatste coschap in Indonesië, aan een nieuwe 
uitdaging: promotieonderzoek op de afdeling klinische genetica. Stiekem moet ik bekennen 
dat ik eigenlijk niet eens wist wat zo’n promotie nu precies inhield. Ik vond onderzoek doen 
én de genetica gewoon erg leuk. Het leek me dus de ideale baan. Han, vanaf het begin af 
aan ben je betrokken geweest als mijn promotor. Ik kan me de eerste keer nog herinneren 
dat ik een overleg gepland had staan met je. Ik was goed voorbereid en had urenlang 
gewerkt aan het schrijven van mijn ‘Training and Supervision Plan’. Dit moest natuurlijk door 
jou als promotor goedgekeurd en ondertekend worden. We spraken er eens goed over, 
waarna je vervolgens het TSP ondertekende zonder ook maar één woord te lezen van wat 
erin stond. Met natuurlijk wel de belangrijke boodschap aan mij dat ik zelf nooit iets zou 
moeten ondertekenen zonder het zelf gelezen te hebben. En dat je er vertrouwen in had dat 
het TSP overeenkwam met wat we net besproken hadden. Terugkijkend was dit eigenlijk 
een belangrijk moment: je sprak je vertrouwen uit in mij. Ik ben je erg dankbaar dat je dit 
vertrouwen altijd hebt gehouden en hebt uitgesproken op momenten dat het nodig was. Je 
hebt me de vrijheid gegeven om mijn eigen weg te zoeken als onderzoeker, en stuurde me de 
goede richting uit en inspireerde me op het juiste moment. Na verloop van tijd begon ik me 
te realiseren dat de stiltes die vielen tijdens een overleg helemaal niet ongemakkelijk waren: 
meestal kwam je na zo’n stilte met een perfecte opmerking waardoor ik weer weken verder 
kon. Dank voor niet alleen de wetenschappelijk input, maar ook de persoonlijke interesse die 
je altijd hebt getoond. Tjitske, aan het einde van mijn eerste jaar werd jij mijn copromotor en 
sloot jij aan bij de overleggen tussen Han en mij. Wat hebben we ons vaak samen afgevraagd 
of Han toch nog wel kwam opdagen voor ons overleg. Maar meestal bleek hij niet zo ver 
weg te zijn en stond hij een paar deuren verder nog snel even iets te overleggen. We hadden 
samen ook onze wekelijkse gesprekken. Het was fijn om met jou te brainstormen over de 
grote lijnen van mijn boekje en de mogelijkheden voor nieuwe onderzoeksprojecten. De 
combinatie van onderzoek en patiëntenzorg heeft voor mij het promotieonderzoek extra 
glans gegeven. Persoonlijk vond ik tijdens mijn onderzoeksperiode niets mooier dan ouders 
te vertellen dat we na jaren zoeken eindelijk een diagnose gevonden hadden. Jij hebt me 
laten zien dat patiëntenzorg niet ten koste hoeft te gaan van onderzoek: je loopt voorop 
in onderzoek, maar met hart voor de patiënten. Dit heb ik – en doe ik nog steeds – altijd 
ontzettend bewonderd. Ik ben ervan overtuigd dat je dit aankomende jaren met veel succes 
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gaat voortzetten! Net als Han was jij, Lisenka, vanaf het begin bij mijn promotietraject 
betrokken. Het WAC-artikel was het eerste project waar ik samen met jou aan werkte. Ik kan 
me nog herinneren dat het moment was gekomen om het artikel te submitten. Mijn eerste 
artikel! Ik had geen idee hoe het submitten van een artikel in zijn werk ging, dus deden we 
het samen. De ‘druk op de knop’ werd uiteraard vastgelegd. Dit is één van de voorbeelden 
die ik zo gewaardeerd heb aan je de afgelopen jaren: we zagen en spraken elkaar niet 
dagelijks, maar als ik een luisterend oor of ergens hulp bij nodig had kon ik altijd bij je 
terecht. Daarnaast waren je kritische blik en je oog voor detail heel fijn. Niet alleen tijdens het 
uitvoeren van het onderzoek, maar ook tijdens het schrijven van artikelen en uiteindelijk mijn 
proefschrift hield je me scherp met je nuttige commentaren. Heel veel dank hiervoor!
Samenwerking met verschillende professies 
Al snel werd mij duidelijk dat ik als PhD student was begonnen op een hele grote afdeling, 
waar mensen werkten met compleet verschillende achtergronden. In het begin was dit 
helemaal niet zo gemakkelijk: zo heb ik als één van de enige arts-onderzoekers toch 
menigmaal uitgelegd aan collega-PhD’s waar de afdeling klinische genetica zich precies 
bevond en wat wij daar precies deden. Daarnaast moet ik eerlijk toegeven dat ik weinig 
snapte van wat er verder ‘in het lab’ gebeurde. Ik realiseerde me dat ik zóveel te leren 
had. Tijdens mijn onderzoekstijd heb ik de mogelijkheid gehad me te verdiepen en verder 
te denken dan waar ik voor opgeleid was. Dank aan alle collega’s in de research en 
diagnostiek voor het altijd geven van uitleg, nuttige feedback en het helpen oplossen 
van moeilijk vragen. Dankzij jullie is mijn kijk op de genetica enorm verbreed. Ronald, we 
hebben afgelopen jaren samen aan heel wat projecten gewerkt. Ons eerste project, USP9X, 
was meteen raak. Op het moment dat ik je vertelde dat we USP9X-patiënten hadden met 
een ciliopathie-achtig fenotype was je meteen een en al oor. Of ik wist dat USP9X hoog 
stond op je ciliopathie-kandidatenlijst? Het werd een fantastisch project waardoor ik niet 
alleen ontzettend veel heb kunnen leren over functionele studies en ciliopathieën, maar 
ook je onderzoeksgroep heb leren kennen. Ook al was ik nooit officieel onderdeel van je 
onderzoeksgroep, ik heb me altijd welkom gevoeld! Dank voor de interesse die je altijd hebt 
getoond en de hele fijne samenwerking die we altijd hebben gehad. Hopelijk kunnen we hier 
in de toekomst een vervolg aan geven! Brooke, it was a great pleasure to work together 
with you on the USP9X project. We struggled about strange lab findings, discussed difficult 
results, and thought about next steps in our project: by combining our results we finally 
published a paper I’m very proud of! Ideke, je was mijn maatje in het RAB11B project. 
Hoe vaak hebben we samen rondgelopen op zoek naar Ronald? Er lag tijdens het project 
een behoorlijk druk op het afronden van je proefschrift. Maar voor ik het wist was het af, 
inclusief supermooie data voor ons artikel!   Marieke, Janita en Barbara, jullie hebben 
mij kennis laten maken met de wereld van GWAS. Dankzij jullie uitleg en hulp ging ik het 
uiteindelijk echt begrijpen. Rolph, jij was gedurende mijn gehele PhD tijd mijn vraagbaak 
in de diagnostiek. Ik ben altijd onder de indruk geweest van de hoeveelheid werk jij verzet. 
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Ik kon altijd bij je binnenlopen en je nam, hoe druk je het ook had, altijd de tijd om mijn 
vraag te beantwoorden. Kun je het je nog herinneren dat ik aan je vroeg waar ik missende 
dossiers kon vinden? Uiteindelijk zijn we samen de hele afdeling over gegaan op zoek naar 
missende dossiers om consenten te achterhalen. Dank voor de energie die je altijd in de 
verschillende projecten hebt gestopt! Nicole, jij was degene die me meenam naar Goldrain, 
waar ik een ontzettend leuke week gehad heb. Dank je wel voor oprechte interesse en je 
altijd scherpe blik op mijn onderzoeksresultaten. Prof. Katsanis, thank you for several fruitful 
collaborations! Dorien, Annette and Misa: thanks for the great work on the WAC-gene! 
Christian en Stefan, jullie fantastische werk droeg bij aan de basis van mijn proefschrift. 
Veel dank! Prof. Wilkie, many thanks for the great collaboration and your always valuable 
comments on the TLK2-project. Maria, it was nice to have drinks at the ASHG and to see our 
projects progressing and improving every year. Thanks for a fantastic collaboration! Lachlan, 
it was great to work with you on USP9X. Your extensive knowledge about this gene was 
very helpful. Geeske en Ype, het was ontzettend leuk om met jullie samen te werken. Jullie 
input voor ons MTOR-artikel en kennis van de pathway is ontzettend waardevol geweest. 
We gaan elkaar vast nog regelmatig tegenkomen! Dr. Mancini, bedankt voor je hulp bij het 
beoordelen van MRI-beelden en de heldere uitleg die je mij gaf. Dr. Banka, it was a pleasure 
to work together with you and your colleagues on the RAC1-project, thank you for the 
successful collaboration. Dr. Nellaker, thanks for your interesting work on the PURA- and 
TLK-faces. Jung-Hyun, Deepali and Erin: it was a special moment to meet you at the AHSG 
conference in Vancouver, after so many conversations by email. Thanks for your hard work 
on the SON gene!
Bijzonder contact met patiënten en hun ouders
Een van het meest inspirerende en motiverende ervaringen tijdens mijn PhD traject was 
het werken met patiënten en hun ouders. Ik vond het bijzonder om te zien dat ouders zo 
open stonden om bij te dragen aan de wetenschap. Mede dankzij hen is dit proefschrift 
geworden zoals het nu is. Hopelijk kunnen veel andere artsen, ouders en hun kinderen 
gebruik maken van de kennis die dankzij patiënten en hun ouders uiteindelijk op papier is 
gezet. Mel and Ceciel, you are definitely the most special parents I’ve met during my PhD 
project. It is unbelievable what you have done (and are still doing!) for all patients with PURA 
syndrome, including your daughters. Mel, I’ll never forget the moment we met for the first 
time in the car on our way to the first PURA conference. I had no idea what to expect and I 
was overwhelmed by your enthusiasm. I’m so glad I decided to stay in the car! Ceciel, it was 
exactly that day we met for the first time as well: waiting for hours on the airport and in the 
airplane (without any food…). We had so much fun when we heard your name on the speaker 
for a last call. All other members of the PURA Foundation board: thanks for keeping a 
fantastic organization going and for your interest in my work and me as person. Many thanks 
as well for the PURA Syndrome Global Research Network: I feel blessed to be involved in 
such an inspiring network of researchers and clinicians. It’s always a pleasure meeting you at 
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the PURA conferences and to discuss future directions of the research team. Dierk, thanks 
for inviting me in Munich, it was great to see your lab and to meet your team. David and 
Diana, thanks to you I became involved in PURA Syndrome. I’m very proud on the results 
of our work we published last year. It was really a pleasure to work with you. I’m convinced 
many more collaborations will follow. Jennifer, thanks for the inspiring conversations with 
drinks at the bar! Belangrijk voor mijn werk in de kliniek was de afdeling klinische genetica. 
Dank aan alle artsen voor het geven van de mogelijkheid om aan te sluiten bij polibezoeken 
van patiënten en het helpen om medische gegevens compleet te krijgen. Dames van het 
secretariaat, het was ontzettend fijn dat ik altijd bij jullie terecht kon als er iets geregeld 
moest worden, geen vraag was te gek voor jullie! Tot slot wil ik alle collega’s van andere 
ziekenhuizen bedanken voor het zorgvuldig verzamelen van klinische details en het 
meewerken aan mijn onderzoek.
Congressen en cursussen… een scala aan anekdotes
Een hele leuke bijkomstigheid van het promotietraject dat ik doorlopen heb, zijn wat 
mij betreft de vele cursussen en congressen in binnen- en buitenland die ik heb mogen 
bezoeken. Het was niet alleen de perfecte manier om nieuwe kennis op te doen en 
buitenlandse collega’s te ontmoeten, maar ook een bijzondere manier om mijn Nijmeegse 
collega’s beter te leren kennen. Wat een hoop goede herinneringen heb ik hieraan…! Ik kijk 
met veel plezier terug op de congressen waar ik met collega’s verbleef in de ‘Nijmegen-
villa’. Dank aan alle collega’s met wie ik met veel plezier samen in één van deze huizen 
heb gezeten. Alex, het mooiste huisfeest dat jij organiseerde en waar ik bij ben geweest 
is toch wel het feest in Glasgow geweest. Tot diep in de nacht hebben we in ‘onze’ villa 
gefeest (en Rolph, jouw binnenkomst was wat mij betreft memorabel: trots showde je de 
verschillende flessen drank in de binnenzakken van je jas). Sandra, in Barcelona deelde 
ik een appartement onder andere met jou. Het was ontzettend gezellig, we hebben 
uiteindelijk over de meest onzinnige dingen zitten kletsen. Anneke, we waren samen naar 
de Manchester Dysmorphology course. We liepen ’s ochtends samen naar de cursusruimte 
omdat we geen zin hadden om met de bus te gaan. Ik vergeet nooit dat je toen opmerkte 
dat je je verbaasde over het feit dat ik net zo snel liep als jij. In het ziekenhuis liep ik namelijk 
altijd nogal traag. Erg grappig vond ik dat en typisch een opmerking voor jou. Nicole, aan 
het einde van een late sessie op de ASHG in Vancouver bleken alle andere collega’s al lang 
en breed te hebben gegeten. Bij een goede Italiaan hebben we uiteindelijk een hele gezellige 
avond gehad. Han, tijdens het congres in Kopenhagen zou jij nog even naar mijn presentatie 
kijken. Dus stonden we daar, midden in de congreshal, mijn presentatie door te nemen terwijl 
we zo ongeveer iedere minuut werden onderbroken doordat iemand een praatje met je kwam 
maken. Maar ondertussen heb je me toen wel een aantal presentatie-skills bijgebracht waar 
ik nu nog altijd gebruik van maak. Illja, wij waren samen in Cardiff. Het was toch hilarisch 
dat wij iedere ochtend een half uur eerder gingen ontbijten omdat we ons tegenover onze 
andere collega’s schaamden dat wij zoveel aten van het enorme ontbijtbuffet. Tegen de 
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tijd dat de andere collega’s arriveerden waren wij net begonnen aan onze derde ronde     . 
Stefan, weet je nog dat we samen met Lot super zenuwachtig die enorme congreshal op de 
ESHG binnenstapten voor ons eerste praatje? Wat een ontlading was het toen we alle drie 
ons praatje achter de rug hadden. We hebben in heel wat Nijmegen-huizen samen gezeten. 
Orlando was toch wel een favoriet… ‘Eitje met bacon?’. Na het congres in Glasgow hebben 
we nog een paar dagen heel veel lol gehad in Edinburgh. Een laatste anekdote, die totaal niet 
in deze alinea past maar me nu toch te binnenschiet: de enorme chocoladetaart die je aan 
me gaf toen ik al die consenten had nagekeken. We hebben meerdere koffiepauzes op die 
dag moeten inlassen om hem op te krijgen! Laurens en Jacob, volgens mij was Kopenhagen 
ons eerste congres samen. Ik was niet helemaal in goede doen, mijn arm was net uit het 
gips. Jullie was zo ontzettend behulpzaam! Laurens, een half jaar later zijn we ook samen 
naar Orlando geweest. Aansluitend aan het congres zijn we naar Universal Studios geweest. 
De afterparty met Harry Potter films moeten we nu toch echt maar eens organiseren! 
Christian, jij was altijd zo ontzettend hard aan het werk tijdens congressen, ongelofelijk 
hoe je dit altijd volhoudt. Want naast het werk mis je nooit eens een borrel of feestje. Na 
het congres in Baltimore hebben wij samen met Lot een bus gepakt voor een weekje New 
York (waar we overigens het appartment van Susanne hebben mogen bewonderen). Wat 
ontzettend gaaf was dit! En heel erg leuk dat Michiel en jij elkaar daar hebben leren kennen. 
Lot, onze eerste buitenland-ervaring was Bertinoro. Wat een goede herinneringen heb ik 
hieraan! Want ondanks dat we beiden op dezelfde afdeling werkten, leerden we elkaar hier 
pas echt kennen. Vanaf dat moment zijn we zo vaak samen (natuurlijk tot in de puntjes en 
alles op tijd voorbereid…) naar congressen geweest. Jij zei altijd dat je het zo fijn vond als 
alles ‘lekker ongecompliceerd’ was. Nou, volgens mij is dat wel gelukt!
Fantastische collega’s 
Als je meer dan vier jaar rondloopt op de werkvloer leer je natuurlijk veel directe collega’s 
steeds beter kennen. Tot mijn plezier werd de groep onderzoekers binnen de Klinische 
Genetica steeds groter. Aisha, Anneke, Arjan, Chantal, Daniëlle, Gijsbert, Janet, 
Illja, Ingrid, Linde, Lot, Marc, Sandra en Yvonne, dank jullie wel voor jullie support en 
gezelschap. Aisha, het was bijzonder om op jouw promotie als paranimf naast je te staan. 
Ik ben blij voor je dat je de voor jou perfecte baan gevonden hebt. Janet, ook al leerden we 
elkaar pas later kennen, we hebben toch al behoorlijk veel momenten gedeeld. Het was erg 
fijn met je te kunnen sparren over onderzoeksideeën en studieprotocollen. Daarnaast vind 
ik jouw doorzettingsvermogen bewonderenswaardig. Ik ben er dan ook van overtuigd dat je 
nog veel mooie dingen gaat bereiken. Illja, je bent een hele tijd mijn kamergenootje geweest. 
Ga ik ooit nog een kamergenootje krijgen die net zo fanatiek als ik sportwedstrijden probeert 
te volgen met haperende wifi in een oranje versierde kamer? Jij bent inmiddels ook bijna 
klaar met je proefschrift. Heel veel succes met de laatste loodjes! Sandra, dit laatste geldt 
ook voor jou. Ik heb enorme bewondering voor de manier waarop jij afgelopen jaren je gezin, 
reisafstand en werk gecombineerd hebt. Hopelijk kan ook jij binnenkort je onderzoeksperiode 
: )
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met succes afsluiten. Corrie, mijn favoriete lunchmaatje. We hebben samen heel wat uurtjes 
doorgebracht in het restaurant. Ik heb ook ontzettend gelachten om sommige uitspraken 
van je. ‘TM!’     . Dank aan de arts-assistenten op de afdeling voor de gezellige lunches en 
uitjes. Gelukkig gaan we elkaar nog regelmatig tegenkomen tijdens het maandelijkse AIOS-
onderwijs. Tot slot wil ik de vele collega’s bedanken die ervoor hebben gezorgd dat ik een 
ontelbare hoeveelheid geslaagde vrijdagmiddag-borrels heb gehad in de Aesculaaf. Deze 
borrels, met aansluitend vaak een etentje in de stad en soms nog wat meer borrels erna, zijn 
een belangrijk onderdeel van de fantastische tijd die ik tijdens mijn onderzoek heb gehad. 
Nieuwe fase: Maastricht!
Ook al vond ik mijn onderzoekstijd fantastisch, uiteindelijk had ik veel zin om weer aan 
de slag te gaan in de kliniek. Voor mij blijft het patiëntencontact toch een heel erg mooi 
onderdeel van mijn vak. Met name richting het einde van mijn onderzoekstijd, tijdens het 
dagenlange schrijven van artikelen en mijn proefschrift, ging ik dit patiëntencontact erg 
missen. Gelukkig kon ik aansluitend aan mijn PhD traject aan de slag op de afdeling klinische 
genetica in Maastricht. Het heeft mij verbaasd hoe snel ik gewend was aan mijn ‘nieuwe’ 
leven. Veel dank aan al mijn Maastrichtse collega’s die ervoor hebben gezorgd dat ik mij zo 
snel op mijn plek heb gevoeld. Ik heb heel veel zin om aankomende jaren mijn opleiding met 
jullie op de afdeling te doorlopen. Yvonne, dank je wel dat je mij de ruimte gaf om eerst mijn 
proefschrift af te maken, alvorens te starten aan mijn opleiding. Dankzij jouw vooruitziende 
blik heb ik in alle rust kunnen starten met een nieuwe fase, waar ik nu erg blij mee ben. 
Maaike, tijdens mijn onderzoekstijd ben ik al weleens bij je langs geweest om samen een 
patiënt te zien op de poli. Ik ben niet vergeten dat jij me aansluitend vroeg om mee te gaan 
lunchen met de rest van de Maastrichtse collega’s. Hierdoor heb je me een kijkje gegeven in 
de genetica-afdeling Maastricht, wat er uiteindelijk mede toe heeft geleid dat ik besloten heb 
in Maastricht aan de slag te willen gaan. Connie, ook wij hebben afgelopen jaren regelmatig 
contact gehad met elkaar. Jouw drive om de nieuwste onderzoeksresultaten te combineren 
met de beste patiëntenzorg is voor mij inspirerend en motiverend. Ik hoop nog veel van je 
te kunnen leren aankomende jaren. Margje, als ik zag dat een patiënt met een interessante 
mutatie door jou was ingestuurd voor WES, was ik altijd erg blij. Als er iemand snel was 
met het aanleveren van complete medische gegevens van patiënten was jij het wel. Als ik 
nu zie hoeveel werk je verricht op de afdeling kan ik hier alleen nog maar meer respect voor 
hebben. Mijn kamergenootjes Vyne en Vivian: wat hebben we het gezellig met elkaar. We 
hebben nog heel wat leuke jaren voor de boeg. Encarna, nu nog collega-AIOS, maar over 
een paar weken ben je niet alleen internist, maar ook klinisch geneticus. Ik heb veel respect 
voor de manier waarop jij keuzes maakt om je uiteindelijke doel te behalen. Tot slot, Sander, 
je was tijdens mijn onderzoeksperiode in Nijmegen altijd al mijn vraagbaak in Maastricht. 
Dat is nu eigenlijk niet veranderd. Dank je wel voor je enthousiasme en interesse voor mijn 
proefschrift!
: )
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Er is meer dan werk alleen
Vers van de schoolbanken begon ik aan mijn eerste ‘echte’ baan. Al snel werd voor mezelf 
duidelijk dat ik het belangrijk vond om naast het werk tijd te hebben om hier juist helemaal 
los van te komen. Terugkijkend denk ik dat het vrij aardig gelukt is, ondanks de hoge 
werkdruk die het publiceren van artikelen, het bezoeken van congressen en het geven 
van presentaties zo nu en dan met zich mee bracht. ‘Norbertusmeiden’, jullie ken ik al 
zo ontzettend lang. Ondanks dat we over het hele land verspreid wonen, zien we elkaar 
nog steeds met regelmaat en hebben we inmiddels heel wat bijzondere momenten samen 
gevierd. Mirthe, ik vind het heel bijzonder dat jij straks als paranimf naast me staat. We 
zien elkaar niet wekelijks, maar het is iedere keer weer alsof het een dag geleden is dat 
ik je heb gesproken. Ike, we hebben de afgelopen jaren heel wat kopjes thee gedronken. 
Ondanks dat we nu wat minder vaak samen thee kunnen drinken, vind ik het ontzettend 
fijn voor je dat je, samen met Muhammad, je plek hebt gevonden in Dordrecht. Tobias en 
Deborah, het is altijd weer gezellig om samen met Michiel bij jullie en Abel (en binnenkort 
zijn broertje!) in Scheveningen langs te komen. Christian, officieel ken ik je natuurlijk via het 
werk, maar inmiddels zie ik je ook regelmatig daarbuiten. We delen een passie voor muziek 
– dat ontdekten we wel tijdens onze lange gesprekken op vrijdagavond in café Samson. We 
hebben inmiddels al behoorlijk wat concerten bezocht, ik hoop dat er nog velen gaan volgen. 
Jasmijn, het is zo leuk dat we contact zijn blijven houden na ons avontuur in Indonesië! We 
hebben elkaar daar heel goed leren kennen en daarom is het iedere keer weer gezellig om 
samen een van onze hobby’s uit te voeren: lekker eten. Tijdens mijn onderzoekstijd ben ik 
naast werk veel bezig geweest met mijn grootste passie: viool spelen. Inge, Laurens en 
Mirjam, en later Desiree, Martijn en Maaike: we hebben toch maar een heel mooi orkest 
opgericht. Het was af en toe puzzelen om alles te organiseren om onze drukke banen heen, 
maar het resultaat mag er wezen denk ik. Joris, Clara, Olga, Hinke, Tom, Emiel, Dirk, 
Maaike, Franke, Hester, Sophie, Simeon, Desiree, Loes, Florien, Sylvie, Christine, en 
alle andere NNK-ers: we hebben nog samen gespeeld in het studentenorkest. Hoe leuk is 
het om muziek te kunnen blijven maken met elkaar!
Lot, het was voor mij niet moeilijk om jou te kiezen als paranimf. Vanaf het begin af aan 
hebben wij lief en leed gedeeld. Je was altijd mijn maatje op het werk, maar ook daarnaast 
hebben we maar al te vaak leuke dingen ondernomen. Jouw tomeloze enthousiasme werkte 
maar al te vaak aanstekelijk op mij.  En hoe leuk is het dat we in 2023 (ja, echt, zo lang nog!) 
allebei klinisch geneticus én gepromoveerd zijn     . Ot-Blokhokkers: via Michiel ben ik 
onderdeel geworden van jullie bijzondere vriendengroep. Ook al heeft inmiddels iedereen zijn 
eigen leven, het blijft toch leuk om met zijn allen bij elkaar te komen. Emiel en Paula, jullie 
waren erbij toen ik - notabene tijdens een etentje - mijn allereerste artikel ging submitten. Wat 
een spanning om 11 uur ’s avonds! Onze etentjes, inmiddels met Ionica erbij, blijven wat mij 
betreft voor herhaling vatbaar. 
: )
526362-L-bw-Reijnders
Processed on: 20-11-2018 PDF page: 247
247
A
Lieve (schoon)familie, dank jullie wel voor de interesse die jullie getoond hebben de 
afgelopen jaren in mijn promotietraject. Ik weet dat ik niet het gemakkelijkste onderwerp heb 
uitgekozen om op te promoveren, maar met dit boekje hoop ik dat jullie toch een beetje een 
beeld krijgen van waar ik afgelopen jaren mee bezig ben geweest. Dank jullie wel ook voor 
alle gezellige uitjes, etentjes en lieve kaartjes zo nu en dan! Lieve opa en oma, daar is mijn 
boekje dan! Er is geen moment voorbijgegaan dat jullie niet vol interesse vroegen hoe het 
ging met ‘de studie’. Het is altijd weer leuk om bij jullie thuis een kopje thee te drinken of een 
kop gewone soep te eten. Ik vind het heel bijzonder dat jullie erbij zullen zijn op deze speciale 
dag! Lieve broers, Roliene en Cas, als ik terugdenk aan de afgelopen jaren komen er veel 
leuke herinneringen naar boven. Het lange weekend in Rome, leuke uitstapjes, gezellige 
spelletjesavonden, borrels en lekkere etentjes. En natuurlijk de mooiste herinnering: de 
geboorte van de kleine Cas. Ik hoop dat we, net als afgelopen jaren, nog veel mooie dingen 
zullen meemaken. Lieve papa en mama, dank jullie wel dat jullie altijd onvoorwaardelijk 
achter de keuzes hebben gestaan die ik gemaakt heb. Jullie waren er op momenten dat ik 
twijfelde en het moeilijk vond om beslissingen te nemen. En jullie waren er ook om alle mooie 
en leuke momenten samen te vieren. Het is fijn om in mijn achterhoofd de wetenschap te 
hebben dat ik altijd bij jullie terecht kan. Ik heb veel zin in aankomende jaren, waarin wij 
samen, met het gezin en de familie hopelijk weer veel gezelligheid en mooie momenten 
samen zullen hebben. Liefste Michiel: mijn werkstukje is klaar. Wat een hoop werk was het, 
ook voor jou. Gedurende bijna vijf jaar heb jij menig suggesties gedaan over wat er allemaal 
in mijn dankwoord moest komen. Twee kantjes gericht aan jou zou toch het minimum zijn. Dit 
was natuurlijk als grap bedoeld. Maar die twee kantjes zou ik met gemak vol schrijven. Het 
was zo ongelofelijk fijn om met jou te sparren over de grote lijnen van mijn proefschrift, na 
te denken over figuren en uiteindelijk: de lay-out van mijn proefschrift te maken. Jouw frisse 
kijk op mijn onderzoek werkte op cruciale momenten zo verhelderend. Na jouw academietijd 
ligt nu ook mijn promotietijd achter ons. Ik heb ontzettend veel zin in de tijd samen die voor 
ons ligt. Ik ben ervan overtuigd dat we, net als de afgelopen jaren, met veel geluk en plezier 
samen alle nieuwe uitdagingen aan zullen gaan. 
Dankwoord / acknowledgements
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